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ABSTRACT
Uncontrolled activation of the coagulation cascade following lung injury has been 
implicated in both lung inflammation and fibrosis. In addition to its role in coagulation, 
thrombin exerts pluripotent cellular effects via the activation of its high-affinity receptor, 
proteinase activated receptor-1 (PARt). PARi is a seven transmembrane domain G 
protein-coupled receptor that exhibits the ability to couple to multiple G protein family 
subunits, including Ga*,, Gaq and G a^ n  within the same cell type. Activation of PARi 
on fibroblasts, a key effector cell in lung fibrosis, results in the induction of several 
mediators, including the potent monocyte and fibrocyte chemoattractant CCL2.
In this thesis, the G-protein and downstream signalling pathways involved in PARr  
mediated CCL2 production and release were examined. Using a novel PARi antagonist 
which blocks the interaction between PARi and Gaq, this thesis shows for the first time 
that PARt coupling to Gaq is essential for thrombin (10nM)-induced CCL2 gene 
expression and protein release in murine lung fibroblasts (MLFs). The work presented 
here further demonstrates that these effects are mediated via the cooperation between 
ERK1/2 and Rho kinase signalling pathways: a calcium-independent PKC, c-Raf and 
ERK1/2 pathway was found to mediate PARrinduced CCL2 gene transcription; 
whereas PLC, calcium, calcium-dependent PKC and Rho kinase pathway influences 
CCL2 protein release. This thesis represents the first demonstration of the cooperation 
between two pathways in mediating the stimulatory effects of thrombin, or indeed any 
other extracellular stimulus, on the induction and release of the potent chemoattractant, 
CCL2. This thesis also examined the signalling receptor and downstream effectors 
involved in thrombin-induced CCL2 production in primary human lung fibroblasts 
(pHALFs). The results demonstrate that PAR! coupling to Gaq is also both necessary 
and sufficient in mediating thrombin-induced CCL2 production at low concentration of 
the proteinase, whereas at high concentrations, these effects may be partially PAR- 
independent. This discrepancy between MLFs and pHALFs may be explained by 
differences of PAR receptor expression between species.
Taken together, this thesis proposes that targeting the interaction between PAR! and 
specific G proteins may allow more selective blockade of PARi pro-inflammatory and 
pro-fibrotic signalling, whilst preserving the essential role of other PARi-mediated 
cellular responses.
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ELISA Enzyme-linked Immunoassay
EMT Epithelial-mesenchymal Transition
Eo Eosinophil
Ep Epithelial cells
EPCR Endothelial Protein C Receptor
ERK Extracellular Signal Related Protein Kinase
ET-1 Endothelin-1
FCS Foetal Calf Serum
FGF2 Fibroblast Growth Factor 2
FITC Fluorescein Isothiocyanate
FSP-1 Fibroblast Specific Protein-1
FXa Coagulation Factor X (active)
GAP GTPase-activating Proteins
GDIs Guanine-nucleotide Dissociation Inhibitors
GEFs Guanine-nucleotide Exchange Factors
GRKs G protein Receptor Kinases
GPCR G-protein-coupled Receptors
HABP High Affinity Receptor Binding Peptide Probe
HEKs Human Embryonic Kidney Cells
HFL-1 Human Feotal Lung Fibrobast-1
HRP Horseradish Peroxidase
HUVECs Human Vascular Endothelial Cells
ICAM-1 Intracellular Adhesion Molecule-1
IFN-y I nterferon-gamma
IGF-1 Insulin-Like Growth Factor-1
IIP Idiopathic Interstitial Pneumonia
IL Interleukin
ILD Interstitial Lung Disease
IP3 Inositol Triphosphate
IPF Idiopathic Pulmonary Fibrosis
JNK Jun N-terminal kinase
kDa Kilodalton
KO Knockout
LARG Leukaemia-associated Rho guanine-nucleotide exchange factor
LIP Lymphoid Interstitial Pneumonia
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LPS
Ma
Mac
MAP kinase
MCPs
MEFs
MIP-1a
MKPs
MLC
MLFs
MMPs
mRNA
Myo
Ne
NSIP
PARs
PBS
PDGF
PGE2
pHALF
PIP2
PKA
PKC
PLC-|3
PTX
PVDF
RANTES
RNA
ROCK
RT-PCR
SDS
SP-C
Sphk-1
SRC
SRF
Lipopolysaccharide 
Mast cells 
Macrophage
Mitogen-activated Protein Kinase 
Monocyte Chemotactic Proteins 
Mouse Embryonic Fibroblasts 
Macrophage-Inflammatory Protein-1 a 
MAP kinase Phosphatases 
Myosin Light Chain 
Mouse Lung Fibroblasts 
Matirx Metalloproteinases 
Messenger Ribonucleic Acid 
Myofibroblasts 
Neutrophil
Nonspecific Interstitial Pneumonia 
Proteinase-activated Receptors 
Phosphate-Buffered Saline 
Platelet-derived Growth Factor 
Prostaglandin E2
primary Human Adult Lung Fibroblast
Phophoinositide Hydrolysis
Protein Kinase A
Protein Kinase C
Phospholipase-0
Pertussis Toxin
Polyvinylidene Difluoride
Regulated on Activation Normally T-cell Expressed and
Secreted
Ribonucleic Acid
Rho Kinase
Reverse Transcription-polymerase Chain Reaction
Sodium Dodecyl Sulphate
Surfactant Protein C
Sphingosine kinase-1
pp60src and related kinases
Serum Response Factor
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SSc Systemic Sclerosis
TF Tissue Factor
TFPI Tissue Factor Proteinase Inhibitor
TGF-a Transforming Growth Factor-a
TGF-3 Transforming Growth Factor-p
THBS-1 Thrombospondin-1
TIMPs Tissue inhibitors of metalloproteinases
TNF-a Necrosis Factor-a
UIP Usual Interstitial Pneumonia
uPA Urokinase-type Plasminogen Activator
VCAM-1 Vascular Adhesion Molecule-1
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Chapter 1: Introduction
1.1 Pulmonary fibrosis
Pulmonary fibrosis is a pathological process that is classically characterized by 
abnormal tissue repair in response to acute or chronic lung injury, resulting in the 
replacement of normal functional tissue with excessive and disorganised extracellular 
matrix (ECM) proteins, such as collagen in the pulmonary interstitium (Figure 1.1). The 
pulmonary interstitium is defined as the alveolar walls (including the epithelium and 
capillary endothelium), septae and the perivascular, perilymphatic and peribronchiolar 
connective tissue. Pulmonary fibrosis is a progressive illness that ultimately leads to 
the loss of lung function and severe respiratory insufficiency, and is an important cause 
of morbidity and mortality in patients.
Normal
Figure 1.1 Alveolar architecture of normal and fibrotic lung. Images show the stark contrast 
in alveolar architecture in the normal and fibrotic lung. In the fibrotic lung, the open alveolar 
architecture is obliterated and replaced with dense fibrotic tissue. (Images taken from 
(Chambers, 2008))
Pulmonary fibrosis is a common consequence and often a central feature of many 
interstitial lung diseases (ILDs). ILDs are a heterogeneous group of over 200 different 
disorders that may share a similar clinical and radiographic presentation, but have 
distinct aetiologies and pathophysiology. A range of varied conditions give rise to ILDs. 
These include diseases with a well defined aetiology (i.e. radiation, occupational 
exposure to substances such as asbestosis, drug-induced lung disease), or diseases 
which progressively affect the lungs as one part of systemic involvement such as 
granulomatous diseases (i.e. sarcoidosis), and connective tissue diseases (i.e. 
rheumatoid arthritis, scleroderma). The ILDs with known causes have been grouped 
together as shown in table 1.1.
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Aetiology Clinical example
Systemic diseases
Collagen vascular diseases Scleroderma 
Rheumatoid arthritis 
SjOrgen's syndrome 
PoJymyositis/dermatomyositis
Immunodeficiency Common variable immunodeficiency
Exposures
Vocational Hypersensitivity pneumonitis 
Hot tub lung 
Bird breeder’s lung 
Compost lung
Environmental Farmer’s lung 
Environmental moulds
Occupational Asbestosis
Berylliosis
Silicosis
Popcorn worker’s lung
Drug-induced lung disease Amiodarone
Methotrexate
Nitofurantoin
Bleomycin
Genetic Familial interstitial pneumonia 
Hermanski-Pudlack syndrome 
Surfactant protein-C mutation
Table 1.1. Clinical classification of ILDs (adapted from (Laurent and Shapiro, 2007))
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However, most cases of ILDs have no known aetiology and are termed as idiopathic 
interstitial pneumonias (IIPs). In the past, the classification of IIPs has always been a 
problem as many of IIPs closely mimic each other clinically but the outcome of each 
can vary greatly. In 2002, the American Thoracic Society (ATS) and European 
Respiratory Society (ERS) consensus panel reclassified IIPs and concluded that IIPs 
comprised a number of clinicpathological entities which were sufficiently different from 
one another to be designated as separate diseases. As shown in table 1.2, IIPs are 
classified into seven distinct disease entities which can be distinguished on the base of 
clinical, radiological and histological characteristics.
Histological pattern Diagnosis based on clinical, radiological, 
and histological findings
Usual interstitial pneumonia Idiopathic pulmonary fibrosis
(UIP) (IPF)
Nonspecific interstitial pneumonia Nonspecific interstitial pneumonia
(NSIP) (NSIP)
Organizing pneumonia Cryptogenic organizing pneumonia 
(COP)
Diffuse alveolar damage Acute interstitial pneumonia 
(AIP)
Respiratory bronchiolitis Respiratory bronchiolitis-associated interstitial 
lung disease (RBILD)
Desquamative interstitial pneumonia Desquamative interstitial pneumonia 
(DIP)
Lymphoid interstitial pneumonia Lymphoid interstitial pneumonia 
(LIP)
Table 1.2 Classification of the Idiopathic Interstitial Pneumonias (Table adapted from: 
American Thoracic Society/European Respiratory Society International Multidisciplinary 
Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002)
Of all IIPs, UIP has the poorest prognosis, whereas NSIP has a better outcome. UIP is 
the histopathologic pattern that identifies patients with Idiopathic pulmonary fibrosis 
(IPF) in lung biopsy specimens. IPF, also known as cryptogenic fibrosing alveolitis 
(CFA), is the most common and fatal of the idiopathic interstitial pneumonias. The 
typical lung biopsy of IPF is seen with areas of normal appearing lung tissue 
interspersed with dense scarring, honeycombing, fibrotic foci and inflammatory cells. 
Honeycombing is due to enlarged and distorted airspaces resulting from destruction of 
normal lung architecture; fibrotic foci are areas of proliferating fibroblasts with
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connective tissue. Although the aetiology of IPF remains unknown, a number of 
environmental factors such as smoking (Baumgartner et a/., 1997) and viral infection 
(Tang et al., 2003) have been implicated. Genetic polymorphisms may also account for 
the prevalence of IPF as the existence of polymorphisms in surfactant protein C 
mutation (SP-C) (Lawson et al., 2004), interleukin-1 (IL-1) receptor antagonist (Whyte 
et al., 2000), as well as polymorphism of the tumour necrosis factor-alpha (TNF-a) 
(Whyte et al., 2000) gene and complement receptor 1 gene (Zorzetto et al., 2003) 
found in familial cases of IPF. However, most cases currently have no known risk factor. 
Clinically, the most common symptoms of IPF are dysponea, poor exercise tolerance 
and a non-productive cough, as well as systemic symptoms such as fever and weight 
loss.
Epidemiological data on pulmonary fibrosis is scant and varies in the literature, but it is 
known that IPF is the most common cases of IIPs, accounting for more than 45% of all 
cases (American Thoracic Society (2000)). There is no geographical pattern of disease 
distribution and no racial or ethnic predisposition. In a large epidemiological study in 
1994, the prevalence of all interstitial lung diseases was reported to be 80/100,00 of 
the general population for men and 60/100,00 for women. Of these cases, the 
prevalence of IPF was found to be 7-20 individuals per 100,000 population (Coultas et 
al., 1994). However, a recent estimate has suggested a prevalence in the United 
States ranging from 14.0 to 42.7 cases per 100,000 population (Raghu, 2006), which is 
higher than that previously reported. It is further estimated that the incidence of IPF in 
the United Kingdom has dramatically increased by 11% between 1991 and 2003, and 
the overall incidence rate per 100,000 person-years is 4.6, which has more than 
doubled (Gribbin et al., 2006). This disease occurs predominantly in men. Most 
patients with IPF are diagnosed between the ages of 40 and 70 and the incidence 
increases with age. The survival rate of pulmonary fibrosis remains significantly low 
with a median survival rate between 3 and 5 years (Hubbard et al., 1998; Mapel et al.,
1998).
Despite improvements have been made in our understanding of the biochemical and 
biological mechanisms of pulmonary fibrosis, this lung disorder continues to pose major 
clinical challenges since effective therapies have yet to be identified and developed. 
Current therapeutic options include conventional anti-inflammatory therapy such as 
corticosteroids, immunosuppressants such as azathioprine, and anti-fibrotic treatment 
such as pirfenidone. Unfortunately, anti-inflammatory treatment with corticosteroids is 
associated with side effects and significant morbidity (Collard and King, 2001; Flaherty
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et at., 2001a). The anti-fibrotic agent pirfenidone (Azuma et at., 2005) and the anti­
oxidant agent acetylcysteine showed early promise in recent !PF trials but future long­
term studies are required to clarify their safety and efficacy (Demedts et a/., 2005).
In summary, pulmonary fibrosis such as IPF represents a severe clinical problem, and 
a better understanding of the pathogenesis underlying disease progression will be 
pivotal for the development of urgently needed effective therapies.
1.2 Pathogenesis of pulmonary fibrosis
Although during the past decades significant advances have been made in the 
understanding of the pathogenesis of pulmonary fibrosis, the exact mechanisms 
underlying the development of pulmonary fibrosis are still not fully understood. In 
particular, the concepts of pathogenesis of pulmonary fibrosis have changed within 
past decades. Initially, it was believed that pulmonary fibrosis is the consequence of 
chronic lung inflammation. The second hypothesis suggests that pulmonary fibrosis 
results from epithelial cell injury and abnormal wound repair in the absence of 
preceding inflammation (Strieter, 2002). The third hypothesis is based on the previous 
two hypotheses and postulates that injury to the lung causes subsequent inflammation, 
whereas the body’s immune response to the injury results in pulmonary fibrosis 
(Strieter, 2005). A very recent review hypothesized that IPF develops as a 
consequence of abnormalities resulted from multiple biological pathways that affect 
inflammation and would repair (Maher et at., 2007).
Recent progress in our understanding of the pathogenesis of pulmonary fibrosis mainly 
comes from studies on animal models of lung fibrosis, the commonest of which is 
bleomycin-induced pulmonary fibrosis model. Bleomycin can induce lung injury, 
inflammation and fibrosis, with many features similar to those seen in humans with 
pulmonary fibrosis. Both human and murine model of pulmonary fibrosis are 
characterized by alveolar epithelial cell injury which occurs early in the pathogenesis 
(Plataki et at., 2005). Alveolar and airway epithelial cells (AEC) are primary target cells 
of lung injury. Following lung injury, the more susceptible type I epithelial cells die and 
detach from alveolar walls, whilst the type II cells may then proliferate and repopulate 
the denuded basement membrane (Haschek and Witschi, 1979). In pulmonary fibrosis, 
the alveolar epithelium is thought to fail to regenerate because of the continued cycle of 
injury and the death of type II epithelial cells (Adamson et at., 1988; Kasper and 
Haroske, 1996). The failure of re-epithelialisation leads to the loss of basement
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membrane integrity, which results in the formation of a provisional matrix on the 
denuded basement membrane of the alveolar wall.
The epithelial injury is followed by subsequent recruitment of neutrophils and 
inflammatory cells, including monocyte, macrophage, lymphocytes and eosinophils into 
the lung (Keane et ai, 2005). During this stage, a number of pro-inflammatory and pro- 
fibrotic mediators (Table 1.3) are produced. These mediators then trigger the migration 
of fibroblasts to the site of injury, and stimulate fibroblasts to proliferate, differentiate to 
myofibroblasts with the deposition of collagen and other extracellular matrix (ECM) 
components into the provisional matrix. In normal wound healing, following deposition 
of limited ECM into the wound space, myofibroblasts contract to close the wound. 
Myofibroblasts and other effector cells including inflammatory cells then undergo 
apoptosis and are cleared from the wound space. Finally, type II epithelial cells 
proliferate to regenerate the epithelium. In pulmonary fibrosis, however, the abnormal 
apoptosis in these important effector cells exaggerates the process of pulmonary 
fibrosis (Thannickal and Horowitz, 2006a; Fattman, 2008). For example, studies have 
shown that fibroblast/myofibroblasts from patients with pulmonary fibrosis are not only 
resistant to apoptosis; they also induce apoptosis of human AEC by secreting soluble 
factors such as angiotensin peptide (Uhal et al., 1995; Wang et ai, 1999). Additionally, 
inflammatory cells such as macrophages appear to have a prolonged survival time 
(Flaherty et al., 2006). Conversely, epithelial cell apoptosis is increased which leads to 
the further damage of basement membrane integrity and facilitates the migration of 
fibroblasts (Kuwano, 2007). Without restoration of the alveolar epithelium, the invasion 
of fibroblasts and myofibroblasts continues which results in excessive matrix deposition 
and finally the interstitial fibrosis.
In summary, it is generally held that acute or repeated lung injury leads to the loss of 
type I epithelial cells, proliferation of type II epithelial cells; recruitment of inflammatory 
cells with the release of pro-inflammatory and pro-fibrotic mediators. This causes the 
migration, proliferation and differentiation of fibroblasts, which leads to the formation of 
fibroblastic foci and results in the dramatic deposition of ECM in the lung parenchyma. 
It is thought that these events occur in a sequential, yet dynamic overlapping manner 
(reviewed in (Keane et al., 2005; Keane et ai, 2006).
1.2.1 Role of inflammation in pulmonary fibrosis
As mentioned in Section 1.2 the theory of the pathogenesis of pulmonary fibrosis has 
shifted during the last decade, and a major debate surrounded is still about the role of
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inflammation in pulmonary fibrosis, particularly in patients with IPF. Evidence for the 
critical involvement of inflammation in pulmonary fibrosis was mainly based on 
observations obtained with animal models of pulmonary fibrosis, where inflammation 
plays a critical role in the development of pulmonary fibrosis. However, this notion has 
now been challenged and the contribution of inflammation to the development of all 
forms of pulmonary fibrosis remains a controversial issue.
It has been suggested by Selman and colleagues that inflammation plays little or no 
role in the pathogenesis of IPF (Selman et al., 2001). Selman and colleagues also 
proposed that pulmonary fibrosis is rather a result of epithelial micro-injury and 
abnormal wound healing with cross-talk between epithelial and fibroblastic cells. This is 
based on the observations that only mild inflammation is seen in lung sections from 
patients with IPF. This theory is also supported by studies in some animal models of 
lung fibrosis. For example, over-expression of the potent pro-fibrotic mediator TGF-p 
has been found to cause progressive fibrosis in mice without any significant 
involvement of inflammation (Sime et a/., 1997). In addition, mice lacking the avp6 
integrin, a critical component for TGF-p activation, develop significant inflammation, but 
fail to progress to fibrosis after bleomycin injury. It therefore seems that inflammation 
may not be necessary to the development of fibrosis. As mentioned previously in 
Section 1.1, this may explain why anti-inflammatory treatment has no beneficial effect 
for patients with pulmonary fibrosis (Raghu, 2006). In conclusion, the evidence 
mentioned above suggests that inflammation is a minor participant for the development 
of some forms of lung fibrosis.
This hypothesis is criticized by researchers who believe that this theory has 
fundamentally ignored the natural history of the pathogenesis of UIP and the “so-called 
evidence" is not convincing (Strieter, 2002). First, this notion is based on observations 
from single biopsy specimen, and these biopsies represent established disease with 
evidence of end-stage fibrosis. Second, in studies with over-expression of TGF-p in 
mice, supply of superphysiological concentrations of TGF-p has bypassed 
inflammation-induced TGF-p expression. As suggested by studies by Lawrence and 
colleagues, TGF-p is necessary for the resolution of inflammation (Lawrence et ai., 
2001), it is therefore possible that expression of physiologically relevant TGF-p may not 
lead to fibrosis. Indeed, studies with transient overexpression of IL-ip have 
demonstrated that the sustained production of TGF-p and the development of fibrosis 
are caused by local production of proinflammatory cytokines and a vigorous 
inflammatory response (Kolb eta/., 2001). This suggests that inflammation is important
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in initiating the fibrotic response but, perhaps, not necessary to sustain this process. 
Finally, the failure of anti-inflammatory treatment may be due to the fact that the 
patients have already developed end-stage disease. In contrast, Flaherty and 
colleagues (Flaherty et al., 2001b) strongly propose that inflammation is a necessary 
event in pulmonary fibrosis based on observations that the patterns of UIP and NSIP 
between lobes co-exist in the same patient in 26% of all patients investigated. This 
study supports the concept of an evolving process from inflammation to fibrosis since 
NSIP is characterized by chronic interstitial inflammation. Animal models of fibrosis 
also demonstrate that the inflammatory response precedes the fibrotic response 
(Chandler, 1990; Christensen et al., 1999). In addition, an influx of inflammatory cells 
has been detected in bronchoalveolar lavage fluid (BALF) and in lung biopsies from 
patients with IPF during the exacerbation period, indicating the role of inflammation in 
pulmonary fibrosis (Parambil et al., 2005; Kim et al., 2006). A very recent review by 
Bringardner and colleagues proposed that inflammation plays a critical, but 
untraditional role in pulmonary fibrosis (reviewed in (Bringardner et al., 2008). In 
conclusion, it is likely that inflammation and fibrotic responses may both be important 
mechanisms leading to self-perpetuating fibrosis.
1.3 Mediators of pulmonary fibrosis
A number of mediators such as cytokines, growth factors and coagulation proteinases 
have been shown to either directly or indirectly be involved in the fibrotic process. 
These cytokines and growth factors, produced by multiple cell types, including 
epithelial, endothelial cells, fibroblasts/myofibroblasts and inflammatory cells during the 
process of pulmonary fibrosis, can in turn activate and mediate interactions between 
these cells as shown in Table 1.3. The following section briefly describes the mediators 
currently known to have the greatest impact on pulmonary fibrosis.
1.3.1 Transforming growth factor-p (TGF-p)
There are three distinct TGF-p isoforms (TGF-P^) in humans and TGF-p! is the most 
widely examined isoform in the context of experimental lung fibrosis (Eickelberg et at,
1999). TGF-Pi is one of the key profibrotic mediators identified in animal models and 
patients with fibrotic lung disease (Khalil et at, 1991; Khalil et ai, 1996). Increased 
TGF-p mRNA and protein levels have been demonstrated in IPF (Broekelmann et at, 
1991). It is important to note that TGF-p localization may vary according to the disease 
stage, with localization to macrophages in early stage and to type II pneumocytes and 
fibroblastic foci at later stages (Khalil and Greenberg, 1991). TGF-p is the most potent 
inducer of collagen production characterised to date, and it promotes the differentiation
28
Chapter 1 Introduction
of fibroblasts into highly-activated myofibroblasts (Zhang et al., 1996), it also plays a 
role in the differentiation of myofibroblasts from alveolar epithelial cells (Willis et al.,
2005). Moreover, in animal models of pulmonary fibrosis, TGF-3 mRNA levels correlate 
with collagen expression (Hoyt and Lazo, 1988) and overexpression of TGF-3 by 
adenoviral gene transfer leads to prolonged and severe interstitial and pleural fibrosis 
(Sime et al., 1997). Finally, TGF-3 may also contribute to fibrosis by inducing AEC 
apoptosis (Flaherty et al., 2004).
1.3.2 Connective tissue growth factor (CTGF)
CTGF is highly expressed in the bleomycin model of lung fibrosis (Lasky et al., 1998) 
and in patients with IPF (Kelly et al., 2006). Although the mechanisms by which CTGF 
contributes to the development of lung fibrosis is currently poorly understood, there is 
evidence that CTGF exerts pro-fibrotic effects by directly stimulating fibroblast function 
and overexpression of CTGF has been shown to induce a mild and transient fibrotic 
response in mice (Bonniaud ef al., 2003). In addition, CTGF may also contribute to 
fibrosis by acting as a downstream mediator of TGF-3, with a particular role in 
stimulating fibroblast matrix production and differentiation (reviewed in (Leask and 
Abraham, 2003)).
1.3.3 Tumour Necrosis Factor-a (TNF-a)
TNF-a is a potent pro-inflammatory and pro-fibrotic cytokine. In vitro studies have 
shown that TNF-a promotes inflammatory cell recruitment and the induction of other 
pro-inflammatory cytokines (Smith etal., 1998). In human fibrotic lung disease, TNF-a 
expression is unregulated in the lungs of patients with IPF (Zhang et al., 1993). In 
animal models, overexpression of TNF-a results in an initial inflammation followed by 
fibrogenesis with TGF-3 upregulation, fibroblast accumulation and extracellular matrix 
deposition (Sime et al., 1998). However, TNF-a may play a dual role in fibrosis as it 
appears to limit the fibrogenic response at later stages (Fujita et al., 2003). In addition, 
TNF-a promotes normal and fibrotic fibroblast apoptosis (Frankel et al., 2006).
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Mediators Major Biological Activities
Major
Targets
Proliferation Chemotaxis Collagen
Synthesis
Fibrogenic
TGFp! Fibroblast ± + ++ ++
PDGF Fibroblast ++ + + +
FGF2 Fibroblast + + + +
TGFa Fibroblast + 0 + +
TNFa Fibroblast + 0 + +
IL-1 Fibroblast + 0 + +
IL-4 Fibroblast + + + +
IL-5 Eosinophil + + + +
IL-10 Fibroblast - + - ±
IL-13 Fibroblast + - + +
IGF-1 Fibroblast + - + +
IFNy Fibroblast - + - -
IL-8 Macrophage + - + +
CCL2/MCP-1 Macrophage - + + +
MIP-1a Macrophage - + + +
CTGF Fibroblast + + + +
Thrombin Fibroblast ++ + + ++
FXa Fibroblast ++ n/k + ++
Table 1.3 Major mediators and their potential roles in lung repair and fibrosis (Modified and 
updated from (Gharaee-Kermani et al., 2007)). ++, major role or strongly stimulatory; +, 
stimulatory; inhibitory; ±, variable-concentration-dependent; 0, no effect; n/k, not known.
1.3.4 Th1 and Th2 cytokines
There is accumulating evidence indicating that a shift from a type 1 (Th1: IL-2, IL-12, 
IL-18, IFN-y) to a type 2 (Th2: IL-4, IL-5, IL-10, IL-13) cytokine profile is likely to be a 
key event in the progression of inflammation to fibrosis (Thannickal et al., 2004). Th2 
cytokines are pro-fibrotic by activating fibroblasts (Piguet et al., 1996; Gharaee- 
Kermani and Phan, 2001). Th2 cytokines are linked to lung fibrosis in animal models,
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although a functional link in humans is still lacking (Antoniou et al., 2005). The 
opposing effects of Th1 and Th2 cytokines in fibrosis are supported by several 
investigations. For instance, Th2 cytokines such as IL-4 and IL-13 promote fibrosis by 
stimulating fibroblast collagen synthesis (Oriente et a/., 2000; Saito et al., 2003), 
whereas the Th1 cytokine IFN-y inhibits fibroblast function and procollagen synthesis 
(Diaz and Jimenez, 1997).
As the work in this thesis is focused on thrombin-induced CCL2 release, the role of 
thrombin and CCL2 in the pathogenesis of pulmonary fibrosis will be described in detail 
in Section 1.5 and Section 1.8, respectively.
1.4 Fibroblasts and pulmonary fibrosis
As already alluded to, fibroblasts migrate to the site of injury and produce extracellular 
matrix under the control of a host of mediators (Table 1.3) produced by inflammatory 
cells, injured and regenerating epithelial cells and fibroblasts themselves. 
Fibroblasts/myofibroblasts are major source of ECM, and the continued invasion of 
fibroblasts with enhanced ability of ECM generation play a critical role in accelerating 
the process of pulmonary fibrosis.
1.4.1 Origin of fibroblasts in pulmonary fibrosis
Fibroblasts are abundant cells in the lung. It has been reported that fibroblasts account 
for 35-50% of cells in the lung interstitium, and this number increases in the lungs of 
patients with pulmonary fibrosis (Jordana et al., 1994). Embryologically, fibroblasts are 
believed to be of mesenchymal origin and were originally thought to replenish 
themselves by proliferation of local fibroblast populations resident in the lung 
parenchyma during wound healing (Serini and Gabbiani, 1999). In recent years, 
however, this notion has been challenged. More recent studies suggest that fibroblasts 
may be derived from a variety of other sources, at least following injury and in fibrotic 
disease. These sources include epithelial cells that undergo transdifferentiation to form 
fibroblasts by a process known as epithelial-mesenchymal transition (EMT), as well as 
circulating fibrocytes and bone marrow-derived mesenchymal stem cells (Abe et al., 
2001; Kalluri and Neilson, 2003; Phillips eta!., 2004).
1.4.1.1 Epithelial-mesenchymal transition
More than 20 years ago, studies by Greenburg and Hay first proposed the possible 
interconversion between epithelial and mesenchymal cells based on the evidence that 
epithelial cells in culture acquire mesenchymal features (Greenburg and Hay, 1982).
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This process is now well-recognized as EMT. EMT is a process whereby epithelial cells 
lose their characteristic markers such as E-cadherin and zona occludens-1 resulting in 
the subsequent loss of polarity. Consequently, the epithelial cells become non­
polarized with remodeled mesenchymal stress fiber and acquire mesenchymal makers 
such as fibroblast specific protein (FSP)-1 and a-smooth muscle actin (a-SMA) (Zavadil 
and Bottinger, 2005). Emerging evidence has now pointed to a role for EMT in fibrotic 
lung diseases such as IPF (Kalluri and Neilson, 2003). It has been shown that AEC can 
undergo EMT in response to TGF-pi stimulation (Willis et al., 2005), and this has also 
been shown in experimental animal studies where epithelial-derived mesenchymal 
cells in TGF-pHnduced fibrosis have been identified (Kim et al., 2006). More 
importantly, studies have identified cells in IPF biopsy samples that co-express 
epithelial and mesenchymal markers, providing strong evidence of EMT during the 
development of lung fibrosis (Willis and Borok, 2007).
1.4.1.2 Fibrocytes in pulmonary fibrosis
Fibrocytes were first described over a decade ago as a population of cells with 
fibroblast-like properties (Bucala et al., 1994). Fibrocytes are defined as circulating 
stem cells derived from bone marrow, which express both leukocyte and mesenchymal 
markers, including CD45, CD34 and collagen I (Bucala et al., 1994; Moore et al., 2005). 
These cells are spindle-shaped and distinguished from monocytes/macrophages, 
dendritic cells and B cells by the lack of specific marker protein expression. Fibrocytes 
represent approximately 0.5% of the peripheral blood leukocyte population and can 
produce fibroblast specific products, such as collagen I, III, and fibronectin (Abe et al.,
2001).
These circulating fibrocytes may serve as a source of fibroblasts in the lung and the 
recruitment of fibrocytes to the lung may be an important factor in the development of 
fibrotic responses, although this is still controversial (Gomperts and Strieter, 2007). 
Fibrocytes have been shown to transit into fibroblasts in culture, suggesting that these 
cells may serve as the circulating precursors for fibroblasts (Schmidt et al., 2003; 
Phillips et al., 2004; Moore et al., 2005). A pathogenic role for fibrocytes in pulmonary 
fibrosis has been postulated from experimental models in which blockade of fibrocyte 
recruitment is protective following both bleomycin and fluorescein isothiocyanate 
challenge (Phillips et al., 2004; Moore et al., 2005; Moore et al., 2006). Evidence to 
support the role of fibrocytes in patients with fibrotic interstitial lung disease has been 
recently provided by Mehrad and colleagues (Mehrad et al., 2007). This study 
demonstrated that the number of fibrocytes in peripheral blood has been upregulated in
32
Chapter 1 Introduction
patients compared with healthy volunteers, suggesting that fibrocytes may be involved 
in the process of pulmonary fibrosis in humans.
It is important to note that fibrocytes express a number of chemokine receptors, 
including CCR2, CCR7, and CXCR4. The recruitment of fibrocytes to the site of injury 
is therefore likely mediated via chemokine and chemokine receptor interaction. Indeed, 
studies have demonstrated that inhibition of CCR2, CCR7, and CXCR4 has been 
shown to be protective in experimental lung fibrosis model and is accompanied by a 
reduction of the number of fibrocytes, suggesting that these receptors mediated signals 
may all serve to recruit fibrocytes to the lung (Abe et al., 2001; Schmidt et al., 2003; 
Phillips et al., 2004; Moore et al., 2005). Of particular interest, CCR2 is a receptor for 
CCL2, CCL7 and CCL12, in which CCL12 is only found in mouse and it is the 
functional homologue of human CCL2 (Moore ef al., 2006). As CCL2 is the main focus 
of this thesis, the role of CCL2 in fibrocyte recruitment will be discussed in more detail 
in Section 1.8.
Although fibroblasts can be derived from a variety of sources, the relative contribution 
of each of these sources to the fibrotic response are currently a topic of intense debate 
due to the potential implications for therapy in would healing and fibrosis.
1.4.2 Fibroblast function in pulmonary fibrosis
1.4.2.1 Extracellular matrix deposition
Fibroblasts are primarily responsible for maintaining the structural integrity of the 
airways and lung parenchyma by producing a variety of ECM components, such as 
collagen, laminin, fibronectin, hyaluronic acid and proteoglycans. In pulmonary fibrosis, 
these components are upregulated by mechanisms that alter the synthetic and 
degradative processes responsible for increased collagen deposition by fibroblasts. For 
example, increased number of fibroblasts at the site of injury leads to the excessive 
deposition of ECM. This may be caused by enhanced fibroblast migration as suggested 
by studies showing that fibroblasts derived from fibrotic lungs exhibit an enhanced 
migratory phenotype (Suganuma ef al., 1995). Increased fibroblast numbers at sites of 
injury may also be the consequences of increased proliferation and reduced apoptosis. 
Studies have demonstrated that fibroblasts derived from fibrotic lungs show higher 
proliferating capacity and are more resistant to apoptosis when compared with 
fibroblasts derived from normal lung (Raghu et al., 1988; Ramos et al., 2001; Moodley 
et al., 2004). In addition, fibroblasts/myofibroblasts isolated from IPF lungs exhibit an 
increased synthetic capacity for collagen and other ECM components compared to
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fibroblasts from normal lung (Hetzel ef al., 2005). As already mentioned in Section 1.3, 
a number of mediators are released after lung injury and these mediators stimulate 
fibroblasts to transdifferentiate into contractile, activated myofibroblasts, which 
synthesize and deposit abundant ECM proteins, such as type I and III collagens (Phan, 
2002). These mechanisms all contribute to the excessive deposition of ECM in the 
fibrotic lung.
ECM degradation is regulated by matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs). MMPs are responsible for ECM degradation, 
whilst TIMPs are endogenous inhibitors of MMPs. In pulmonary fibrosis, the imbalance 
between MMPs and TIMPs is another important mechanism leading to the excessive 
deposition of ECM. Studies have shown that TIMPs are more widely distributed than 
MMPs in the lungs from IPF patients (Selman et al., 2000). Furthermore, there is 
decreased production of MMPs and increased production of TIMPs by fibroblasts 
derived from IPF patients compared with fibroblasts derived from normal lung (Selman 
et al., 2000; Ramos et al., 2001). These studies suggest that there is a prevailing non- 
degradative microenvironment in the lungs of patients with IPF.
1.4.2.2 Production of inflammatory and fibrotic mediators
Fibroblasts were thought to be passive participant in tissue repair through their end 
stage production of extracellular matrix proteins. Although the elaboration of matrix is a 
key factor in fibrosis, the roles of fibroblasts and myofibroblasts likely extend beyond 
the production of ECM proteins. It appears that these mesenchymal cells are not just 
the primary cellular source of collagen, but also a major source of inflammatory and 
fibrogenic cytokines in pulmonary fibrosis (Jordana et al., 1994). These cells express 
fibrogenic cytokines, chemokines, growth factors and their receptors, adhesion 
molecules, and are able to recruit and activate inflammatory cells (please see Table 1.3) 
(Phan, 2002). For example, IL-8 , the member of CXC chemokine family generated by 
macrophages, is an activator and chemoattractant for neutrophils. IL-8 has been 
identified as a marker implicated in the development of airway inflammation and a 
major contributor to the neovascularisation in fibrotic diseases (Lynch et al., 1992; 
Bonfield et al., 1995; Nocker et al., 1996; Keane et al., 1997). Surprisingly, studies 
have demonstrated that the major source of this important inflammatory chemokine 
was the interstitial fibroblast rather than the macrophage (Keane et al., 1997), further 
supporting the important role of fibroblasts in inflammation.
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In addition, fibroblasts may also contribute to the production of mediators via its 
interaction with other inflammatory and immune cells. There is abundant evidence that 
the interaction between fibroblasts and these cells is bi-directional. For example, 
macrophage inflammatory protein 1a (MIP-1a) production by macrophage was found to 
be markedly increased when these macrophages were co-cultured with fibroblasts 
(Steinhauser et al., 1998). T cells can modulate fibroblast proliferation and collagen 
synthesis by generating IL-4. On the other hand, studies have demonstrated that 
fibroblasts can also mediate the activation state of T cells (Hogaboam et al., 1998b). 
For example, enhanced release of adhesion molecules and cytokine production by T 
cells is caused by the interaction between fibroblasts and T cells, such as VCAM-1 and 
IL-6 (Bombara eta/., 1993).
Finally, generation of these mediators by fibroblasts directly or indirectly can in turn 
stimulate fibroblasts via autocrine mechanism which further exaggerates profibrotic 
effects of fibroblasts such as proliferation, differentiation and matrix deposition.
1.4.2.3 Cross-talk between fibroblasts and epithelial cells
Epithelial and mesenchymal cell interaction is important in lung development, and the 
tight regulation of epithelial and mesenchymal cell functions is necessary for normal 
alveolarization (Hogan and Yingling, 1998). Current hypotheses propose that abnormal 
interaction between epithelial cells and fibroblasts may play an important role in the 
pathogenesis of pulmonary fibrosis by preventing resolution of wound repair (reviewed 
in (Horowitz and Thannickal, 2006)). For example, re-epithelialisation after injury is 
essential for would healing and excessive AEC apoptosis interrupts this process and 
therefore plays a critical role in the pathogenesis of pulmonary fibrosis. Studies of IPF 
tissue have shown that AEC apoptosis is increased in cells adjacent to fibroblastic foci, 
suggesting that fibroblasts/myofibroblasts may play a role in epithelial cell apoptosis 
(Uhal et al., 1998; Barbas-Filho ef al., 2001). Indeed, fibroblasts/myofibroblasts derived 
from patients with IPF have been found to induce human AEC apoptosis by secreting 
soluble factors such as angiotensin peptides (Uhal et al., 1995; Wang et al., 1999). In 
addition, excessive proliferation of fibroblasts contributes to fibrosis and this can be the 
result of reduced inhibitory effects of epithelial cells on fibroblasts. It is well known that 
cyclooxygenase-2 (COX-2) derived prostaglandin E2 (PGE2) plays an important role in 
pulmonary fibrosis by inhibiting fibroblast proliferation and procollagen gene expression 
(Wilborn et al., 1995; Moore et al., 2003; Hodges et al., 2004). Studies have 
demonstrated the reduced expression of COX-2 in bronchial epithelial cells in patients 
with IPF (Petkova et al., 2003).
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Taken together, these findings support the concept that the fibroblast is a major 
effector cell in mediating lung fibrosis by synthesizing ECM components and 
inflammatory mediators, as well as displaying abnormal interactions with epithelial cells.
1.5 Role of the coagulation cascade in pulmonary fibrosis
The coagulation cascade is a complex and highly regulated proteolytic system with its 
prime function of generating insoluble, cross-linked fibrin strands which bind and 
stabilize the weak platelet haemostatic plug, formed at the sites of injury. The 
coagulation cascade is now gaining recognition as a multifunctional signalling system 
implicated in a number of physiological and pathophysiological events, including 
pulmonary fibrosis. There is increasing evidence that the coagulation cascade plays an 
important role in pulmonary fibrosis as activation of the coagulation cascade has been 
demonstrated to be a characteristic feature of several fibroproliferative lung disorders in 
humans and in animal models (Chapman et al., 1986; Kotani et al., 1995; Chambers, 
2003, 2008).
1.5.1 Activation of the coagulation cascade
One of the earliest events following tissue injury is the activation of the coagulation 
cascade. The coagulation cascade is activated when damage to the vascular network 
of the lung occurs from both external and internal insults. The classical model of blood 
coagulation involves a cascade of zymogen activation reactions via two highly 
regulated pathways, namely the extrinsic and intrinsic coagulation pathways (Figure 
1.2 ).
The coagulation proteinases of both pathways circulate in the plasma as inactive 
zymogens and the majority of zymogens are activated by limited proteolysis. At each 
stage, a precursor protein is converted to an active proteinase by cleavage of one or 
more peptide bonds in the precursor molecule. Both extrinsic and intrinsic pathways 
activate the “common pathway” via FX activation. The final proteinase generated is 
thrombin. Activated thrombin then mediates the aggregation of platelets and the 
conversion of fibrinogen to fibrin; hence a stable clot consisting of aggregated platelets 
enmeshed in fibrin is formed and temporarily plugs damaged vessels.
The extrinsic pathway is felt to be the main mechanism leading to the activation of the 
coagulation cascade in vivo. However, the final production of thrombin triggered by the 
extrinsic pathway is limited. In order to maintain coagulation, thrombin synthesized 
through the initial TF/FVIIa/FXa ternary complex catalyses the activation of FXI, FIX,
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FVIII and FX. This leads to the initiation of intrinsic pathway which results in the 
prolonged generation of the prothrombinase complex, a major burst in thrombin activity, 
and subsequent sustained blood coagulation via dramatic amplification of the original 
signal (reviewed in (Chambers, 2008)). It is therefore concluded that initial activation of 
the extrinsic pathway following vascular injury generates limited amounts of thrombin, 
which in turn triggers the initiation of the intrinsic pathway where the coagulation is 
maintained by the dramatic amplification of the initial signal.
Extrinsic pathway
Trauma
Vila VII
Tissue factor
Intrinsic pathway
Damaged
surface
ThrombinProthrombin 
«)
F ib r in
Antithrombin
Common
pathway
Activted protein C 
Protein S
a
Protein C + 
Thrombomobudin
Cross-linked 
fibrin clot
Figure 1.2 The coagulation cascade. This figure shows the activation of coagulation 
proteinases leading to the generation of thrombin via both the extrinsic and intrinsic pathways 
TFPI: tissue factor pathway inhibitor. the inhibitory pathway; the positive feedback.
The coagulation cascade is tightly regulated by both negative feedback mechanisms as 
shown in figure 1.2, and by locally produced and circulating endogenous 
anticoagulants. The major anticoagulants include tissue factor pathway inhibitor (TFPI), 
antithrombin, and the thrombin-thrombomodulin protein C system The major 
proteinase inhibitor of the extrinsic pathway is TFPI which targets the TF-Vlla-FXa
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transient ternary complex. Antithrombin regulates the intrinsic pathway by irreversibly 
neutralizing serine proteinases in the presence of heparin. The thrombin- 
thrombomodulin-protein C system is initiated when thrombin binds to thrombomodulin 
on the vascular endothelium. Thrombin then rapidly activates protein C to activated 
protein C (APC), which can be further enhanced by the activation of endothelial cell 
protein C receptor (EPCR). Following its subsequent release from the cell surface, 
APC binds to protein S and inactivates FVa and Villa in order to inhibit further thrombin 
generation. Other physiological inhibitors include heparin cofactor II, proteinase nexin-1, 
a2-macroglobulin, a 1-antitrypsin, and protein Z-dependent proteinase inhibitor. Heparin 
cofactor II and proteinase nexin-1 mainly target thrombin, and protein Z-dependent 
proteinase inhibitor target FXa, whereas a2-macroglobulin and a 1-antitrypsin inhibit 
thrombin, FIXa, Xa and Xla (reviewed in (Chambers, 2008)).
1.5.2 Evidence for the involvement of the coagulation cascade in pulmonary 
fibrosis
Excessive activation of the coagulation cascade has been implicated in promoting lung 
inflammation and subsequent interstitial and alveolar fibrosis (Chambers and Laurent,
2002). Levels of procoagulant factors are elevated in a number of fibroproliferative lung 
disorders in humans and in animal models. For example, levels of active thrombin are 
increased in BALF from patients with lung diseases characterized by remodeling, 
including systemic sclerosis, chronic lung disease of prematurity, and asthma 
(Hernandez-Rodriguez ef a/., 1995; Gabazza et al., 1999; Dik et al., 2003), and in 
animal models of acute and chronic lung injury (Tani et al., 1991; Huang et al., 2001). 
Several other procoagulant factors including fibrinogen, FVII and FX have also been 
identified in patients with intra-alveolar fibrosis associated with organizing pneumonia 
(BOOP) (Peyrol ef al., 1990). Similarly, tissue factor VII A/I la complexes have been 
identified in BALF from patients with ARDS (Idell et al., 1989). In addition, TF 
expression is upregulated in the lungs of patients with IPF and systemic sclerosis 
(Imokawa ef al., 1997). More importantly, FX has recently been shown to be 
upregulated and locally produced in IPF patients in recent studies performed in our 
laboratory (Krupiczojc ef al., in revision).
A number of studies have raised the possibility that excessive activation of the 
coagulation cascade in fibrotic and proliferative lung diseases may be the consequence 
of decreased production of anti-coagulant factors. For example, decreased protein C 
activation is found to be associated with abnormal collagen turnover in patients with 
interstitial lung disease (Yasui et al., 2000). There is also evidence that the protein C
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pathway is deficient in the lungs of patients with IPF and sarcoidosis, as well as 
collagen vascular disease-associated interstitial lung disease (Kobayashi et al., 1998). 
Plasma and intra-alveolar protein C levels are also decreased in patients with 
ALI/ARDS (Ware ef al., 2007). Similarly, levels of endogenous anticoagulants such as 
antithrombin in patients with ARDS have been found to be reduced (Gando et al.,
2003).
A central role for the coagulation cascade in the pathogenesis of pulmonary fibrosis 
has been demonstrated by studies showing that blockade of this cascade is protective 
in experimental lung fibrosis. For example, previous work in our laboratory has shown 
that direct thrombin inhibition leads to a significant reduction in lung collagen 
accumulation in the bleomycin model of lung injury and fibrosis (Howell et al., 2001). 
Heparin, which inhibits local activation of coagulation proteinases by potentiating the 
formation of antithrombin lll-serine proteinase complexes, has been shown to improve 
gas exchange in an animal model of acute lung injury and attenuate pulmonary fibrosis 
in the bleomycin mouse model (Piguet et al., 1996; Abubakar et al., 1998). Similarly, 
intratracheal instillation of the endogenous anticoagulant APC has also been shown to 
be protective in the bleomycin model (Yasui etal., 2001). More recently, it was reported 
that intratracheal gene transfer of TFPI decreases bleomycin-induced thrombin 
generation and pulmonary fibrosis in rats (Kijiyama et al., 2006). In humans, a recent 
multicenter study demonstrated that anti-coagulant treatment has a beneficial effect on 
survival in IPF patients (Kubo et al., 2005). The patient selection in this study is 
controversial but the outcome supports the importance of the role of coagulation 
cascade in pulmonary fibrosis. Taken together, these data support the notion that TF- 
mediated coagulation in the extravascular intra-alveolar space is important and that 
anticoagulant therapy could be beneficial.
As previously mentioned, the coagulation cascade primarily promotes haemostasis at 
sites of vascular injury by generating a stable, insoluble, cross-linked fibrin blood clots. 
In pulmonary fibrosis, however, it mediates a number of cellular responses that may 
play critical roles in the pathogenesis of this disease (reviewed in (Chambers, 2008)). 
Most of these cellular effects are mediated by a unique family of ubiquitously 
expressed receptors, termed proteinase-activated receptors (PARs) (Vu et al., 1991). 
These effects and receptors will be discussed in the forthcoming sections in detail.
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1.6 Proteinase-activated receptors
The PARs belong to the superfamily of G-protein coupled receptors (GPCRs) with 
seven transmembrane domains, and are activated via proteolytic cleavage by 
proteinases (Dery etal., 1998; Coughlin, 2000; Macfarlane et al., 2001; Hollenberg and 
Compton, 2002). There are currently four members (PARi^) in this family (Table 1.4). 
Collectively, the proteinases of the coagulation cascade can activate all four members 
of the PAR family. In addition, a recent report has suggested that PARi can be 
activated by the matrix metalloproteinase, MMP1 (Boire et al., 2005). The mechanisms 
for PAR activation will be discussed in detail in Section 1.6.1. Our current 
understanding on the major activators, pharmacology, expression patterns, and major 
G protein signalling pathways of the PARs is summarized in Table 1.4.
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PAR* p a r * p a r 3 PAR*
Activating
Proteinases
Thrombin, 
APC/EPCR, 
FVIIa/TF/FXa,Trypsin 
;Plasmin; Cathepsin 
G;MMP-1
Trypsin,
Tryptase,
FVIIa/TF/FXa
Matriptase/MT-
serine
Thrombin
Trypsin
Thrombin 
Trypsin, 
FVI!a/X 
Cathepsin G
Tethered ligand SFLLRN (h) 
SFFLR (m, r)
SLIGKV (h) 
SLIGRL (m, r)
TFGRAP((h)
SFNGGP(m)
GYPGQV(h)
GYPGKV(m)
Antagonists RWJ-5611 
RWJ-58259 
SCH 530348 
SCH 79797
ENMD-1068 YD-3
Inhibitory
proteinases
Cathepsin G 
Elastase, Chymase
Elastase,
Chymase
Cathepsin G Unknown
Chromosoal
Location
5q13 5q13 5q13 19p12
Cleavage site Arg41-Ser42 Arg36-Ser37 Lys38-Thr39 Arg47-Gly48
Hirudin-like 
binding site
Yes No Yes No
PAR-Coupled-G
proteins
G q/n, Gj/o, G12/13, Gpv Gq/11, Gj, G12/13 Gq, G 0 G12/13, Gq
Expression in 
the lung
Airways, blood 
vessels, lung 
parenchyma
Airways, blood 
vessels, 
bronchial 
glands, lung 
parenchyma
Airways Airway, blood 
vessels, 
cardiovascular 
system
Table 1.4 Pharmacology and characteristics of proteinase-activated receptors (Macfarlane 
et al., 2001; Steinhoff et al., 2005; Chambers, 2008; Jeong et al., 2008). The letters denote the 
amino acid sequences of peptides in one letter code: APC/EPCR, activated protein C and 
endothelial cell protein C receptor (cofactor) complex; h, human; m, mouse; r, rat.
1.6.1 Mechanisms of PAR activation
Most GPCRs are activated reversibly by small hydrophilic molecules to elicit cellular 
responses (Wettschureck and Offermanns, 2005). Unlike classical GPCRs, the PARs 
on the other hand are, in essence, peptide receptors that effectively carry their own 
ligands which are recognized by specific proteinases. These unique activation sites lie 
hidden until revealed by receptor cleavage. Cleavage of their extracellular N-terminus 
by proteinases generates a new N-terminus that acts as an intramolecular ligand by 
interacting with the second extracellular loop of the receptor. This induces a
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conformational shape change, which enables the receptor to interact with 
heterotrimeric G proteins and initiate downstream signalling responses (Figure 1.3).
Protease
Tethered Ligand
<111111
PAR GTP m
Cell Signalling
Wl
Cellular responses
Figure 1.3 Mechanism of activation of PAR,. Figure shows cleavage of a 41 amino-acid 
sequence from the N-terminus of the receptor by the coagulation proteinase binding to this 
region. An intrinsic tethered ligand is then unmasked and is able to interact with the second 
extracellular loop of the receptor. This in turn leads to a conformational change at the C- 
terminus followed by the association with heterotrimeric G-proteins. The interaction between the 
receptor and G-proteins initiates cell signalling and subsequently leads to a number of cellular 
responses.
The tethered ligand mechanism of activation is not the only feature to separate PARs 
from other GPCRs, the sequence of this proteolytically revealed tethered ligand has 
also become the most clear-cut molecular characteristic that distinguishes one PAR 
from another. This has lead to the development of short synthetic activating peptides 
corresponding to the tethered ligand integral to the receptor. These short synthetic 
peptides can experimentally activate PARs in vitro without the need for proteolysis (Vu 
et al., 1991; Scarborough et al., 1992). Although they are generally less efficient than 
the in vivo physiological activators (proteinases) of the PARs, these PAR-activating 
peptides have become valuable tools to identify the involvement of receptors in 
functional studies in systems where more than one PAR receptor is expressed.
Although activation of PAR receptors mainly involves the stimulation by proteinases; 
PAR receptors can also activate each other under certain circumstances. This 
intermolecular activation between PARs occurs when more than one PAR is present.
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For example, PAR2 is cleaved and activated by trypsin and tryptase. It cannot be 
activated by thrombin directly and was assumed to play no role in thrombin-triggered 
signalling events. This concept has now been challenged by studies suggesting that 
PAf^ cleaved by thrombin can transactivate PAR2 (O'Brien et al., 2000). Evidence for 
this transactivation mechanism was obtained in studies performed with COS-7 ceils co- 
expressing PAR2 with a PARt mutant that can be cleaved, but not activated by 
thrombin. The experiments showed that neither the PAR! mutant nor intact PAR2 
responded to thrombin when expressed alone in COS-7 cells. However, robust 
signalling arose in response to thrombin when the cells were transfected with both 
constructs and the signal was nearly half that seen in cells expressing wild type PAR1 
alone. This study strongly demonstrated that PAR2 can be transactivated and may also 
contribute to thrombin signalling.
The ability of PAR3 to generate intracellular signal remains in doubt since it lacks the 
cytoplasmic tail domain which couples to G proteins in other PARs (Ishihara ef al., 
1997). However, increasing evidence suggests that PAR3 can play a cofactor-like role 
in the cleavage of other PARs and participate in signalling. For example, in mouse 
platelets, PAR3 was shown to assist efficient cleavage of PAR4 by thrombin (Nakanishi- 
Matsui et al., 2000). This study showed that co-expression of mPAR3 (murine PAR3) 
and mPAR4 accelerated the rate of thrombin-induced mPAR4 cleavage and mPAR4 can 
be activated by thrombin at much lower EC50 than if mPAR4 is expressed alone. In 
addition, PAR3 can also function as an important allosteric modulator for PARt 
signalling as suggested by recent studies by McLaughlin and colleagues (McLaughlin 
et al., 2007). Using bioluminescent resonance energy transfer-2 (BRET2), it was found 
that PARt and PAR3 may form constitutive heterodimers under physiological conditions. 
Upon activation, the PAR1/3 heterodimers induce signalling distinct from PAR^i 
homodimers by increasing the PARt-Ga^ interaction. It is also worth mentioning that a 
most recent report demonstrated that PAR3 can mediate thrombin-induced IL-8 release 
in human embryonic kidney (HEK) cells (Ostrowska and Reiser, 2008a). However, 
whether PAR3 can signal on its own still remains controversial and further studies in 
other cell types, including fibroblasts are required.
The preferential activation of PARs may vary when a proteinase can activate multiple 
PARs and when these PARs are expressed at the same time. This variation has been 
seen for proteinases at different concentrations, such as thrombin, or in different cell 
types. For instance, both PAR1 and PAR4 can be activated by thrombin. However, 
PAR4 is much less sensitive to thrombin, with an EC50 for the proteinase approximately
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100-fold higher than the corresponding EC50 for PAR* (Major et al., 2003). Activation of 
PARi by thrombin is facilitated by the hirudin-like sequence towards the N-terminal end 
of PARi which can interact with thrombin’s anion-binding exosite. However, PAR4 lacks 
a hirudin-like binding sequence. Moreover, both the N- and C- termini of PAR4 are 
markedly different from the other receptors, as is the cleavage site. This may explain 
why thrombin is less efficient at activating PAR*. It has been suggested that PAR4 may 
serve as a co-receptor for PAR1 by sustaining the cellular effects of thrombin when 
PAR* becomes rapidly inactivated (Shapiro et al., 2000). In addition, recent studies in 
human platelets have reported the existence of PARi-PAR4 complex (Leger et al.,
2006). This study also provided evidence that PAR4 cleavage is accelerated on 
coexpression with PAR1( and its activity is markedly enhanced by thrombin-PARi 
interaction.
1.6.2 Regulation of PAR signalling
Activation of PARs by proteinases is an irreversible process and the tethered ligand will 
not diffuse away, which may therefore enable continuous activation. Once activated, 
the PARs need to be turned off to prevent indefinite signalling. On the other hand, the 
PARs also have to be replaced to re-establish sensitivity to proteinases. A number of 
mechanisms may contribute to the termination of PAR signalling. These include 
receptor inactivation, receptor desensitization, and receptor endocytosis (Dery et al., 
1998; Hollenberg and Compton, 2002; Ossovskaya and Bunnett, 2004).
1.6.2.1 Receptor inactivation
As shown in Table 1.4, PARs may be subject to proteolytic inactivation by proteinases 
such as cathepsin G and neutrophil elastase. These proteinases inactivate PAR* by 
cleaving the receptor at a specific site between the C-terminus and its tethered ligand, 
thus amputating the ligand from the receptor body. These deactivated receptors are 
refractory to proteinase activation, but still react to activating peptides (Renesto et al., 
1997).
1.6.2.2 Receptor desensitization
Receptor desensitization involves uncoupling the receptor from its G proteins and the 
downstream signalling pathways (Bohm et al., 1996). In this process, receptor-G 
protein interaction is effectively interrupted by receptor phosphorylation which leads to 
the termination of signal transduction. This process is mediated via two mechanisms 
involving in two classes of protein kinases. One is homologous receptor desensitisation 
which involves agonist-dependent phosphorylation of specific C-terminal residues of
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the receptor by G protein receptor kinases (GRKs) such as GRK3 (Ishii et al., 1994). 
These GRKs utilise proteins known as 3-arrestins as cofactors. The other mechanism 
is heterologous receptor desensitisation that occurs as a result of C-terminal 
phosphorylation by other intracellular protein kinases such as protein kinase C and A 
(Yan etal., 1998).
1.6.2.3 Receptor endocytosis and cycling
Following activation, PARs are recruited into clathrin-coated pits and internalised by 
endocytosis to be degraded intracellularly (Hoxie et al., 1993). Most of the internalized 
receptors are transferred to lysozomes rather than being recycled to the plasma 
membrane, like other GPCRs (Trejo and Coughlin, 1999). It has been shown that the 
process of lysosomal sorting is regulated by the cytoplasmic tail of PAR, (Brass et al., 
1994). It is also worth mentioning that some cleaved receptors are found to traffic back 
to the cell surface, and remain unresponsive to the same proteinase. However, these 
receptors are still sensitive to activation by the PAR activating peptides such as SFLLR 
in in vitro studies (Hammes and Coughlin, 1999).
1.6.2.4 Receptor resensitisation
The ability of a cell to regain responsiveness to PAR activation depends on both the 
replacement of new receptors from the intracellular receptor stores and the synthesis of 
new receptors (Dery ef a/., 1998). These mechanisms are cell-specific. For instance, 
cleaved PAR1 cannot be replaced in platelets because they lack an intracellular pool of 
intact receptors, and lack the ability to synthesize large amounts of protein (Coughlin,
2000). Hence, platelets cannot regain responsiveness following thrombin stimulation 
(Coughlin, 1999). In contrast, abundant intracellular stores of PARs have been reported 
in endothelial cells (Horvat and Palade, 1995), fibroblasts (Hein et al., 1994), and 
epithelial cells (Kong et al., 1997). These receptors are protected from extracellular 
proteinases and can be located to the cell surface to replace cleaved receptors without 
the delay needed to synthesize new receptors, although in all cell types, the major 
mechanism for receptor replenishment after prolonged exposure to activating 
proteinases is new receptor synthesis.
1.7 Proteinase-activated receptor-1 (PAR,)
PARi, the main high-affinity thrombin receptor, was the first PAR to be cloned and 
characterized. PAR, can also be activated by FXa, the ternary complex, TF/FVIIa/FXa 
(Riewald et al., 2001), APC (Riewald et al., 2002), and plasmin (Mandal et al., 2005). 
The efficient activation of PAR, by thrombin is facilitated by a hirudin-like binding
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domain C-terminus to the tethered ligand at N-terminus of PAR,. The attraction 
between this domain and thrombin’s anion binding exosite enables thrombin to 
effectively complex with PAR, and thus initiate cleavage of PARi. In contrast, efficient 
activation of PARi by FXa is facilitated by FXa complexing with TF and FVIIa at the site 
of its generation, which enables FXa to localize to the cell surface. In this regard, FXa 
is five times more potent at activating PARi compared to FXa alone (Riewald et al.,
2001). Similarly, APC utilizes cell surface EPCR as a cofactor to facilitate its activation 
of PARi (Riewald et ai, 2002).
PARi is widely distributed on a number of cell types, including human platelets, 
endothelial cells, epithelial cells, fibroblasts, smooth muscle cells, monocytes, 
lymphocytes, mast cells, T cells positive for CD8 , CD16, and either CD56 or CD57, 
natural killer cells, CD34+ haematopoietic progenitor cells, dental pulp cells, neurons, 
glial cells, mast cells, and certain tumour cell lines (Steinhoff et ai, 2005). Previous 
studies have shown that PARi knockout (KO) mice are protected from experimentally- 
induced glomerulonephritis (Cunningham et al., 2001), arthritis (Yang et ai, 2005), and 
cerebral infarction (Junge et ai, 2003). PARi antagonism was also found to be 
protective against experimental liver fibrosis (Fiorucci et ai, 2004). These studies 
clearly support the critical role of PARi in mediating responses to tissue injury. In 
contrast, one study showed that PARi KO mice are not protected in mouse models of 
endotoxemia where multiple PARs (PAR1j4) appear to be important for the crosstalk 
between inflammation and coagulation (Pawlinski et ai, 2004). It is therefore likely that 
the contribution of PARi to tissue inflammatory and fibrotic responses is both injury- 
and organ-specific. However, emerging evidence suggests that PAR, contributes to 
pulmonary fibrosis and PAR, may represent an attractive novel target for therapeutic 
intervention for both acute and chronic lung injury (reviewed in (Chambers, 2008)).
1.7.1 PARt in pulmonary fibrosis
Supporting evidence for the importance of PARi in pulmonary fibrosis has been 
provided by a recent finding from our laboratory that PAR, actively participates in acute 
inflammation and the chronic fibrotic phase of bleomycin-induced pulmonary fibrosis 
(Howell et ai, 2005). However, establishing the importance of this signalling receptor to 
human fibrotic lung disease remains challenging. Supportive evidence for the role of 
PAR, in human fibrotic lung disease was provided by the findings that PARi expression 
is up-regulated in lung tissues of patients with IPF (Howell et ai, 2001). Studies by 
Bogatkevich and colleagues have also shown that PARi is upregulated in lung tissues 
of patients in early and late stages of pulmonary fibrosis associated with scleroderma
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(Bogatkevich et al., 2005). In both cases, the upregulation of PARt was attributed to 
resident alveolar macrophages and to fibroproliferative foci where fibroblasts 
accumulate. The critical role of PAR! in human fibrotic lung diseases is also supported 
indirectly by studies employing cultured primary lung fibroblasts. Studies have shown 
that in cultured airway cells under normal conditions, PARt is the predominant receptor 
expressed by primary adult lung fibroblast (Sokolova et al., 2005), and endothelial cells 
(Fujiwara et al., 2004), indirectly suggesting the importance of PARi in the pathological 
situations in the lung since these cells are important effector cells in the process of 
pulmonary fibrosis.
There is a wealth of evidence suggesting that PARi is the major receptor involved in 
mediating thrombin’s pluripotent cellular effects in the pathogenesis of pulmonary 
fibrosis (Chambers and Laurent, 2002; Howell etal., 2002; Chambers, 2008). PARi is a 
major focus of the work performed in this thesis and will be discussed in greater depth 
in forthcoming sections.
1.7.2 PARi-mediated cellular effects of thrombin in pulmonary fibrosis 
PARi plays an important role in normal tissue repair following injury by mediating a 
number of thrombin-mediated cellular effects, such as platelet aggregation, influencing 
endothelial and epithelial cell permeability, inflammatory cell recruitment, mesenchymal 
cell migration, proliferation and ECM deposition (Chambers, 2003, 2008).
1.7.2.1 Platelet aggregation
A large number of studies have confirmed that thrombin is a major agonist for platelets, 
initiating a series of events leading to platelet aggregation in vitro and in vivo (Eidt etal., 
1988). Platelet aggregation is a key process in hemostasis and thrombus formation and 
has been found to be correlated with lung inflammation and collagen deposition 
induced by bleomycin (Piguet and Vesin, 1994). The interaction of thrombin and 
platelets ensures the rapid formation of haemostatic plugs at sites of vascular injury. 
The interaction also enables thrombin to indirectly control the activity of the cells at the 
site of injury by triggering the release of a great variety of mediators from platelets 
immediately after injury. These mediators include thromboxane A2, platelet factor-4, 
PDGF (Hart et al., 1990; Soma et al., 1992) and TGF-p 1 (Schini-Kerth et al., 1997). 
Thrombin also mediates the translocation of P-selectin and CD40 ligand to the plasma 
membrane of platelets, facilitating binding to endothelial cells (Henn etal., 1998).
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Many of these effects can be mimicked with PARi selective agonists and blocked with 
PAR, neutralising antibodies, suggesting a central role for PAR, in mediating these 
responses. However, studies have proved that some of the effects of thrombin on 
platelets can also be mediated by PAR4 in human platelets. As mentioned previously, 
PAR4 can mediate human platelet activation in response to higher concentrations of 
thrombin (Kahn et al., 1999). Interestingly, thrombin mediates murine platelet 
aggregation via activation of PAR3 and PAR4 (Kahn et al., 1998), rather than PAR4 
alone. In this system, murine platelets only express PAR3 and PAR4, PAR3 does not 
mediate cellular effects directly, rather, it acts as a cofactor for the effective cleavage 
and activation of PAR4 (Nakanishi-Matsui etal., 2000).
1.7.2.2 Disruption of endothelial and alveolar membrane barrier function 
Activation of PAR, is thought to contribute to the development of fibroproliferative lung 
disease by increasing pulmonary vascular permeability via an endothelial-dependent 
mechanism. This is thought to be a major mechanism leading to leak of coagulation 
proteinases and intra-alveolar fibrin deposition (Idell, 2003). PAR, activation on 
endothelial cells by thrombin promotes the expression of tissue factor (Bartha et al.,
1993), and adhesion molecules such as E- and P-selectin and intracellular adhesion 
molecule (ICAM)-1 (Sugama et al., 1992; Shankar et al., 1994). These molecules can 
further promote the initiation of coagulation and platelet adhesion and can also attract 
inflammatory cells to sites of injury. At higher concentrations, thrombin increases 
vascular permeability by influencing endothelial cell shape and disrupting endothelial 
cell-cell junctions via activation of PAR, (Lum et al., 1993; Rabiet et al., 1996). 
Consistent with this observation, direct systemic infusion of thrombin increases 
pulmonary microvascular permeability in the lungs of experimental animals’(Lo et al., 
1985). Furthermore, microvascular permeability is abrogated in lungs isolated from 
PAR, KO mice after systemic perfusion with thrombin (Vogel et al., 2000). Platelet 
adhesion is also thought to contribute to increased endothelial permeability by 
releasing serotonin (Henn et al., 1998). Platelet adhesion can be triggered by PAR, 
activation at low thrombin concentrations. Conversely, activation of PAR, may also 
promote the recovery of endothelial barrier integrity (Komarova et al., 2007). The 
barrier-protective effect of PAR, is mediated by the activation of sphingosine-1- 
phosphate 1 (S1Pi) in an autocrine or paracrine manner as a consequence of 
sphingosine kinase-1 (SphK-l)-mediated S1Pi generation (Komarova et al., 2007). 
Depletion of either SphK-1 or the S1P, receptor inhibits barrier enhancement induced 
by PAR, activation (Feistritzer and Riewald, 2005).
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In addition to vascular permeability, PARt activation by thrombin can also increase lung 
permeability by promoting epithelial cell apoptosis (Chin et al., 2003). Activation of 
PARt induced tight junctional zonula-occludens 1 disruption and apoptotic nuclear 
condensation in a caspase-3-dependent manner in epithelial cells, which ultimately led 
to the apoptosis of epithelial cells. As mentioned previously, excessive epithelial cell 
apoptosis leads to disruption of basement membrane integrity and facilitates the 
continuous migration of fibroblasts, which ultimately leads to the formation of 
fibroproliferative foci and the destruction of alveolar structure (reviewed in (Thannickal 
and Horowitz, 2006b; Fattman, 2008)).
1.7.2.3 Inflammatory cell recruitment
Although the contribution of inflammation to IPF remains controversial at the present 
time, there is compelling evidence that thrombin exerts potent pro-inflammatory effects 
and these effects are mainly mediated via PAR! (Sower et ai, 1995; Naldini et ai,
2002). Thrombin induces the release of potent pro-inflammatory mediators which have 
been implicated in the pathogenesis of pulmonary fibrosis, including CCL2, IL-6 and IL- 
8 (reviewed in (Chambers, 2008). Thrombin is a potent chemoattractant and mitogen 
for inflammatory cells (Grand et ai, 1996). For example, thrombin induces the 
expression of the T cell chemokine, RANTES, via PARi in fibroblasts (Hirano et ai,
2002). Thrombin may further influence inflammatory cell trafficking by inducing the 
expression of endothelial cell adhesion molecules, including E-selectin, P-selectin and 
ICAM-1 via PAR^dependent mechanisms (Sugama et ai, 1992; Shankar et ai, 1994; 
Kaplanski ef ai, 1997; Kaplanski et ai, 1998). These inflammatory mediators can in 
turn promote initiation and propagation of the coagulation cascade by upregulating the 
local expression of tissue factor (Leslie and Detty, 1986; van der Poll et ai, 1991; van 
der Poll ef ai, 1994).
1.7.2.4 Pro-fibrotic effects
Thrombin is a potent pro-fibrotic mediator in pulmonary fibrosis. Thrombin is likely to 
play an important role in the fibroproliferative response to lung injury by exerting its 
potent mitogenic effects on lung fibroblasts (Trejo et ai, 1996) and its stimulatory 
effects on extracellular matrix production (Chambers ef ai, 1998). Thrombin is 
mitogenic for fibroblasts in vitro and also in vivo (Dawes ef al., 1993; Ohba ef ai, 1994). 
There is good evidence that these mitogenic and pro-fibrotic effects of thrombin are 
mediated via the activation of PARi. In support of this notion, previous studies 
conducted in host laboratory have shown that thrombin is present in BALF obtained 
from patients with pulmonary fibrosis associated with systemic sclerosis. This fluid is
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furthermore mitogenic for cultured lung fibroblasts and this mitogenic activity can be 
blocked with the thrombin inhibitor, hirudin (Hernandez-Rodriguez et a/., 1995). 
Thrombin is capable of promoting the transformation of fibroblasts into a-SMA positive 
myofibroblasts, the predominant fibroblast phenotype present in active fibrotic lesions, 
by activating PAR, (Bogatkevich et a!., 2001), Finally, thrombin is also a 
chemoattractant for lung fibroblasts (Dawes et al., 1993) and therefore may also 
contribute to fibrosis by recruiting fibroblasts to the site of lung injury. Additionally, the 
central role of PAR, in mediating FXa stimulatory effects on lung fibroblast function has 
also been established by studies performed in our laboratory (Blanc-Brude et al., 2001). 
PAR, activation is also fibrotic by inducing apoptosis of epithelial cells (Suzuki et al., 
2005) as mentioned in Section 1.4.2.3 (Pan et al., 2001).
It should be noted that most of the PARi-mediated thrombin cellular effects occur via 
the generation of secondary mediators from a variety of cell types. Table 1.4 lists the 
major mediators and their documented cellular source. Further evidence that PAR, 
may be important in influencing both inflammation and fibrosis has been provided by 
studies performed in our and other laboratories showing that PAR, knockout mice are 
protected from bleomycin-induced lung injury (Howell et al., 2005) and experimental 
liver fibrosis (Fiorucci et al., 2004). PAR, is found to be highly expressed in the lungs of 
patients with IPF (Howell et al., 2005) and in patients with pulmonary fibrosis 
associated with systemic sclerosis (Bogatkevich et al., 2005). Taken together, these 
observations suggest that PAR, signalling in response to thrombin plays a central role 
in the pathogenesis of pulmonary fibrosis.
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Mediators Cellular source Major effect
bFGF Vascular smooth muscle cells (Stouffer and 
Runge, 1998)
Pro-fibrotic
CCL2 Monocytes (Colotta et al., 1994)
HUVEC (Marin et al. ,2001)
Dermal fibroblasts (Bachli et al., 2003) 
Hepatic stellate cells (Fiorucci et al., 2004)
Pro-inflammatory and 
pro-fibrotic
CTGF Lung fibroblasts (Chambers et al., 2000) 
Epithelial cells (Riewald et al., 2001)
Pro-fibrotic
Endothelin-1 Endothelial cells (Marsen et al., 1995)
Vascular smooth muscle cells (Lepailleur-Enouf et 
al., 2000)
Monocytes (Srivastava and Magazine, 1998)
Pro-fibrotic
ICAM-1 A/CAM-1 HUVEC (Kaplanski et al., 1998) Pro-inflammatory
IGF-1 Vascular smooth muscle cells (Du et al., 2001) Pro-fibrotic
IL-1p Macrophages/Monocytes (Naldini et al., 2002) Pro-inflammatory
IL-6 Lung fibroblasts (Sower et al., 1995)
Lung epithelial cells (Asokananthan et al., 2002) 
Endothelial cells (Johnson et al., 1998)
Smooth muscle cells (Kranzhofer et al., 1996) 
Monocytes (Naldini et al., 2000)
Pro-inflammatory
IL-8 Lung fibroblasts (Ludwicka-Bradley et al., 2000) 
Bronchial epithelial cells (Asokananthan et al., 
2002)
HUVECs (Marin etal., 2001)
Monocytes (Asokananthan et al., 2002)
Pro-inflammatory
PDGF Alveolar macrophages (Tani etal., 1997)
Lung fibroblasts (Blanc-Brude ef al., 2005)
Lung epithelial cells (Shimizu et al., 2000)
HUVEC (Shankar et al., 1994)
Vascular smooth muscle cells (Stouffer and 
Runge, 1998)
Pro-fibrotic
PGE2 HUVEC (Houliston et al., 2002)
Colonic fibroblasts (Seymour et al., 2003) 
Epithelial cells (Asokananthan et al., 2002)
Pro-inflammatory and 
anti-fibrotic
RANTES Synovial fibroblasts (Hirano et al., 2002) Pro-inflammatory
TGF-01 Platelets (Soslau et al., 1997)
Vascular smooth muscle cells (Bachhuber et al., 
1997)
Epithelial cells (Jenkins et al., 2006)
Pro-fibrotic
TNF-a Microglia (Suo et al., 2002) Pro-inflammatory and 
pro-fibrotic
Table 1.5 Pro-inflammatory and pro-fibrotic mediators induced in response to PAR) 
activation. HUVEC: human vascular endothelial cells.
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1.7.3 PARi signalling
1.7.3.1 G protein coupled-receptor signal transduction overview
Signal transduction systems enable cells to receive signals from extracellular stimuli 
and mount appropriate responses. Although a great number of receptors have been 
involved in detecting extracellular stimuli, the GPCRs have been so far regarded as the 
major receptor type for signal transduction and GPCRs represent the largest group of 
cell surface receptors encoded by the mammalian genome (>1% of human genes) 
(Wess, 1998). GPCRs such as PARi have been implicated in regulating several 
cellular processes in the lung (reviewed in (Chambers, 2008)).
a-Subunlts Members of each a-subunits Expression
Ga* Gas Ubiquitous
GasXi Neuroendocrine
Ga0if Olfactory epithelium, brain
Gayo Gan Widely distributed
Gai2 Ubiquitous
CD Q CO Widely distributed
G g0 Neuronal, neuroendocrine
G az Neuronal, platelets
GOgust Taste cells, brush cells
G at.r Retinal rods, taste cells
G at.c Retinal cones
Gaq /11 CD Q £1 Ubiquitous
G an Almost ubiquitous
G a i4 Kidney, lung, spleen
Ga-15/16 Hematopoietic cells
Ga-12/13 GO|2 Ubiquitous
Gai3 Ubiquitous
Table 1.6 Heterotrimeric G proteins (Modified from (Wettschureck and Offermanns, 2005))
To understand the physiological actions of a given GPCR such as PAR1 here, it is 
essential to identify the specific G proteins with which it is able to interact. G proteins 
are heterotrimeric guanine nucleotide-binding proteins which consist of a, (3 and y 
subunits. Although there are many gene products encoding each subunit, four main 
classes of G proteins can be distinguished according to the primary sequences of their 
a subunits, as follows: Gaj/0l Gas, Gaq/n and Gai2/13 (each with different members,
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Table 1.6). It should be pointed out that the Ga15 and Gene from the Gaq/11 family are 
the murine and human versions of the same gene. In addition, there are 6 different G 
protein (3 and 12 distinct y-subunits that have been described. The (3y complexes are 
extremely stable and usually regarded as one functional unit (Wess, 1998).
GPCRs such as PARi interact with G proteins upon activation by upstream agonists. 
This interaction subsequently promotes the exchange of GDP for GTP on the Ga 
subunits, which leads to the dissociation of Gpy from Ga. The free Gpy and Ga 
subunits recognize and activate specific effector enzymes to initiate the desired 
physiological responses (Vauquelin and Van Liefde, 2005). G-protein deactivation is 
rate-limiting and occurs when the Ga subunit hydrolyzes GTP to GDP.
Investigation during the last few years demonstrated that the PARi-mediated effects 
mentioned above are transduced by various signaling pathways leading to diverse 
functions of PARi under physiological and pathophysiological conditions. However, our 
understanding of signalling pathways involved in PARi-mediated cellular events is still 
far from complete. As a G protein-coupled receptor, PARi exerts its multiple cellular 
effects by concomitant activation of several G proteins, including Gaj,0, Gaq and Ga i2/13 
as shown in figure 1.4 (Coughlin, 2000; McLaughlin et al., 2005; Nguyen et al., 2005). 
Detailed studies of PARi-mediated signal transduction in different cells and tissues 
have been reviewed by Steinhoff et al (Steinhoff et al., 2005). This thesis will focus on 
the signalling pathways in the lung.
1.7.3.2 PARr G protein signalling pathways in pulmonary fibrosis
PARi is preferentially linked to GOq/n and Gaj/0 families, but it can also couple to Go^n  
with less efficiency (Wess, 1998). It is well-established that G-protein involvement in 
PARi signalling is both cell- and tissue-specific. The forthcoming sections will be 
focused on PARt-G protein signalling in platelets, endothelial cells, epithelial cells and 
fibroblasts as these PARi-mediated cellular responses may be important in the context 
of pulmonary fibrosis.
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Figure 1.4 Major PAR,-G-protein mediated signalling pathways
Figure shows the major G protein-mediated signalling pathways after coupling to PAR,. In 
general, the G a ,^  pathway couples to Rho guanine-nucleotide exchange factors (GEFs) 
resulting in activation of Rho, Rho kinase (ROCK), and myosin light chain (MLC) kinase; Gdq 
activates phospholipase C-p (PLCp) to generate inositol triphosphate (IP3) and diacylglycerol 
(DAG), which mobilize intracellular Ca2+ and activate protein kinase C (PKC); whereas the Ga, 
pathway inhibits adenylyl cyclase. The GPy subunits activate pathways including 
phosphoinositide 3-kinase (PI3k), PLCp, G protein-coupled receptor kinases (GRK), K* 
channels, and non-receptor tyrosin kinases. (Figure modified from (Coughlin, 2000; McLaughlin 
et al., 2005)
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PARi-Gcij/o pathway
Gcii/0 family members are generally pertussis-toxin sensitive, apart from Gaz. Different 
binding sites are required for PARi coupling to distinct G protein a subunits. For 
example, the third intracellular loop of PARi is implicated in PARi coupling to the 
pertussis-toxin sensitive Gaj/0. After coupling, Gai/0 inhibits adenylate cyclase and the 
generation of cyclic adenosine monophosphate (cAMP) (Hung et al., 1992a). This 
results in potentiation of calcium ion mobilisation in response to thrombin. Gaj/0 
pathway is important in platelet aggregation as platelet responses at site of injury are 
regulated by intracellular cAMP levels (Yang et al., 2002). Studies have shown that 
thrombin-dependent activation of murine platelets is mediated, at least in part, via the 
activation of Gai2 ((Jantzen etal., 2001).
PARt-Gaj/0 coupling also activates Src tyrosine kinase, which then stimulates Ras, Raf, 
and the mitogen-activated protein kinase (MAP kinase). This pathway has been shown 
to be necessary for thrombin-induced fibroblast proliferation (Della Rocca et al., 1999). 
There is also direct evidence indicating that members of the Gaj/0 family are involved in 
thrombin-induced fibroblast proliferation. Microinjection of mouse lung fibroblasts with 
anti-Ga0 antibody attenuates thrombin-induced DNA synthesis (Baffy et al., 1994) and 
inhibition of Gai2 with anti-Gai2 antibody in NIH 3T3 fibroblasts also inhibited the 
mitogenic effects of thrombin (LaMorte et al., 1993). This function of the Gaj/0 family is 
overlapping with Gaq as discussed below. Gaj/0 has also been shown to be involved in 
thrombin-induced fibroblast transformation along with G a i^  (Martin et al., 2001). 
Finally, Gaj/0 also participates in the effects of thrombin in endothelial cells. Recent 
studies demonstrated that PARi-Gaj/o coupling is responsible for the increased 
expression of thrombospondin-1 (THBS-1) induced by thrombin in vascular endothelial 
cells (McLaughlin etal., 2005).
PARt-Gdqrti pathway
PARi-Gaq/n is another major thrombin signaling pathway. The cononical effector 
molecules of activated Gaqare the (3-isoforms of phospholipase C (PLC-p) (Babich et 
al., 1990). Gaq binds and stimulates PLC-p to initiate inositol lipid signalling. PLC-p 
triggers phosphoinositide hydrolysis (PIP2) to generate inositol triphosphate (IP3) and 
diacylglycerol (DAG). This in turn mobilizes calcium from intracellular stores, increasing 
the intracellular calcium concentration from approximately 10'7M to 10 3M, and also 
causes the activation of protein kinase C (PKC) (Berridge, 1993). Calcium, as a second 
messenger, activates calcium-dependent kinases and phosphatases such as CaM 
kinases, Ras guanine-nucleotide exchange factors (GEFs) and MAP kinases. PKC is a
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key enzyme in ERK (one of the MAP kinases) signaling and Raf is the primary target of 
PKC (Kolch, 2000).
There are 5 members in the Gaq/n family, but Gaq and Gan are the most ubiquitously 
distributed across tissues and they share the most structural and functional similarities 
(Hubbard and Hepler, 2006). Genetic studies using whole animal models demonstrate 
the importance of Gaq family members in cardiac, lung, brain and platelet function 
among other physiological processes (Hubbard and Hepler, 2006). In vivo studies with 
Gaq-deficient mice also point to a role for Gaq in the regulation of airway smooth 
muscle contraction/relaxation (Borchers et al., 2003). Gaq-deficient mice display 
defective lung function (assessed by both tracheal tension and in vivo lung function 
measurement) and the mice fail to respond to allergen challenge. Gaq is the only 
member of the Gaq family that is expressed in platelets, and Gaq-deficient mice have 
shown increased bleeding times and impaired platelet function such as aggregation in 
response to collagen (Offermanns et al., 1997). Moreover, platelets derived from Gaq- 
deficient mice are completely unresponsive to thrombin stimulation, suggesting the 
unique role of Gaq in mediating the effects of thrombin in platelets (Moers et al., 2004). 
This is consistent with in vitro studies showing that PARt activation by thrombin leads 
to calcium-dependent shape changes of human platelets and this is achieved by the 
activation of Gaq (Hung et al., 1992b).
In vitro studies have also shown an important role for Gaq signalling in mediating 
thrombin's effects on fibroblasts and endothelial cells (Dery et al., 1998). As previously 
described (Section 1.7.1.4), thrombin exerts important effects on fibroblasts and 
promotes their proliferation and differentiation. The mitogenic effects of thrombin in 
fibroblasts are mediated by PARi coupling to Gaq, since inhibition of Gaq by 
microinjection of anti-Gaq antibodies caused a dramatic decrease of fibroblast DNA 
synthesis after thrombin stimulation (LaMorte et al., 1993; Baffy et al., 1994). This is 
accompanied by a decrease in calcium mobilization, suggesting that Gaq also 
modulates thrombin-induced calcium mobilization in fibroblasts. PARi-Gaq is required 
for fibroblast differentiation since thrombin does not induce the differentiation in 
fibroblasts derived from Gaq-deficient mice (Marinissen et al., 2003).
In endothelial cells, PARt-Gaq is responsible for NFxB activation and ICAM-1 
transcription induced by thrombin and this is coordinately regulated by Gpy dimers 
dissociated from Gaq (Rahman and MacNee, 1998; Miho et al., 2005). Thrombin- 
induced calcium mobilization in endothelial cells is also Gaq-dependent as
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demonstrated by two individual studies (McLaughlin et al., 2005; Singh et al., 2007). 
However, conflicting results have been shown by these two studies in terms of 
thrombin-induced endothelial permeability and the discrepancy may be explained by 
the methodologies used in both studies. Data obtained by McLaughlin and colleagues 
suggest that Ga12/13 rather than Gaq is responsible for thrombin-induced endothelial 
permeability. This conclusion is based on experiments showing that the Rho kinase 
inhibitor Y-27632 rather than the calcium chelator BAPTA-AM inhibits this effect, but is 
not based on direct experimental evidence from Ga12/i3or Gaq inhibition. As classically, 
Rho kinase and calcium are downstream effectors of Gai2/13 and Gaq, respectively, 
Ga12/13 rather than Gaq was felt to mediate thrombin-induced endothelial permeability. 
In contrast, Singh and colleagues reported that Gaq is responsible for mediating 
thrombin-induced endothelial cell permeability, and this was confirmed by using Gaq 
mutants that block Gaq signalling directly. This study also demonstrated that Rho rather 
than Ca2+ is involved as a downstream effector of Gaq in mediating this response of 
thrombin.
PARrG12/i3 pathway
PARt also transduces signals via the a subunits of Ga^and Gch3 (Offermanns et al.,
1994). Upon activation, Ga^and Gdi3 appear to selectively interact with the small Rho 
GTPase, Rho (which will be discussed in the forthcoming section). As discussed above, 
Gaq deficiency results in decreased airway smooth muscle contraction, Ga^and Ga13 
signalling pathway is also shown to be responsible for the hyperresponsiveness of 
airway smooth muscle contraction in rats after repeated antigen challenge (Chiba and 
Misawa, 2001). The levels of Ga^and Gai3 proteins are found to be upregulated in 
bronchial smooth muscle after 24 hours repeated antigen challenge, and this is 
associated with a dramatic increase in bronchial smooth muscle contraction.
As already mentioned, activation of PARi by thrombin induces fibroblast transformation 
via both Ga,yo and Ga12/i3. This study further demonstrated the involvement of 
downstream serum response factor (SRF) and NFkB in this response (Martin et al.,
2001). There is also evidence that PARt coupling to Ga12/i3 mediates thrombin-induced 
fibroblast transformation via the activation of the Jun N-terminal kinase (JNK) pathway 
(Marinissen et al., 2003). Apart from mediating mitogenic effects of thrombin on 
fibroblasts, the PAR^Gct^ pathway is found to be responsible for thrombin-stimulated 
DNA synthesis and cell migration in smooth muscle cells (Seasholtz et al., 1999). As 
mentioned previously, PARi coupling to Gaq mediates platelet aggregation in a 
calcium-dependent manner (Hung et al., 1992b). Studies have also shown that
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activation of PARi can induce platelet aggregation via a calcium-independent 
mechanism mediated by Gai2/i3 (Offermanns et al., 1994). The role of Gai3 in platelets 
has been demonstrated in studies by Moers and colleagues showing that platelets 
lacking Gai3 fail to respond to thrombin (Moers et al., 2004). The Gai3 signalling 
cascade includes the activation of Rho and thus induction of cytoskeletal changes 
affecting cell migration. In endothelial cells, thrombin-induced endothelial barrier 
dysfunction is mediated by the PARi-Gai2m pathway (Birukova et al., 2004a). However, 
studies by Singh and colleagues have demonstrated that the PARi-Gaq pathway 
mediates thrombin-induced endothelial barrier dysfunction. The discrepancy in findings 
may be explained by the different concentrations of thrombin used in both studies, 
since the concentration of thrombin (50 nM) in studies by Birukova and colleagues is 5 
times higher than that used in studies by Singh and colleagues. It is well-recognized 
that thrombin at higher concentrations signals via different mechanism compared to 
thrombin at lower concentrations.
PAR^Gfiy pathway
GPCR-G protein signalling is no longer regarded as a linear pathway from agonist- 
activated receptor to Ga-stimulated effector. Gpy dimers also function as signalling 
molecules (Hall et al., 1999). For example, Gpy has been found to mediate airway 
SMC proliferation induced by thrombin. After activation by thrombin, Gpy is dissociated 
from the Ga subunit and mediates SMC growth via the activation of PI3-kinase 
(Krymskaya et al., 1999). Furthermore, the involvement of Gpy in PARi signalling has 
been established by studies showing that Gpy regulates thrombin-induced NFkB 
activation and ICAM-1 expression in endothelial cells (Rahman etal., 1999; Rahman et 
al., 2001; Rahman ef al., 2002). Gpy signalling may also participate in apoptosis by 
activation of the PI3K-Akt pathway, a major pathway involved in regulating apoptosis 
(Jun et al., 2003). In Chinese hamster embryonic fibroblasts, the sequestration of Gpy 
dimers from Gaj2 and Gaq inhibits thrombin-regulated PI3K-Akt pathway (Goel et al., 
2004). Moreover, Gpy dimers from Ga0 were found to be necessary for thrombin- 
induced changes in endothelial barrier permeability (Vanhauwe etal., 2002).
Functional selectivity of PAR^G protein signalling
It is important to note that functional selectivity does exist as a feature of PARi-G 
protein interactions when PARi is activated by different agonists. For example, both 
thrombin and the PARi specific agonist peptide, TFLLR, activate PARi on endothelial 
cells to influence barrier permeability and calcium mobilization. However, PARi 
activated by thrombin preferentially couples to Gai2nz and therefore produces a greater
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effect on barrier permeability, whereas activation by TFLLR is associated with more 
efficient receptor coupling to Gaq and a greater effect on calcium mobilization 
(McLaughlin et al., 2005). This phenomenon has been termed ‘functional selectivity’, 
and may provide a potential explanation for the distinct gene expression profiles 
observed in cytokine-stimulated endothelial cells in response to activation of PARi by 
APC and thrombin (Riewald and Ruf, 2005).
1.7.4 Role of signal molecules downstream of PARi-G protein coupling in 
pulmonary fibrosis
The substantial network of signalling pathways downstream of PARi-G protein coupling 
requires multiple interactions at several levels by important protein kinases as shown in 
figure 1.4. These protein kinases actually mediate most of the signal transduction in 
eukaryotic cells and they are activated by phosphorylation. Of particular interest, the 
roles of PKC isoforms, mitogen-activated protein kinases (MAPKs) and RhoA/Rho 
kinase downstream of PARi-G protein coupling in pulmonary fibrosis will be discussed 
in detail in the forthcoming sections.
1.7.4.1 Protein kinase C
1.7.4.1.1 Overview
The intracellular serine/threonine kinase, PKC, is ubiquitously expressed in various cell 
types. Twelve different isozymes have been identified to date that differ in their 
structure, biochemical properties, tissue distribution, subcellular localization, and 
substrate specificity. The PKC isozymes are generally classified as conventional (a, (31, 
(32, y), novel (6 , e, q. 0, M)> atypical (£, A), and isoform v which is currently not classified 
(Hayashi et al., 1999; Dempsey et al., 2000). These isozymes can be further divided 
into two groups: Ca2*-dependent (conventional) PKC, and Ca2+-independent (novel and 
atypical isozymes) PKC which do not require Ca2+ for their activation.
All PKC isozymes can be activated by diacylglycerol (DAG) apart from £ and A. DAG is 
produced following the activation of PLC. Activation of membrane receptor by stimuli 
results in activation of PLC or phospholipase A2 (PLA2) via a G-protein-dependent 
mechanism. Activated PLC then hydrolyzes PIP2 to produce DAG and IP3. The 
production of IP3 leads to the release of endogenous Ca2\  which in turn binds to the 
cytosolic PKC and translocates PKC to the membrane. The PKC finally interacts with 
DAG and is transformed into a fully active enzyme (Mochly-Rosen and Gordon, 1998).
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Individual PKC isozymes have been shown to mediate many cellular responses, 
namely, permeability, contraction, migration, hypertrophy, proliferation, apoptosis, and 
secretion. These cellular responses have been implicated in clinical disorders such as 
pulmonary edema, adult respiratory distress syndrome, interstitial lung disease, asthma, 
and pulmonary hypertension (Dempsey etal., 2000; Dempsey etal., 2007).
The important roles of PKCs in the lung have been demonstrated by studies involving 
isolated organ preparations and whole animal models, including knockout and 
transgenic mice (Littler et al., 2003; Littler et al., 2005). Persistent hypoxic pulmonary 
vasoconstriction leads to vascular remodeling and fixed pulmonary hypertension, and 
these effects are abolished by PKC-e deletion (Littler et al., 2003). However, there are 
few PKC-related studies in the settings of the human lung. Gene expression profiling of 
lung tissue from patients with pulmonary fibrosis failed to demonstrate an upregulation 
of genes encoding the PKC isozymes (Zuo et al., 2002). However, much of the 
regulation of PKC occurs at the protein level, including phosphorylation and localization, 
gene array studies may therefore underestimate the importance of PKCs in various 
disease settings, including pulmonary fibrosis.
1.7.4.1.2 Protein kinase C signalling
The PKC-dependent signal transduction pathways have been found to regulate many 
intracellular events in fibroblasts involved in the development of fibrosis. Previous 
studies have shown that at least four PKCs are expressed in interstitial fibroblasts 
including PKC-a, PKC-y, PKC-5 and PKC-e (Ludwicka-Bradley et al., 2000; Luzina et 
al., 2006). Fibroblast proliferation and differentiation are critical for the development of 
fibrosis, and current evidence suggests that these events are mediated by different 
PKC isozymes after thrombin stimulation in vitro. For example, inhibition of PKC-a, but 
not PKC-e, by antisense oligonucleotides prevents thrombin-induced lung fibroblast 
proliferation, whereas thrombin-induced myofibroblast differentiation is mediated by 
PKC-e (Bogatkevich et al., 2001; Bogatkevich et al., 2003; Bogatkevich et al., 2005). 
Resistance to apoptosis in lung fibroblasts is another important mechanism contributing 
to the pathogenesis of pulmonary fibrosis and can also be induced by thrombin. This 
process is found to be mediated by PKC-e, not PKC-a following PARi activation 
(Bogatkevich etal., 2005).
Collagen contraction is important in tissue remodeling in fibrotic lung disease. The 
ability of fibroblasts to contract three-dimensional collagen gels has therefore been 
used as an in vitro model of the tissue contraction which characterises both normal
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repair and fibrosis. Studies have shown that thrombin can induce collagen gel 
contraction mediated by human lung fibroblasts and inhibition of both PKC-e and PKC- 
6 reduce this effect of thrombin, suggesting that both PKC-e and PKC-5 may contribute 
to tissue remodeling in these lung diseases (Fang et al., 2004; Fang et al., 2008). 
Fibroblasts not only play important roles in fibrosis via their ability to synthesize 
extracellular matrix, but also via the release of a host of cytokines and chemokines. 
Studies have demonstrated that PKC-y is responsible for thrombin-induced synthesis 
of IL-8 by lung fibroblasts (Ludwicka-Bradley et al., 2000). IL-8 may play a key role in 
the pathogenesis of pulmonary fibrosis by recruiting and activating neutrophils within 
the local microenvironment (Miller etal., 1992).
PKC may also contribute to pulmonary fibrosis by regulating the endothelial barrier. It is 
reported that PKC-a plays an important role in lung endothelial injury in response to 
thrombin activation of PAF  ^ and it is via the downstream Rho kinase pathway 
(reviewed in (Siflinger-Bimboim and Johnson, 2003)). In contrast, studies have also 
shown that thrombin can promote endothelial permeability via the activation of PKC-^ 
via a Rho kinase-independent mechanism (Li et al., 2004). In addition, thrombin has 
been found to induce ICAM-1 and VCAM-1 expression via the activation of PKC-6 in 
endothelial cells (Wu and Aird, 2005; Bijli etal., 2008). Finally, studies have shown that 
thrombin induces IL-8 production in lung epithelial cells via the activation of PKC-a.
In conclusion, current evidence suggests that PKC-a, PKC-y, PKC-5 and PKC-e are 
likely to play important roles in the pathogenesis of pulmonary fibrosis.
1.7.4.2 Mitogen-activated protein kinases pathways
As described above, PARi-G protein signaling pathways can ultimately lead to the 
activation of the MAPKs family (please see figure 1.4 and figure 1.5). The MAP kinase 
signal transduction pathways are the major pathways by which extracellular stimuli are 
transmitted as intracellular signals. They are key components of intracellular signaling 
pathways that control important cellular activities, such as gene expression, cell 
proliferation and programmed cell death. The elucidation of the molecular mechanisms 
whereby GPCRs activate MAPKs is believed to be central to understanding how these 
receptors regulate these important cellular events. MAP kinases are a group of highly 
conserved, eukaryote-specific serine/threonine kinases. There are three major 
subgroups in this family, namely c-Jun amino-terminal kinases (JNK1/2/3), extracellular 
signal-regulated kinases (ERK1/2), and p38 kinases (p38a, (3, y, 6). In general, the 
MAPKs are sequentially phosphorylated by upstream kinases (Figure 1.5) (Kyriakis
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and Avruch, 2001). Briefly, the MAPK cascade is initiated by the MAPK kinase kinases 
(MAPKKKs or MEKKs). The MEKKs activate the downstream MAPK kinases (MAPKKs 
or MEKs) by phosphorylation of specific serine and threonine amino acid residues 
(Widmann et al., 1999). MEKs in turn phosphorylate certain threonine and tyrosine 
residues of MAPKs. Upon activation, the MAPKs translocate to the cell nucleus where 
they phosphorylate nuclear proteins, including transcription factors and histone proteins, 
thereby affecting an intricate balance of regulatory molecules controlling gene 
expression (Treisman, 1996).
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Figure 1.5 Multiple signaling pathways link G protein-coupled receptors to the nucleus.
Molecules linking G protein-coupled receptors to MAPK, JNK, p38 and ERK5 are depicted. 
Arrows, positive stimulation; blocked lines, inhibition; dashed lines, interactions not well 
established. Adapted from Gutkind SJ etal [online] httD://www.stke.org/cQi/content/full/ 
OC sigtrans:2000/40/rel 2000
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The MAP kinase family has been the subject of intense investigation for many years 
owing to their major role in cellular growth, differentiation and survival, and the 
pathological effects (e.g. carcinogenesis) that result from dis-regulated MAPK activity. 
MAPKs represent an important point of convergence for several different signalling 
pathways; they affect multiple aspects of normal airway function and also significantly 
contribute to lung pathophysiology such as inflammation and the survival of resident 
lung cells (Yoshida et al., 2002; Pelaia et al., 2005; Bennett, 2006). The important 
involvement of MAPKs in lung fibrosis has been suggested by studies demonstrating 
that activated MAPKs are significantly increased in lung homogenates from patients 
with IPF compared with controls (Yoshida etal., 2002).
1.7.4.2.1 PAR.-ERK1/2 signalling
The most widely studied MAPK cascade is that of the ERK1/2 MAP kinases. These 
enzymes were the first MAPKs to be identified in mammalian cells as serine/threonine 
kinases. The phosphorylation cascade in the ERK1/2 module is initiated by the 
MAPKKK and c-Raf (Figure 1.5). Dual phosphorylation of both threonine and tyrosine 
is required for the full activation of ERK1/2. ERK1/2 activation can be induced by 
several different growth factors, cytokines, as well as by stimulation of GPCRs (Boulton 
et al., 1991; Johnson and Lapadat, 2002). This pathway is involved in cell-cycle 
regulation, cell proliferation and protection from apoptosis in the lung (Yoshida et al.,
2002).
ERK1/2 pathway is preferentially involved in cell proliferation. ERK1/2 signalling has 
been found to be critical in mediating lung fibroblast proliferation in response to several 
stimuli including thrombin (Pages et al., 1993). Studies have demonstrated that 
thrombin induces fibroblast proliferation and differentiation via the activation of ERK1/2 
(Trejo etal., 1996; Bogatkevich et al., 2005). In addition, plasmin-induced human lung 
fibroblast proliferation is mediated by PARi activation and downstream ERK1/2 
pathway (Mandal et al., 2005). Moreover, studies have demonstrated that the ERK1/2 
pathway plays an important role in PARi-activation-induced SMC proliferation (Lee et 
al., 2001; Schauwienold etal., 2003).
ERK1/2 may also be important in pulmonary fibrosis as an anti-apoptotic effector for 
fibroblasts. In vitro studies have demonstrated that thrombin inhibits lung fibroblast 
apoptosis via the activation of ERK1/2 pathway (Chalmers et al., 2003). In lung tissues 
from patients with IPF, the activation of ERK1/2 has been found to be significantly 
decreased in epithelial cells but not fibroblasts, suggesting that the persistent
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accumulation of fibroblasts in the lung is partially caused by decreased apoptosis 
mediated by ERK1/2 signalling (Yoshida et al., 2002). Finally, ERK1/2 pathway is 
involved in pulmonary fibrosis by mediating inflammatory chemokine and growth factor 
release. Studies have shown that PAR^activation-induced IL-8 production in airway 
epithelial cells requires the activation of both ERK1/2 and JNK (Ostrowska and Reiser, 
2008b). PDGF is mitogenic to fibroblasts and ERK1/2 also mediates thrombin-induced 
PDGF production in endothelial cells (Wu and Aird, 2005).
1.7,4.2.2 PAR^ JNK signalling
JNKs are activated upon exposure of cells to cytokines, growth factors, and 
environmental stress, such as UV irradiation or heat shock (Davis, 2000). Dual 
threonine and tyrosine phosphorylation of JNK by MAKK4 and MAKK7, results in JNK 
activation and nuclear location. JNK signalling has been implicated in multiple 
biological processes, including embryonic development, inflammation, cell proliferation 
and differentiation, and apoptosis regulation (Bennett, 2006).
JNKs may be involved in pulmonary fibrosis through its regulation of apoptosis. The 
role of JNK in regulating apoptosis is complicated since it may exhibit pro- or anti- 
apoptotic effects, which are depend on the strength, duration and type of stimulus (Lin, 
2003; Liu and Lin, 2005). Evidence for the pro-apoptotic effect of JNK in the lung has 
been provided in studies using cigarette-smoke-induced lung apoptosis model in rats 
(Kuo et al., 2005). In addition, activated JNK is found to be increased in epithelial and 
endothelial cells but not fibroblasts in lung sections from patients with IPF, which may 
explain the excessive epithelial cell apoptosis and fibroblast apoptotic resistance in 
pulmonary fibrosis (Yoshida et al., 2002). There is also in vitro evidence that JNK is 
pro-apoptotic in the lung. Studies have shown that leukocyte elastase induces 
apoptosis of human lung epithelial cells by a mechanism involving the activation of 
PARi and downstream JNK pathway (Suzuki et al., 2005). Taken together, these 
studies suggest that JNK is pro-apoptotic, which differs from the antiapoptotic effect of 
ERK1/2 in pulmonary fibrosis.
Studies have demonstrated that activation of JNK is involved in thrombin-induced 
fibroblast transformation (Marinissen et al., 2003). The JNK pathway has also been 
found to mediate PARi activation-induced inflammatory mediator release, including IL- 
8 in airway epithelial cells (Ostrowska and Reiser, 2008b), ICAM-1 in endothelial cells 
(Miho etal., 2005), and tissue factor in endothelial cells (Wu and Aird, 2005).
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1.7.4.2.3 PARi-P38 signalling
P38 is a ubiquitous and highly conserved, proline-directed serine/threonine protein 
kinase. It was initially discovered in a pharmacological screen when a cellular 
functional assay was used for the identification of compounds that modulate TNF-a 
production from a lipopolysaccharide (LPS)-stimulated human monocytic cell line (Lee 
et al., 1994). The primary role of p38 is considered to be in mediating inflammatory 
response in disease settings (Schindler et al., 2007). It is reported that p38 is 
associated with pulmonary events and is predominately involved in inflammation in 
pulmonary disease (Konstan and Davis, 2002; de Boer et al., 2007). This is supported 
by studies showing that the production and action of many of the potential mediators of 
airway inflammation are dependent on the p38 kinase cascade (Pelaia et al., 2005; 
Schindler et al., 2007).
Studies so far have demonstrated that P38 is mainly involved in PARi-induced 
inflammatory mediator release in pulmonary fibrosis. For example, thrombin has been 
reported to induce CCL2 production via the activation of p38 MAPK in both human 
endothelial cells (Marin et al., 2001) and smooth muscle cells (Brandes et al., 2001). 
P38 is also found to mediate thrombin-induced tissue factor expression in human 
pulmonary artery endothelial cells (Wu and Aird, 2005). However, this result contrasts 
with studies showing that JNK activation mediates thrombin-induced tissue factor 
expression in endothelial cells (Steffel et al., 2006). The discrepancy may be explained 
by the different thrombin concentrations used in both studies. As already mentioned 
previously, thrombin at different concentrations may signal via distinct pathways. In 
addition, the p38 pathway has also been shown to mediate thrombin-induced tissue 
factor production in smooth muscle cells (BelAiba et al., 2006). Moreover,, thrombin- 
induced VCAM-1 expression in endothelial cells is mediated by the p38 pathway 
(Steffel et al., 2006). Finally, p38 may be important in pulmonary fibrosis by regulating 
endothelial cell permeability. Studies have shown that thrombin-induced endothelial cell 
permeability is p38 MAPK-dependent (Borbiev etal., 2004).
1.7.4.3 RhoA/Rho kinase
Low molecular weight G proteins of the Rho subfamily belong to the RAS superfamily 
which consists of Rho, Rac and Cdc42. There are three members in the Rho family, 
namely RhoA, RhoB and RhoC. RhoA is the best characterized member and will be 
discussed in detail in this thesis. Unlike heterotrimeric G proteins, the Rho GTPases 
are not directly activated through ligand binding to GPCRs. Activation of small Rho 
GTPases and their downstream effectors is mediated through heterotrimeric G proteins
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and primarily through G proteins of the Ga12m family (Sah et al., 2000). However, 
recent evidence strongly indicates that the Rho family can also be activated by the 
Gaq/11 family (reviewed in (Hubbard and Hepler, 2006)).
The activation of Rho GTPases is similar as the process of G protein activation. The 
cycling of Rho GTPases between the inactive GDP-bound form and the activated GTP- 
bound form is controlled by guanosine nucleotide exchange factors (GEFs), GTPase- 
activating proteins (GAP) and guanine nucleotide dissociation inhibitors (GDIs). GEFs 
promote exchange of GTP for GDP and thereby activate Rho; GAPs inactivate Rho by 
enhancing the intrinsic GTP-hydrolysis activity; GDIs bind to the GDP-bound Rho 
protein and allow translocation between membranes and the cytosol.
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Figure 1.6 Schematic illustrations of RhoA/Rho kinase and downstream effector MLC 
activation. Both Gaq and Ga12m can activate RhoA, which in turn leads to the activation of Rho 
kinase. Following activation, Rho kinase activates MLC directly. Rho kinase can also activate 
MLC indirectly by phosphorylating the MLC phosphatases. GEF: guanine nucleotide exchange 
factors; GAP; GTPase activating proteins; GDI: guanine nucleotide dissociation inhibitors; MLC; 
myosin light chain
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RhoA is involved in the control of the organization of actin cytoskeleton, celt migration, 
smooth muscle contraction, gene transcription and cell growth (Sah et al., 2000; 
Wennerberg and Der, 2004; Wennerberg etal., 2005). Rho kinase (ROCK) is a major 
target of RhoA, including ROCKa and ROCK (3 (Kaibuchi et al., 1999). Myosin light 
chain (MLC) is one of the major downstream substrates of RhoA/Rho kinase signalling 
(Amano et al., 1996). Rho kinase can activate MLC directly via phosphorylation 
mechanism. It can also indirectly activate MLC by phosphorylating the myosin-binding 
subunit of MLC phosphatase, which in turn renders the phosphatase inactive and thus 
prevents MLC dephosphorylation (Kimura etal., 1996).
There is a wealth of in vitro evidence that RhoA/Rho kinase signalling mediates several 
cellular events related to pulmonary fibrosis, including cell migration, cell survival and 
cell transformation. Inhibition of Rho kinase by Y-27632 inhibits macrophage, 
neutrophil, fibroblasts and smooth muscle cell migration in response to various stimuli 
in vitro, including thrombin (Seasholtz et al., 1999; Shimizu et al., 2001). Thrombin- 
induced lung fibroblast differentiation can be mediated by both Gaq and Gai2/i3 as 
discussed previously. RhoA is also found to play a role in thrombin-induced lung 
fibroblast differentiation and it is downstream of PKC activation (Bogatkevich et al.,
2003). In addition, RhoA/Rho kinase is involved in TGF-p activation in fibroblasts. 
Previous studies performed in our laboratory have demonstrated that RhoA/Rho kinase 
mediates avp6 integrin-dependent TGF-p activation induced by PARi activation in 
fibroblasts (Jenkins etal., 2006).
RhoA/Rho kinase plays a critical role in modulating vascular tone in pulmonary fibrosis 
associated with arterial hypertension (reviewed in (Fukumoto et al., 2007)). Studies 
have shown that RhoA and Rho kinase mediate thrombin-induced vascular smooth 
muscle cell proliferation and migration (Seasholtz et al., 1999). In addition, RhoA/Rho 
kinase signalling is found to regulate endothelial barrier function. Thrombin-induced 
barrier dysfunction of pulmonary endothelial monolayer is associated with dramatic 
cytoskeletal reorganization, activation of actomyosin contraction, and gap formation. 
RhoA/Rho kinase activation is a key mechanism of this effect of thrombin as inhibition 
of RhoA and Rho-kinase by dominant-negative constructs significantly blocked 
thrombin-induced endothelial barrier dysfunction (Birukova et al., 2004b). Moreover, 
RhoA/Rho kinase regulates thrombin-induced ICAM-1 expression in endothelial cells 
(Anwar et al., 2004). Finally, Rho kinase has been shown to be involved in irreversible 
platelet aggregation induced by PAR* activation (Missy etal., 2001).
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1.7.5 The development of PARi antagonists
As already alluded to, increasing evidence has been accumulating regarding the 
deleterious role of PARi in lung injury and fibrosis. Therefore, blocking PARi or 
interfering with the signalling pathways downstream of PARi activation may be a 
promising therapeutic strategy. This section will briefly summarize recent progress in 
the development of PARi antagonists for both clinical use and experimental purposes.
1.7.5.1 Tethered ligand-based PARi antagonists
A number of peptide and peptidomimetic PARt antagonists aiming for clinical use are 
currently available, but the clinical utility of these agents remains to be established. For 
example, the heterocycle-based peptide-mimetic of PARi antagonists, indole-based 
RWJ-56110 and indazole-based RWJ-58259 have been reported to be selective for 
PARi in vitro and have been proved to be effective in non-human primate models of 
thrombosis, including a cynomolgus monkey arterial injury model (Derian et al., 2003; 
Maryanoff et al., 2003). Studies with another related indole-based PARi antagonist 
showed protective effects in a rat model of liver fibrosis at a dose of 1.5 mg kg' 1 day'1. 
In contrast, the non-peptide PARt antagonists such as the pyrroloquinazoline 
analogues, SCH 79797, has been reported to be toxic for lung fibroblasts (Sokolova 
and Reiser, 2007) and have potential off-target effects (Di Serio et al., 2007).
Recently, a new series of PARt antagonists have been developed. These antagonists 
are based on the core structure of the tetracyclic piperidine alkaloid, himbacine, from 
Australian magnolia trees (Chackalamannil et al., 2005). The most potent one among 
these antagonists demonstrates good affinity with a K, of 4.3 nM against PARi, up to 
70% blockade of platelet aggregation in the cynomolgus monkey model at a dose of 3 
mg kg'1, and approximately 60% oral bioavailability (Chelliah etal., 2007).
The orally active PARi antagonist, SCH-205831, developed by Schering, which inhibits 
PARt by competitively inhibiting the tethered ligand-binding site has been found to be 
effective as an antithrombotic agent in humans (Chackalamannil et al., 2005). A phase 
II clinical trial of a related PARi antagonist, SCH 530348, has been reported to be 
successful, providing hope for the availability of an effective orally available PARr  
targeted antithrombotic compound (Camerer, 2007) (http//:www.sch- 
plough.com/Schering_plough/news/ release.jsp?releaselD=977603).
1.7.5.2 PARi antagonists that blocks PARi-dependent activation o f G proteins
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As mentioned in previous sections, PARi mediates its cellular responses via different G 
proteins. An entirely different strategy for targeting PARi is to specifically inhibit PARi 
interactions with individual G proteins and there are currently several promising tools 
available, such as pepducins (Leger et al., 2006), G-protein selective PARi antagonists 
(Caden Biosciences) and G protein minigenes encoding the COOH-terminal peptide 
sequences of various Ga subunits (Gilchrist et al., 2001). These latter tools are 
available to further our understanding in experimental models in vitro and possibly in 
vivo, but are unlikely to progress as potential therapeutic agents for use in humans.
Pepducins are designed to bind to the receptor-G protein interface on the inner leaflet 
of the plasma membrane and have been studied in the context of PAR, and PAR4 
signalling (Covic et al., 2002b). For example, the anti-PARt pepducin, P1 pal-12, has 
been shown to effectively inhibit PARHnduced platelet aggregation (Covic et at., 
2002b). However, the specificity of pepducins is still controversial. Studies by 
Stampfuss and colleagues have argued that the anti-PAR4 pepducin, P4pal-10, may 
also inhibit other GPCR-mediated responses, including thromboxane receptors 
(Stampfuss et al 2003 9 1447). In addition, the cross-inhibition between PARi and 
PAR4 by pepducins has been reported (Covic et al., 2002a). Therefore, pepducins may 
be a potential tool for predicting an interaction between PAR  ^ and PAR4, rather than 
specific inhibitors for inhibiting PARi-G protein interaction (reviewed in (Leger et al.,
2006).
It has become increasingly clear that the carboxyl termini of the G protein a subunits 
are critical in G-protein signalling (Reviewed in (Gilchrist et al., 1998; Wess, 1998)). 
Dominant negative constructs targeting the carboxyl terminus can be used as 
competitive inhibitors of receptor-G protein interactions. In this regard, Dr Gilchrist and 
co-workers have generated minigene plasmid constructs that encode the 11 unique 
COOH-terminal sequences of various Ga subunits (Gilchrist et al., 2001). Instead of 
competing with binding of Mg2*, these G protein minigenes directly interfere with G 
protein-receptor interaction. The C-terminal region of various G protein a subunits has 
been shown to be not only the essential region for receptor contact, but also critical in 
determining the specificity of GPCR-G protein interactions (Hamm and Gilchrist, 1996; 
Hamm, 1998). In addition, substituting a single amino acid has been shown to annul 
the ability of the GOj to bind the A1 adenosine receptor, further supporting the unique 
importance of the C-termina! region for receptor-G protein signalling (Gilchrist et al., 
1998). These minigenes have previously been shown to effectively inhibit G-protein
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signalling, including thrombin-mediated cellular effects (Ellis etal., 1999; Gilchrist etal., 
2001; Vanhauwe etal., 2002).
Similar as the Ga minigenes, novel G protein selective PARi antagonists have also 
been designed according to the 11 amino acids found at the carboxyl-terminus of Ga 
subunits. Q94 is a recently developed novel PARt selective Gaq protein signalling 
antagonist (Caden Biosciences) and has been used in this thesis. The Gaq antagonist 
Q94, is a small cell permeable molecule (MW<500) that meets the Lipinski Rule of Five. 
The compound was chosen on the basis of its ability to compete for binding at the 
carboxyl-terminus of PARi, with a high affinity receptor binding peptide probe (HABP) 
designed around the 11 amino acids found at thq carboxyl-terminus of Gaq. The HABP 
probe (T2-14) was selected from a proprietary library of Gaq related peptides, 
constructed by sequential substitution of the 11 native C-terminal amino acids with 
each of the 20 known amino acids. IC50 values for binding of the HABPs to the receptor 
carboxyl-terminus showed that T2-14 has a higher binding affinity for PARi than the 
native Gaq C-terminal peptide (Appendix, Table 1). The selective nature of the T2-14 
for PARi was further supported by the observations that both a (32AR-X probe 
(identified by screening the activated p2-adrenergic receptor with a Gas library), and 
RHO8 probe (identified by screening activated Rhodopsin with a Gat library) showed 
little or no binding affinity for PARi. Q94 was found to compete off the highly selective 
T2-14, from activated PARi receptors with an IC50 of 916 nM (Appendix, Figure A.1, left 
panel). Additionally, this compound was found to effectively inhibit TRAP induced 
calcium transients (Appendix, Figure A.2, right panel).
Taken together, inhibition of PARi seems to be safer than direct inhibition of the 
activating proteinases as it allows selective inhibition of the potentially deleterious 
receptor-mediated cellular effects of coagulation proteinases, while preserving their 
essential roles in homeostasis. As a G protein-coupled receptor, selective inhibition of 
PARi-G protein pathways may then represent a novel therapeutic approach for a 
number of respiratory conditions associated with excessive coagulation proteinase 
signalling.
1.8 CCL2 (CC chemokine ligand 2)
1.8.1 Overview
The aim of this thesis is to examine the expression of CCL2 in lung fibroblasts following 
PARi activation by thrombin, and to examine the signalling pathways involved. CCL2, 
also known as JE in the mouse, is a member of the CC chemokine family. Chemokines
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are small (7-10 kDa) secreted proteins that function in leukocyte trafficking and 
recruitment, and are characterised as basic heparin-binding proteins (Puneet et al., 
2005). They are distinguished from other cytokines by being the only members of the 
cytokine family that act on G protein-coupled receptors. The chemokine families are 
named according to the structure of conserved cysteine-containing motifs. In the CXC 
chemokine family, the first two NH2-terminal cysteines are separated by a non­
conserved amino acid residue. The CC chemokines are defined by the two cysteine 
residues being adjacent to each other (Chung, 2001). The C chemokines only contain 
one cysteine amino acid.
Currently four monocyte chemoattractant proteins (MCPs) have been characterized in 
humans, of which CCL2 (MCP-1) was the first to be discovered and the best 
characterized. CCL12 (MCP-5) is only found in mouse and it has recently been 
suggested that CCL12 is the functional homologue of human CCL2 (Sarafi et al., 1997; 
Moore et al., 2006). CC chemokine receptor 2 (CCR2) is the major high affinity CCL2 
signalling receptor. Two isoforms of CCR2 have been cloned and termed CCR2A and 
CCR2B (Charo et al., 1994). CCR2 also acts as a receptor for three other MCPs, 
including CCL8 (MCP-2), CCL7 (MCP-3) and CCL13 (MCP-4), which can bind to 
multiple chemokine receptors as indicated in figure 1.7 (Keane et al., 2005)
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Figure 1.7 Multiple CCR2 specific ligands. CCL12 is the functional homologue of human 
CCL2 and only found in the mouse.
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1.8.2 Regulation of CCL2 production
1.8.2.1 Mediators ofCCL2 production
CCL2 is produced by several cell types, including endothelial cells, epithelial cells, 
mononuclear cells, fibroblasts, osteoblasts, keratinocytes, astrocytes and mast cells 
(Puneet et al., 2005). This chemokine is produced in response to a variety of 
inflammatory signals, including early response cytokines, PDGF, IL-1, IL-4, IL-6 , IL-10, 
IL-31, TNF-a, IFN-y, TGF-p and bacterial LPS (reviewed in (Rose et al., 2003; Ip et al.,
2007). It is also produced in response to thrombin (Colotta et al., 1994), FXa (Bachli ef 
a/., 2003) and viral infection (Bussfeld et al., 2000). Additionally, CCL2 expression can 
be induced by agents and factors that stress cells (Shyy et al., 1995; Glabinski et al., 
1996; Faller et al., 1997). In contrast, CCL2 production can be inhibited by some 
agents that suppress inflammation, such as retinoic acid, glucocorticoids, 
dexamethasone (Zhou etal., 2007), and estrogen (Frazier-Jessen and Kovacs, 1995).
1.8.2.2 Mitogen-activated protein kinase signalling and CCL2 production
The intracellular signal transduction pathways involved in CCL2 production have not 
been fully elucidated. However, MAPKs have been demonstrated to play a role in 
regulating CCL2 production in response to a variety of stimuli, including thrombin. 
Within the MAPK family, the p38 MAPK has been particularly associated with 
inflammatory cytokine production. Indeed, a variety of studies have suggested that p38 
MAPK plays an important role in CCL2 production in different cell types in response to 
various stimuli. For example, both TNF-a and CXCL2 have been shown to induce 
endothelial cell CCL2 production via the activation of p38 MAPK (Goebeler et al., 1999; 
Calderon et al., 2006). In addition, p38 MAPK seems to be uniquely involved in 
thrombin-induced CCL2 production in cells that have been investigated so far, including 
human endothelial cells (Marin et al., 2001) and smooth muscle cells (Brandes et al., 
2001). Moreover, plasmin is also found to induce CCL2 production in monocytes via 
p38 MAPK (Burysek et al., 2002).
Although JNK is related to environmental stress, there is recent evidence that JNK is 
also involved in CCL2 production. For example, studies have demonstrated that 
pneumocystis stimulates CCL2 production by alveolar epithelial cells through a JNK- 
dependent mechanism as inhibition of JNK inhibited this response, while inhibition of 
both p38 and ERK1/2 had no effect (Wang ef al., 2007). In addition, JNK has also been 
found to mediate IL-18-induced CCL2 production in rheumatoid arthritis synovial tissue 
fibroblasts (Amin et al., 2007). In contrast, the third MAPK family member, ERK1/2, 
which is associated with growth and differentiation signals, has not been found to
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mediate CCL2 production so far. In addition to MAPKs, recent studies have examined 
the role of PKC in CCL2 production, and demonstrated that PKCa but not PKCS is 
involved in IL-18-induced CCL2 production by rheumatoid arthritis synovial tissue 
fibroblasts via the activation of JNK (Amin et al., 2007).
1.8.2.3 CCL2 gene regulation
Several functional binding sites for transcription factors are present in the 5’-flanking 
region of the human CCL2 gene, including NF-kB, Sp1, AP-1, TRE, and NF-IL-6 (Ping 
etal., 1996; Ping etal., 1999a; Ping etal., 1999b; Finzer etal., 2000; Ping etal., 2000). 
Among these transcription factors, NF-kB has been shown to be important and two 
closely located NF-kB binding sites, termed A1 and A2, were identified in the 5’-flanking 
region of the human CCL2 gene (Ueda et al., 1994; Ueda et al., 1997). Among the 
variety of inducers of CCL2 expression, TNF-a is perhaps the most potent and 
regulation of CCL2 by TNF-a occurs primarily at the transcription level. It is reported 
that NF-kB plays a critical role in TNF-a-induced CCL2 gene expression in epithelial 
cells as deletion of the two NF-kB binding sites completely abolished this effect of TNF- 
a (Xing and Remick, 2007). In addition, NF-kB is also found to be involved in TNF-a- 
induced CCL2 gene expression in primary human endothelial cells and murine 
fibroblasts (Ping et al., 1996; Goebeler et al., 2001). It has also been reported that both 
SP1 and NF-kB are important in TNF-a-induced CCL2 expression (Ping ef al., 1999b; 
Ping et al., 2000; Guo et al., 2003). In contrast, other studies have suggested that AP-1 
is necessary for TNF-a-mediated induction of murine CCL2 gene in clonal osteoblastic 
and HPV 18-positive carcinoma cells (Ping et al., 1996; Finzer et al., 2000). This 
discrepancy in findings may be explained by differences in the cell type examined.
In addition, NF-kB is also an important transcriptional factor for LPS and IL-1(3-induced 
CCL2 gene expression as suggested by several studies (Ueda et al., 1997; Xing and 
Remick, 2007). In conclusion, NF-kB, SP 1 and AP-1 appear to be involved in CCL2 
gene expression with NF-kB the most important transcriptional factor identified in terms 
of CCL2 induction in response to inflammatory stimuli.
1.8.3 Role of CCL2 in pulmonary fibrosis
CCL2 is a potent chemoattractant for mononuclear cells, basophils, T cells, immature 
dendritic cells, and natural killer cells (Rose et al., 2003). Although other chemokines 
have similar functions and the unique CCL2 receptor CCR2 acts as receptor for other 
ligands, CCL2 has been shown to be essential for monocyte recruitment in several 
inflammatory models in vivo and in fibroproliferative lung disease, such as ARDS and
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IPF (Lu et al., 1998; Rose et al., 2003). In addition, a recent study has reported an 
elevation of CCL2 protein levels in BALF from patients with mustard-gas-induced 
pulmonary fibrosis (Emad and Emad, 2007).
In the setting of human IPF, several studies have demonstrated the elevation of CCL2 
mRNA and protein levels in pulmonary epithelial cells, monocytes/macrophages, 
vascular endothelial and in smooth muscle cells by in situ hybridisation and 
immunohistochemistry (Antoniades et al., 1992; Standiford et al., 1993). Moreover, 
unpublished studies from the host laboratory have shown that fibroblast-like cells in the 
IPF lung are strongly immunoreactive for CCL2 (Figure 1.8) (Mercer et al, unpublished). 
In addition, pulmonary fibroblasts from IPF patients exhibit a reduced ability to 
downregulate CCL2 expression in the presence of either PGE2 or the glucocorticoid, 
dexamethasone (Standiford et al., 1993). Cultured primary human lung fibroblasts 
derived from fibrotic lesions from subjects with IPF display a greater ability to express 
CCL2 in the presence of either TNF-a or IL-1 (3, as compared to normal controls 
(Standiford et al., 1993). These findings strongly support the notion that CCL2 may play 
an important role in the pathogenesis of pulmonary fibrosis.
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Figure 1.8 Immunohistochemical localisation of CCL2 in a lung tissue specimen from a 
patient with IPF. The spindle-shaped (fibroblast-like) cells are positive for CCL2 by 
immunostaining (Panel A and B, as indicated by arrows). These cells are negative for the 
epithelial maker CK7 and the macrophage marker CD68. Magnification (x 100 and x 400). 
(Image kindly provided by Dr Paul Mercer, Centre for Respiratory Research, UCL)
There is compelling evidence that CCL2 plays a pathological role as a pro- 
inflammatory mediator following lung injury. CCL2 is upregulated in response to 
bleomycin challenge in rodents in a time-dependent manner (Smith et al., 1996; Zhang
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et a!., 2004). CCL2 mRNA levels are significantly elevated in BALF cells at 24 hours 
post-bleomycin challenge, while in lung tissue, it is maximally elevated at 7 days, 
correlating with eosinophil and mononuclear cell infiltration. In addition to its ability to 
modulate inflammatory cell recruitment in the lung, CCL2 has been suggested to be 
involved in Th2 cytokine polarization in the context of pulmonary fibrosis (Hogaboam et 
al., 1998a; Gu et at., 2000). Karpus and co-workers have shown that T cell activation in 
the presence of CCL2 enhances IL-4 generation (Karpus et al., 1997). Neutralization of 
CCL2 leads to a reduction in IL-4 expression levels and an augmentation in IFN-y 
production by CD4+ lymphocytes when co-cultured with fibroblasts (Hogaboam et al., 
1998a). Lymph node cells from CCL2-deficient mice synthesize extremely low levels of 
IL-4, IL-5 and IL-10, but normal amounts of INF-y and IL-2, and CCL2-deficient mice 
are unable to mount a type 2 response, which is thought to be important in driving lung 
fibrosis in animal models (Gu et al., 2000). Taken together, CCL2 may have both a 
direct role in the pathogenesis of pulmonary fibrosis through its effects on inflammatory 
cell infiltration, and an indirect role by controlling of T helper cell polarization.
Furthermore, CCL2 also exerts pro-fibrotic effects. It stimulates fibroblast collagen 
production via the induction of TGF-(3i and a reduction in PGE2 production, and CCL2 
may also contribute to excessive collagen production via the recruitment of fibrocytes 
(Gharaee-Kermani et al., 1996; Moore et al., 2003; Moore et al., 2005). CCL2 
treatment of rat lung fibroblasts results in the concentration- and time-dependent 
expression of type I procollagen, and this effect can be attenuated with antisense TGF- 
Pi (Gharaee-Kermani et al., 1996). In addition, recent studies have demonstrated that 
CCL2 upregulates a-SMA and procollagen I and III gene expression in fibroblasts 
derived from the lungs of IPF patients (Murray et al., 2008). CCL2 can limit PGE2 
production in alveolar epithelial cells after injury, thus promoting fibroproliferation and 
collagen deposition by fibroblasts since PGE2 has been shown to be able to limit 
fibroblast proliferation, collagen synthesis, and promote collagen degradation (Moore et 
al., 2003). As discussed in section 1.4.1.2, fibrocytes are believed to be a source of 
fibroblasts and therefore contribute to lung fibrosis. Studies have demonstrated that 
CCR2, the high-affinity receptor for CCL2, mediates fibrocyte recruitment via the 
interaction with CCL2 (Moore et al 2005). This study has also shown that CCL2 
induces collagen synthesis by fibrocytes. Moreover, deficiency of CCR2 has also been 
shown to be protective in both fluorescein isothiocyanate (FITC) and bleomycin- 
induced pulmonary fibrosis (Moore etal., 2001; Gharaee-Kermani et al., 2003). Finally, 
overexpression of a CCL2 dominant-negative inhibitor causes a consistent reduction in 
the degree of bleomycin-induced fibrosis (Inoshima etal., 2004).
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In addition, a very recent study from Liu and colleagues proposed that CCL2 may 
contribute to fibrosis via its ability to regulate apoptosis (Liu et al., 2007). Apoptosis of 
lung structural cells is crucial in the process of normal tissue repair and insufficient 
apoptosis of lung fibroblasts may contribute to the development of fibrosis. In this study, 
CCL2 was added to fibroblast cultures and was found to inhibit staurosporin- and 
serum deprivation-induced apoptosis. Interestingly, CCL2 mediates fibroblast apoptotic 
resistance via the release of IL-6 since IL-6 release is upregulated after CCL2 
stimulation, and neutralization of IL-6 by specific antibodies block CCL2-induced 
inhibition of fibroblast apoptosis. Taken together, these findings suggest that CCL2 
may be an important mediator in fibrotic lung disease by promoting a range of cellular 
responses.
76
Chapter 1 Introduction
1.9 Summary, hypothesis and aims
Pulmonary fibrosis is the end stage of a heterogeneous group of disorders, 
characterised by excess deposition of extracellular matrix within the pulmonary 
interstitium. Excessive local procoagulant activity is a characteristic feature of 
pulmonary fibrosis and likely to be important in its pathogenesis. In this chapter, the 
role of the high affinity thrombin receptor PARi in promoting pro-inflammatory and pro- 
fibrotic cellular effects of thrombin has been reviewed. As PARi is a G-protein-coupled 
receptor, PARt-G protein signal transduction and downstream signalling pathways in 
pulmonary fibrosis were also been reviewed.
Previous studies from our laboratory have shown that the protection from bleomycin- 
induced lung inflammation and fibrosis is associated with a reduction in the 
upregulation of the PARHnducible mediator, CCL2 (Howell et al., 2005). However, the 
signalling pathway leading to CCL2 production via PARt remains unknown. The 
existing evidence for CCL2 as an important pro-inflammatory and pro-fibrotic mediator 
in pulmonary fibrosis makes it a compelling candidate for PARi-G protein signalling 
studies. The aim of this thesis is to elucidate the G-protein signal transduction 
pathways by which activation of PARi leads to CCL2 production in order to identify 
potential novel targets for therapeutic intervention.
This thesis will therefore specifically address the following hypothesis:
PARi activation leads to the production and release of the pro-inflammatory and 
pro-fibrotic chemokine, CCL2, via its interaction with heterotrimeric G-proteins 
and activation of multiple downstream signalling cascades.
To address this hypothesis, my project has the following specific aims:
I) To elucidate the specific G-protein signal transduction pathway by which activation of
PARi induces the production of CCL2 by mouse lung fibroblasts in vitro.
II) To examine the effect of PARt selective G-protein signalling antagonists on mouse 
lung fibroblast CCL2 expression in vitro.
III) To delineate the signal transduction pathways downstream of PARi-G-protein 
coupling for CCL2 production induced by thrombin in mouse lung fibroblasts in vitro.
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IV) To examine the role of PARi in thrombin-induced CCL2 production in primary 
human lung fibroblasts.
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Chapter 2: Materials & Methods
Materials
2.1. General plastic ware, chemicals and solvents
All chemicals were of analytical grade or above and obtained from Sigma Aldrich (UK), 
unless otherwise indicated. All water used for the preparation of buffers was distilled 
and deionised using a Millipore Water Purification System (Millipore R010 followed by 
Milli-Q Plus; Millipore Ltd, Watford, UK). Cell culture plastic-ware was purchased from 
NUNC (NUCN™, Denmark). Polypropylene centrifuge tubes and pipettes were 
obtained from Falcon (New Jersey, USA), unless otherwise stated. Other disposable 
plasticware was purchased from Sterilin (Ashford, Middlesex, UK).
2.2 Reagents
2.2.1 Cell culture reagents
High-glucose Dulbecco's Modified Eagle’s Medium (DMEM), penicillin-streptomycin, L- 
glutamine, 0.25% trypsin-EDTA, geneticin and hygromycin were from Gibco BRL 
(Gibco BRL, Paisley, UK). Foetal calf serum (FCS) was obtained from Invitrogen 
(Invitrogen, UK). New born calf serum (NCS) (heat inactivated) was purchased from 
Imperial Laboratories (Andover, Hampshire, UK). Luria Bertani (LB) broth for bacterial 
culture was purchased from Invitrogen (Invitrogen, UK).
2.2.2 Kits
Wizard® Plus Minipreps DNA Purification system (Promega, UK); Qiagen® Plasmid 
Maxi Kit (Qiagen, UK); OptEIA™ Mouse CCL2 ELISA Set, TMB Substrate Reagents 
set Microtest™ 96-well ELISA plates were from BD Biosciences, Pharmingen (San 
Diego, CA, USA). Lipofectamine 2000 was purchased from Invitrogen (Invitrogen, UK). 
BCA™ protein Assay Reagents A & B were purchased from Pierce (Pierce, USA). 
Enhanced chemiluminescence (ECL) kit was purchased from Amersham 
(Buckinghamshire, UK). DNA-free™ kit was obtained from Ambion (Ambion Ltd. UK). 
RT-PCR kit for cDNA synthesis was purchased from Applied Biosystems (Roche, 
Lewes, UK). Others: Proteinase inhibitor cocktail was obtained from Sigma (Sigma, 
UK). TRIzol was purchased from Gibco (Gibco BRL, Paisley, UK).
2.3 Coagulation factors, cytokines and peptides
Thrombin, extracted from human plasma, was purchased from Calbiochem (Merck 
Biosciences, UK). The PARi agonist peptide TFLLR-NH2, the reverse peptide RLLFT-
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NH2 and FTLLR-NH2 were synthesized and provided by Professor R. Mecham 
(University of Washington, MO, USA). The PARi agonist peptide SFLLRN was 
purchased from Sigma (Sigma, UK). Purified human factor Xa (FXa) was obtained from 
American Diagnostica Inc. (Greenwich, CT, USA). The PAR2 agonist peptide SLIGKV 
was purchased from Auspep (Australia). The PAR4 agonist peptide AYPGKF was 
obtained from Bachem (Bachem, Germany), and the reverse peptide YAPGKF was 
purchased from Chempep (Chempep, USA). TNF-a was purchased from R&D Systems 
(UK). All preparations were dissolved in DMEM culture medium, aliquot and stored at - 
80 °C.
2.4 Inhibitors
PARt antagonist RWJ-58259 was kind gift from Dr Claudia Derian (Johnson & Johnson 
Pharmaceutical Research & development, USA). The novel small molecule PARi 
antagonist Q94 which selectively blocks the PARi interaction with Gaq was developed 
by Dr Annette Gilchrist (Caden Biosciences, USA). Inhibitors used are listed in Table
2.1. RWJ-58259 was added to the cells 15 minutes before subsequent experiments. 
Q94 was added to the cells 3 hours prior to the addition of treatments, and 
cycloheximide was put onto the cells 1 hour prior to the subsequent experiments. All 
the other inhibitors used were added 30 minutes before subsequent treatment. All the 
inhibitors were dissolved in appropriate solutions as indicated in Table 2.1, aliquot and 
stored at -80 °C.
Anti-PARi antibodies ATAP2 and WEDE15 were employed in this study to block PARi 
cleavage by thrombin. ATAP2 is a monoclonal IgGi-anti PARi antibody which binds to 
an epitope within the PARi tethered ligand domain, and was purchased from Santa 
Cruz (Sc-13503, Santa Cruz Biotechnology, CA, USA). WEDE15 is also a monoclonal 
IgGi-anti PARt antibody that binds to the hirudin-like domain, and was obtained from 
Beckman Coulter (Beckman Coulter, UK). Both antibodies were dissolved in double­
distilled water, ATAP2 stock was kept at fridge and WEDE15 stock was stored at -20 
°C. Antibodies were added to the cells (final concentration: 25 pg/ml of each) 30 
minutes prior to the subsequent treatments with thrombin.
All inhibitors and antagonists used in this thesis are listed in Table 2.1.
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Inhibitors Function Dissolved
by
Stock
concentration
Source
Actinomycin D RNA inhibitor Ethanol 10 pg/ml Sigma
BAPTA-AM Calcium chelator DMSO 20 mM Calbiochem
Blebbestatm MLC inhibitor DMSO 20 mM Calbiochem
C3 exoenzyme RhoA inhibitor ddH20 10 pg/ml Tebu-Bio
c-Raf kinase 
inhibitor
c-Raf kinase 
inhibitor
DMSO 10 mM Calbiochem
Cycloheximide Protein synthesis 
inhibitor
ddH20 10 pg/ml Sigma
GF109203X Broad-spectrum 
PKC inhibitor
DMSO 10 mM Calbiochem
G06976 Ca2+-dependent 
PKC inhibitor
DMSO 10 mM Calbiochem
H-1152 Rho kinase 
inhibitor
ddH20 10 mM Calbiochem
PD98059 MEK inhibitor DMSO 50 mM Calbiochem
Pertussis toxin Gcti/o inhibitor ddHzO 50 mg/ml Calbiochem
Q94 Gaq inhibitor DMSO 10 mM Caden
Biosciences
Ro-318425 Broad-spectrum 
PKC inhibitor
DMSO 10 mM Calbiochem
RWJ-58259 PAR-, antagonist DMSO 10 mM Johnson & 
Johnson
SB 203580 P38 inhibitor DMSO 10 mM Calbiochem
SB 202474 Inactive control for 
SB203580
DMSO 10 mM Calbiochem
TI-JIP JNK inhibitor DMSO 10 mM Calbiochem
U73122 PLC inhibitor DMSO 20 mM Calbiochem
U73343 Inactive control for 
U73122
DMSO 20 mM Calbiochem
U0126 MEK inhibitor DMSO 10 mM Calbiochem
Y-27632 Rho kinase 
inhibitor
ddH20 30 mM Calbiochem
Table 2.1 Inhibitors and antagonists
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2.5 Antibodies.
Antibodies used in this study are listed in Table 2.2.
Antibody Name Antibody
Property
Supplier and 
Catalogue N°
Dilution
Used
Application
Anti-p38 Rabbit
polyclonal IgG
Cell signalling 
Technology, MA, USA 
#9212
1:2500 Western Blot
Anti-phospho-p38 Rabbit
polyclonal IgG
Cell signalling 
Technology, MA, USA 
#9215
1:1000 Western Blot
Anti ERK1/2 IgG Rabbit
polyclonal IgG
Cell Signalling 
Technology, MA, USA 
#9102
1:5000 Western Blot
Anti phospho- 
ERK1/2
(Thr202/Tyr 204) 
IgG
Rabbit
polyclonal IgG
Cell Signalling 
Technology, MA, USA 
#9101
1:5000 Western Blot
Anti c-Raf IgG Rabbit
polyclonal IgG, 
400 pg/ml
Cell Signalling 
Technology, MA, USA 
#9422
1:5000 Western Blot
Anti phospho-c-Raf
(Ser289/296/301)
IgG
Rabbit
polyclonal IgG
Cell Signalling 
Technology, MA, USA 
#9431
1:5000 Western Blot
Anti MLC IgG Rabbit
polyclonal IgG
Cell Signalling 
Technology, MA, USA 
#3672
1:1000 Western Blot
Anti-phospho-MLC
IgG
Rabbit
polyclonal IgG
Kind gift from Dr James 
M. Staddon (Eisai 
London Research 
Laboratories, UK)
1:500 Western Blot
Anti rabbit IgG- 
HRP
Goat polyclonal 
IgG, 400 pg/ml
Santa Cruz 
Biotechnology, CA, 
USA sc-2004
1.25000 Western Blot
Anti-human CCL2 
(capture)
Mouse lgG2B R&D, # MAB 679 2 pg/ml ELISA
Biotinylated anti­
human CCL2 
(detecting)
Goat IgG R&D, # BAF 279 2 pg/ml ELISA
Anti-CCL2 Goat IgG R&D, # AF-279-NA 10 pg/ml Immunocytofl
-uorecence
Table 2.2 List of antibodies for ELISA, Western Blot and immunocytofluorecence.
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2.6 Primers
Primers used for gene expression studies are listed in Table 2.2. Primers were 
designed by Dr Chris Scotton (Centre for Respiratory Research, UCL).
Primers Forward Reverse
mCCL2 AGCTCT CT CTT C CT CC ACC AC CGTTAACTGCATCTGGCTGA
mPARi AG C C AG C C AG AAT C AG GAG AGGGGGACCAGTTCAAATGTA
mPAR2 CG GG ACG C AAC AACAGTAA GTTCCACCGGAACCCC M IC
mPAR3 TGCCAAAGTGGCATAAATGT TCCAGCCCTCTATGTCAGAA
FT1PAR4 AGACCCCCAGCCATCTACGA GTCTGAGGACTTCGGCTCCT
hPR, C C ATCGTT GT GTT CAT CCTG G ACCCAAACT GCCAAT CACT
hPAR2 CACCATCCAAGGAACCAATAG TGCAGAAAACTCATCCACAGA
hPAR3 TCAGAGTGGCATGGAAAATG AAGGCAGAAAAGGGGAACTC
hPAR4 GAAGGCTGTACTGGGTCGAA AAGTGACCTCCGCTAGTGACA
Table 2.3 Primers used for RT-PCR and quantitative real time RT-PCR
H=human, M=murine
2.7 Vectors.
2.7.1 MEK1 -pBabePuro constructs
The MEK1-pBabePuro constructs were kind gifts from Dr. Christopher J Marshall 
(Cancer Research in UK): wild type MEK1-pBabePuro contains the wild type rat MEK1 
gene; the dominant negative MEK1 -pBabePuro construct transcribes inactive MEK1 
encoding substitution of Alanine for Serine at Ser-221; constitutively active MEK1- 
pBabePuro construct transcribes constitutively active MEK1 encoding Glutamic Acid 
substitutions at Ser-217 and Ser-221 (Cowley et al 1994). The wild type MEK1 
sequence was obtained from Genebank (Rat MKK, Genbank #: Z30163). The mutants 
were directionally subcloned into the pBabePuro vector using the BamHI and EcoRI 
restriction sites in the MCS region (See Figure 2.1).
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Figure 2.1 Schematic diagram of pBABEpuro-basic vector
Diagram represents circular map of pBABEpuro-basic vector and unique restriction sites within 
the MCS. Vector components (clockwise from 1): 5’ LTR: 5’ long terminal repeats; MCS: 
multiple cloning sites; SV40 IEP: simian virus 40 immediate early promoter; 3’ LTR: 3’ long 
terminal repeats; Amp': ampicillin resistance gene. *: restriction sites used in the current study. 
Taken from the Stewartlab website at http://www.stewartlab.net.
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2.7.2 pRevTRE2 and pRevTet-on vectors
The pRevTRE2 vectors encoding enhanced green fluorescent protein (pRevTRE2- 
EGFP) or encoding the 11 amino acids of the C-terminus of Go subunits (pRevTRE2- 
Gaq, pRevTRE2-GOi, pRevTRE2-Ga12 and pRevTRE2-Ga13) were kind gifts from Dr 
Annette Gilchrist (Caden Biosciences, USA). These minigenes were inserted into the 
pRevTRE2 vector between its BamHI and Hindlll sites (See figure 2.2). The amino acid 
sequences transcribed by inhibitory mutants were shown in table 2.4.
LTR
Amp
pRevTRE2
6.5 kbI pBR322
\  ori Hyg
LTR
MCS
S329 3339 3349 23E9 3369 3379 3 3 S 9 3 3 8 9
ACCCGGGGATCCGTCGACGGCCATTATGGCCGTTTAAACTCGAGGCCGCCTCGGCCAAGCTT6CGGCCGCAAACATCGATAAAA 
BanH  I Sal I Sfi I Pm* I Xh0 \ Sfi I H m i III N o li Cla I
Restriction Map and Multiple Cloning Site (MCS) of pRevTREZ. Unique restriction sites are in bold._________________
Figure 2.2 Schematic map of pRevTRE2 vector.
Diagram represents circular map of pRevTRE2 vector and unique restriction sites within the 
MCS. Vector components (clockwise from 1): 5' LTR: 5’ long terminal repeats; ijj+: the extended 
viral packaging signal; Hygr: hygromycin resistance gene; ( te tO )7/P mincMv: seven direct repeats 
of the tetO (operator) sequence upstream of a minimal promoter of cytomegalovirus; MCS: 
multiple cloning site; 3’ LTR: 3’ long terminal repeats; Ampr: ampicillin resistance gene.
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Vector
pRevTRE2-Goq
pRevTRE2-Gdj
pRevTRE2-Gai2
pRevTRE2-Gai3
Amino acid sequence
LQLNLKEYNAV
IKNNLKDCGLF
LQENLKDIMLQ
LHDNLKQLMLQ
Description
Gaq inhibitory mutant 
Goi inhibitory mutant 
Gdi2 inhibitory mutant 
Go13 inhibitory mutant
Table 2.4. G protein minigene vectors
pRevTet-on vector encoding the TRE required to drive transcription of pRevTRE2 was 
obtained from Clontech (Clontech, UK).
pRevTet-On N*°
7.6 kb
Figure 2.3. Schematic map of pRevTet-On vector
Diagram represents circular map of pRevTet-On and its unique sites. Vector components 
(clockwise from 1): 5’ LTR: 5’ long terminal repeats; ijj+: the extended viral packaging signal; 
Neor: neomycin resistance gene; PCm'. promoter of cytomegalovirus; rtTA: reverse tetracycline- 
controlled transactivator; 3’ LTR: 3' long terminal repeats; Ampr: ampicillin resistance gene. 
Image taken from Clontech websit at http://www.clontech.com
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2.8 Fibroblasts and retroviral packaging cells
Wild type mouse lung fibroblasts (MLFs) cell line and the PAR! deficient (PARi -/-) 
mouse lung fibroblasts cell line were kind gifts of Dr. Shaun Coughlin (Cardiovascular 
Research Institute, University of California, San Francisco, CA, USA). These fibroblasts 
were immortalised through SV40 transformation and used between passage 12 and 25 
without any noticeable alteration in phenotype.
Normal primary human adult lung fibroblasts (pHALFs) were a kind gift of Dr. Robin 
McAnulty from our laboratory and used at passages below 10. These fibroblasts have 
previously been shown to be high responsiveness to stimulation by coagulation 
proteinases (Chambers et al., 2000). Primary fibroblasts were initially grown from 1mm3 
explants dissected from normal human lung tissue. The explants were cultured in 
DMEM supplemented with 10% FCS. The culture medium was replaced with fresh 
medium one day after isolation and every three days thereafter for three weeks. Cells 
were collected by trypsinisation. Fibroblasts were separated by morphological 
characterisation and by differential immunocytochemical staining for a section of 
smooth muscle cell, endothelial and fibroblast markers such as a-smooth muscle actin 
(a-SMA), von willebrand factor, vimentin and myosin.
Phoenix ecotropic packaging cells and helper free amphotropic packaging cells 
GP*env AM 12 (Abbreviated as AM 12) were kind gifts obtained from Dr Sam M Janes 
from host laboratory (Centre for Respiratory Research, UCL).
2.9 Bacterial cell culture
All vectors were propagated in Escherichia coli (E.coli) cells, DH5a-Subcloning 
Efficiency strain which were obtained from Life Technologies (Life Technologies Ltd, 
Paisley, UK) and were grown in LB broth or on LB agar plates. Clones were stored at - 
80°C.
Methods
2.10 Fibroblast cell culture
Mouse lung fibroblast (MLFs), PARi deficient mouse lung fibroblasts and primary 
human adult lung fibroblasts (pHALFs) were maintained in static culture on 75 cm2 
triangular culture flasks in Dulbecco’s modification of Eagle's medium (DMEM), 
supplemented with penicillin (200 units/ml), streptomycin (200 units/ml), glutamine (4 
mM) and 10% (VA/) FCS. Cells were propagated in monolayer cultures in 10%-FCS 
DMEM in humidified atmosphere of air containing 10% C 02 at 37 °C. Cells were
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passaged by routine trypsinisation protocols when monolayer cultures reached 80-90% 
confluence. Cells were routinely tested for mycoplasma contamination using MycoAlert 
Assay (Cambrex, UK) and were negative for mycoplasma infection. If any mycoplasma 
contamination was detected, all of those cell stocks were disposed of.
Upon reaching visual confluence (4 to 5 days), cells were sub-cultured (passaged) into 
new culture flasks. The medium was removed and the cell layer was washed twice with 
10 ml Ca2+ and Mg2+ free phosphate buffered saline (PBS) to remove any remaining 
culture media. Cells were brought into suspension by adding 1 ml of trypsin (0.05%, 
w/v) / EDTA (0.02%, w/v) solution and incubated at 37°C until cell detachment from the 
tissue culture plasticware occurred (approximately 3 minutes for fibroblasts). The cells 
were observed under an Olympus TCK-2 inverted phase contrast light microscope 
(Olympus Opitcal Ltd, London, UK) to ensure that they had rounded up. Trypsin was 
neutralised by addition of 9 ml of DMEM supplemented with 10% FCS. The cell 
suspensions were split at a ratio of 1 to 6. Under these conditions, cells remained 
viable for about 12 to 25 passages after supply for MLFs, and up to 3-10 passages for 
pHALFs.
To plate cells for experiments, cells from one tissue culture flask were put in 
suspension in DMEM-10% FCS and aspirated into a 50 ml sterile polypropylene 
centrifuge tube (BD Bioscience, UK). They were centrifuged (1000g, 5 min, 4°C) using 
a bench centrifuge (Sorvall T600B, UK), prior to plating. The supernatant was 
discarded and the cell pellet was brought into a single cell suspension with 1 ml 
DMEM-10% FCS by gentle mixing. A further 9 ml culture media was added and an 
aliquot of the suspension was removed for counting with a sterile pipette. Cells were 
counted using an improved Neubauer haemocytometer (BDH-Merck, Ltd, Lutterworth, 
UK) and the density of the cell suspension was adjusted with DMEM-10% FCS.
Cell densities vary from cell to cell. The pHALFs were mainly used for ELISA and were 
usually seeded in 96-well plates with a density of 8 X 103/well. MLFs were applied in 
multiple experiments with varied densities in different culture plates. The number of 
MLFs seeded is indicated in Table 2.5.
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Tissue Culture Plate Number of Cells Volume of Medium Application
96 well plate 9 x 103/ well 100 pi ELISA
24 well plate 4 x 104/ well 500pl Infection, ELISA
12 well plate 10 x 104/ well 1 ml ELISA, Western 
Blotting
6 well plate 20 x 104/ well 2 ml Infection, Western 
Blotting, qRT-PCR
Table 2.5 Mouse lung fibroblast seeding densities for various experimental procedures
2.11 Plasmid manipulations
2.11.1 Transformation of bacteria
For the production of large amounts of cloned DNA, plasmids were transformed into 
Escherichia Coli strain DH5a. For transformation, 10 ng of plasmid DNA was added to 
100 pi of competent cell suspension and incubated on ice for 30 minutes. Cells were 
then subjected to heat shock at 42 °C for 20 seconds before returning to ice for 2 
minutes. 900 pi of LB medium was added to cells and incubated at 37 °C for 1 hour, 
with shaking. 100 pi of suspension was plated onto LB-agar plates containing ampicillin 
(100 pg/ml) and grown at 37 °C for 16-18 hours.
2.11.2 Plasmid amplification and purification
Protocols for plasmid purification were based on the alkaline lysis method (Birnboim, 
1983). This method depends on the fact that high molecular weight linear chromosomal 
DNA will be denatured when cells are lysed at pH 12.0-12.6, whereas low molecular 
weight supercoiled plasmid DNA is unaffected. Neutralisation of pH in the presence of 
high salt concentrations subsequently precipitates chromosomal DNA, which can then 
be separated from the mixture.
2.11.2.1 Miniprep of Plasmid DNA
Buffers used: Cell Resuspension Solution: 50 mM Tris-HCI, pH 7.5; 10 mM EDTA; 100 
pg/ml RNase A; Cell Lysis Solution: 0.2 M NaOH; 1% SDS; Neutralisation Solution: 
1.32 M potassium acetate, pH 4.8; Column Wash Solution: 80 mM potassium acetate;
8.3 mM Tris-HCI; 40 pM EDTA.
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Minipreparation of plasmids was used to isolate newly constructed plasmids from 
culture to enable subsequent screening by automated sequencing. Single colonies 
obtained from transformed bacteria were used to inoculate a 5 ml overnight culture of 
LB medium containing appropriate antibiotic in a 50 ml loose-capped tube. Solutions 
and columns supplied with the Wizard® Plus Minipreps DNA Purification System 
(Promega) were then used. 1.5 ml of culture was poured into a microfuge tube and 
centrifuged at 10, 000 g for 1 minute. Medium was removed and the dried cell pellet 
was resuspended in 200 pi of Cell Resuspension Solution by vigorous vortexing. 200 pi 
of Cell Lysis Solution was added, and mixed gently by inverting tubes 4 times. To 
precipitate genomic DNA and cell debris, 200 pi of Neutralisation Solution was added, 
mixed by inverting as above, and centrifuged at maximum speed for 5 minutes. The 
resulting supernatant was applied to a silica gel Wizard© minicolumn and washed with 
2 ml of Column Wash Solution at 10, 000 g for 2 minutes. The minicolumn was 
transferred to a new microfuge tube and 50 pi of nuclease-free water was added to the 
column. After 1 minute, the minicolumn was centrifuged again at 10, OOOg for 1 minute 
to elute the plasmid DNA.
2.11.2.2 Maxiprep of Plasmid DNA
Buffers used: Resuspension Solution: 50 mM Tris-HCI, pH 7.5; 10 mM EDTA; 100 
pg/ml RNase A; Lysis Buffer: 0.2 M NaOH; 1% SDS; Neutralisation Buffer: 3 M 
potassium acetate, pH 5.5; Equilibration Buffer: 50 mM MOPS, pH 7; 750 mM NaCI; 
15% ethanol; Wash Buffer: 50 mM MOPS, pH 7; 1 M NaCI; 15% ethanol; Elution Buffer: 
50 mM Tris-CI, pH8.5; 1.25 M NaCI; 15% ethanol; TE: 10 mM Tris, pH 8, 1 mM EDTA.
Large quantities of purified plasmids were obtained using the Qiagen® Plasmid Maxi Kit. 
A single colony was picked from a freshly streaked selection plate and used to 
inoculate a 5 ml starter culture of selective LB medium, and incubated for -8  hours at 
37 °C on an orbital shaker. The starter culture was then diluted 1:500 into 100 ml of 
selective LB medium and grown for 12-16 hours at 37 °C on an orbital shaker. Cells 
were harvested by centrifugation at 6000 g for 15 minutes at 4 °C. Supernatant was 
discarded and pellets were resuspended in 10 ml of chilled Resuspension Buffer. 10 ml 
of Lysis Buffer was added to the suspension and mixed gently by inverting. Cells were 
lysed for 5 minutes at room temperature before stopping the reaction by addition of 10 
ml Nuetralisation Buffer and mixed again by inverting. Mixtures were incubated on ice 
for 20 minutes to allow precipitation of cell debris, genomic DNA and SDS. The sample 
was then centrifuged at 13,000 g for 1 hour at 4 °C. Subsequently, the supernatant was
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passed through a glass wool column to remove any residual precipitate and applied to 
a Qiagen column equilibrated with 10 ml of Equilibration Buffer and washed twice with 
30 ml Wash Buffer. The bound plasmid was eluted in 15 ml Elution Buffer and 
precipitated by adding 10.5 ml of room temperature isopropanol. Mixtures were 
centrifugation at 13,000 g for 30 minutes at 4°C and pellets resuspended in 400 pi TE 
and transferred to a microfuge tube. Plasmid DNA was precipitated by addition of 40 pi 
of 3 M sodium acetate and 900 pi of ethanol, before mixing and centrifugation at 10, 
000 g for 5 minutes. Supernatant was removed and pellets were subsequently washed 
with 70% ethanol before centrifugation, as above, and resuspension of DNA in 200 pi 
TE buffer.
2.11.3 Restriction Enzyme Digestion of DNA
Screening of DNA preparations were conducted by restriction enzyme digestions. 
Master mixes were prepared using appropriate restriction enzymes and their buffers 
from New England Biolab (UK), and mixed with the plasmid DNA. A typical reaction 
was set up as detailed in Table 2.6.
Component Volume
10x 4-CORE or Multi-CORE buffer 2 pi
Enzyme 1 1 pi (10 units)
Enzyme 2 1 pi (10 units)
Plasmid DNA 1-3 pg
Nuclease free water Make up to 20 pi
Table 2.6 Restriction enzyme digestion master mix recipe.
Digests were incubated at optimal temperature for 2 hours before separation on 
agarose gels.
2.11.4 Agarose gel electrophoresis of DNA
Following restriction enzymatic digestion, the DNA was separated by agarose gel 
electrophoresis. During use of agarose gels in this study, it was only necessary to use 
standard molecular biology grade agarose for DNA separation at different percentages, 
according to fragment size (see Table 2.7).
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Agarose (%) DNA fragment size range
0.5 700 bp to 25 kb
0.8 500 bp to 15 kb
1.0 250 bp to 12 kb
1.2 150 bp to 6 kb
1.5 80 bp to 4 kb
Table 2.7 Agarose gel percentages used in separation of DNA fragments.
Gels were cast by melting agarose in 1x TBE buffer (90 mM Tris-borate, 2 mM EDTA) 
containing 0.5 pg/ml of ethidium bromide and pouring into appropriately sized casting 
trays. Samples were mixed with 6 x loading buffer (0.25% bromophenol blue, 0.25% 
xylene cyanol, 30% glycerol), loaded into wells and run at 5-10V/cm. Fragments were 
visualised under UV light and photographed.
2.12 Retrovirus expression system
2.12.1 Retroviral producer cell lines
Phoenix is a second-generation retrovirus producer lines derived from the human 
embryonic kidney 293 cell line for the generation of helper free ecotropic and 
amphotropic retroviruses. The cell lines had been created by placing into 293T cells 
constructs capable of producing gag-pol and envelope protein from ecotropic and 
amphotropic viruses. For both the gag-pol and envelope constructs non-Moloney 
promoters were used to minimize recombination potential. Different promoters for gag- 
pol and envelope were used to reduce their inter-recombination potential. Gag-pol was 
introduced with hygromycin as the co-selectable marker and the envelope proteins 
were introduced with diphtheria resistance as the co-selectable marker. AM12 cells 
were designed in conjunction with pBabePuro vector to reduce the risk of generation of 
wild type Mo MuL Viruses via homologous recombination (Markowitz et a l., 1988).
2.12.2 Cell culture
The Phoenix packaging cells and AM 12 cells were propagated in monolayer cultures in 
DMEM-10% FCS in humidified atmosphere (95% air/ 5% C 0 2). For cells transduced 
with MEK1 -pBabePuro constructs, the culture medium was supplemented with 2.5 
pg/ml puromycin (100 mg puromycin powder dissolved in 100 ml PBS, sterilized using 
a 0.22 pm filter and stored at -20 °C before use); for cells transduced with pRevTet-on
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vector, the culture medium was supplemented with geneticin (400 pg/ml); for cells 
transduced with pRevTRE2-EGFP, pRevTRE2-Gaq, pRevTRE2-Gai, pRevTRE2-Ga12 
or pRevTRE2-Ga13, the culture medium was supplemented with 500 pg/ml hygromycin. 
For cells transduced with both pRevTet-on vector and pRevTRE2-EGFP or G protein 
minigene vectors, the culture medium was supplemented with both geneticin (400 
pg/ml) and hygromycin (500 pg/ml). Culture mediums were regularly replaced with 
fresh medium every 3 days.
2.12.3 Transduction with MEK1-pBabePuro constructs
Figure 2.4 Establishing a inducible cell line with MEK1 constructs. The MEK1 constructs 
were transiently transfected into Phoenix packaging cell line. The resulting virus-containing 
supernatants are used to infect AM 12 cells. High-titer virus producing line was established with 
puromycin selection. The resulting virus containing supernatants from AM12 were used to infect 
MLFs and successfully infected MLFs are selected by puromycin.
2.12.3.1 Transient transfection of phoenix Cells
Buffer used: 2 X HBS: 280 mM NaCI, 10mM KCI, 1.5 mM Na2HP04, 12 mM D+Glucose, 
50 mM HEPES, pH 7.0.
Phoenix Cell
Transfect packaging cell 
line with regulatory and 
expression vectors
MEK1
Constructs
Target Cells
Infect AM12
cells with collected
virus
Target cells
infect MLFs 
with collected 
virus
Select
(Puro)
Select j 
(Puro) I
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Ecotropic virus producer cell lines were generated by transfecting the phoenix 
packaging cells with retroviral vectors. The transfection process used was a calcium 
phosphate precipitation infection protocol. 80-90% confluent phoenix cells from one 
T75 tissue culture flask were passaged into four T75 tissue culture flasks with 10% 
DMEM-FCS without any antibiotics 12-20 hours before the transfection, and the cells 
shall be 80-90% confluent before transfection. 5 minutes prior to transfection, cells in 
the flask were washed twice with DMEM and supplemented with 5 ml DMEM only; 
chloroquine (25 pM) was next added to each flask. Chloroquine increases the 
transfection efficiency by neutralizing vesicle pH and thereby inhibiting lysosomal 
DNAse. 10 pg DNA, 438 pi ddH2Ot and 61 pi 2 M CaCI2 were mixed and brought to a 
500 pi total volume with ddH20. 0.5ml 2 x HBS was added, mixed by bubbling air 
through the mixture. The HBS/DNA was then added into 5 ml medium (no serum) on 
the cells, and mixed gently by rocking the flask back and forth. 24 hours post- 
transfection the medium was replaced by 10% heat inactivated-FCS-DMEM (no 
antibiotics). Retroviral supernatants were collected at 65-90 hours after transfection, 
filtered through a 0.45 pm filter to remove cells and added to target cells, or stored at - 
80 °C for the next experiments.
2.12.3.2 Infection o f AM12 cells
Virus released into the medium by confluent Phoenix cells was used to produce stable 
high titre AM 12 virus producer cells. AM 12 cells were seeded in T25 flasks at 1-2 x 105 
densities 12-24 hours before infection and cultured with DMEM containing 10% heat- 
inactivated FCS. 5 ml infection medium (virus containing medium collected from the 
phoenix cells; supplemented with 5 pg/ml polybrene (Sigma) was added to the cells. 
Polybrene is a polycation that reduces cell surface-associated charges, enhancing the 
interaction between the retrovirus and the cell membrane. After 12 hours infection at 
37°C the medium was replaced with fresh culture medium containing 10% heat- 
inactivated FCS). The selection medium containing puromycin (2.5 pg/ml) was used 48 
hours later and changed every 3 days until cells reached confluence. After 1 week 
selection, cells were passaged into T75 flasks. When cells reached 80% confluence, 
the selection medium was replaced with 5 ml DMEM containing 10% heat-inactivated 
FCS in order to collect high titer viral supernatants. Retroviral supernatants were 
collected 24 hours later, filtered through a 0.45 pm filter to remove cells and added to 
target cells, or stored at -80 °C for the next experiments.
2.12.3.3 infection o f mouse iung fibroblasts
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MLFs cells were seeded onto 24-well plate 12-20 hours before infection. 500 pi 
supernatant containing the virus from confluent AM12 cells was mixed with polybrene 
(5 pg/ml) and placed on MLFs, following incubation for 24 hours at 37°C. The media 
were then replaced with 10% FCS-DMEM for another 24 hours. Cells were then 
selected with the selection medium containing puromycin (2.5 pg/ml). Relative 
experiments were carried out when the selected cells reached confluence.
2.12.4 Transduction with pRevTRE2 vectors
For inhibition of G-protein signalling by minigenes, the RevTet-On expression system 
(BD Biosciences) was employed (Figure 2.5). The RevTet-On system uses the 
pRevTet-On and pRevTRE response vector. The pRevTet-on vector encodes the 
reverse tetracycline sensitive regulatory element (rtTA) consisting of a reverse Tet 
repressor (rTetR) and VP16 activation domain. In the presence of doxycycline, this 
protein interacts with the pRevTRE response vector, binding at the Tet response 
element (TRE), initiating transcription of the gene of interest. In the current study, G- 
protein minigenes were cloned into the upstream multiple cloning site (MCS). The TRE 
contains seven direct repeats of the 42bp tetO sequence and the minimal immediate 
early promoter of cytomegalovirus (PmjncMv)-
Figure 2.5 Mechanism of BD RevTet-On™ gene expression. In the presence of doxycycline, 
the rtTA binds to the TRE which drives the transcription in the presence of Dox. (Taken from BD 
RevTet™ System User Manual, BD Biosciences).
c o p y  o f p R e vT e i-on  
re g u la io ry  p la s m id
PC M Y V 1----------1\  rtetR VP16
♦ DOX
PminCMV
95
Chapter 2 Materials & Methods
2.12.4.1 Constructing a stable expression cell line.
To create a stable cell line that expresses the gene of interest upon induction, a series 
of transfection and infection as diagrammed in Figure 2.6.
Packaging Cells Target Cells
Transfect packaging cell 
line with regulatory and 
expression vectors
Infect target 
cells with 
collected virus
Neof
pRevTet-
/  p R e v T R E  ^  minigenes
Collect virus
containing
supernatant
Select (Gen)
Tet-On cell line
Select (Hyg)
Double-stable cell line expressing the 
target gene under doxycycline control
Figure 2.6 Establishing an inducible cell line with the BD RevTet™ System. The pRevTet- 
On vector and the pRevTRE2 vectors were separately transfected into the viral packaging cell 
line. The resulting virus-containing supernatants were used to serially infect target cells: first 
with pRevTet-on virus to produce a Tet-On cell line, then with pRevTRE virus to integrate the G 
protein minigenes. Expression is induced by the addition of doxycycline. (Modified from BD 
RevTet™ System User Manual, BD Biosciences)
Briefly, the first step was to make two different retroviruses: one to deliver the pRevTet- 
On regulator construct to the target cells and the other to deliver G protein minigenes.
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To produce the virus, pRevTet-On vector and pRevTRE2-minigenes were transfected 
into the phoenix cells in parallel. When packaging is complete, supernatant containing 
pRevTet-On virus was used to infect the target cells first. Geneticin selection of this 
culture was next applied in order to obtain a population of cells that have integrated 
rtTA. Next the Tet-On cell line was infected with pRevTRE2-minigene virus. 
Hygromycin selection of this culture was used to generate a population of cells 
containing all the components needed for Tet-regulated expression. Detailed 
descriptions for G protein minigenes are described in the forth coming sections.
2.12.4.1.1 Transient transfection of packaging celis with pRevTet-on vector, 
pRevTRE2-EGFP and pRevTRE2-Ga minigenes vectors
The Phoenix cells were transiently transfected with pRevTet-On vector, pRevTRE2- 
EGFP or pRevTRE2-Ga minigenes (Gai Gaq Gai2 and Gai3 minigenes) using 
Lipofectamine™ 2000. The amount of DNA transfected and the volumes of reagents 
varied depending on the type of assay and plate type used, and these were detailed in 
Table 2.8. In the current study, T75 flask of cells was used for transfection. One day 
before transfection, Phoenix cells were plated in T75 in growth medium without 
antibiotics so that cells will be 80-90% confluent at the time of transfection. On the day 
of transfection, 30 pg plasmid DNA was mixed with 1875 pi Opti-MEM® I Reduced 
Serum Medium without serum. In parallel, 75 pi Lipofectamine™ 2000 was diluted in 
1875 pi Opti-MEM® I Reduced Serum Medium. Both solutions were incubated for 5 
minutes at room temperature. After incubation, diluted plasmid DNA was combined 
with the diluted Lipofectamine™ 2000 followed by further incubation for 20 minutes at 
room temperature. After incubation, the plasmid DNA-Lipofectamine™ 2000 complexes 
were added into 12 ml medium (no serum) on the phoenix cells. The cells were then 
incubated at 37°C in a 5% C 02 incubator for 6 hours. Medium was next replaced by 
DMEM-10% heated-inactivated FCS without any antibiotics and left on cells overnight. 
Virus containing supernatants were collected at 65-90 hours after transfection, filtered 
through a 0.45 pm filter to remove cell debris and added to target cells, or stored at -80 
°C for the next experiments.
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Culture
vessels
Surface of 
area per well
Volume of 
plating medium
Volume of 
dilution medium
DNA Lipofectami 
ne™ 2000
96-well 0.3 cm2 100 pi 2 *25 pi 0.2 pg 0.5 pl
24-well 2 cm2 500 pi 2 *50 pi 0.8 pg 2 pl
12-well 4 cm2 1 ml 2 x100 pi 1.6 pg 4 pl
6-well 10 cm2 2 ml 2 *250 pl 4 pg 10 pl
60-mm 20 cm2 5 ml 2 *500 pl 8 M9 20 pl
10-cm 60 cm2 15 ml 2 *1.5 ml 24 pg 60 pl
T75 flask 75 cm2 18 ml 2 *1.875 ml 30 pg 75 pl
Table 2.8 Volumes of reagents used in Lipfectamine™ 2000 transfection
2.12.4.1.2 Producing a stable Tet-On-MLF celt line
MLFs were seeded in T75 12-18 hours before infection so that MLFs will be 30-50% 
confluent at the time of infection. After 24 hours incubation, virus-containing 
supernatant from phoenix cells were then collected and applied on MLFs seeded 12-18 
hours before the infection. 24 hours after infection, the MLFs were rescued by 
replacing the virus-containing medium with DMEM containing 10% heat-inactivated 
FCS without any antibiotics. After 24 hours further incubation, the MLFs were then 
selected with 400 pg/ml geneticin. The selection medium containing 400 pg/ml 
geneticin was changed every 3 days until cells reached confluence. Minimum of one 
week selection was carried out before used for subsequent experiments or frozen 
down as stock.
2.12.4.1.3 Infection of Tet-On-MLF cell line with pRevTRE2-EGFP and pRevTRE2- 
Ga minigenes
The Phoenix cells were transiently transfected with pRevTRE2-EGFP and pRevTRE2- 
Ga minigenes (Gai( Gaq, Ga12 and Ga13 minigenes) in parallel as described in Section 
2.12.4.1. The virus-containing supernatants were collected and applied onto the Tet- 
On-MLFs cells seeded 12-18 hours before the infection. 24 hours after infection, the 
cells were rescued by replacing the virus-containing medium with DMEM containing 
10% heat-inactivated FCS without any antibiotics. After the rescue, cells were selected 
with both 400 pg/ml geneticin and 500 pg/ml hygromycin for a week. Relative 
experiments were carried out when the cells survived from selection and reached 
confluence, with the addition of 3 pg/ml of doxycycline in culture medium in order to 
induce the expression of gene of interest.
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2.13 Enzyme-linked immunoassay (ELISA)
2.13.1 Cell conditions and cell supernatants collection
Cells were seeded 48 hours before assay. In order to avoid edge effects, cells were 
only dispensed into the central 1 0 x 6  wells of the 96-well plate. The outer wells were 
filled with 100 pl DMEM-5% FCS only. After 24 hours in culture and before confluence, 
cells were washed with serum-free DMEM twice, and the cells were quiesced in 0.1% 
FCS-DMEM (MLFs) or serum-free DMEM (pHALFs) and used at sub-confluence. 
Before each experiment, the starvation medium was removed and replaced with fresh 
serum-free DMEM, with or without mediators or inhibitors for a selected length of time 
(details please refer to individual experiment described in results section). Serum-free 
conditioned media were then collected from cell culture plates, spun to remove cell 
debris. Samples were used for ELISA immediately, or stored in -80°C and defrosted on 
ice before ELISA.
2.13.2 Murine CCL2 ELISA
Buffers used: Coating buffer: 0.2 M sodium phosphate, PH 6.5; Assay dilute: PBS 
with 10% heat-inactivated FBS; Washing buffer: PBS with 0.05% Tween-20; Stop 
solution: 1 M H3P04.
ELISA: Microtest™ 96-well ELISA plates were obtained from BD Biosciences, 
Pharmingen (San Diego, CA, USA). The assay was reported to recognise total murine 
CCL2. The lowest reference on the standard curve 15.6 pg/ml and the highest was 
1000 pg/ml. The protocol followed was identical to that in the accompanying literature. 
Briefly, the Microtest™ 96-well ELISA plates were coated with 50 pl of anti-mouse 
CCL2 capture antibody (diluted 1:250 in coating buffer) and were then left overnight at 
4°C. After overnight incubation, plates were washed and were next blocked with 100 pl 
assay dilute for 1 hour at room temperature. After the incubation, plates were again 
washed, 50 pl of each sample and serial dilutions (0-1000 pg/ml) of standard CCL2 
protein were added to each well accordingly and incubated for 2 hours at room 
temperature. Following incubation, plates were then washed, 50 pl of the anti-mouse 
CCL2 detecting antibody (diluted 1:250 in assay diluents) was added to each well for 1 
hour at room temperature. After further washes, plates were finally incubated with 50 pl 
per well of the substrate solution for 30 minutes at room temperature. 25 pl of stop 
solution was subsequently added to each well after 30 minutes incubation. Plates were 
next read at A1 450nm, A2 550nm with a plate reader (Multiskan MCC/340, Titertek).
2.13.3 Human CCL2 ELISA
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Buffers used: Bicarbonate buffer (pH9.6): 1.59g Na2C03 , 2.93g NaHC03 and 0.2g 
NaN3 in 1L double-distilled water, filtered and stored at room temperature; Blocking 
buffer: 1% BSA in PBS; Coat and Block wash buffer (C/B wash): 0.1M KP04 and 
0.05% Tween20; Assay wash buffer: PBS with 0.05% Tween-20; Stop solution: 1 M 
H3P04.
ELISA: The assay was reported to recognise total human CCL2. The lowest reference 
on the standard curve 34 pg/ml and the highest was 2150 pg/ml. Briefly, dissolve anti- 
human CCL2 capture antibody in bicarbonate buffer (1:250). Apply 50 pi aliquots to 
each well and incubate at room temperature for a minimum of 5 hours. Wash the plate 
with C/B wash buffer and add 100 pi blocking buffer to each well. Incubate the plate 
with blocking buffer overnight at 4 °C. Make up standards or dilute samples with 0.1% 
BSA in PBS. Apply 50 pi aliquots of each standards and samples to each well and 
incubate at room temperature for 2 hours. Plates were then washed with assay wash 
buffer. Dilute anti-human CCL2 detecting antibody in blocking buffer (1:250) and add 
50 pi aliquots to each well followed by 2 hours incubation at room temperature. Plates 
were next washed with assay wash buffer. Dilute streptavidin-HRP 1:2000 in 0.1% BSA 
in PBS and add 50 pi aliquots to each well. Incubate plates at room temperature for 1 
hour followed by further wash with assay wash buffer. Plates were finally incubated 
with 50 pi per well of the substrate solution for 30 minutes at room temperature. Final 
reaction was terminated by adding 50 pi of stop solution in each well and kept in dark 
at room temperature for 30 minutes. Plates were next read at A1 450nm, A2 550nm 
with a plate reader.
2.14 Western blotting
Western Blotting was used in order to study the expression levels of proteins of interest. 
Samples to be analysed were solubilised with detergents and reducing agents and 
separation of proteins from crude lysate was achieved by SDS-PAGE. Transfer onto a 
PVDF membrane followed by chemiluminescnet detection was carried out for specific 
protein analysis, such as detection and quantitation. Using specific antibodies, amounts 
and levels of protein phosphorylation were determined.
2.14.1 Preparation of Buffers:
Washing buffer: PBS with 0.2 M Na3V 04; 0.5 M NaF; 1 x Lysis buffer: 50 mM Tris (pH 
8 ), 1% Triton X 100, 100 mM NaCI, 1 mM MgCI2, 1 mM Na3V04, 20 mM NaF, 1 mM (3- 
glycerophosphate, 1 tablet of protease inhibitor cocktail in 10 ml lysis buffer. Laemmli 
buffer: 100mM dithiothreitol (DTT), 0.005% bromophenol blue; 1 x running buffer: 0.025
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M Triz, 0.19 M Glycine, 0.1% SDS; Transfer buffer: 25 mM Tris, 0.2 M glycine, 1% SDS, 
20% methanol; 1 x TBS-Tween: 10 mM Tris (pH 8), 150 mM NaCI, 0.1% Tween 20; 
Blocking buffer: 5% w/v non-fat milk powder in 1 x TBS-Tween.
2.14.2 Preparation of cell extracts
MLF cells were seeded 24 to 48 hours prior to subsequent treatment. After each 
treatment (each result section will contain the particular experimental details), cells 
were lysed. Specifically, cells were washed twice with ice-cold washing buffer. Cells 
from 6-well plates were kept on ice and lysed in 200 pi of lysis buffer supplemented 
with a complete protease inhibitor cocktail (‘complete-Mini’ pellets from Roche, UK). 
Viscous lysates were scraped and collected into labelled microfuge tubes, and placed 
on ice followed by spinning for 10 minutes at 13, OOOg in order to remove cell debris. 
The chromosomal DNA was sheared by repeated passaging through a hypodermic 
needle (25G) for 25 times per sample. Whole cell extracts were stored in -80 °C before 
use.
2.14.3 BCA Protein assay
Protein concentrations of samples were assessed according to the read out of BCA 
Protein Assay (bicinchoninic assay, pierce, USA). The BCA assay works by the biuret 
reaction whereby protein reduces Cu2* to Cut+ in an alkaline medium. Each Cu1* ion 
then complexes with 2 molecules of bicinchoninic acid to form a water-soluble purple- 
coloured reaction product that exhibits a strong absorbance at 562 nm which is linear 
with increasing protein concentration over a broad working range from 20 pg/ml to 
2000 pg/ml. The amount of protein in samples was derived by comparison a bovine 
serum albumin standard curve. The assay was performed by adding 200 pi of freshly 
prepared BCA working reagent to 20 pi of each sample or standard (assayed in 
duplicate) in a 96-well plate. The plate was covered with plate seal and agitated on a 
plate shaker for 30 seconds followed by 30 minutes incubation at 37 °C. The plate was 
then cooled to room temperature and read at 540 nm on a Titertek Multiscan MCC/340 
plate reader (Labsystems, Finland).
2.14.4 Separation of proteins by S DS-polyaery lam ide gel electrophoresis 
SDS-PAGE gels were prepared according to the recipes outlined in Tables 2.9 and
2.10 and cast using the Bio-Rad Mini-Protean II casting apparatus. For electrophoresis, 
an aliquot of each sample (equivalent to 5 pg of protein for the detection of ERK1/2, 30 
pg for detection of p38 and c-Raf, 100 pg for the detection of MLC and GaO was added 
with laemmli buffer (5% in the final mix) and incubated for 10 minutes at 80 °C and then
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returned to the ice until they were loaded onto a SDS-PAGE gel: 10% SDS-PAGE gel 
for the detection of ERK1/2, p38 and c-Raf which contained 10% resolving gel and 5% 
stacking gel; 15% SDS-PAGE gel for the detection of MLC which contained 15% 
resolving gel and 5% stacking gel, and 12.5% SDS-PAGE gel for the detection of Gaj 
which contained 12.5% resolving gel and 5% stacking gel. The resolving gel mixture 
was overlaid with water-saturated butan-2-ol while the TEMED and APS (Ammonium 
persulphate)-catalysed polymerisation occurred. This was to achieve a smooth and 
level surface when the gel was set. The butan-2-ol was thoroughly washed off and a 
stacking gel containing loading wells was poured above the set resolving gel.
5% 10% 12.5% 15% 20%
1.5 M Tris pH 8.9 2.5ml 2.5ml 2.5ml 2.5ml 2.5ml
30%, 37:1 acryl/bisac 1.7ml 3.3ml 4.2ml 5.0ml 6.7ml
Water 5.7ml 4.1ml 3.2ml 2.4ml 0.7ml
20% SDS 100 pi 100 pi 100 pi 100 pi 100 pi
10% APS 67 pi 67 Ml 67 Ml 67 pi 67 Ml
TEMED 4 Ml 4 Ml 4 pi 4 pi 4 Ml
Table 2.9 SDS-PAGE resolving gel recipes
10 ml 5 ml
1 M Tris pH 6.8 1.25 ml 0.63 ml
30% Acryl/bis 1.6 ml 0.8 ml
Water 7.0 ml 3.5 ml
20% SDS 100 pi 50 pi
10% APS 67 pi 33 pi
TEMED 10 pi 5 pi
Table 2.10 SDS-PAGE stacking gel recipes.
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Samples prepared as above, were loaded onto the SDS-poiyacrylamide gels. A pre­
stained 4 kDa apparent molecular mass (Mr) ladder (SeeBlue TM; Novex Inc./R&D 
Systems Europe Ltd, Abingdon, UK) was run in a separate lane to easily identify 
various Mr. Samples were electrophoresed at 120V for 2hours in running buffer.
2.14.5 Transfer of proteins onto PVDF membrane
Resolved proteins were transferred to a polyvinylidene difluoride (PVDF) membrane 
using a horizontal semi-dry transfer method (multiphor II; Pharmacia LKB, Sweden). 
The PVDF membrane was pre-equilibrated in transfer buffer for at least 10 minutes 
prior to blotting. All other components were also soaked beforehand in transfer buffer. 
PVDF membrane was placed on top of eight pieces of Whatmann 3MM filter paper and 
overlaid with the gel. Air bubbles were removed by rolling over the membrane using a 
pipette. A second layer of filter paper was placed on top of the gel to complete the 
sandwich. The cassette assembly was placed into a tank and a current of 40 
mA/membrane was applied for one and half hours.
2.14.6 Detection of proteins by ECL
Following transfer, the membrane was probed with specific antibodies and proteins 
detected by chemiluminescence. Specifically, the membrane (bearing the covalently 
bound proteins) was incubated in blocking buffer for 1 hour at room temperature on a 
rotating platform. The membrane was then incubated overnight at 4°C in 0.25% BSA 
buffer containing an appropriate dilution of antibody for the protein of interest. 
Membranes were washed 3 x, 5-minute each, at room temperature in TBS-tween (10 
mM Tris, pH 8 , 150 mM NaCI, 0.1% Tween 20) and then incubated for 1 hour at room 
temperature with a 1:2500 dilution of horseradish peroxidase (HRP)-linked secondary 
antibody in 0.25% milk buffer (Santa Cruz Biotechnology). Following 3 x, 5-minute 
washes in 0.5% tween-TBS, blots were developed by enhanced chemiluminescence 
(ECL) according to manufacturer’s instructions (Amersham). Exposure time was 
adjusted accordingly to ensure accurate quantification of protein bands. 
Immunoreactive bands were visualized by exposing the membrane to autoradiography 
film developer (Kodak, UK). A list of all antibodies used in this study for western blotting 
is detailed in Table 2. 2.
2.14.7 Quantification of protein bands
Semi-quantitative analysis of western blots was performed using densitometry. The 
blots underwent transmissive greyscale scanning at 300 dpi on a standard flatbed 
scanner (Epson, UK). The scanned images were transferred to the public domain NIH
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image 1.61 program (developed at the U.S. National Institute of Health and available 
on the internet at http://rsb.info.nih.gov/nih-imaae/ and the optical density of each 
protein band was calculated with reference to a calibration curve. This calibration curve 
was specifically generated by scanning a Kodak photographic Step Tablet (Kodak, UK) 
with known optical density gradient using the same settings as described above. The 
obtained optical density for the activated protein of the target gene was then 
normalised against the optical density for the total protein of the same target gene, 
allowing correction for protein loading and therefore meaningful comparison between 
samples.
2.15 mRNA study
2.15.1 RNA isolation, purification and quantitation
Cells were seeded in 6 well tissue culture plates in DMEM-10% FCS prior to 
subsequent treatment. Each result section will contain the particular experimental 
details. Following stimulation, the media was removed and the cell layer was scraped 
into 1 ml of TRIzol. TRIzol is a phenol-based reagent for single-step isolation of RNA 
from cells. It is a solution of phenol and guanidine isothiocyanate which disrupts cell 
membranes by dissolving cell components but maintaining the integrity of RNA. Total 
RNA was isolated according to the manufacturer’s instructions (Invitrogen, UK). The 
homogenate was incubated at room temperature for 10 minutes, followed by the 
addition of 200 pi chloroform and centrifugation at 13,000 g for 15 minutes at 4°C. The 
supernatant was aspirated into a new tube, with 500pl isopropanol added to each 
sample, centrifuged at 13,000 g for 10 minutes at 4°C. Supernatants were then 
discarded and the pellets were washed with 1 ml 80% ethanol. Samples were 
centrifuged at 13,000 g for 10 minutes at4°C and the supernatants aspirated. Samples 
were centrifuged at 13,000 g for 1 minute at room temperature again in order to 
remove as much remaining liquid as possible. Pellets were partially air-dried (about 30 
minutes) until a clear gel obtained and re-suspended in 20 pi DEPC-treated water.
The samples (2 pi each) were mixed with H20  (5 pi for each sample), and RNA loading 
buffer containing ethidium bromide (3 pi). The mixture was then heated to 65°C for 5 
minutes, prior to loading onto an agarose gel to check RNA quality. To prepare a 1% 
agarose gel, 2 g of agarose were added to 162 ml DEPC-treated water and heated in a 
microware. After cooling the agarose solution down to about 65°C, formaldehyde to 9% 
(v/v; about 18 ml) and 20 ml of 20 X MOPS (0.4 M 3-N-morpholino-propane sulphonic 
acid, 32 nM sodium acetate and 4 mM EDTA), were added. The gel was then cast into 
a gel tray, containing a loading comb and left to set at room temperature. The gel was
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finally submerged in running buffer (1 X MOPS). RNA samples were loaded into the 
wells of the agarose gel and separated by electrophoresis in an electrophoresis 
chamber (International Biotechnologies Inc., CT, USA) at a constant voltage of 70 V for 
1 hour. RNA loading and integrity were confirmed by the presence of the ethidium 
bromide stained 18S and 28S ribosomal RNA bands, which were visualised with a 
Syngene Gene Bio-imaging system (Synoptics, UK).
In order to avoid DNA interference in the final qRT-PCR experiments, RNA purification 
was carried out for any samples that have been proofed to be in a good condition by 
electrophoresis described above. Total RNA was treated with DNase to remove 
contaminating genomic DNA, using DNA-free™ kit (Ambion Ltd. UK). 17 pi of each 
sample from above was added with 2 pi DNase buffer and 1 pi rDNase following 
incubation at 37°C for 30 minutes. Further 2 pi DNase inactivation reagent was added 
and samples were incubated 5 minutes at room temperature, mixed twice during the 
incubation period. Samples were centrifuged at 10,000 g for 2 minutes at RT, the 
purified RNA were transferred to a fresh tube and stored at -70*0 until used.
The purified RNA was again analysed by running samples on an agarose gel as 
described above. RNA was next quantified in order to prepare equal amount of RNA of 
each sample for cDNA synthesis. For RNA quantification, 2 pi of each RNA sample 
was diluted in 50 pi ddH20. The absorbance of each sample was sequentially 
measured at a wavelength of 260 nM and 280 nM using a UV spectrophotometer 
(Ultraspec 3000, Pharmacia Biotech, Buckinghamshire, UK). The ratio of the optical 
density units at 260 nM and 280 nM was used as a gross indicator of the purity of the 
RNA sample. Ratios between 1.7 and 1.9 were considered acceptable. RNA 
concentration was calculated based on the assumption that 40 pg of total RNA in 1 ml 
water gives an absorbance reading of 1 optical density unit at 260 nM. The volume of 
the RNA sample containing 3 pg total RNA from fibroblast cultures was calculated and 
made up to a total volume of 10 pi with DEPC-treated water.
2.15.2 cDNA synthesis
cDNA was prepared by reverse transcription (RT) using a RT-PCR kit from Applied 
Biosystems (Roche, Lewes, UK). Reactions were performed according to the 
manufacturer’s instructions. Briefly, 3 pi RNA (equivalent to 1 pg) from above was 
added to the reaction mix (4 pi MgCI2; 2 pi 10 x Buffer; 8 pi dNTP mix; 1 pi reverse 
transcriptase). Reactions were then performed using a tetrad (PTC-225, Peltier 
Thermal cycle) according to the manufacturer’s instruction: incubation at room
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temperature for 10 minutes, 42°C for 15 minutes, 99°C for 5 minutes and then 5°C for 
5 minutes. Samples were stored at -20°C before use.
2.15.3 RT-PCR
RT-PCR was performed using a tetrad (PTC-225, Peltier Thermal cycler, Global 
Medical Instrumentation, USA). For each pair of primers, a master mix was prepared 
which contained all reagents except the cDNA. The final volume of each PCR reaction 
was 25 pi, containing cDNA, AmpliTaq DNA polymerase, buffer, dNTPs, magnesium 
chloride (all from Applied Biosystems, UK) and 0.25 pM of each primer. The following 
cycling conditions were used: 94 °C 5 minutes; 94 °C 30 seconds for 35 cycles; 60 °C 
30 seconds; 72 °C for 30 seconds; 72 °C for 7 minutes and 25 °C for 30 seconds.
10 pi of each PCR reaction was added to 5 pi of loading buffer (40% w/v sucrose; 
0.25% w/v bromophenol blue; 0.25% w/v xylene cyanol, made up in distilled water) and 
electrophoresed through a 2% agarose gel containing 0.5 pg/ml ethidium bromide. 
Bands were visualised by UV transilumination. The size of the PCR products was 
estimated using a co-migrated DNA size marker (Roche Diagonostics).
2.15.4 Quantitative Real time RT-polymerase chain reaction (qRT-PCR) 
Quantitative real time RT-PCR was conducted using the Platinum SYBR Green qPCR 
SuperMix UDG (Invitrogen, UK) with 1 ng of cDNA and forward and reverse primers 
each at a final concentration of 500 nM, on a LightCycler 1.5 Real-time Detection 
System following the manual and analysed using LightCycler Real-time PCR Detection 
System Software Version 3.5 (all from Roche, Hertfordshire, UK). Cycling conditions 
were as follow: one cycle of 50 °C (2 minutes), 95 °C (2 minutes); 50 cycles of 95 °C (5 
seconds), 55 °C (5 seconds), 72 °C (15 seconds). Melting curve analysis was used to 
confirm the specificity of the PCR product.
The magnesium concentration for each primer set was then optimised. A number of 
real time RT-PCR reactions were performed in parallel, using template cDNA from a 
sample known to express the gene of interest but substituted with varying 
concentrations of Mg2+. Reactions with the steepest logarithmic amplification plot, and 
typically also the lowest cycle number at which detectable amplification occurred, 
indicated the optimal Mg2* concentration for use with the given primer set.
The efficiency of each primer pair was also assessed by determining crossing point (Cp) 
values for RT-PCR reactions using a series of half logarithmic dilutions of template
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cDNA. Cp values were defined as the earliest point of the linear region of the 
logarithmic amplification plot reaching a threshold level of detection. Log 
concentrations of samples were plotted against Cp values, and the slope of the plot 
determined. Efficiency was then given by the equation: Efficiency =io('1/slope). Primers 
were only used if the PCR efficiency was greater than 95%.
To examine the quantitative differences in the mRNA target gene expression in each 
sample, PCR product was measured at the end of each cycle. Cp values were 
determined from the linear region of the logarithmic amplification plots. Each sample 
was also tested for expression of the ‘houskeeping’ gene 18S and this was used to 
normalise between samples. Relative quantitation was calculated according to the E*‘ 
AACP method. Briefly, ACP=Cp target gene-Cp 18S. All the samples were then 
compared to the control (untreated group). The AACP=ACP -  Average ACP control. 
Primers with efficiency over 1.8 were used. The fold increase=1.8A‘AACP.
2.16 Immunocytofluorescence staining
Immunocytofluorescece staining was used to recognize the intracellular CCL2 protein 
production. MLFs were plated on an 8-well chamber glass-slides in a density of 3 X 104 
/ well. After 24 hours, cells were starved in 0.1% FBS-DMEM for 24 hours. Following 
stimulation (details please see individual results section), cells were rinsed with PBS 
gently and then fixed for 15 minutes with 4% formaldehyde in PBS. Following fixation, 
cells were then rinsed with ice-cold sterile PBS for 3 times, 10 minutes each. After 
washing, cells were permeabilized with 0.2% Triton X-100 at room temperature for 10 
minutes. Cells were then rinsed again with ice-cold sterile PBS for 3 times, 10 minutes 
each. To avoid non-specific binding, the cells were then incubated with 4% normal 
rabbit serum for 1 hour at room temperature. After 1 hour incubation with normal rabbit 
serum, cells were incubated with primary antibody (goat polyclonal anti-CCL2, R&D) for 
1 hour at room temperature following three washes with ice-cold sterile PBS, 10 
minutes each. Secondary antibody (FITC-conjugated rabbit anti-goat IgG) was 
incubated in the dark for 1 hour at room temperature and subsequently slides were 
washed three times with ice-cold sterile PBS, 10 minutes each. Finally, the cells were 
stained with DAPI for 10 minutes in dark followed by two washes with ice-cold sterile 
PBS, 5 minutes each. The chambers slide was then mounted with Gevotol and covered 
with cover slip, left overnight at room temperature in dark. Slides were analyzed the 
following day.
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Immunocytofluoresence images were acquired by confocal microscopy using the Bio- 
Rad MRC 1024 confocal system (Hercules, CA), and the images were analyzed for the 
pixel intensity of the fluorescence using the Bio-Rad LaserPix image analysis software.
2.17 Data handling and statistical analysis
All data are presented as mean ± standard errors of the mean (SEM) from three 
triplicate cultures, unless otherwise indicated. Statistical evaluation was performed 
using an unpaired t-test for single group comparisons and Newman-Keuls one way 
analysis of variance (ANOVA) for multiple group comparisons. The mean values of 
various parameters were considered to be significantly different when the probability of 
the differences of that magnitude, assuming the null hypothesis to be correct, fell below 
5% (i.e. p<0.05).
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Chapter 3: Results (I)
3.1 Role of PARi activation in mouse lung fibroblast CCL2 protein production in 
vitro
The aim of the first studies was to determine whether thrombin has the potential to 
influence the production of CCL2 by wild type mouse lung fibroblasts (MLFs), and to 
identify the signalling receptor involved.
3.1.1 Effect of thrombin on CCL2 protein production by mouse lung fibroblasts
In order to determine the effect of thrombin on MLF CCL2 production and release, 
MLFs were exposed to various concentrations of thrombin, and CCL2 protein levels in 
culture supernatants were assessed by ELISA. Previous studies from Bachli and 
colleagues showed that thrombin induces a significant increase of CCL2 protein 
production after 6 hours incubation in dermal fibroblasts (Bachli et a!., 2003). Hence, a 
6 hour incubation period was used to examine the concentration-dependent effect of 
thrombin in MLFs. Figures 3.1 A & B show that thrombin stimulated CCL2 protein 
release in a time- and concentration-dependent manner from 0.03 nM onwards. CCL2 
production continued to increase at concentrations higher than 0.03 nM and the effect 
did not plateau at the highest concentration of thrombin (300 nM) examined. Time- 
course experiments (Figure 3.1B) with thrombin at a physiologically relevant 
concentration (10 nM) showed that the significant increase was observed from 2 hours 
onwards, and the sharpest increase in CCL2 release occurs over the first 12 hours. For 
comparison, the basal CCL2 protein production did not change over the 24 hours 
incubation period
3.1.2 The role of PARi in thrombin induced-CCL2 production by mouse lung 
fibroblasts
Four PAR receptors (PAR^) have been identified, and PARi, PAR3, and PAR4 are all 
activated by thrombin. In order to determine the role of PAR receptors for mediating the 
effect of thrombin on CCL2 production, the expression of PAR1-4 receptors in MLFs 
was first examined. Total RNA for MLFs was extracted using TRIzol, and quantitative 
real time RT-PCR (qRT-PCR) was performed for all four PARs. Values were 
normalized to 18S RNA and reported as a relative value by setting arbitrarily PAR4 
mRNA expression as 1. As shown in Figure 3.2, the expression of PAR2 and PAR3 was 
not detectable, whereas PARi mRNA levels were 346 fold higher than PAR4.
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PARi is the high-affinity thrombin receptor. It is cleaved at lower thrombin 
concentrations and preferentially cleaved when other PARs are present. The 
involvement of PARt in thrombin-induced MLF CCL2 production was first examined. 
Serum-starved PARi knockout MLFs (PARi KO MLFs) were stimulated with 10 nM, 30 
nM and 100 nM thrombin for 6 hours (Figure 3.3A). CCL2 protein levels in 
supernatants were assessed by ELISA. The results show that 10 nM thrombin did not 
induce CCL2 production in PARi KO MLFs, suggesting that thrombin at 10 nM induces 
MLF CCL2 production via the activation of PARi. In contrast, a significant increase in 
CCL2 production was obtained with thrombin at concentrations of 30 nM and 100 nM 
(Figure 3.3A). It is well-known that thrombin can also signal via PAR4 or via PAR- 
independent mechanism at relatively high concentrations (O'Brien et a!., 2001). In 
order to further investigate if PAR4 mediates thrombin-induced CCL2 release in PARi 
KO MLFs, the effects of PAR4 agonist peptide AYPGKF and the reverse peptide 
YAPGKF were examined. Experiments were also performed with TNF-a as a positive 
control known to induce CCL2 independent of PAR signalling (Figure 3.3B). The results 
show that both AYPGKF and YAPGKF did not induce CCL2 release, whereas TNF-a 
induced a significant increase of CCL2 release. These data suggest that thrombin at 
concentrations higher than 10 nM induces MLF CCL2 production in a PAR- 
independent manner.
To further verify that 10 nM thrombin-induced CCL2 protein production was PARi- 
dependent, wild type and PARi KO MLFs were exposed to thrombin (10 nM) and the 
specific PARi agonist peptide TFLLR (200 pM) for 6 hours (Figure 4A). As shown in 
figure 3.4A, thrombin and TFLLR induced a 4.6 fold and an 8.2 fold increase 
respectively in CCL2 protein levels, by wild type MLFs (all p<0.01). In contrast, PARi 
KO MLFs were completely unresponsive to both thrombin and TFLLR (Figure 3.4A). 
The effect of the inactive reverse peptide RLLFT on thrombin-induced CCL2 production 
was also examined in parallel cultures and the results show that RLLFT had no effect 
in both wild type and PAR! KO mouse lung fibroblasts. These data suggest that the 
effect obtained with TFLLR in MLFs is PAR 1-mediated.
In order to further confirm that thrombin-induced CCL2 production was PARi- 
dependent at 10 nM, the effect of the specific PAR! antagonist RWJ-58259 on 
thrombin-induced CCL2 production was investigated (Figure 3.4B). Cells were pre­
incubated with increasing concentrations of RWJ-58259 for 15 minutes prior to 
stimulation with 10 nM thrombin for 6 hours. The results show that inhibition of PARi by 
RWJ-58259 blocked CCL2 protein production in a concentration-dependent manner
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from 0.3 pM (-Log [0.3 pM]=6.5) onwards. RWJ-58259 at 3 pM (-Log [3 pM]=5.5) 
inhibited this response by 95.6 ± 5.18% (p<0.01). The IC50 of RWJ-58259 was 
determined to be 0.4 pM for this response.
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Figure 3.1: Thrombin stimulates MLF CCL2 protein production in a concentration- and 
time-dependent manner.
Panels A and B show concentration response (A) and time-course (B) data for the effect of 
thrombin on MLF CCL2 protein production. MLFs were exposed to thrombin (0.003 nM to 300 
nM) for 6 hours, or exposed to thrombin (10 nM) for varying durations (2 to 24 hours). 
Supernatants from cell cultures following incubation were analyzed for CCL2 protein secretion 
by ELISA. The amount of secreted CCL2 is expressed as pg/ml and each value represents the 
mean ± SEM from triplicates at each concentration or time point. Data show the representative 
of three independent experiments. p<0.05 comparison with unstimulated cells or time point- 
matched media control.
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Figure 3.2: PAR gene expression in MLFs.
Figure shows the gene expression levels of PARs in MLFs. Total RNA for MLFs were exacted 
using TRIzol. Quantitative real-time RT-RCR (qRT-PCR) was performed using the Platinum 
SYBR green qPCR SuperMix UDG. Expression levels of PAR1( PAR2, PAR3 and PAR4 was 
normalized by 18S RNA and reported relative to PAR4 expression. Data show the 
representative of three independent experiments.
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Figure 3.3 Thrombin at concentrations higher than 10 nM induces CCL2 production via a 
PAR-independent mechanism.
Panel A shows the concentration response effect of thrombin on PARi KO MLF CCL2 protein 
production. PARi KO MLFs were exposed to thrombin (10, 30 and 100 nM) for 6 hours. Panel B 
shows the effects of PAR4 agonist AYPGKF, the reverse peptide YAPGKF and TNF-a on PAR! 
KO MLF CCL2 production. Cells were stimulated with AYPGKF, YAPGKF and TNF-a for 6 
hours. CCL2 levels in culture supernatants were measured by ELISA. The amount of secreted 
CCL2 is expressed as pg/ml and each value represents the mean ± SEM from triplicates at 
each condition. Data show the representative of three independent experiments. *p<0.05, 
**p<0.01 comparison with unstimulated cells.
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Figure 3.4 PARi is necessary and sufficient for thrombin (10 nM) induced CCL2 protein 
production
Panel A shows the effects of thrombin, PAR, agonist TFLLR-NH2, and the reverse peptide 
RLLFT-NH2 on CCL2 protein production in MLFs and PAR, KO fibroblasts. Cells were exposed 
to thrombin (Thr, 10 nM), TFLLR (TF, 200 pM) or RLLFT (RL, 200 pM) for 6 hours. Data are 
presented as fold-increase relative to media control. Panel B shows effect of the PAR, 
antagonist RWJ-58259 on MLF CCL2 protein production in response to thrombin. Data are 
presented as a percentage of the maximal response obtained with thrombin with drug vehicle 
alone (0.03% DMSO in DMEM). Cells were treated with increasing concentrations of RWJ- 
58259 for 15 minutes before stimulation with thrombin for 6 hours. Final concentrations of 
DMSO were kept constant for all treatment conditions. The first bar represents the highest 
concentration of RWJ-58259 and shows that this compound has no effect on basal CCL2 
production. Negative log of the concentrations of RWJ-58259 are presented. Data represent the 
mean ± SEM of triplicates. Data show the representative of three independent experiments. 
CCL2 levels in culture supernatants were measured by ELISA. ++p<0.01 comparison with 
unstimulated cells; "p^-OI comparison with thrombin alone.
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3.1.3 Effect o f thrombin on CCL2 mRNA ievels in mouse lung fibroblasts
The data obtained so far strongly indicate that PARt is necessary and sufficient for 
thrombin-induced MLF CCL2 protein release at 10 nM. To determine whether thrombin 
could similarly influence CCL2 gene expression, the effect of thrombin on CCL2 mRNA 
levels was assessed by qRT-PCR. As shown in figure 3.5 A, thrombin increased CCL2 
mRNA levels significantly within 30 minutes, with a maximal increase (21 ± 2.9 fold 
relative to control) observed at 6 hours (Figure 3.5A, p<0.01). CCL2 mRNA levels 
declined after 9 hours and returned to baseline level at 24 hours. To determine if 
thrombin induces CCL2 protein release transcriptionally or post-transcriptionally, the 
effect of actinomycin-D (act-D: inhibitor of transcription) and cycloheximide (CHX: 
inhibitor of protein synthesis) on CCL2 mRNA levels induced by thrombin was next 
examined. MLFs were pre-incubated with act-D (1 pg/ml) for 30 minutes, or pre­
incubated with CHX (1 pM) for 1 hour, and subsequently stimulated with 10 nM 
thrombin for 2 hours (Figure 3.5 B&C). As shown in figure 3.5B, act-D almost 
completely abolished thrombin-induced CCL2 mRNA levels (88.27 ± 0.037%), 
suggesting that thrombin-induced CCL2 protein release is not due to the release of 
prestored CCL2. In contrast, experiments performed in the presence of CHX (Figure 
3.5C) showed that CHX alone significantly induced CCL2 mRNA levels, and that 
thrombin-induced CCL2 mRNA expression was also dramatically enhanced by CHX. 
This suggests that CCL2 mRNA levels are highly regulated by a labile repressor at 
baseline, which may not be overcome by the addition of thrombin.
3.1.4 Effect o f PARi on thrombin-induced CCL2 mRNA levels
To determine whether PARi mediates thrombin-induced CCL2 production via the 
increase of CCL2 mRNA level, the influence of the specific PARi antagonist RWJ- 
58259 on thrombin-induced CCL2 mRNA levels was investigated (Figure 3.6). Pre- 
incubation of MLFs with RWJ-58259 (1 pm) for 15 minutes prior to stimulation with 10 
nM thrombin for 2 hours almost completely abolished this response, indicating that 
PARi is necessary for thrombin-induced CCL2 mRNA levels, and PARt mediates 
thrombin-induced CCL2 production via a transcriptional mechanism.
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Figure 3.5 Thrombin increases CCL2 protein via increased gene expression in MLFs.
Panel A shows time-course data for the effect of thrombin on CCL2 mRNA levels. MLFs were 
exposed to serum-free control medium (DMEM) or thrombin (10 nM) for varying duration from 
0.5 to 24 hours. CCL2 mRNA levels at each time point were assessed by qRT-PCR. Data are 
expressed as fold change relative to time zero for each time point (mean ± SEM from triplicates) 
following normalization to 18S RNA. Panel B shows the effect of act-D on thrombin-induced 
CCL2 mRNA levels. MLFs were exposed to thrombin for 2 hours with or without pre-incubation 
with act-D (1 pg/ml) for 30 minutes. CCL2 mRNA levels were determined as in panel A. act-D 
was dissolved in ethanol and the same amount of ethanol was added for all cultures (0.1% 
ethanol in DMEM). Panel C shows the effect of CHX on thrombin-induced CCL2 mRNA levels. 
MLFs were exposed to thrombin for 2 hours with or without pre-incubation with CHX (1 pM) for 
1 hour. CCL2 mRNA levels were determined as in panel A. Data represent mean + SEM from 
triplicates at each condition, and show the representative of three independent experiments. 
p<0.05, comparison with time-point matched medium control; ++p<0.01, comparison with 
unstimulated cells; "p<0.01, comparison with thrombin alone.
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Figure 3.6 PAR<| mediates thrombin-induced MLF CCL2 mRNA levels.
Figure shows the effect of RWJ-58259 on thrombin-induced MLF CCL2 mRNA levels. MLFs 
were exposed to thrombin for 2 hours with or without pre-incubation with RWJ-58259 (1 pM) for 
15 minutes. CCL2 mRNA levels at each condition were assessed by qRT-PCR. Data are 
expressed as fold change relative to untreated group (mean ± SEM from triplicates) following 
normalization to 18S RNA. Data show the representative of three independent experiments.
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3.1.5 Summary
The results described in this section examining the effect of thrombin on MLF CCL2 
protein release and mRNA levels showed that:
• Thrombin induces MLF CCL2 protein release in a time and concentration- 
dependent manner from 0.03 nM onwards.
• PARi is strongly expressed in MLFs; PAR2 and PAR3 are not detectable, 
whereas PAR4 is weakly expressed.
• PARi is necessary and sufficient for mediating thrombin (10 nM)-induced CCL2 
production in MLFs.
• The effect of thrombin on MLF CCL2 release at higher concentrations {> 10 nM) 
is likely to be independent of PAR signalling.
• Thrombin induced MLF CCL2 mRNA levels in a time-dependent manner and 
this is mediated by PARi since inhibition of PARi by RWJ-58259 abolished this 
response.
• Gene transcription is an important mechanism leading to the enhanced CCL2 
production in MLFs in response to thrombin as the transcription inhibitor act-D 
completely abolished thrombin-induced CCL2 mRNA levels.
• De novo protein synthesis is not required for thrombin-induced CCL2 mRNA 
levels since the protein synthesis inhibitor CHX did not inhibit this response.
In summary, thrombin (10 nM) induces CCL2 protein release and mRNA levels via the 
activation of PARi, and gene transcription is an important mechanism leading to the 
enhanced CCL2 protein production.
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3.2 The role of G proteins in thrombin-induced CCL2 mRNA levels and protein 
production
In order to begin to unravel the mechanisms by which thrombin exerts its stimulatory 
effects on CCL2 mRNA and protein levels, I first examined the potential involvement of 
G proteins, since PARt exerts its pluripotent cellular effects via the ability to interact 
with multiple downstream G proteins, including Gouo, Gaq/11 and Gai2/i3-
3.2.1 Effect o f pertussis toxin (PTX) on PAR^dependent CCL2 production
To evaluate whether PARi-mediated CCL2 production is Gai-dependent, the effect of 
Gctj specific inhibitor PTX on this response was examined. MLFs were pre-incubated 
with PTX (100 ng/ml) for 6 hours prior to exposure to thrombin (10 nM) for 6 hours 
(Figure 3.7A). The data show that PTX increased the basal and thrombin-induced 
CCL2 production. This finding suggests that a Ga, protein-coupled pathway exerts 
negative regulatory control of CCL2 production, and thrombin-induced CCL2 
production is independent of PARi coupling to Goi and its associated downstream 
signalling pathways. In order to verify the complete ADP-ribosylation of Gctj after 
pretreatment of MLFs with PTX, untreated and PTX-treated (100 ng/ml; for 6 hours) 
MLFs were lysed, and lysates were analyzed by western blotting with an antibody 
against Gctj (Figure 3.7B). Complete ADP-ribosylation after PTX treatment is indicated 
by the decreased mobility of Gaj-type G-proteins in SDS-polyacrylamide gels. This data 
further confirm that the lack of an inhibitory effect of PTX on thrombin-induced CCL2 
release is not due to the incomplete inhibition of Gaj activity.
3.2.2 PARf coupling to Gaq is necessary for PARr mediated CCL2 protein release 
and CCL2 mRNA levels
As PARi can also interact with Gaq and Gai2/13, the next experiments performed were 
to evaluate whether thrombin-induced CCL2 protein production was dependent on 
PARi coupling to Gaq and/or Ga12/13. A genetic inhibition approach was employed to 
address this question. MLFs were transduced with retroviral constructs encoding EGFP 
or Gaq, Gat and Ga12/13 minigenes. These G protein minigenes encode 11 unique 
carboxyl-terminal amino acid residues of Ga subunits and have previously been shown 
to effectively inhibit G protein signalling, including thrombin-mediated cellular effects 
(Ellis et al., 1999; Gilchrist et al., 2001; Vanhauwe et aI., 2002). Transfection efficiency 
was monitored by visualizing EGFP expression in control cells and approximately 90% 
of EGFP-transduced cells were EGFP positive as shown in Figure 3.8 A&B. 
Transduced-MLFs were then exposed to thrombin for 6 hours. The supernatants were 
analyzed for CCL2 production by ELISA. As shown in figure 3.8C, the Gaq C-terminal
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antagonist encoding minigene completely abolished thrombin-induced CCL2 release. 
In contrast, transduction with a control minigene encoding EGFP, or C-terminal Gai( 
Ga12 or Gan had no effect on this response, suggesting that subsequent activation of 
Gaq by PARi mediates thrombin-induced CCL2 production in MLFs, whereas Gat and 
Gai2/13 are not involved.
In order to further confirm the role of Gaq in mediating PARi activation-induced CCL2 
production, I next examined the effect of a novel small molecule antagonist, Q94, on 
this response. Q94 is a small molecule that specifically targets PARi coupling to Gaq. 
Figure 3.9A shows that Q94 blocked PAR 1-mediated CCL2 production in a 
concentration-dependent manner with complete inhibition obtained at 10 pM. 
Furthermore, inhibition of PARi coupling to Gaq with Q94 (10 pM) also completely 
abolished PAR^specific agonist peptide TFLLR-induced CCL2 production (Figure 
3.9B), further suggesting that PARi coupling to Gaq is necessary and sufficient for 
mediating thrombin-induced CCL2 production. In order to evaluate the specificity of 
Q94, the effect of Q94 on TNF-a-induced CCL2 production in MLFs was examined 
(Figure 3.9C). Experiments performed with TNF-a as the stimulus showed that Q94 (3 
and 10 pM) had no effect on TNF-a-stimulated CCL2 production, indicating that the 
antagonist was specific for PARi in blocking this response.
To evaluate whether PARi-coupling to Gaq mediates thrombin-induced CCL2 
production via increased CCL2 mRNA levels, the role of Gaq in thrombin-induced CCL2 
mRNA levels was next examined. MLFs were pre-incubated with Q94 (10 pM) for 3 
hours before exposure to thrombin for 2 hours. The subsequent mRNA levels were 
assessed by qRT-PCR. As shown in figure 3.10, Q94 significantly blocked thrombin- 
induced CCL2 mRNA levels by about 70% (p<0.01).
Taken together, these data show that PARi coupling to Gaq plays a central role in 
mediating thrombin-induced CCL2 protein production and mRNA levels.
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B
PTX
Figure 3.7 Pertussis toxin (PTX) increases basal and thrombin-induced CCL2 protein 
production.
Panel A shows the effect of Gj/0 inhibition by PTX on basal and thrombin-induced CCL2 
production. Cells were pre-incubated with PTX (100 ng/ml) for 6 hours before being exposed to 
thrombin (10 nM) for 6 hours. Supernatants from cell cultures following incubation were 
analyzed for CCL2 protein secretion by ELISA. Data represent the mean ± SEM of triplicates. 
++p<0.01, comparison with medium control in the absence of PTX; p<0.01, comparison with 
thrombin alone. Panel B shows the complete ADP-ribosylation of Gas after pretreatment of cells 
with PTX. Cells were treated with or without PTX (100 ng/ml) for 6 hours. Cell lysates were 
analyzed by western blotting with an antibody against Gdi. Data show the representative of 
three independent experiments.
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Figure 3.8 Gaq is necessary for mediating thrombin-induced CCL2 protein production.
Panel A and B show the representative analysis for MLF positive for enhanced green 
fluorescent protein (EGFP), showing the efficient transduction of the plasmid vector carrying 
GFP gene. Panel B shows the effects of G protein minigenes on thrombin-induced CCL2 
protein production. MLFs transduced with the pRevTRE2-EGFP, pRevTRE2-Gaq, pRevTRE2- 
Ga12, pRevTRE2-Ga13, or pRevTRE2-Gai were exposed to thrombin (10 nM) for 6 hours and 
CCL2 levels in culture supernatant were measured by ELISA. Data are expressed as fold 
increase of CCL2 production relative to GFP control. Data show the representative of three 
independent experiments. ++p<0.01, comparison with medium control; p<0.01, comparison with 
thrombin alone.
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Figure 3.9 PARi coupling to Goq is necessary and sufficient for thrombin-induced CCL2 
protein production.
Panel A, B and C show the effects of antagonist Q94 on thrombin (A, 10 nM), TFLLR (B, 200 
pM) and TNF-a (C, 10 ng/ml)-induced CCL2 production. Data are presented as a percentage of 
the maximal response obtained with thrombin, TFLLR, TNF-a and drug vehicle alone (0.1% 
DMSO in DMEM). Cells were treated with increasing concentrations of Q94 for 3 hours before 
exposure to thrombin, TFLLR or TNF-a for 6 hours. Final concentrations of DMSO were kept 
constant for all treatment conditions. The first bars represent the highest concentration of Q94 
used and show that this compound has no effect on basal CCL2 production in three 
experiments. Negative log of the concentrations of Q94 are presented. Data show the
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representative of three independent experiments.++ p<0.01, comparison with medium control; 
p<0.01, comparison with thrombin, TFLLR or TNF-a alone.
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Figure 3.10 PARi coupling to Gaq is necessary for thrombin-induced MLF CCL2 mRNA 
levels.
Figure shows the effect of Q94 on thrombin-induced CCL2 mRNA levels. MLFs were exposed 
to thrombin for 2 hours with or without pre-incubation with Q94 (10 pM) for 3 hours. Data 
represent the mean ± SEM of triplicates, and show the representative of three independent 
experiments. ++p<0.01, comparison with medium control; ** p<0.01, comparison with thrombin 
alone.
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3.2.3 Summary
The results described in this section examining the role of G protein a subunits in 
PARnnduced CCL2 protein release and mRNA levels showed that:
• Thrombin-induced CCL2 production in MLFs is not dependent on PARi 
coupling to G a , as inhibition of Gcij by both PTX and GOj minigene did not inhibit 
this response.
• Gai2 and Gdi3 are not involved in mediating thrombin-induced CCL2 production 
since inhibition of both Gai2 by Gdi2 minigene and Gdi3 by Gdi3 minigene did 
not block this response of thrombin.
• PARi coupling to Goq is necessary for mediating thrombin-induced CCL2 
production since this effect of thrombin was completely abolished by both Gaq 
minigene and the Goq selective PARi antagonist Q94.
• PARi coupling to Goq is also sufficient for mediating thrombin-induced CCL2 
production as Q94 abolished the CCL2 production induced by PARi-specific 
agonist peptide TFLLR.
• PARi coupling to Goq mediates thrombin-induced CCL2 protein release via 
increased CCL2 mRNA levels since inhibition of PARi coupling to Goq by Q94 
significantly inhibited thrombin-induced CCL2 mRNA levels.
In summary, thrombin-induced CCL2 protein release and mRNA levels are mediated 
by PARt coupling to Gaq.
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3.3 The role of MAP kinases in thrombin-induced MLF CCL2 production
Thrombin is known to exert its numerous cellular effects in fibroblasts via MAP kinase 
(p38, JNK and ERK1/2 kinases) pathways (Bogatkevich eta!., 2005; Wang et al., 2006), 
and previous studies performed in MLFs have shown that activation of Gaq by PARi 
leads to the activation of ERK1/2 (Trejo et al., 1996). However, in terms of thrombin- 
induced CCL2 release by other cell types, the p38 MAPK pathway has been shown to 
play an important role (Brandes et al., 2001; Marin et al., 2001). Thus, experiments 
were performed next to determine the relative roles of these MAPK kinases in PAR^ 
mediated CCL2 production.
3.3.1 Effect o f MAP kinase inhibition on thrombin-induced MLF CCL2 production
The role of p38 in thrombin-induced MLF CCL2 production was first examined. Cells 
were pre-incubated with increasing concentrations of the p38 specific inhibitor 
SB203580 for 30 minutes prior to stimulation with thrombin (10 nM) for 6 hours. As 
shown in figure 3.11 A, inhibition of p38 MAPK pathway with SB203580 had no effect 
on basal or thrombin-induced CCL2 production. In order to verify the specificity of 
SB203580, the effect of its inactive control SB202474 on thrombin-induced CCL2 
production was examined (Figure 3.11B). Surprisingly, the results show that 
SB202474 at the highest concentration used significantly inhibited thrombin-induced 
CCL2 release by -50%, suggesting that at the high concentrations these compounds 
may exert off-target effects. To further exclude the involvement of p38 in thrombin- 
induced CCL2 release, thrombin-induced p38 phosphorylation was examined. MLFs 
were stimulated with thrombin over a period ranging from 30 seconds to 2 hours 
(Figure 3.12A). P38 phosphorylation was examined by western blotting using a 
phospho-p38 specific antibody. Time-course data showed that thrombin induced p38 
phosphorylation in 2 minutes and phosphorylated p38 was undetectable in un­
stimulated cells. The signal faded away after 2 minutes and diminished after 1 hour 
stimulation. The effect of SB203580 on thrombin-induced p38 phosphorylation was 
next examined. Cells pre-incubated with SB203580 (2 pM) for 30 minutes were 
exposed to thrombin for 2 minutes, cell lysate were analyzed by western blotting. The 
results show that SB203580 at highest concentration used completely inhibited 
thrombin-induced p38 phosphorylation. It is therefore concluded that although thrombin 
activated p38 MAPK in MLFs, p38 is not involved in mediating PARHnduced CCL2 
release.
The role of JNK was next examined. MLFs were pre-incubated with JNK inhibitor TI-JIP 
for 30 minutes before exposed to thrombin for 6 hours (Figure 3.13). Surprisingly, the
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data show that inhibition of JNK pathway by TI-JIP did not block thrombin-induced 
CCL2 production, but rather it increased both basal and thrombin-stimulated CCL2 
protein release in a concentration-dependent manner from 1 pM onwards (all p<0.01) 
(Figure 3.13), These data suggest that JNK pathway did not mediate thrombin-induced 
CCL2 production.
Conversely, preincubation of MLFs with the MEK1/2 inhibitor U0126 blocked thrombin- 
induced CCL2 production in a concentration-dependent manner from 0.3 pM (-Log [0.3 
pM]=6.5) onwards (Figure 3.14A). At 10 pM (-Log [10 pM]=5), U0126 inhibited 
thrombin-induced CCL2 production by 84.7±0.26% (p<0.01). The IC50 of U0126 was 
determined to be 1.3 pM for this response. As MEK1/2 is a direct upstream activator of 
ERK1/2, the inhibitory effect obtained with U0126 infers the involvement of ERK1/2 in 
PARi-mediated CCL2 production. To further strengthen the results obtained with 
U0126 and to further confirm the involvement of ERK1/2 in this response, another 
widely used, but structurally unrelated MEK1/2 inhibitor PD98059 was also employed 
and the effect of PD98059 on thrombin-induced CCL2 production was also examined. 
As shown in figure 3.14B, PD98059 at the commonly used concentration (50 pM) also 
inhibited PARi-mediated CCL2 production, suggesting that MEK1/2 by referring to 
ERK1/2 is involved in PAR^mediated CCL2 production.
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Figure 3.11 Thrombin-induced CCL2 production by MLFs and this effect is not blocked 
by p38 kinase inhibition.
Panel A and B show the effects of SB203580 and SB204797 on CCL2 protein production in 
response to thrombin. Data are presented as a percentage of the maximal response obtained 
with thrombin and drug vehicle alone (0.02% DMSO in DMEM). Cells were treated with 
increasing concentrations of SB203580 or SB 204797 for 30 minutes before exposure to 
thrombin (10 nM) for 6 hours. Final concentrations of DMSO were kept constant for all treatment 
conditions. The first bars represent the highest concentration of inhibitors used, and show that 
these compounds have no effect on basal CCL2 production. Negative log of the concentrations 
of each inhibitor are presented. Data show the representative of three independent experiments. 
++ p<0.01, comparison with unstimulated cells; ”  p<0.01, comparison with thrombin alone.
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Figure 3.12 Thrombin induces p38 phosphorylation in a time-dependent manner and this 
effect is inhibited by SB203580 in MLFs.
Panel A shows that thrombin induced p38 phosphorylation in a time-dependent manner. MLFs 
were exposed to thrombin (10 nM) for the indicated time periods. P38 phosphorylation was 
assessed by western blotting using an anti phospho-p38 antibody. Protein loading control was 
verified by blotting with an anti-total p38 antibody (lower panel). Panel B shows the effect of 
SB203580 on thrombin-induced p38 phosphorylation. Cells were pre-incubated with p38 (2 pM) 
for 30 minutes followed by thrombin stimulation for 2 minutes. P38 phosphorylation was 
assessed by western blotting using an anti phosphor-p38 antibody (upper panel). Protein 
loading control was verified by blotting with a total p38 antibody (lower panel). Data show the 
representative of three independent experiments.
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Figure 3.13 Thrombin-induced CCL2 production by MLFs is not attenuated by JNK 
inhibition.
Figure shows the effect of Tl-JfP on CCL2 protein production in response to thrombin. Data are 
presented as a percentage of the maximal response obtained with thrombin and drug vehicle 
alone (0.1% DMSO in DMEM). Cells were treated with increasing concentrations of TI-JIP for 30 
minutes before exposure to thrombin (10 nM) for 6 hours. Final concentrations of DMSO were 
kept constant for all treatment conditions. The first bar represents the highest concentration of 
TI-JIP examined, and shows that this compound increases the basal CCL2 production. 
Negative log of the concentrations of each inhibitor are presented. Data show the representative 
of three independent experiments. ++ p<0.01, comparison with untreated cells; p<0.01, 
comparison with thrombin alone.
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Figure 3.14 Thrombin-induced CCL2 production is attenuated by MEK1/2 inhibition. 
Panel A and panel B show the effects of U0126 (A) and PD98059 (B) on CCL2 protein 
production in response to thrombin (10 nM). Data are presented as a percentage of the maximal 
response obtained with thrombin with drug vehicle alone (0.1% DMSO in DMEM). Cells were 
treated with increasing concentrations of U0126, or PD98059 for 30 minutes before stimulation 
with thrombin for 6 hours. Final concentrations of DMSO Were kept constant for aH treatment 
conditions. The first bars represent the highest concentration of inhibitors used and show that 
these compounds have no effect on basal CCL2 production. Negative log of the concentrations 
of U0126 are presented. Data represent the mean ± SEM of triplicates, and show the 
representative of three independent experiments.. ++p<0.01, comparison with unstimulated cells; 
*p<0.05 and **p<0.01, comparison with thrombin alone.
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3.3.2 Further experimental evidence for the involvement of ERK1/2 in PARi- 
mediated CCL2 production
3.3.2.1 Thrombin induces endogenous ERK1/2 phosphorylation: a time course
To further investigate the involvement of ERK1/2 in PARi-mediated CCL2 production, 
thrombin-induced ERK1/2 phosphorylation was first examined. MLFs were challenged 
with thrombin (10 nM) over a period ranging from 30 seconds to 30 minutes (Figure 
3.15A). ERK1/2 phosphorylation was examined by western blotting using a phospho- 
ERK1/2 specific antibody. The amount of phosphorylated ERK1/2 induced by thrombin 
in MLFs was normalized against the total amount of ERK1/2 (lower panel) and 
determined by densitometry (Figure 3.15B). As shown in figure 3.15A, thrombin 
induced ERK1/2 phosphorylation in a time-dependent manner in MLFs. 
Phosphorylated ERK1/2 was undetectable in un-stimulated cells (upper panel, lane 1). 
Thrombin induced strong phosphorylation of ERK1/2 as early as 30 seconds (upper 
panel, lane 2), with a maximal activation obtained at 2 minutes (upper panel, lane 3). 
The signal decreased after 5 minutes (upper panel, lane 4), and no ERK1/2 
phosphorylation was seen after 30 minutes (upper panel, lane 6).
3.3.2.2 Effects o f PARi antagonist (RWJ-58259), Gaq selective PARi antagonist 
(Q94) and MEK1/2 inhibitor (U0126) on thrombin-induced ERK1/2 
phosphorylation
In order to determine whether ERK1/2 pathway is downstream of PARi and PARi 
coupling to Gaq, the effects of a potent and selective PARi antagonist RWJ-58259, and 
the Gdq selective PAR, antagonist Q94 on thrombin-induced ERK1/2 phosphorylation 
were examined (Figure 3.16). As shown in figure 3.16 A&B, pretreatment of MLFs with 
RWJ-58259 (1 pM) for 15 minutes completely abolished thrombin-induced ERK1/2 
phosphorylation at 2 minutes. Pretreatment with Q94 (10 pM, Figure 3.16C) for 3 hours 
also completely blocked this response of thrombin, suggesting that ERK1/2 pathway is 
downstream of PAR, coupling to Gaq.
To determine whether MEK1/2 is upstream of ERK1/2 in the pathway leading to CCL2 
production, the effect of U0126 on thrombin-induced ERK1/2 phosphorylation was 
examined. The data show that U0126 significantly blocked thrombin-induced ERK1/2 
phosphorylation in a concentration-dependent manner from 1 pM onwards (Figure 
3.17). U0126 at 1 pM blocked ERK1/2 phosphorylation by 100%. These data 
demonstrate that PAR, and MEK1/2 act at upstream of ERK1/2 in the signalling 
pathway leading to CCL2 production by thrombin.
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3.3.2.3 BRK1/2 is necessary and sufficient for CCL2 production induced by 
thrombin
To further confirm the role of ERK1/2 pathway in PARHnduced CCL2 production, a 
genetic approach was used. As MEK1 is the upstream regulator of ERK1/2, wild type 
MEK1 (wt-MEK1), dominant negative MEK1 (dn-MEK1) or constitutively active MEK1 
(ca-MEK1) were transduced into MLFs. Figure 3.18A shows that thrombin-induced 
ERK1/2 phosphorylation was blocked by up to 70% in cells transduced with dn-MEK1. 
Figure 3.18B shows that ca-MEK1 significantly increased basal ERK1/2 
phsophorylation, but had no additive effect on thrombin-induced ERK1/2 
phosphorylation. Transduced-MLFs were then exposed to 10 nM thrombin for 6 hours 
(Figure 3.18C). The results show that transduction with dn-MEK1 significantly reduced 
thrombin-induced CCL2 production by 52±3.5% (p<0.01), whereas transduction with 
ca-MEK1 significantly increased the CCL2 basal production by 3.7±0.3 fold (p<0.01), 
but had no additive effect on thrombin-stimulated CCL2 production. These results 
provide further evidence that MEK1-ERK1/2 pathway is both necessary and sufficient 
for PAR^mediated CCL2 production in MLFs.
3.3.3 Effect o f ERK1/2 on thrombin-induced CCL2 mRNA levels
To determine whether ERK1/2 mediates PARHnduced CCL2 production via the 
increase of CCL2 mRNA level, the effect of ERK1/2 inhibition by U0126 on thrombin- 
induced CCL2 mRNA levels was examined (Figure 3.19). MLFs were pre-incubated 
with U0126 (1 pm) for 30 minutes prior to stimulation with 10 nM thrombin for 2 hours. 
As shown in figure 3.19, at concentration of U0126 that blocked thrombin-induced 
ERK1/2 phosphorylation, thrombin-induced CCL2 mRNA accumulation was blocked by 
~70%. The data suggest that ERK1/2 mediates thrombin-induced CCL2 production via 
a transcriptional mechanism.
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Figure 3.15 Time course of activation of extracellular mitogen-regulated kinases ERK1/2 
by thrombin in MLFs.
Panel A shows time-course data for the effect of thrombin on MLF ERK1/2 phosphorylation. 
MLFs were exposed to thrombin (10 nM) for the indicated time periods. Phosphorylated ERK1/2 
was assessed by western blotting using an anti phospho-ERK1/2 antibody (upper panel). 
Protein loading was verified by blotting with an anti-ERK1/2 antibody (lower panel). The relative 
increase in ERK1/2 phosphorylation normalized to total ERK1/2 was determined by performing 
quantitative densitometry (panel B). Data represent an average of three independent 
experiments ± SEM. "p ^ .O I, comparison with medium control at time zero.
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Figure 3.16 PAR, antagonism blocks thro mb in-evoked ERK1/2 phosphorylation in MLFs.
Panel A shows the effect of PAR, inhibition by RWJ-58259 on ERK1/2 phosphorylation in 
response to thrombin in MLFs. Cells were pre-incubated with RWJ-58259 (1 pM) for 15 min 
before exposure to 10 nM thrombin for 2 minutes. Phosphorylation of ERK1/2 was assessed by 
western blotting using an anti phospho-ERK1/2 antibody (upper panel). Protein loading was 
verified by blotting with an anti-ERK1/2 antibody (lower panel). The relative increase in ERK1/2 
phosphorylation normalized to total ERK1/2 was determined by performing quantitative 
densitometry (panel B). Panel C shows the effect of Q94 on thrombin-induced ERK1/2 
phosphorylation. Cells were pre-incubated with Q94 (10 pM) for 3 hours before exposure to 10 
nM thrombin for 2 minutes. Phosphorylation of ERK1/2 was assessed by western blotting using 
an anti phospho-ERK1/2 antibody (upper panel). Protein loading was verified by blotting with an 
anti-ERK1/2 antibody (lower panel). Data show the representative of three experiments.
135
Chapter 3 Results (I)
A
t-ERK1/2
P-ERK1/2
Thr
U0126 - - 7 7 - - 6 6 - - 5 5-log(M)
B 101
CM 2 8-
5 *
or 2Ui . 6-
O Zo > 4-*-*re re
or o 2-
0-
Thrombin
U0126 7 6 5 7 6 5 -log(M)
Figure 3.17 Inhibition of MEK1/2 kinase by U0126 attenuates thrombin-induced ERK1/2 
phosphorylation.
Figure shows the effect of MEK1/2 kinase inhibition by U0126 on ERK1/2 phosphorylation 
induced by thrombin in MLFs. Cells were treated with increasing concentrations of U0126 for 30 
minutes before stimulation with thrombin (10 nM) for 2 minutes. Phosphorylation of ERK1/2 was 
detected by using an anti phospho-ERK1/2 antibody (upper panel, A). Protein loading was 
verified by blotting with an anti-ERK1/2 antibody (lower panel, A). The relative increase of 
ERK1/2 phosphorylation normalized to total ERK1/2 was determined by performing quantitative 
densitometry (panel B). Data show the representative of three experiments.
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Figure 3.18 MEK1 is necessary and sufficient for thrombin-induced CCL2 production.
Panel A and B show the effects of wt-MEK1, dn-MEK1 or ca-MEK1 on thrombin-induced 
ERK1/2 phosphorylation. MLFs transduced with MEK1-pBabePuro constructs expressing the 
wt-MEK1, dn-MEK1 or ca-MEK1 were exposed to thrombin (10 nM) for 2 minutes. ERK1/2 
phosphorylation was assessed by western blotting of cell lysates using an anti-phospho-ERK1/2 
antibody (upper panel). Protein loading was verified by blotting with an anti-ERK1/2 antibody 
(lower panel). The graphs represent the densitometry analysis of the blots as a result of 
phospho-ERK1/2 relative to total ERK1/2 and are representative of three separate experiments 
performed with three replicates per sample. Panel C shows the effects of MEK1 constructs on 
thrombin-induced MLF CCL2 protein production. MLFs were transduced with MEK1-pBabePuro 
constructs expressing the wt-MEK1, dn-MEK1 or ca-MEK1. Cells were exposed to 10 nM 
thrombin for 6 hours. Levels of CCL2 protein production in supernatants were measured by 
ELISA. Data represent the mean ± SEM from triplicates, and show the representative of three 
independent experiments. ++p<0.01, comparison with basal CCL2 protein levels for the group 
with wt-MEK1. "pcO.OI, comparison with thrombin-induced CCL2 protein levels for the group 
with wt-MEK1.
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Figure 3.19 Inhibition of ERK1/2 inhibited thrombin-induced CCL2 mRNA levels
Panel shows the effect of U0126 on thrombin-induced CCL2 mRNA levels. MLFs were exposed 
to thrombin (10 nM) for 2 hours with or without pre-incubation with U0126 (1pM), for 30 minutes. 
CCL2 mRNA levels were determined by qRT-PCR. Final concentrations of DMSO were kept 
constant for ail treatment conditions (0.01% DMSO in DMEM). Data represent the mean ± SEM 
from triplicates, and show the representative of three independent experiments. ++ p<0.01, 
comparison with medium control; ” p<0.01, comparison with thrombin alone.
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3.3.4 Summary
The results described in this section examining the role of MAP kinases in thrombin- 
induced MLF CCL2 protein release and mRNA levels showed that:
• Thrombin-induced CCL2 production is not dependent on p38 activation.
• JNK is also not involved in thrombin-induced CCL2 production.
• ERK1/2 pathway is necessary for mediating thrombin-induced CCL2 production 
as inhibition of ERK1/2 by both U0126 and PD98059 blocked PARi-induced 
CCL2 production in a concentration-dependent manner.
• The involvement of ERK1/2 in thrombin-induced CCL2 production is further 
confirmed by experiments showing that transduction of MLFs with dn-MEK1 
significantly reduced thrombin-induced CCL2 production.
• ERK1/2 pathway is also sufficient for mediating thrombin-induced CCL2 
production as transduction of MLFs with ca-MEK1 had no additive effect on 
thrombin-induced CCL2 production.
• ERK1/2 pathway is downstream of PAR! coupling to Gaq for mediating 
thrombin-induced CCL2 production.
• Inhibition of ERK1/2 inhibited thrombin-induced CCL2 mRNA levels.
In summary, ERK1/2 pathway downstream of PARi coupling to Gaq is involved in 
thrombin-induced CCL2 production via a transcriptional mechanism.
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3.4 The role of c-Raf and PKC in PARHnduced MLF CCL2 protein release and 
mRNA levels
It has been shown that PARi-Gciq interaction leads to the activation of ERK1/2 via the 
activation of both c-Raf and PKC in MLFs (Trejo et al., 1996). In addition, PKC is a 
well-known downstream effector of Gaq. I therefore performed experiments to examine 
the role of c-Raf and PKC in thrombin-induced MLF CCL2 protein release and mRNA 
levels.
3.4.1 Effect o f c-Raf inhibition on PARi-induced CCL2 production
Cells were pre-incubated with c-Raf inhibitor for 30 minutes prior to stimulation with 
thrombin for 6 hours. The results show that c-Raf inhibitor inhibited thrombin-induced 
CCL2 release in a concentration-dependent manner from 1 pM (-Log [1 pMj=6) 
onwards (Figure 3.20A). At 10 pM (-Log (10 pM]=5), c-Raf inhibitor produced a 95 ± 
1.2% reduction in thrombin induced-CCL2 production (p<0.01). The IC5o of c-Raf 
inhibitor was determined to be 1.5 pM for this response. To further determine whether 
c-Raf mediates thrombin-induced CCL2 production via ERK1/2 activation, the effect of 
c-Raf inhibition on ERK1/2 phosphorylation induced by thrombin was examined. Cells 
were pre-incubated with increasing concentrations of c-Raf inhibitor before exposure to 
thrombin for 2 minutes. As shown in Figure 3.20B, c-Raf inhibitor concentration- 
dependently inhibited thrombin-induced ERK1/2 phosphorylation with complete 
inhibition obtained at 3 pM. These data provide strong evidence that c-Raf mediates 
thrombin-induced CCL2 protein production via the activation of ERK1/2.
3.4.2 Effect o f PKC inhibition on PARi-induced CCL2 production
In order to establish whether PARrmediated CCL2 production is PKC-dependent, the 
effects of broad spectrum PKC inhibitors, Ro-318425 and GF109203X, on this 
response were examined. MLFs were pre-incubated with GF109203X or Ro-318425 for 
30 minutes prior to stimulation with thrombin for 6 hours. The results show that both 
GF109203X (Figure 3.21 A) and Ro-318425 (Figure 3.21 B) blocked thrombin-induced 
CCL2 release in a concentration-dependent manner from 0.1 pM (-Log [0.3 pM]=7) 
onwards for GF109203X, and from 0.3 pM (-Log [0.3 pM]=6.5) onwards for Ro-318425. 
At 10 pM (-Log [10 pM]=5), GF109203X produced a complete reduction in thrombin 
induced-CCL2 production, whereas Ro-318425 produced a 82 ± 0.39% reduction 
(p<0.01) in this response. The IC50 of GF109203 and Ro-318425 were determined to 
be 0.73 pM and 0.93 pM, respectively, for this response. These data suggest that 
PARi-mediated CCL2 production is indeed PKC-dependent.
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Previous studies performed with MLFs have shown that PARi coupling to Gaq can 
activate PKC and downstream c-Raf and ERK1/2 (Trejo, 1996), I next performed 
experiments to determine whether PKC mediates thrombin-induced CCL2 production 
via the activation of both c-Raf and ERK1/2. The effects of PKC inhibition on c-Raf and 
ERK1/2 phosphorylation induced by thrombin were examined by western blotting. Cells 
were pre-incubated with Ro-318425 for 30 minutes before exposure to thrombin for 2 
minutes (for ERK1/2 phosphorylation) or 10 minutes (for c-Raf phosphorylation). As 
shown in Figure 3.22 A&B, Ro-318425 concentration-dependently inhibited ERK1/2 
phosphorylation, and at 1 pM, Ro-318425 almost completely blocked thrombin-induced 
ERK1/2 phosphorylation (about 90%). Inhibition of PKC by Ro-318425 (1 pM) also 
completely inhibited c-Raf phosphorylation induced by thrombin (Figure 3.22 C).
These data provide strong evidence that PKC mediates thrombin-induced CCL2 
protein production via the activation of c-Raf and ERK1/2. ERK1/2, c-Raf and PKC are 
in a linear pathway downstream of PARi coupling to Gaq in mediating thrombin-induced 
CCL2 protein production.
3,4.3 Effect o f c-Raf and PKC inhibition on PARi-mediated CCL2 mRNA levels
To determine whether c-Raf and PKC are also involved in thrombin-induced CCL2 
mRNA levels, I next examined the effects of c-Raf and PKC inhibition on this response 
(Figure 3.23). MLFs were pre-incubated with c-Raf inhibitor (3 pM, panel A) or Ro- 
318425 (1 pM, panel B) for 30 minutes prior to exposure to thrombin for 2 hours. The 
mRNA levels were assessed by qRT-PCR. As shown in Figure 3.23, at concentrations 
of c-Raf inhibitor and Ro-318425 that blocked thrombin-induced ERK1/2 
phosphorylation, thrombin-induced CCL2 mRNA accumulation was blocked by 75% 
and 81% respectively. These data suggest that c-Raf and PKC are involved in 
thrombin-induced MLF CCL2 production via a transcriptional mechanism.
Taken together, data obtained so far demonstrate that PKC, c-Raf and ERK1/2 are in a 
linear pathway for thrombin-induced CCL2 gene expression and protein production.
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Figure 3.20 Inhibition of c-Raf by c-Raf kinase inhibitor inhibits thrombin-induced MLF 
CCL2 production and ERK1/2 phosphorylation.
Panel A shows the effect of c-Raf kinase inhibitor on CCL2 protein production in response to 10 
nM thrombin, presented as a percentage of the maximal response obtained for thrombin with 
drug vehicle alone (0.1% DMSO in DMEM). Cells were treated with increasing concentrations of 
c-Raf kinase inhibitor for 30 minutes before exposure to thrombin for 6 hours. Final 
concentrations of DMSO were kept constant for all treatment conditions. The first bar represents 
the highest concentration of c-Raf kinase inhibitor and shows that this compound has no effect 
on basal CCL2 production. Negative log of the concentrations of c-Raf kinase inhibitor are 
presented. Data represent the mean ± SEM of triplicates. Panel B shows the effect of c-Raf 
kinase inhibitor on thrombin-induced ERK1/2 phosphorylation in MLFs. ERK1/2 phosphorylation 
was assessed by western blotting of cell lysates using an anti-phospho-ERK1/2 antibody (upper 
panel). Protein loading was verified by blotting with an anti-ERK1/2 antibody (lower panel). Data 
show the representative of three independent experiments. *+p<0.01, comparison with 
unstimulated cells; p<0.05 and ” pc0.01, comparison with thrombin alone.
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Figure 3.21 The protein kinase C (PKC) inhibition by GF109203X and Ro-318425 inhibits 
thrombin-induced CCL2 production.
Figure shows the effects of GF109203X and Ro-318425 on CCL2 protein production in 
response to thrombin. Data are presented as a percentage of the maximal response obtained 
for thrombin with drug vehicle alone (0.1% DMSO in DMEM). Cells were treated with increasing 
concentrations of inhibitors for 30 minutes before exposure to thrombin for 6 hours. Final 
concentrations of DMSO were kept constant for all treatment conditions. The first bars represent 
the highest concentration of inhibitors used and show that these compounds have no effect on 
basal CCL2 production. Negative log of the concentrations of inhibitors are presented. Data 
represent the mean ± SEM of triplicates, and show the representative of three independent 
experiments. ^pcO.01, comparison with unstimulated cells; "p<0.01, comparison with thrombin 
alone.
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Figure 3.22 PKC inhibition by Ro-318425 attenuates thrombin-induced ERK1/2 and c-Raf 
phosphorylation.
Panel A shows the effect of Ro-318425 on thrombin-induced ERK1/2 phosphorylation. Cells 
were treated with increasing concentrations of Ro-318425 for 30 minutes before stimulation with 
thrombin (10 nM) for 2 minutes. ERK1/2 phosphorylation was assessed by western blotting of 
cell lysates using an anti-phospho-ERK1/2 antibody (upper panel). Protein loading was verified 
by blotting with an anti-ERK1/2 antibody (lower panel). The relative increase of ERK1/2 
phosphorylation normalized to total ERK1/2 was determined by performing quantitative 
densitometry (Panel B). Panel C shows the effect of Ro-318425 on thrombin-induced MLF c-Raf 
phosphorylation. Cells were treated with Ro-318425 (1 pM) for 30 minutes before stimulation 
with thrombin (10 nM) for 10 minutes. c-Raf phosphorylation was assessed by western blotting 
of cell lysates using an anti-phospho-c-Raf antibody (upper panel). Protein loading was verified 
by blotting with an anti-c-Raf antibody (lower panel). The blot is representative of three separate 
experiments performed.
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Figure 3.23 Inhibition of c-Raf and PKC inhibited thrombin-induced CCL2 mRNA levels
Panel A and B show the effects of Ro-318425 (A) and c-Raf inhibitor (B) on thrombin-induced 
CCL2 mRNA levels. MLFs were exposed to thrombin (10 nM) for 2 hours with or without pre­
incubation with c-Raf inhibitor (3 pM) or Ro-318425 (1 pM) for 30 minutes. CCL2 mRNA levels 
were determined by qRT-PCR. Final concentrations of DMSO were kept constant for all 
treatment conditions (0.01% DMSO in DMEM). Data represent the mean ± SEM from triplicates, 
and show the representative of three independent experiments. +*p<0.01, comparison with 
medium control; *^<0.01, comparison with thrombin alone.
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3.4.4 Effect of Ca7*-dependent PKC inhibitor G66976 on thrombin-induced CCL2 
protein production and mRNA levels
In order to determine which PKC isoform (s) is/are involved in thrombin-induced CCL2 
production, the effect of G66976 on this response was first examined. GP6976 is widely 
accepted as a Ca2+-dependent PKCs (PKC isoforms a, (31, |32, r) inhibitor (Martiny- 
Baron et ai., 1993). Cells were pre-incubated with increasing concentrations of G66976 
(Figure 3.24) for 30 minutes before exposure to thrombin for 6 hours. The data 
obtained show that G66976 blocked PAR^mediated CCL2 protein production in a 
concentration-dependent manner from 0.1 pM onwards. At 10 pM, G06976 inhibited 
thrombin-induced CCL2 production by 83.4% ± 3.2% (p<0.01). The IC50 of G06976 was 
determined to be 0.5 pM for this response. These data suggest that Ca2+-dependent 
PKC is involved in thrombin-induced CCL2 production.
In order to further confirm whether Ca2+-dependent PKC mediates thrombin-induced 
CCL2 protein production via the transcriptional mechanism, the effect of G06976 on 
thrombin-induced CCL2 mRNA levels was examined (Figure 3.25, panel A). MLFs 
were pre-treated with G66976 for 30 minutes prior to exposure to thrombin (10 nM) for 
2 hours. Surprisingly, inhibition of Ca2+-dependent PKC did not inhibit thrombin-induced 
CCL2 mRNA levels, suggesting that Ca2+-dependent PKC mediates thrombin-induced 
CCL2 protein production via a non-transcriptional mechanism. However, as shown in 
figure 3.21 B and figure 3.23 A, inhibition of general PKC isoforms by the broad 
spectrum inhibitors Ro-318425 inhibited thrombin-induced CCL2 protein release and 
CCL2 mRNA levels. These data suggest that Ca2+-dependent PKC and Ca2+- 
independent PKC mediate thrombin-induced CCL2 protein production via a different 
mechanism.
Previous results have shown that PKC mediates thrombin-induced CCL2 protein 
production via the activation of ERK1/2 (Figure 3.22 A). In order to determine whether 
Ca2+-dependent PKC mediates thrombin-induced CCL2 release via ERK1/2, the effect 
of G&6976 on thrombin-induced ERK1/2 phosphorylation was examined. As shown in 
Figure 3.25B, inhibition of Ca2+-dependent PKC by G06976 did not inhibit ERK1/2 
phosphorylation induced by thrombin, further suggesting that Ca2*-dependent PKC and 
Ca2+-independent PKC mediate thrombin-induced CCL2 protein production via a 
different mechanism.
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Figure 3.24 Inhibition of Ca2+-dependent PKC by G56976 attenuates thrombin-induced 
CCL2 production.
Figure shows the effect of Go6976 on thrombin-induced CCL2 protein production. Cells were 
pre-incubated with increasing concentrations of G66976 for 30 minutes before exposure to 
thrombin (10 nM) for 6 hours. Data are presented as a percentage of the maximal response 
obtained with thrombin and drug vehicle alone (0.1% DMSO in DMEM). Final concentrations of 
DMSO were kept constant for all treatment conditions. The first bar represents the highest 
concentration of GQ6976, and shows that this compound has no significant effect on basal 
CCL2 production. Negative log of the concentrations of G66976 are presented. Data represent 
the mean ± SEM from triplicates, and show the representative of three independent experiments. 
++p<0.01, comparison with medium control; "p<0.01, comparison with thrombin alone.
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Figure 3.25 Inhibition of Ca2*-dependent PKC does not interfere with thrombin-induced 
CCL2 mRNA levels and ERK1/2 phosphorylation.
Panel A shows the effect of G06976 on thrombin-induced CCL2 mRNA levels. MLFs were 
exposed to thrombin (10 nM) for 2 hours with or without pre-incubation with G66976 (1 pM) for 
30 minutes. CCL2 mRNA levels were determined by qRT-PCR. Final concentrations of DMSO 
were kept constant for all treatment conditions (0.01% DMSO in DMEM). Data represent the 
mean ± SEM from triplicates, and show the representative of three independent experiments. 
Panel B shows the effect of G66976 on thrombin-induced ERK1/2 phosphorylation. Cells were 
treated with G66976 (1 pM) for 30 minutes before exposure to thrombin for 2 minutes. 
Phosphorylation of ERK1/2 was assessed by western blotting of cell lysates using an anti- 
phospho-ERK1/2 antibody (upper panel). Protein loading was verified by blotting with an anti- 
ERK1/2 antibody (lower panet) The blots are representative of three separate experiments 
performed. **p<0.01, comparison with medium control.
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3.4.5 Summary
The results described in this section examining the role of c-Raf and PKC in mediating 
the effects of thrombin on MLF CCL2 protein release and mRNA levels showed that:
• c-Raf is involved in PARHnduced CCL2 gene expression and protein 
production via an ERK1/2-dependent mechanism in MLFs.
• Ca2+-independent PKC mediates PARHnduced CCL2 gene expression and 
protein production via the activation of both c-Raf and ERK1/2.
• The Ca2+-independent PKC, c-Raf and ERK1/2 are in a linear pathway in 
mediating thrombin-induced CCL2 protein production via a transcriptional 
mechanism.
• Ca2+-dependent PKC is involved in thrombin-induced CCL2 production but not 
gene expression.
• Ca2+-dependent PKC mediates thrombin-induced CCL2 production in an 
ERK1/2-independent manner.
In summary, Ca2+-independent PKC, c-Raf and ERK1/2 are in a linear pathway for 
thrombin-induced CCL2 gene expression and protein production; whereas Ca2+- 
dependent PKC mediates thrombin-induced CCL2 production via a post-transcriptional 
mechanism.
149
Chapter 3 Results (I)
3.5 The role of PI_C-Ca2+ pathway and RhoA/Rho kinase in PARi-mediated protein 
release and mRNA levels
The data obtained so far point to a central role for Gaq and ERK1/2 in mediating the 
effects of PAR! activation on CCL2 production. The data obtained also suggest that 
Ca2+-independent PKC and Ca2+-dependent PKC mediate PARi-induced CCL2 release 
via different mechanisms. Gaq is well-known to trigger an increase in intracellular Ca2+ 
concentration by stimulating PLC-p activity, which eventually leads to the activation of 
Ca2+-dependent PKC (Berridge, 1993). Moreover, thrombin is known to mediate Ca2+ 
signalling via PAR! in fibroblasts, and this can be inhibited by BAPTA (Trejo etal., 1996; 
Tanaka et at., 2004). It is therefore important to investigate the role of PLC-Ca2+ 
pathway in PARi-induced CCL2 production. In addition, although Ga12/13 is generally 
considered as a major activator of RhoA/Rho kinase, there is emerging evidence that 
Gaq is also able to signal via Rho kinase by activating PLC-Ca2+ pathway (Singh et a., 
2007). Therefore, the roles of PLC-Ca2+ pathway and RhoA/Rho kinase in PAR!- 
mediated CCL2 release were next examined.
3.5.1 Effect of PLC and Ca2+ inhibition on thrombin-induced CCL2 protein release 
and mRNA levels
To determine whether PLC and Ca2+ are also involved in thrombin-induced CCL2 
production via a non-transcriptional mechanism, the same as Ca2+-dependent PKC, the 
role of PLC and Ca2+ in thrombin-induced CCL2 production was first examined. Cells 
were treated with increasing concentrations of U73122 (PLC inhibitor, Figure 3.26A), or 
BAPTA-AM (Ca2+ chelator, Figure 3.26B) for 30 minutes before exposure to thrombin 
for 6 hours. As shown in Figure 3.26A, inhibition of PLC by U73122 inhibited thrombin- 
induced CCL2 production in a concentration-dependent manner from 1 pM, and a 
complete inhibition was obtained with U73122 at 6 pM. The IC5o of U73122 was 
determined to be 1.5 pM for this response. In order to verify the specificity of U73122, 
the effect of the inactive control compound for U73122, U73343, was also examined in 
parallel cultures, and was found to have no effect on this response at the highest 
concentrations used (Figure 3.26A). Similarly, the calcium chelator BAPTA-AM also 
blocked this response of thrombin in a concentration-dependent manner from 0.3 pM 
onwards (Figure 3.26B). At 3 pM, BAPTAM-AM attenuated this response by 72 ± 5% 
(p<0.01). The IC50 of BAPTA-AM was determined to be 1 pM for this response.
The role of PLC (Figure 3.27A) and Ca2+ (Figure 3.27B) in thrombin-induced CCL2 
mRNA levels was next examined. Cells were pre-incubated with U73122 (2 pM) or 
BAPTA-AM (2 pM) for 30 minutes before exposure to thrombin for 2 hours. CCL2
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mRNA levels were assessed by qRT-PCR. As shown in figure 3.27, inhibition of both 
PLC and Ca2+ by U73122 and BAPTA-AM had no effect on thrombin-induced CCL2 
mRNA levels, suggesting that PLC and Ca2+ also mediate thrombin-induced CCL2 
protein release via a non-transcriptional mechanism.
To further confirm that PLC and Ca2+ pathways mediate thrombin-induced CCL2 
protein production via a different mechanism as indicated in Ca2+-independent PKC 
pathway, the role of PLC (Figure 3.28A) and Ca2+ (Figure 3.28B) on thrombin-induced 
ERK1/2 phosphorylation was examined. Cells were pre-incubated with U73122 (2 pM) 
or BAPTA-AM (2 pM) for 30 minutes before exposure to thrombin for 2 minutes. 
ERK1/2 phosphorylation was measured by western blotting. As shown in figure 3.28, 
both inhibitors did not inhibit thrombin-induced ERK1/2 phosphorylation, suggesting 
that PLC and Ca2+ mediate thrombin-induced CCL2 protein release via an ERK172- 
independent mechanism.
Data obtained so far strongly suggest that the PLC, Ca2+ and Ca2+-dependent PKC are 
involved in PARi-induced CCL2 release via a non-transcriptional mechanism and it is 
not via the activation of ERK1/2.
3.5.2 Effect of RhoA and Rho kinase inhibition on thrombin-induced CCL2 
protein release and mRNA levels
As mentioned previously that Gaq is also able to signal via Rho kinase by activating the 
PLC-Ca2+ pathway (Singh et a!., 2007), the involvement of RhoA and Rho kinase in 
PARi-induced CCL2 release was next examined. Cells were treated with increasing 
concentrations of C3 exoenzyme (RhoA inhibitor, Figure 3.29) for 30 minutes before 
exposure to thrombin for 6 hours. The highest concentration of C3 exoenzyme used 
was 0.2 pg/ml as cells died at concentrations higher than 0.2 pg/ml. The data obtained 
show that C3 exoenzyme blocked PARTmediated CCL2 production in a concentration- 
dependent manner from 0.02 pg/ml onwards. At 0.2 pg/ml, C3 exoenzyme significantly 
inhibited this response of thrombin by 43 ± 0.2% (p<0.01). The IC5o of C3 exoenzyme 
was determined to be 0.2 pg/ml for this response. As Rho kinase is a well-known 
downstream effector of RhoA, the involvement of Rho kinase in this response was next 
examined. Two structurally un-related Rho kinase inhibitors, Y-27632 and H-1152, 
were used. Inhibition of Rho kinase with these two inhibitors inhibited thrombin-induced 
CCL2 protein production in a concentration-dependent manner from 3 pM and 1 pM 
onwards, respectively. At 30 pM, Y-27632 blocked this response by 85.5 ± 7.07% and 
the IC60 of Y-27632 was determined to be 3 pM for this response (Figure 30A). H-1152
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at 10 pM blocked this response by 86.4 ± 4.36% and the IC50 of H-1152 was 
determined to be 2.7 pM for this response (Figure 30B). In order to determine the 
mechanism in which RhoA/Rho kinase mediates thrombin-induced CCL2 production, 
the role of RhoA/Rho kinase in thrombin-induced CCL2 mRNA levels was next 
examined (Figure 3.31). Cells were pre-incubated with C3 exoenzyme (0.2 pg/ml, 
Figure 3.31 A) or Y-27632 (3 pM, Figure 3.31 B) for 30 minutes before exposure to 
thrombin for 2 hours. CCL2 mRNA levels were assessed by qRT-PCR. The results 
show that inhibition of RhoA and Rho kinase did not inhibit the increase of CCL2 
mRNA levels induced by thrombin, suggesting that RhoA/Rho kinase mediates 
thrombin-induced CCL2 protein production via a post-transcriptional mechanism.
In order to determine whether RhoA and Rho kinase influence thrombin-induced CCL2 
production via the activation of ERK1/2, the effects of RhoA (Figure 3.32A) and Rho 
kinase (Figure 3.32 B) inhibition on thrombin-induced ERK1/2 phosphorylation were 
examined. Cells were pre-incubated with C3 exoenzyme (0.2 pg/ml) or Y-27632 (3 pM) 
for 30 minutes before exposure to thrombin for 2 minutes. Figure 3.31 showed that 
none of these two inhibitors interfered with thrombin-induced ERK1/2 phosphorylation, 
indicating that RhoA and Rho kinase mediate thrombin-induced CCL2 production in an 
ERK1/2-independent manner.
Data obtained so far strongly suggest that RhoA/Rho kinase mediate thrombin-induced 
CCL2 production via a post-transcriptional mechanism and it is via an ERK1/2- 
independent manner.
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Figure 3.26 inhibition of PLC (U73122) and Ca2+ (BAPTA1-AM) attenuates thrombin- 
induced CCL2 production.
Figure shows the effects of U73122, negative control U73343 and BAPTA-AM on thrombin- 
induced CCL2 protein release. Cells were pre-incubated with increasing concentrations of 
inhibitors for 30 minutes before exposure to thrombin (10 nM) for 6 hours. Data are presented 
as a percentage of the maximal response obtained with thrombin and drug vehicle alone (0.1% 
DMSO in DMEM). Final concentrations of DMSO were kept constant for all treatment conditions. 
The first bars represent the highest concentrations of inhibitors used, and show that these 
compounds have no significant effect on basal CCL2 production. Negative log of the 
concentrations of inhibitors are presented. Data represent the mean ± SEM from triplicates, and 
show the representative of three independent experiments. *+p<0.01, comparison with medium 
control; ”p<0.01, comparison with thrombin alone.
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Figure 3.27 Inhibition of PLC (U73122) and Ca2+ (BAPTA-AM) does not interfere with 
thrombin-induced CCL2 mRNA levels.
Panel A and B show the effects of U73122 (A) and BAPTA-AM (B) on thrombin-induced CCL2 
mRNA levels. MLFs were exposed to thrombin (10 nM) for 2 hours with or without pre­
incubation with U73122 (2 pM) or BAPTA1-AM (2 pM) for 30 minutes. CCL2 mRNA levels were 
determined by qRT-PCR. Final concentrations of DMSO were kept constant for all treatment 
conditions (0.01% DMSO in DMEM). Data represent the mean ± SEM from triplicates, and show 
the representative of three independent experiments. ++ p<0.01, comparison with medium 
control.
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Figure 3.28 Inhibition of PLC (U73122) and Ca2+ (BAPTA-AM) does not interfere with 
thrombin-induced ERK1/2 phosphorylation.
Panel A and B show the effects of U73122 and BAPTA-AM on thrombin-induced ERK1/2 
phosphorylation. Cells were treated with U73122 (2 pM) or BAPTA-AM (2 pM) for 30 minutes 
before exposure to thrombin for 2 minutes. Phosphorylation of ERK1/2 was assessed by 
western blotting of cell lysates using an anti-phospho-ERK1/2 antibody {upper panel, A&B). 
Protein loading was verified by blotting with an anti-ERK1/2 antibody {lower panel, A&B). The 
blots are representative of three separate experiments performed.
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Figure 3.29 Inhibition of RhoA (C3 exoenzyme) attenuates thrombin-induced CCL2 
production.
Figure shows the effect of C3 exoenzyme on thrombin-induced CCL2 protein release. Cells 
were pre-incubated with increasing concentrations of C3 exoenzyme for 30 minutes before 
exposure to thrombin (10 nM) for 6 hours. Data are presented as a percentage of the maximal 
response obtained with thrombin and drug vehicle alone. The first bar represents the highest 
concentration of C3 exoenzyme used, and shows that this compound has no significant effect 
on basal CCL2 production. Data represent the mean ± SEM from triplicates, and show the 
representative of three independent experiments. ++p<0.01, comparison with medium control; 
~p<0.01, comparison with thrombin alone.
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Figure 3.30 Inhibition of Rho kinase by Y-27632 and H-1152 attenuates thrombin-induced 
CCL2 production.
Panel A and B show the effects of Y-27632 and H-1152 on thrombin-induced CCL2 protein 
release. Cells were pre-incubated with increasing concentrations of inhibitors for 30 minutes 
before exposure to thrombin (10 nM) for 6 hours. Data are presented as a percentage of the 
maximal response obtained with thrombin and drug vehicle alone (1% DMSO in DMEM for Y- 
27632, H-1152 is dissolved in H20). Final concentrations of DMSO were kept constant for all 
treatment conditions. The first bars represent the highest concentration of inhibitors used, and 
show that these compounds have no significant effects on basal CCL2 production. Negative log 
of the concentrations of inhibitors are presented. Data represent the mean ± SEM from 
triplicates, and show the representative of three independent experiments. ++p<0.01, 
comparison with medium control; ”p<0.01, comparison with thrombin alone.
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Figure 3.31 Inhibition of RhoA (C3 exoenzyme) and Rho kinase (Y-27632) does not 
interfere with thrombin-induced CCL2 mRNA levels.
Panel A and B show the effects of C3 exoenzyme (A) and Y-27632 (B) on thrombin-induced 
CCL2 mRNA levels. Cells were treated with C3 exoenzyme (0.2 |jg/ml) or Y-27632 (3 (jM) for 
30 min before exposure to thrombin for 2 hours. CCL2 mRNA levels were determined by qRT- 
PCR. Data represent the mean ± SEM from triplicates, and show the representative of three 
independent experiments. ++p<0.01, comparison with medium control.
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Figure 3.32 Inhibition of RhoA (C3 exoenzyme) and Rho kinase (Y-27632) does not 
interfere with thrombin-induced ERK1/2 phosphorylation.
Panel A and B show the effects of C3 exoenzyme (A) and Y-27632 (B) on thrombin-induced 
ERK1/2 phosphorylation. Cells were treated with C3 exoenzyme (0.2 pg/ml) or Y-27632 (3 pM) 
for 30 minutes before exposure to thrombin for 2 minutes. Phosphorylation of ERK1/2 was 
assessed by western blotting of cell lysates using an anti-phospho-ERK1/2 antibody (upper 
panel, A&B). Protein loading was verified by blotting with an anti-ERK1/2 antibody (lower panel, 
A&B). The blots are representative of three separate experiments performed.
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3.5.3 Effect o f MLC inhibition on thrombin-induced CCL2 protein release and  
mRNA levels
Data obtained so far have strongly suggested that PLC, Ca2+, Ca2+-dependent PKC, 
RhoA and Rho kinase mediate thrombin-induced CCL2 production in an ERK172- 
independent manner and via a non-transcriptional mechanism. Similarities among 
those kinases in mediating thrombin’s effects on MLFs suggest that these kinases 
might act in a linear pathway. As MLC is a downstream substrate of Rho kinase 
(Amano et al., 1996), I next performed experiments to determine whether MLC is also 
involved in thrombin-induced CCL2 production. Cells were treated with increasing 
concentrations of blebbestatin (MLC inhibitor, Figure 3.33A) for 30 minutes before 
exposure to thrombin for 6 hours. The data obtained show that this inhibitor blocked 
PARr mediated CCL2 production in a concentration-dependent manner from 1 pM 
onwards. At 20 pM, blebbestatin blocked thrombin-induced CCL2 production by 72 ± 
4.7% (p<0.01). The IC5o of this inhibitor was determined to be 4.9 pM for this response.
In order to determine whether MLC mediates thrombin-induced CCL2 production via a 
transcriptional or non-transcriptional mechanism, the effect of MLC inhibition on 
thrombin-induced CCL2 mRNA levels was examined. Cells were pre-incubated with 
blebbestatin (3 pM) before exposure to thrombin for 2 hours. As shown in figure 3.32B, 
blebbestatin did not block PARi-induced CCL2 mRNA levels, suggesting that MLC 
mediates thrombin-induced CCL2 production also via a post-transcriptional mechanism.
3.5.4 PLC-Rho kinase pathway m ediates thrombin-induced CCL2 production via 
the activation o f MLC
To determine whether PLC, Ca2+, Ca2+-dependent PKC, RhoA and Rho kinase are in a 
linear pathway in mediating thrombin’s effects on MLFs via the activation of MLC, the 
effect of PLC, Ca2+, Ca2+-dependent PKC, RhoA and Rho kinase inhibition on 
thrombin-induced MLC phosphorylation was examined. Figure 3.34A shows that 
thrombin induced MLC phosphorylation within 10 minutes of stimulation and that this 
response was abolished by U73122, BAPTA-AM, Go679 and Y-27632 (Figure 3.34B). 
These data indicate that PLC, Ca2+, Ca2+-dependent PKC, RhoA signal to Rho kinase 
rather than ERK1/2 in mediating the effects of thrombin on CCL2 release. To further 
confirm that PLC-Rho kinase pathway is downstream of PARi-coupling to Gaq, the 
effect of Gaq selective PARi antagonist Q94 on thrombin-induced MLC phosphorylation 
was next examined (Figure 3.34C). Data show that Q94 completely abolished 
thrombin-induced MLC phosphorylation, suggesting that the PLC-Rho kinase pathway
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acts downstream of PARt coupling to Gaq in mediating thrombin-induced CCL2 
production.
LogfBlebbestatin (M )]
□  Vehicle
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Figure 3.33 inhibition of MLC by blebbestatin attenuates thrombin-induced CCL2 
production, but not CCL2 mRNA levels.
Panel A shows the effect of blebbestatin on thrombin-induced CCL2 protein release. Cells were 
pre-incubated with increasing concentrations of blebbestatin for 30 minutes before exposure to 
thrombin (10 nM) for 6 hours. Data are presented as a percentage of the maximal response 
obtained with thrombin and drug vehicle alone (0.5% DMSO in DMEM). Final concentrations of 
DMSO were kept constant for all treatment conditions. The first bar represents the highest 
concentration of blebbestatin, and shows that this compound has no significant effect on basal 
CCL2 production. Negative log of the concentrations of blebbestatin are presented. Panel B 
shows the effect of blebbestatin on thrombin-induced CCL2 mRNA levels. MLFs were exposed 
to thrombin (10 nM) for 2 hours with or without pre-incubation with blebbestatin (3 pM) for 30 
minutes. CCL2 mRNA levels were determined by qRT-PCR. Data represent the mean ± SEM
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from triplicates, and show the representative of three independent experiments. +*p<0.01, 
comparison with medium control; "p<0.01, comparison with thrombin alone.
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Figure 3.34 Thrombin induces MLC phosphorylation in a time-dependent manner and it is 
inhibited by the inhibition of PLC, Ca2+, Ca2+-dependent PKC, Rho kinase and the 
inhibition of PAR! coupling to Gaq by Q94 .
Panel A shows the effect of thrombin on MLC phosphorylation in MLFs. MLFs were exposed to 
thrombin (10 nM) for the indicated time periods. Panel B and C show the effects of U73122 (2 
pM), BAPTA-AM (2 pM), G66976 (1 pM), Y-27632 (3 pM) and Q94 (10 pM) on thrombin- 
induced MLC phosphorylation in MLFs. Cells were pre-incubated with these inhibitors for 30 
minutes followed by thrombin stimulation for 10 minutes. MLC phosphorylation was assessed 
by western blotting using an anti phosphor-MLC antibody (upper panel). Protein loading control 
was verified by blotting with a total MLC antibody (lower panel). Representative blots of three 
separate experiments are presented.
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3.5.5 Summary
The results described in this section examining the role of PLC-Ca2+ pathway and 
RhoA/Rho kinase in thrombin-induced MLF CCL2 protein release and mRNA levels 
showed that:
• PLC and Ca2+ are involved in thrombin-induced CCL2 production via a post- 
transcriptional mechanism as inhibition of both PLC and Ca2+ inhibited 
thrombin-induced CCL2 protein release, but had no effect on thrombin-induced 
CCL2 mRNA levels.
• RhoA and Rho kinase also mediate thrombin-induced CCL2 production via a 
post-transcriptional mechanism.
• PLC, Ca2+, Ca2+-dependent PKC, RhoA and Rho kinase mediate thrombin- 
induced CCL2 production via an ERK1/2-independent mechanism.
• MLC is involved in thrombin-induced CCL2 production via a post-transcriptional 
mechanism as inhibition of MLC inhibited thrombin-induced CCL2 protein 
release, but had no effect on thrombin-induced CCL2 mRNA levels.
• Inhibition of PLC, Ca2+, Ca2+-dependent PKC, RhoA and Rho kinase inhibited 
thrombin-induced MLC phosphorylation, suggesting that these kinases are in a 
linear pathway for mediating thrombin-induced CCL2 production via a MLC- 
dependent mechanism.
• Inhibition of PARi coupling to Gaq by the novel Gaq-selective PARt antagonist 
Q94 inhibited thrombin-induced MLC phosphorylation, suggesting that MLC 
pathway is downstream of PARi coupling to Gaq for mediating thrombin- 
induced CCL2 production in MLFs.
In summary, PLC-Rho kinase pathway mediates thrombin-induced CCL2 protein 
production via a post-transcriptional mechanism, possibly via protein secretion. This 
pathway is also downstream of PARi coupling to Gaq.
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3.6 Inhibition of Rho kinase by Y-27632 has no effect on intracellular protein 
production
The results obtained thus far demonstrate an essential role for ERK1/2 in PARt 
activation-induced CCL2 production by influencing CCL2 mRNA levels; whereas the 
Rho kinase pathway acts via a post-transcriptional mechanism. To begin to elucidate 
the mechanism by which the Rho kinase pathway influences this response, 
immunocytofluoresence was employed to examine thrombin-induced intracellular CCL2 
protein production.
MLFs seeded in the 8-well tissue culture chambers were pre-incubated with U0126 (10 
pM) or Y-27632 (10 pM) for 30 minutes before exposure to thrombin for 3 hours. The 
chamber was then fixed and plotted with an anti-CCL2 antibody and normal goat IgG 
as isotype control. Figure 3.35 shows that unstimulated cells yield no immunostaining 
or a very weak signal for CCL2 (Figure 3.35B). In contrast, following stimulation with 
thrombin for 3 hours, up to 60% of cells were brightly stained as would be expected for 
cells which are actively synthesizing CCL2 (Figure 3.35C). The effect of thrombin was 
almost completely blocked in the presence of U0126 with only 5-10% of cells displaying 
a very weak signal for CCL2 (Figure 3.35D). In contrast, in the presence of the Rho 
kinase inhibitor, Y-27632, up to 60% of cells stained with CCL2 antibody brightly 
(Figure 3.35E), indicating that these cells are actively synthesizing CCL2. The isotype 
control was completely negative indicating that the signal obtained with the CCL2 
antibody was specific (Figure 3.35A). The mean pixel intensity of three randomly 
chosen fields of view was calculated for each group (Figure 3.35F), and the data are 
presented as fold change over control. Thrombin induced a 2.8 ± 0.1 fold increase in 
fluorescent signal over control and this was significantly inhibited by U0126. In contrast, 
pre-treatment of cells with Y-27632 did not block thrombin-induced intracellular CCL2 
accumulation (3.2 ± 0.5 fold increase over control).
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Figure 3.35 Immunocytofluorescence demonstrates that CCL2 intracellular protein 
production is blocked by MEK1/2 inhibition (U0126) but not by Rho kinase inhibition (Y- 
27632). Panel A, isotype control. Panel B, untreated cells. Panel C shows the effect of thrombin 
on CCL2 intracellular protein production. Panel D shows the effect of U0126 on CCL2 
intracellular protein production induced by thrombin. Panel E shows the effect of Y-27632 on 
CCL2 intracellular protein production induced by thrombin. Cells were pre-incubated with or 
without U0126 (10 pM) or Y-27632 (10 pM) for 30 min before stimulation with thrombin (10 nM) 
for 3 hours. At the end of incubation, cells were immunostained with normal goat IgG (A) or anti- 
CCL2 antibody (B-E) and followed by DAPI staining. Areas of CCL2 localization are shown in 
green, nuclei appear blue. Panel F shows the pixel intensity analysis for each group. Data 
represent the fold increase over control. Data show the representative of three independent 
experiments. ++p<0.01, comparison with untreated cells; p<0.01, comparison with thrombin 
alone.
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In summary, the results in this section show that blockade of ERK1/2 signalling results 
in near total blockade of thrombin-induced intracellular CCL2 production. In contrast, 
blockade of Rho kinase signalling is not essential for CCL2 protein production but likely 
affects the subsequent release of CCL2 from the cell, because thrombin-induced CCL2 
levels in cell culture supernatants were inhibited by Y-27632 (Figure 3.30).
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Chapter 4: Results (II)
Identification of PARi in mediating thrombin-induced CCL2/MCP-1 release in 
primary human adult lung fibroblasts
The previous chapter identified the signalling pathways involved in thrombin-induced 
CCL2 release in mouse lung fibroblasts. Thrombin is also known to induce the 
expression of CCL2 in primary dermal fibroblasts via the activation of PARt (Bachli et 
ai, 2003), but whether it can do so in primary human lung fibroblasts and the signalling 
receptor involved are not known. The aim of this chapter was therefore to determine 
whether thrombin stimulates the production of CCL2 by primary human adult lung 
fibroblasts (pHALFs), and to identify the signalling receptor (s) involved.
pHALFs were previously isolated in the host laboratory from lung explants (for a more 
detailed description see Materials and Methods Section 2.8). As they are derived 
directly from human lung tissue, these cells provide the closet representation of human 
biology, compared to ordinary immortalized cell lines. In addition, they have been well 
characterized in our laboratory and have previously been used to establish the effects 
of thrombin and TGF-p stimulation on fibroblast function (Chambers eta!., 2003).
4.1 Effect of thrombin on CCL2 release by primary human adult lung fibroblasts
In order to determine the effect of thrombin on pHALF CCL2 release, time-course 
experiments were performed with a standard concentration of 10 nM. pHALFs were 
exposed to 10 nM thrombin for various durations, and CCL2 protein levels in culture 
supernatants were assessed by ELISA. Figure 4.1A shows that thrombin induced 
pHALF CCL2 production in a time-dependent manner from 6 hours onwards, and the 
sharpest increase in CCL2 production occurs over the first 9 hours. In cells without 
thrombin treatment, there was also baseline production of CCL2 after 12 hour 
incubation with DMEM. Based on these results, a 6 hour time point was chosen for all 
subsequent experiments.
For concentration-response experiments, pHALFs were incubated with increasing 
concentrations of thrombin (0.001 nM to 10 nM) for 6 hours and CCL2 protein levels in 
culture supernatants were measured by ELISA. Figure 4.1 B shows that thrombin 
stimulated CCL2 production in a concentration-dependent manner from 0.3 nM
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onwards. CCL2 production continued to increase at all concentrations examined and 
the effect did not plateau at the highest concentration of thrombin (10 nM) examined.
4.2 The expression of PARs in primary human adult lung fibroblasts
In order to begin to investigate the involvement of PARs in thrombin-induced CCL2 
release in pHALFs, the expression of PAR^ receptors in pHALFs was first examined. 
PAR expression was analysed in whole cell lysates by RT-PCR. Figure 4.2 shows that 
prominent PCR products were obtained for PAR1t PAR2 and PAR3, whereas there was 
only faint band for PAR4, suggesting that PAR4 is expressed at much low levels in 
these cells compared with PARi_3.
4.3 The roles of PAR agonists in CCL2 release by primary human adult lung 
fibroblasts
In order to determine which receptor (s) is/are involved in mediating thrombin-induced 
CCL2 release by pHALFs, the effect of PAR1t PAR2 and PAR4 activating peptides on 
pHALF CCL2 production was next examined. The role of PAR3 in this study was not 
investigated due to the lack of PAR3-selective agonist and antagonist, and the lack of 
evidence that this receptor can signal on its own in fibroblasts.
4.3.1 Effect of P A ^  agonist peptides TFLLR-NH2 on CCL2 release by primary 
human adult lung fibroblasts
In the previous chapter, PARt was shown to be the major receptor involved in 
thrombin-induced CCL2 release in MLFs, so that the effect of the PARi specific agonist 
peptide TFLLR on pHALF CCL2 release was examined first. Cells were stimulated with 
increasing concentrations of TFLLR (6 pM to 200 pM) for 6 hours, and CCL2 protein 
levels in culture supernatants were assessed by ELISA. As shown in Figure 4.3, the 
PAR! specific activating peptide TFLLR induced pHALF CCL2 production in a 
concentration-dependent manner from 20 pM onwards. CCL2 production continued to 
increase at all concentrations and the effect did not plateau at the highest 
concentration of TFLLR (200 pM) examined. To confirm the specificity of the PARi 
agonist peptide TFLLR in influencing CCL2 protein levels, the effect of the reverse 
peptide FTLLR on CCL2 protein levels was also examined in parallel cultures. Figure
4.3 shows that FTLLR significantly induced CCL2 release at 200 pM, suggesting that 
the stimulatory effect obtained with TFLLR at 200 pM may be non-PARr mediated and 
non-specific. TFLLR at 60 pM significantly increased CCL2 production, whereas FTLLR 
at the same concentration had no effect on this response, so that 60 pM was used as a 
standard concentration for TFLLR for all subsequent studies.
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4.3.2 Effect of FXa, SLIGKV (PAR2 activating peptide) and AYPGKF (PAR4 
activating peptide) on CCL2 release by primary human adult lung fibroblasts
Both PAF^ and PAR4 mediate the effect of thrombin in human platelets. PAR2 is not a 
thrombin receptor, but it has been reported that PAR2 can also mediate thrombin’s 
effect after transactivated by PARi. As both PAR2 and PAR4 are expressed by pHALFs, 
it is important to investigate the role of PAR2 and PAR4 in thrombin-induced CCL2 
release by pHALFs. The effect of PAR2 and PAR4 activating peptides on pHALF CCL2 
release was therefore examined. Both thrombin and TFLLR were used as positive 
controls. FXa can signal via both PARt and PAR2, the effect of FXa on pHALF CCL2 
release was also examined.
Cells were exposed to thrombin (10 nM), FXa (10 nM), TFLLR (60 pM), SLIGKV (200 
pM) and AYPGKF (200 pM) for 6 hours. CCL2 protein levels in culture supernatants 
were assessed by ELISA. As shown in Figure 4.4, both FXa, and SLIGKV significantly 
induced pHALF CCL2 release by 5.6 ± 0.7 fold and by 6.6 ± 0.3 fold, respectively. 
However, both FXa, and SLIGKV were less efficient when compared to the level of 
induction (8.7 ± 0.7 fold) seen following stimulation with thrombin. TFLLR induced 
pHALF CCL2 release by 6.9 ± 0.9 fold, but the differences between TFLLR and 
thrombin were not significant. In contrast, the PAR4 agonist peptide AYPGKF exerted 
no effect on CCL2 production, suggesting that PAR4 is not involved. These data show 
that both PARi and PAR2 activation are sufficient for pHALF CCL2 release.
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Figure 4.1 Thrombin stimulates pHALF CCL2 protein production in a time- and 
concentration-dependent manner.
Panels A and B show time-course (A) and concentration response (B) data for the effect of 
thrombin on pHALF CCL2 protein production. pHALFs were exposed to 10 nM thrombin for 
varying durations (2 to 24 hours), or exposed to various concentrations of thrombin (0.001 to 10 
nM) for 6 hours. Supernatants from cell cultures following incubation were analyzed for CCL2 
production by ELISA. The amount of secreted CCL2 is expressed as pg/ml and each value 
represents the mean ± SEM from triplicates at each condition. Data show representative of 
three independent experiments. p<0.05, comparison with time point-matched media control 
(panel A), or unstimulated cells (panel B).
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Figure 4.2 Expression of PAR1j4 in pHALFs.
Figure shows the expression of PAR,_4 as analysed by RT-PCR in whole cell lysates of pHALFs. 
1 pg of cDNA was used for each set of primers and the same volume of final PCR products was 
run in a 1% agarose gel containing ethidium bromide. pHALFs show expression of PAR,, PAR2, 
PAR3, and much low level of PAR^ PAR, primers amplify a 148bp product; PAR2 primers 
amplify a 128bp product; PAR3 primers amplify a 111 bp product and PAR4 primers amplify a 
119bp product. -VE, negative control. Data show representative of three independent 
experiments.
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Figure 4.3 Effect of TFLLR and the reverse control peptide FTLLR on CCL2 production by 
primary human adult lung fibroblasts.
Panel A and B show the effects of TFLLR and FTLLR on pHALF CCL2 production. pHALFs 
were incubated with various concentrations of TFLLR and FTLLR (6 pM to 200 pM) for 6 hours. 
Supernatants from cell cultures following incubation were analyzed for CCL2 production by 
ELISA. The amount of secreted CCL2 is expressed as pg/ml and each value represents the 
mean ± SEM from triplicate wells for each condition. Data show representative of three 
independent experiments. +p<0.05, comparison with unstimulated cells.
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Figure 4.4 Effect of thrombin, TFLLR, FXa, SLIGKV, and AYPGKF on CCL2 production by 
primary human adult lung fibroblasts.
Panel shows the effect of PAR!, PAR2 and PAR4 agonist peptides on CCL2 production by 
primary human adult lung fibroblasts. pHALFs were exposed to thrombin (Thr, 10 nM), FXa (10 
nM), TFLLR (TF, 60 pM), SLIGKV (SL, 200 pM) and AYPGKF (AY, 200 pM) for 6 hours. 
Supernatants from cell cultures following incubation were analyzed for CCL2 production by 
ELISA. The amount of secreted CCL2 is expressed as pg/ml and each value represents the 
mean ± SEM from triplicates at each concentration. Data show representative of three 
independent experiments. ++p<0.01, comparison with unstimulated cells; *p<0.05, comparison 
with thrombin.
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4.4 Summary
The results described in this section examining the effects of PAR agonists on pHALF 
CCL2 production showed that:
• Thrombin induces pHALF CCL2 production in a concentration-dependent 
manner from 0.3 nM onwards.
• Thrombin (10 nM) induces pHALF CCL2 production in a time-dependent 
manner from 6 hours onwards, and the sharpest increase in CCL2 production 
occurs over the first 9 hours.
• PARi is strongly expressed in pHALF; PAR2 and PAR3 are also expressed, 
whereas PAR4 is expressed at much lower levels.
• PAR-i specific agonist peptide TFLLR can mimic the effect of thrombin on CCL2 
release in pHALFs, suggesting that PAR-i is sufficient for pHALF CCL2 release.
• Activation of PAR2 by the PAR2 activating peptide SLIGKV induces pHALF
CCL2 production.
• The PAR! and PAR2 activator FXa stimulates significant pHALF CCL2 release,
but is less efficient than thrombin at equivalent concentrations.
• PAR4 agonist peptide AYPGKF did not induce pHALF CCL2 release, 
suggesting that PAR4 is not involved.
In conclusion, both PARi and PAR2 activation are sufficient for CCL2 production by 
pHALFs.
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4.5 Role of PARi activation in CCL2 release by primary human adult lung 
fibroblasts
4.5.1 Effect o f RW J-58259 on thrombin (10 nM)-induced CCL2 release by primary 
human adult lung fibroblasts
The previous chapter showed that PARi is the major receptor involved in mediating 
thrombin-induced CCL2 release in MLFs at 10 nM of the proteinase. In order to 
examine whether this is also the case for pHALFs, the effect of PARi specific 
antagonist RWJ-58259 on this response was next examined. Cells were pre-incubated 
with various concentrations (0.01 pM to 3 pM) of the PARi specific antagonist RWJ- 
58259 for 15 minutes before exposure to thrombin (10 nM) for 6 hours, and CCL2 
protein levels in culture supernatants were assessed by ELISA. Surprisingly, unlike the 
results obtained for MLFs, RWJ-58259 did not inhibit thrombin-induced CCL2 release 
in pHALFs (Figure 4.5A). On the contrary, RWJ-58259 at concentrations higher than 1 
pM increased both basal and thrombin-induced CCL2 release in pHALFs (Figure 4.5 B).
The lack of an effect of RWJ-58259 might be explained by insufficient inhibition of 
PARi activation. These data can also be interpreted as indicating that PARt might not 
be involved in mediating thrombin (10 nM)-induced CCL2 release in pHALFs. In order 
to investigate these possibilities further, the effect of RWJ-58259 on PAR! agonist 
peptide TFLLR, and the PAR1/2 activator FXa-induced pHALF CCL2 release was next 
examined.
4.5.2 Effect o f RW J-58259 on TFLLR and FXa-induced CCL2 release by primary 
human adult lung fibroblasts
Cells were pre-incubated with various concentrations of the PARi specific antagonist 
RWJ-58259 for 15 minutes before exposure to TFLLR (60 pM) for 6 hours, and CCL2 
protein levels in culture supernatants were assessed by ELISA. As shown in Figure 4.6, 
RWJ-58259 significantly inhibited TFLLR-induced CCL2 release in a concentration- 
dependent manner from 0.1 pM onwards. At 1 pM (-Log [1 pM]=6), RWJ-58259 
inhibited this response by 72 ± 8% (p<0.05). These data indicate that PARi is both 
sufficient and necessary for TFLLR-induced CCL2 release by pHALFs.
The effect of RWJ-58259 on FXa-induced pHALF CCL2 release was next examined. 
Cells were pre-incubated with various concentrations of the PARi specific antagonist 
RWJ-58259 for 15 minutes before exposure to FXa (10 nM) for 6 hours. Figure 4.7A 
shows that RWJ-58259 inhibited FXa-induced CCL2 production in pHALFs in a
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concentration dependent-manner from 0.1 pM onwards. At 0.1 pM (-Log [0.1 pM]=7), 
RWJ-58259 inhibited this response of FXa by 79 ± 6% (p<0.05), but had no effect on 
basal CCI2 production. However, only 54% inhibition of FXa-induced CCL2 production 
was obtained with RWJ-58259 at 1 pM. This may be explained by the increase in basal 
CCL2 production induced by RWJ-58259 at 1 pM which is sometimes observed in 
pHALFs (Figure 4.7B). These data suggest that PARi is the major signalling receptor 
involved in this response of FXa.
Inhibition of both TFLLR and FXa-induced pHALF CCL2 release by RWJ-58259 
suggests that the lack of an effect of PARi inhibition on thrombin-induced pHALF CCL2 
release may be interpreted as indicating that PAR  ^ is not necessary for mediating this 
response of thrombin in pHALFs. Previous studies have demonstrated that cleaved 
PARi is able to mediate thrombin's cellular response indirectly via the transactivation of 
PAR2 (O’Brien et al 2000). It is therefore possible that thrombin might act via the 
transactivation of PAR2 to induce CCL2 production in pHALFs when PARi activation is 
inhibited by RWJ-58259 which blocks the receptor activation by binding the second 
extracellular loop but does not prevent unmaking of the tethered ligand. Further 
experiments were performed to investigate this possibility.
4.5.3 Effect o f PARi specific antibodies ATAP2 and WEDE15 on thrombin (10 
nM)-induced CCL2 release by prim ary human adult lung fibroblasts
To further investigate the participation of PARi in thrombin-induced CCL2 release in 
pHALFs, two previously developed monoclonal antibodies which block PARi cleavage 
by thrombin were employed. The first antibody, ATAP2, binds to an epitope within the 
PARi tethered ligand domain (Brass et al., 1994), whereas the second antibody, 
WEDE15, binds to the hirudin-like domain that interacts with thrombin’s anion-binding 
exosite (Hoxie et al., 1993). Cells were pre-incubated with ATAP2, WEDE15, or the 
combination of both ATAP2 and WEDE15 (25 pg/ml each) for 30 minutes before 
exposure to thrombin (10 nM) for 6 hours. Pre-incubation time and concentration of 
both ATAP2 and WEDE15 were chosen according to previous studies performed by 
O’Brien and colleagues (O'Brien et al., 2000). This study also reported that neither 
antibody was sufficient on its own to completely prevent PARi signalling; whereas 
complete blockade occurred only when the two antibodies were added together.
As shown in Figure 4.8, the combination of ATAP2 and WEDE15 had little effect on 
basal CCL2 production. Both ATAP2 and WEDE15 antibodies significantly inhibited 
thrombin-induced pHALF CCL2 release by 48.2 ± 7% (p<0.05) and 27.6 ± 1% (p<0.05),
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respectively. These data suggest that PARi cleavage is necessary for thrombin- 
induced CCL2 production in pHALFs. The combination of ATAP2 and WEDE15 
blocked thrombin-induced CCL2 release by 67.1 ± 7%. This further inhibition was 
significant when compared with the induction obtained with ATAP2 or WEDE15 alone. 
These data suggest that PARi is at least in part, responsible for thrombin-induced 
CCL2 release in pHALFs.
Although it has been reported that PARi can transactivate PAR2 for mediating 
thrombin’s effect when PARi activation is inhibited, PARi cleavage is required in order 
to transactivate PAR2 by its free tethered ligand. It has previously been reported that 
complete blockade of PARi cleavage by thrombin occurs when both ATAP2 and 
WEDE15 are added together (O’Brien et al., 2000). However, complete inhibition of 
CCL2 production was not obtained with the combination of ATAP2 and WEDE15 in this 
study. Taken together, these data therefore suggest that up to 70% of thrombin- 
induced CCL2 release is PARi-mediated, and the remaining 30% being mediated via a 
PARi-independent mechanism in pHALFs.
4.5.4 Effect o f Q94, U0126 and Y-27632 on thrombin (10 nM)-induced CCL2 
release b y  prim ary human adult lung fibroblasts
Previous results obtained with MLFs showed that PARi coupling to Gaq and 
downstream ERK1/2 and Rho kinase pathways mediate thrombin (10 nM)-induced 
CCL2 production. To further investigate the signalling pathways involved in thrombin 
(10 nM)-induced CCL2 production by pHALFs, the role of Gaq, ERK1/2 and Rho kinase 
was next examined. Cells were treated with increasing concentrations of Q94 (Figure 
4.9A), U0126 (Figure 4.9B) and Y-27632 (Figure 4.9C) for 30 minutes before exposure 
to thrombin (0.3 nM) for 6 hours. Figure 4.9 shows that all three inhibitors attenuated 
thrombin-induced pHALF CCL2 production in a concentration dependent manner. At 10 
pM, U0126 and Y-27632 inhibited this effect of thrombin by 74 ± 2.4% and 80 ± 6.9%, 
respectively, in contrast, the maximum inhibition obtained with Q94 was 53 ± 5%. 
These data confirm that PARi is a major signalling receptor involved in thrombin- 
induced CCL2 release in pHALFs, but that not all of thrombin’s effects are mediated via 
PARi. In contrast, both the ERK1/2 and Rho kinase signalling pathways account for 
most of thrombin-induced CCL2 release by pHALFs.
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Figure 4.5 Inhibition of PARi by RWJ-58259 does not inhibit thrombin (10 nM)-induced 
CCL2 release by primary human adult lung fibroblasts
Panel A shows the effect of the PARi antagonist RWJ-58259 on pHALF CCL2 protein 
production in response to 10 nM thrombin. Data are presented as a percentage of the maximal 
response obtained with thrombin and drug vehicle alone (0.03% DMSO in DMEM). The first bar 
represents the highest concentration of RWJ-58259 which increased the basal CCL2 release 
(see panel B). Panel B shows the effect of RWJ-58259 on basal CCL2 production in pHALFs, 
and the amount of secreted CCL2 is expressed as pg/mi. Cells were treated with increasing 
concentrations of RWJ-58259 for 15 minutes before stimulation with thrombin for 6 hours. Final 
concentrations of DMSO were kept constant for all treatment conditions. Negative log of the 
concentrations of RWJ-58259 are presented. Data represent the mean ± SEM of triplicates, and 
show representative of three independent experiments. ++p<0.01, comparison with unstimulated 
cells; ~p<0.01, comparison with thrombin; ^<0.05, comparison with DMSO control.
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Figure 4.6 PARi is necessary and sufficient for TFLLR-induced CCL2 release by primary 
human adult lung fibroblasts
Panel shows the effect of the PARt antagonist RWJ-58259 on pHALF CCL2 release in 
response to TFLLR (60 pM). Data are presented as a percentage of the maximal response 
obtained with TFLLR and drug vehicle alone (0.01% DMSO in DMEM). Cells were treated with 
increasing concentrations of RWJ-58259 for 15 minutes before stimulation with TFLLR for 6 
hours. Final concentrations of DMSO were kept constant for all treatment conditions. The first 
bar represents the highest concentration of RWJ-58259 used and shows that this compound 
has no effect on basal CCL2 production. Negative log of the concentrations of RWJ-58259 are 
presented. Data represent the mean ± SEM of triplicates, and show representative of three 
independent experiments. ++p<0.01, comparison with unstimulated cells; 'p^-Ofj, comparison 
with TFLLR.
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Figure 4.7 PARi is necessary for FXa-induced CCU2 release by primary human adult lung 
fibroblasts
Panel A shows the effect of the PARi antagonist RWJ-58259 on pHALF CCL2 release in 
response to FXa (10 nM). Data are presented as a percentage of the maximal response 
obtained with FXa and drug vehicle alone (0.01% DMSO in DMEM). The first bar represents the 
highest concentration of RWJ-58259 which increased the basal CCL2 release (see panel B). 
Panel B shows the effect of RWJ-58259 on basal CCL2 production in pHALFs, and the amount 
of secreted CCL2 is expressed as pg/ml. Cells were treated with increasing concentrations of 
RWJ-58259 for 15 minutes before stimulation with FXa for 6 hours. Final concentrations of 
DMSO were kept constant for all treatment conditions. Negative log of the concentrations of 
RWJ-58259 are presented. Data represent the mean ± SEM of triplicates, and show 
representative of three independent experiments. ++p<0.01, comparison with unstimulated cells; 
^<0.05, comparison with thrombin. ~p<0.01, comparison with DMSO control.
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Figure 4.8 PAF^ is partially involved in thrombin (10 nM)-induced CCL2 release by 
primary human adult lung fibroblasts
Panel shows the effect of the PAR! antibodies (ATAP2 and WEDE15) on pHALF CCL2 release 
in response to 10 nM thrombin. Data are presented as a percentage of the maximal response 
obtained with thrombin and drug vehicle alone. Cells were incubated with ATAP2 (A), WEDE15 
(W), or with both ATAP2 and WEDE15 (A+W) for 30 minutes before exposure to thrombin for 6 
hours. The concentration used for both antibodies is 25 pg/ml. The first bar represents the 
group of cells treated with ATAP2 and WEDE15 only, and shows that these antibodies have no 
significant effect on basal CCL2 release. Data represent the mean ± SEM of triplicates, and 
show representative of three independent experiments. ++p<0.01, comparison with unstimulated 
cells; *p<0.05, comparison with thrombin; *p<0.05, comparison with cells treated with both 
antibodies and thrombin.
181
Chapter 4 Results (II)
H U  *Log[Q94(M)] 
n  Vehicle
[Thrombin](10nM)
-log[Y -27632(M )]
| | Vehicle§ 100
6.5 6 5.5
rmrombin](10 nM }
-Log[U0126(M)]
| | Vehicle
0 6.5 6 5 .5 5
i  [Ttiroinbin]{10 n M )  -
Figure 4.9 Inhibition of Gaq (Q94), MEK1/2 (U0126) and Rho kinase (Y-27632) attenuates 
thrombin (10nM)-induced pHALF CCL2 release.
Figure shows the effects of Q94, U0126 and Y-27632 on thrombin-induced CCL2 release. Cells 
were pre-incubated with increasing concentrations of inhibitors for 30 minutes before exposure 
to thrombin (10 nM) for 6 hours. Data are presented as a percentage of the maximal response 
obtained with thrombin and drug vehicle alone (0.1% DMSO in DMEM). Final concentrations of 
DMSO were kept constant for all treatment conditions. The first bars represent the highest 
concentrations of inhibitors used, and show that these compounds have no significant effect on 
basal CCL2 production. Negative log of the concentrations of inhibitors are presented. Data 
represent the mean ± SEM from triplicates, and show representative of three independent 
experiments. ++p<0.01, comparison with medium control; *p<0.05, comparison with thrombin 
alone; **p<0.01, comparison with thrombin.
182
Chapter 4 Results (II)
4.6 Summary
The results described in this section exploring the role of PARi on pHALF CCL2 
release induced by thrombin (10 nM) showed that:
• Inhibition of PARi by RWJ-58259 inhibited both TFLLR- and FXa-induced 
pHALF CCL2 release in a concentration-dependent manner, suggesting that 
PARi activation is sufficient for CCL2 release in pHALFs.
• Inhibition of PAR-i by RWJ-58259 did not inhibit pHALF CCL2 release induced 
by thrombin at a standard concentration of 10 nM. In contrast, the Gaq selective 
PAR  ^ antagonist Q94 blocked this response of thrombin by about 50%, 
suggesting that PARi is partially involved in mediating thrombin-induced CCL2 
release in pHALFs.
• Inhibition of PARi cleavage by ATAP2 or WEDE15 inhibited 10 nM thrombin- 
induced pHALF CCL2 release by 48.2 ± 7% and 27.6 ± 1% respectively, 
suggesting that PARi is necessary for pHALF CCL2 release induced by 
thrombin.
• Inhibition of PARi cleavage by both ATAP2 and WEDE15 did not fully block this 
effect of thrombin (67.1 ± 7%). It has been reported that complete inhibition of 
PARi cleavage is obtained with the combination of ATAP2 and WEDE15. 
These data therefore suggest that PARHndependent mechanism may also be 
involved.
• Inhibition of ERK1/2 and Rho kinase inhibited thrombin-induced pHALF CCL2 
release in a concentration-dependent manner by up to 74 ± 2.4% and 80 ± 
6.9%, respectively, suggesting that both ERK1/2 and Rho kinase signalling 
pathways account for most of thrombin-induced CCL2 release.
Taken together, these data suggest that thrombin (10 nM) induces pHALF CCL2 
protein release via both PARi-dependent and PARi-independent mechanisms. PAR! 
coupling to Gaq is partially involved, whereas both ERK1/2 and Rho kinase signalling 
pathways account for most of thrombin-induced pHALF CCL2 release.
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4.7 The role of PAF^ in low concentration (0.3 nM) of thrombin-induced CCL2 
release by primary human adult lung fibroblasts
The data obtained thus far suggested that thrombin-induced CCL2 release by pHALFs 
at 10 nM is partially PARi-dependent. Extensive studies by other investigators have 
demonstrated that thrombin at different concentrations may signal via different PAR 
receptors to mediate their downstream cellular responses (Reviewed in (O'Brien et al., 
2001)). The data presented in figure 4.1B show that thrombin induces CCL2 release in 
a concentration-dependent manner from 0.3 nM onwards. To determine the relative 
contribution of PAR, to thrombin-induced CCL2 release at lower concentrations, the 
role of PARi in 0.3 nM thrombin-induced pHALF CCL2 release was examined.
4.7.1 Effect o f RWJ-58259 on low concentration thrombin (0.3 nM)-induced CCL2 
release b y  prim ary human adult lung fibroblasts
In order to investigate the role of PAR! in CCL2 production in response to low 
concentration of thrombin (0.3 nM) in pHALFs, the effect of RWJ-58259 on this 
response was examined. Cells were pre-incubated with various concentrations of the 
PAR! specific antagonist RWJ-58259 for 15 minutes before exposure to thrombin (0.3 
nM) for 6 hours. The highest concentration of RWJ-58259 used was 1 pM because 
previous experiments demonstrated that RWJ-58259 affects basal CCL2 production at 
higher concentrations (see Figure 4.5). Figure 4.10 shows that RWJ-58259 significantly 
inhibited thrombin-induced CCL2 release in a concentration-dependent manner from 
0.1 pM onwards. At 0.3 pM (-log [0.3 pM]=6.5), RWJ-58259 inhibited this response by 
76 ± 6.5% (p<0.01). These data suggest that PARi is necessary for mediating CCL2 
release induced by thrombin at low concentrations of the proteinase (0.3 nM).
4.7.2 Effect o f ATA P2 and WEDE15 on low concentration thrombin (0.3 nM)- 
induced CCL2 release b y  prim ary human adult lung fibroblasts
in order to further investigate the role of PARi in mediating low concentration of 
thrombin (0.3 nM)-induced CCL2 release in pHALFs, the effect of the two PARr  
specific monoclonal antibodies, ATAP2 and WEDE15, on low concentration of thrombin 
(0.3 nM)-induced CCL2 release was examined. Cells were pre-incubated with ATAP2, 
WEDE15, or the combination of both ATAP2 and WEDE15 (25 pg/ml each) for 30 
minutes. Cells were then stimulated with thrombin (0.3 nM) for 6 hours. Figure 4.11 
shows both ATAP2 and WEDE15 significantly inhibited thrombin-induced CCL2 
release by 83 ± 10% (p<0.01) and by 77 ± 3% (p<0.01), respectively. The combination 
of ATAP2 and WEDE15 blocked thrombin-induced CCL2 release by 93 ± 1.3%
(p<0.01).
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4.7.3 Effect o f Q94, U0126 and Y-27632 on low concentration thrombin (0.3 nM)- 
induced CCL2 release by primary human adult lung fibroblasts
To determine the role of Gaq, ERK1/2 and Rho kinase in low concentration of thrombin 
(0.3 nM)-induced pHALF CCL2 release, the effect of Q94, U0126 and Y-27632 on this 
response was next examined. Cells were treated with increasing concentrations of 
Q94 (Figure 4.12A), U0126 (Figure 4.12B) and Y-27632 (Figure 4.12C) before 
exposure to thrombin (0.3 nM) for 6 hours. Figure 4.12 shows that all three inhibitors 
blocked thrombin-induced pHALF CCL2 production in a concentration-dependent 
manner. At 10 pM (-log [10 pM]=5), Q94, U0126, and Y-27632 inhibited this response 
of thrombin by 86.7 ± 7.5%, 85.5 ± 2% and 89.3 ± 2% (all p<0.01), respectively. These 
data suggest that PARi-Gaq, ERK1/2 and Rho kinase signalling pathways mediate 
thrombin-induced CCL2 release by pHALFs at 0.3 nM of this proteinase. In contrast, 
previous results showed that PARrGaq is not fully involved in thrombin-induced CCL2 
release in pHALFs at 10 nM. This discrepancy is consistent with the notion that 
thrombin at different concentrations may signal via different mechanism to mediate its 
downstream cellular responses.
185
Chapter 4 Results (II)
150
0</)co
CL
CO
CD
^  100-o
T3 _O E
ir  O
c
X I
CN
— I *+ _
O  o
O ^
0Oi_
0
CL
50-
+ +
X
■  -Log[RWJ-58259(M)] 
| | Vehicle
7 6.5
[Thrombin] (0.3 nM)
Figure 4.10 PARi is necessary and sufficient for thrombin-induced CCL2 release by 
primary human adult lung fibroblasts at low concentrations of the proteinase (0.3 nM).
Panel shows the effect of the PARt antagonist RWJ-58259 on pHALF CCL2 release in 
response to 0.3 nM thrombin. Data are presented as a percentage of the maximal response 
obtained with thrombin and drug vehicle alone (0.01% DMSO in DMEM). Cells were treated with 
increasing concentrations of RWJ-58259 for 15 minutes before stimulation with thrombin for 6 
hours. Final concentrations of DMSO were kept constant for ail treatment conditions. The first 
bar represents the highest concentration of RWJ-58259 used and shows that this compound 
has no effect on basal CCL2 production. Negative log of the concentrations of RWJ-58259 are 
presented. Data represent the mean ± SEM of triplicates, and show representative of three 
independent experiments. ++p<0.01, comparison with unstimulated cells; **p<0.01, comparison 
with thrombin.
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Figure 4.11 PARi is sufficient and necessary for mediating thrombin (0.3 nM)-induced 
CCL2 release by primary human adult lung fibroblasts
Panel shows the effect of the PARi blocking antibodies (ATATP2 and WEDE15) on pHALF 
CCL2 release in response to thrombin at 0.3 nM. Data are presented as a percentage of the 
maximal response obtained with thrombin and drug vehicle alone. Cells were treated with 
ATAP2 (A), WEDE15 (W), or with both ATAP2 and WEDE15 (A+W) for 30 minutes before 
stimulation with thrombin for 6 hours. The concentration used for both antibodies is 25 pg/ml. 
The first bar represents the group of cells treated with ATAP2 and WEDE15 only, and shows 
that this antibody mixture has no significant effect on basal CCL2 production. Data represent 
the mean ± SEM of triplicates, and show representative of three independent experiments. 
++p<0.01, comparison with unstimulated cells; ~p<0.01, comparison with thrombin.
187
Chapter 4 Results (II)
•O -o p £o. 2M £
O o o ^
_ 120d)
§ ioo-
Q.
SO­
SO- 
40- 
20 - 
0-
X -Log[Q94(M)]
□  Vehide
l i i *
6.5 6 5.5
[Thrombin](0.3 nM)
120
O 1 0 0 -
-Log[U0126(M)]
| l vehide
S.6 6.6
. [Throm bin ](0 .3  nM )
l-Log[Y-27632(M)]
I | Vehide
3 20
0 6.5 6 5.5
[Thrombln](0.3 nM)
Figure 4.12 Inhibition of Gaq (Q94), and MEK1/2 (U0126) and Rho kinase (Y-27632) 
attenuates thrombin (0.3 nM)-induced pHALF CCL2 release.
Figure shows the effects of Q94, U0126 and Y-27632 on thrombin-induced CCL2 release. Cells 
were pre-incubated with increasing concentrations of inhibitors for 30 minutes before exposure 
to thrombin (0.3 nM) for 6 hours. Data are presented as a percentage of the maximal response 
obtained with thrombin and drug vehicle alone (0.1% DMSO in DMEM). Final concentrations of 
DMSO were kept constant for all treatment conditions. The first bars represent the highest 
concentrations of inhibitors used, and show that these compounds have no significant effect on 
basal CCL2 production. Negative log of the concentrations of inhibitors are presented. Data 
represent the mean ± SEM from triplicates, and show representative of three independent 
experiments. ++p<0.01, comparison with medium control; *p<0.05 and **p<0.01, comparison with 
thrombin.
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4.8 Summary
The results described in this section exploring the role of PARi on pHALF CCL2 
release induced by thrombin at low concentration (0.3 nM) showed that:
• 0.3 nM thrombin-induced pHALF CCL2 release was inhibited by RWJ-58259 in 
a concentration-dependent manner, suggesting that PAR! is necessary for 
mediating this response.
• Inhibition of PARi by ATAP2, WEDE15 or both ATAP2 and WEDE15, 
completely inhibited 0.3 nM thrombin-induced pHALF CCL2 release, further 
suggesting that the effect of 0.3 nM thrombin on pHALF CCL2 release is 
mediated by the activation of PAR!.
• Inhibition of PARi coupling to Gaq, MEK1/2, and Rho kinase inhibited thrombin- 
induced pHALF CCL2 production in a concentration-dependent manner. Full 
blockade was obtained at highest concentrations of all inhibitors, suggesting 
that Gaq, ERK1/2, and Rho kinase play major roles in this response of thrombin 
at 0.3 nM.
In conclusion, thrombin (0.3 nM)-induced pHALF CCL2 release is mediated by PARi 
coupling to Gaq, ERK1/2 and Rho kinase signalling pathways.
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Chapter 5: Discussion
Overview
The activation of the coagulation cascade leading to the generation of thrombin is one 
of the earliest events following tissue injury. PAR1( the main high-affinity thrombin 
signalling receptor, contributes to excessive inflammation and tissue remodelling in a 
number of disease settings, including atherosclerosis (Major et al., 2003), vascular 
neointima formation (Cheung et al., 1999), glomerulonephritis (Cunningham et al.,
2000), liver fibrosis (Fiorucci et al., 2004), inflammatory bowel disease (Vergnolle et al.,
2004), acute lung injury (Jenkins et al., 2006) and fibrotic lung disease (Howell et al.,
2005). In this setting, we have recently shown that the dramatic attenuation of the 
acute inflammatory and late fibrotic response in PARr deficient mice following 
bleomycin-induced lung injury is associated with a marked reduction in pulmonary 
levels of CCL2 (Howell et al., 2005). CCL2 has been shown to play an important role in 
pulmonary fibrosis as a pro-inflammatory and pro-fibrotic chemokine (Zhang et al., 
1994; Moore et al., 2001; Gharaee-Kermani et al., 2003; Inoshima et al., 2004). 
Delineation of the signalling pathways downstream of PARi activation which lead to 
CCL2 production may identify multiple novel therapeutic targets for respiratory 
conditions associated with excessive coagulation proteinase signalling.
The aim of this study was to further our understanding of the signal transduction 
mechanisms underlying thrombin-induced CCL2 production. Thrombin has been shown 
to induce CCL2 production in various cell types, such as human glomerular mesangial 
cells (Grandaliano et al., 1994), human proximal tubular cells (Grandaliano et al, 2000), 
macrophages (Szaba and Smiley, 2002), dermal fibroblasts (Bachli et al, 2003) and 
stellate cells (Fiorucci et al, 2004) etc. To the best of my knowledge, the present study 
is the first to examine the effect of thrombin on the expression of CCL2 and to delineate 
the signal transduction mechanisms for CCL2 production in mouse lung fibroblasts 
(MLFs) and in primary human lung fibroblasts (pHALFs), the major cell type 
responsible for progressive lung fibrosis in animal models and in patients with 
pulmonary fibrosis. In this study, by using a novel PARr Gaq antagonist which blocks 
the interaction between PARi and Gaq, we report for the first time that PARi coupling to 
Gaq is essential for thrombin-induced CCL2 gene expression and protein release in 
MLFs. The studies further demonstrate that these effects are mediated via the co­
operation between ERK1/2 and Rho kinase signalling pathways: a calcium- 
independent PKC, c-Raf and ERK1/2 pathway was found to mediate PARr induced
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CCL2 gene transcription; whereas the PLC, calcium-dependent PKC and Rho kinase 
pathway influences CCL2 protein release. This thesis also examined the signalling 
receptor and downstream effectors involved in thrombin-induced CCL2 production in 
pHALFs. The results demonstrate that PARi coupling to Gaq is also both necessary 
and sufficient in mediating thrombin-induced CCL2 production at low concentration (0.3 
nM) of the proteinase, whereas at high concentrations (10 nM), these effects may be 
partially PARHndependent. This discrepancy between MLFs and pHALFs may be 
explained by differences of PAR receptor expression between species. Investigation of 
the downstream signalling pathways revealed that both ERK1/2 and Rho kinase are 
involved in thrombin (0.3 nM and 10 nM)-induced pHALF CCL2 release.
5.1 Signal transduction in thrombin (10 nM)-induced CCL2 production in mouse 
lung fibroblasts
5.1.1 Thrombin induces CCL2 production in a concentration- and time-dependent 
manner in MLFs
In order to delineate the signalling events that lead to CCL2 production, I first examined 
the effect of thrombin on MLF CCL2 production. In this study, thrombin was shown to 
stimulate CCL2 production in a concentration-dependent manner from 0.03 nM 
onwards. Strikingly, this concentration response experiment did not plateau at 300 nM, 
the highest concentration examined. It is possible that the maximal stimulatory 
concentration (300 nM) of thrombin used here is not high enough to reach a plateau. In 
normal human plasma, the zymogen prothrombin is present at concentrations around
1.4 pM, but concentrations of around 130 nM have been calculated to represent the 
maximum concentration of active thrombin generated during blood clotting in vivo 
(Walz et al., 1985; Davie and Kulman, 2006). Therefore, the concentrations used in the 
present experiments are at near-physiological concentrations, and concentrations in 
excess of 300 nM are unlikely to be reached in extra vascular compartments in vivo. 
Time-course experiments showed a significantly time-dependent increase of CCL2 
after thrombin (10 nM) stimulation, suggesting that thrombin-induced CCL2 protein 
production in MLFs is not from the pre-stored CCL2, but synthesised de novo.
5.1.2 Thrombin exerts its stim ulatory effects on CCL2 release via activation of 
PARi
Thrombin exerts most of its cellular effects via activation of at least three PARs (PAR1t 
PAR3, and PAR4) by limited proteolytic cleavage of the N-terminal extracellular domain 
and the unmasking of a tethered ligand (Vu et al., 1991). PAR! is the high affinity
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thrombin receptor. It is cleaved at lower thrombin concentrations and preferentially 
cleaved when other PARs are present. However, it is widely accepted now that 
thrombin can also signal via PAR4 when relatively higher concentrations of thrombin 
are used, including 30 nM (Kahn et ai, 1999).
As both PARi and PAR4 are expressed in MLFs, and also no plateau was achieved in 
the concentration-response experiments in the present study, it is therefore possible 
that PAR4 might be needed for thrombin responses obtained with high concentrations 
in MLFs. Indeed, in the present study, concentration-response experiments with PARi 
KO MLFs showed that at 10 nM, thrombin had no effect on CCL2 production, 
suggesting that PARi might mediate the response of thrombin at 10 nM. In contrast, 
significant increases in CCL2 production were observed at 30 nM and 100 nM of 
thrombin. This further suggests that the activation of PAR4 might be involved in 
thrombin responses. However, experiments showed that the PAR4 specific agonist 
peptide AYPGKF and its scrambled control peptide YAPGKF failed to induce any CCL2 
production in PARi KO MLFs, suggesting that PAR4 plays no role in this response of 
thrombin in MLFs. As thrombin is a protease, the effects of higher concentrations may 
therefore be due to the release of mediators bound to the pericellular matrix. In this 
regard, thrombin has previously been shown to release TGF-p bound to the pericellular 
matrix (Taipale etal., 1992).
Thrombin concentration in BALF in patients with systemic sclerosis is around 15 nM 
compared with about 4 nM for healthy controls (Hernandez-Rodriguez et ai, 1995). 10 
nM thrombin, which is possibly PAR-t specific in this study, is therefore a concentration 
physiologically relevant and representative of levels found in the lungs of patients with 
fibrotic lung disease. In addition, 10 nM is a commonly used concentration of thrombin 
in numerous studies (Singh et at., 2007), 10 nM of thrombin was then used for all 
subsequent studies.
The essential role of PARi in mediating CCL2 release induced by thrombin (10 nM) in 
MLFs was further strengthened by studies using the highly selective PARi peptide 
agonist TFLLR. TFLLR selectively activates PARi as it mimics the tethered ligand 
sequence of PARi and directly binds to the activation site of PAR1r bypassing the need 
for proteolytic cleavage of the receptor. TFLLR uniquely activates PARt and unlike the 
other commonly used peptide SFLLR, it does not cross-activate PAR2 in mesenchymal 
cells (Hollenberg et a i, 1997). The work presented here shows that this specific PARi 
activating peptide TFLLR significantly induced CCL2 release in MLFs. The
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concentration of TFLLR needed to stimulate this effect is usually much higher than for 
thrombin since PAR activating peptides are generally less efficient than the in vivo 
physiological activators of PARs (Hollenberg and Compton, 2002). This may be 
explained by the following possibilities. First, following cleavage of PARi by thrombin, 
the tethered ligand may adopt a specific position that favours a more efficient activation 
of the receptor compared to free-floating activating peptide. Second, activation of PAR-, 
by thrombin is uniquely facilitated by a hirudin-like sequence towards the N-terminus of 
PARi which can interact with thrombin’s anion-binding exosite.
It is worth mentioning that in these experiments, the CCL2 response obtained was 
usually greater for TFLLR over thrombin, although the concentration for TFLLR was 
much higher than thrombin. Similar differences in potency and efficacy between 
thrombin and thrombin receptor activating peptide (TRAP) have also been observed in 
PARi-mediated CCL2 release in vascular endothelial cells (Marin et ai, 2001). 
However, this may conflict with the notion that PAR activating peptides are generally 
less efficient for PAR activation than those in vivo physiological activators of PARs as 
described above. One possible explanation lies in the mechanism by which PAR! 
mediates the cellular response of thrombin via the activation of G-proteins, and this will 
be further discussed in detail in the next section (5.1.4.1.2)
PARi KO MLFs failed to respond to TFLLR, further supporting the unique role of PAR! 
in mediating thrombin-induced CCL2 release. It should be noted that the scrambled 
control peptide, RLLFT at comparable concentration, did not have any effect in both 
MLFs and PARi KO MLFs. These results support the notion that the stimulatory effects 
of TFLLR on CCL2 release were PARi-mediated, rather than the possible activation of 
other non-PAR receptors. In this regard, a study has demonstrated that PAR activating 
peptides at elevated concentrations may activate receptors other than PARs (Roy et ai,
1998).
Finally, the critical role of PARi in thrombin-induced CCL2 release in MLFs was 
established by studies utilising the potent and selective PARi antagonist, RWJ-58259 
(Damiano et ai, 2003). This antagonist is a small indazole-based compound which 
specifically inhibits the tethered ligand of PARi binding to its second extracellular loop, 
and thus prevents receptor activation. RWJ-58259 has been shown to significantly 
block PARi-mediating signalling events both in vitro and in vivo (Andrade-Gordon et ai,
2001). In the present study, RWJ-58259 inhibited thrombin-induced CCL2 release in a 
concentration-dependent manner from concentrations as low as 0.1 pM, with an IC50
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value of 0.4 pM. This antagonist completely abolished this effect of thrombin at 3 pM, a 
concentration that is much lower than the IC50 (8 pM) of RWJ-58259 previously 
described to block thrombin-induced platelet responses in in vitro culture systems 
(Andrade-Gordon et al., 2001). Higher concentrations of RWJ-58259 are required when 
elevated concentrations of thrombin are present. However, thrombin concentrations in 
the present study were comparable with the studies by Andrade-Gordon (10 nM versus 
8 nM). This higher IC50 of RWJ-58259 in studies by Andrade-Gordon may then be due 
to the potency of thrombin towards PAR4 activation in platelets. The ability of the PARt 
antagonist to inhibit thrombin signalling in MLFs at lower concentrations further reflects 
that PARi is the main thrombin-sensitive receptor on these cells in the present study.
Taken together, these data provide compelling evidence that PARi is the signalling 
receptor involved in thrombin (10 nM)-induced CCL2 release in MLFs.
5.1.3 Thrombin stim ulates CCL2 mRNA levels in an immediate-early gene 
response fashion
In addition to the impressive induction of CCL2 at the protein level, thrombin also 
induced a rapid and robust increase in CCL2 mRNA levels. The increase of CCL2 
mRNA levels induced by thrombin is actinomycin-D (act-D) sensitive, further 
suggesting that the observed increase in CCL2 release is not due to the release of pre­
stored CCL2. These data are consistent with previous reports of thrombin-induced 
CCL2 production in endothelial cells and monocytes (Colotta et al., 1994). As act-D is 
an inhibitor of gene transcription, the attenuation of CCL2 mRNA levels by act-D further 
indicates that gene transcription is likely to be an important mechanism for mediating 
thrombin-induced CCL2 protein release in MLFs. In addition, PARi antagonism 
abolished thrombin-induced CCL2 mRNA levels, suggesting that PARi mediates 
thrombin-induced CCL2 release via increased gene transcription.
CCL2 is a well-known immediate-early gene in fibroblasts that has been proposed by 
several studies (Cochran et al., 1983; Shyy et al., 1994; Sridhar et al., 1999; Kinser et 
al., 2004). Immediate-early genes are a functional diverse family of genes that are 
induced at transcriptional level in response to stimuli including growth factors and 
serum, and the induction is not dependent on new protein synthesis (Sridhar et al.,
1999). Indeed, results obtained in this study further confirmed this notion. The effect of 
thrombin on CCL2 mRNA levels in MLFs was very rapid (within 30 minutes), 
cycloheximide-insensitive, maximal (21 fold increase relative to control) at 6 hours, and 
the signal diminished after 9 hours. This suggests that the CCL2 response to thrombin
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is typical of that of an immediate-early gene. For comparison, the induction of CCL2 at 
the mRNA level obtained with thrombin in dermal fibroblast was reported to be much 
delayed, prolonged and with less magnitude (Bachli et al., 2003). In this study, the 
increase of CCL2 mRNA levels was delayed until 2.25 hours, and was prolonged up to 
at least 24 hours with a maximal of 4-fold increase. This is unusual for an immediate- 
early gene response and is not concordant with many other studies indicating that 
CCL2 is an immediate-early gene (Sridhar et al., 1999; Kinser et al., 2004). The 
discrepancy between the present study and work by Bachli EB and colleagues may be 
explained by the cell lines employed in both studies as both are fibroblasts, but derived 
from different organs.
It is worth mentioning that although cycloheximide did not inhibit thrombin-induced 
CCL2 mRNA levels in this study, cycloheximide significantly enhanced the basal and 
thrombin-stimulated increase of CCL2 mRNA in MLFs. Cycloheximide is an inhibitor of 
protein synthesis. Induction by cycloheximide is generally interpreted as the result of 
reduced synthesis of RNAses (Goppelt-Struebe and Stroebel, 1995). This is typical for 
immediate-early gene responses, the expression of which is independent of de novo 
protein synthesis. Cycloheximide-dependent increase of CCL2 mRNA levels in the 
present study is concordant with other studies performed in smooth muscle cells, 
endothelial cells and mesangial cells (Colotta et al., 1992; Colotta et al., 1994; Goppelt- 
Struebe and Stroebel, 1995).
In summary, following exposure to 10 nM thrombin, significant CCL2 protein production 
is obtained in MLFs. Gene transcription appears to be an important pathway for 
thrombin-induced CCL2 production in MLFs and de novo protein synthesis appears not 
to be required. These effects of thrombin are further mediated via PARt at this 
concentration of the proteinase.
5.1.4 Delineation o f the signalling pathways involved in PARi-mediated CCL2 
production by m ouse lung fibroblasts
Like the other important body organs, lung is a highly complex, but well-organised 
system in which signal transduction plays critical roles by transducing extracellular 
stimuli into appropriate cellular responses. Understanding the mechanisms by which 
extracellular stimuli modify the functions of the cells may not only provide valuable 
insight into the pathogenesis of lung disease, it may also lead to the identification of 
novel therapeutic targets for pharmacological intervention.
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5.1.4.1 Role o f G proteins in PAR^mediated CCL2 release and mRNA 
accumulation
5.1.4.1.1 Strategies used to study GPCR-G protein signalling
PARi exerts its pluripotent cellular effects by concomitant activation of Gdj/o, Gaq and 
Gcti2/13- These G proteins act as molecular switches that couple PARi to their relevant 
effector systems such as kinases or ion channels. Although many of the resultant 
biological consequences of PARi activation in fibroblasts are known, less is known 
about which G proteins mediate these events. Previously, unlike kinases, direct 
inhibitors of G proteins were rarely available with the exception of pertussis toxin for 
Gaj/o and this may hinder the in-depth investigation of the role of specific G protein in 
signal transduction studies. There are now several promising tools available which can 
specifically inhibit the interaction of G protein-coupled receptors with individual G 
proteins. In particular, the newly developed small, cell permeable molecules namely 
pepducins seem to be promising for thrombin signalling studies since they are 
specifically designed to block PAR^G protein coupling. Pepducins are designed to bind 
to the receptor-G protein interface on the inner leaflet of the plasma membrane and 
have been developed in the context of PARi and PAR4 signalling. However, the cross­
inhibition between PARi and PAR4 by pepducins makes this type of inhibitor a potential 
tool for predicting an interaction between PARi and PAR4, rather than a specific 
inhibitor for inhibiting PARn-G protein interactions (reviewed in (Leger et al., 2006). In 
addition, pepducins usually can not distinguish between different members of the same 
G-protein family mediating similar functional responses.
Genetic approaches, on the other hand, are a novel approach to selectively suppress 
or knockout the expression of distinct G-protein subunits. This approach has been 
extensively used in both in vivo and in vitro studies although it is not likely to be 
developed as a therapeutic approach for humans. The dominant-negative strategy is 
one of the most frequently used genetic approaches to examine the involvement of G 
proteins in a given physiological response mediated by GPCRs. Traditionally, the 
dominant-negative strategy involves generating dominant-negative constructs of the 
Ga subunit in which mutations are introduced at residues known to contact the 
magnesium ion (Slepak et al., 1993; Slepak et al., 1995). G proteins and small GTPase 
are activated after GTP binds to the a subunits following the release of GDP from the 
GDP-Mg2+ complex. The GTP is then bound very tightly as a complex with Mg2+. The 
efficiency of this approach is therefore largely dependent on the degree to which Mg2+ 
is necessary to support GDP binding. This approach has been successfully used to 
generate dominant-negative constructs for small GTPase, e.g. p21ras (John et al.,
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1993), as the GTPase p21ras forms a tight and nearly irreversible GDP-Mg2+ complex. 
However, it has been rather disappointing for making dominant-negative G proteins 
including Gait Ga0, Gaq, and Gan (reviewed in (Gilchrist et al., 2002)). The possible 
reason for this is that the dominant-negative G proteins of Ga subunits bind Mg2+ in the 
GDP-Mg2+ complex with lower affinity than in the GTP-Mg2+ complex. In addition, these 
dominant-negative constructs of Ga subunits cannot usually distinguish between 
different members of the same G-protein family. The application of this approach is 
therefore quite limited.
It is now well-accepted that the carboxyl terminus of G protein a subunits are critical in 
G protein signalling (Reviewed in (Gilchrist et al., 1998; Wess, 1998). Dominant- 
negative constructs targeting the carboxyl terminus can be used as competitive 
inhibitors of receptor-G protein interactions. In this regard, Dr Gilchrist and co-workers 
have generated minigene plasmid constructs that encode the 14 unique COOH- 
terminal sequences of various Ga subunits (Gilchrist et al., 2001). Instead of competing 
with binding of Mg2\  these G protein minigenes directly interfere with G protein- 
receptor interaction. The C-terminal region of various G protein a subunits has been 
shown to be not only the essential region for receptor contact, but also critical in 
determining the specificity of GPCR-G protein interactions (Hamm and Gilchrist, 1996; 
Hamm, 1998). This has been proposed by studies using ADP ribosylation by pertussis 
toxin, peptide competition, site-directed mutagenesis, peptide-specific antibodies, and 
chimeric proteins. For example, substituting a single amino acid has been shown to 
annul the ability of Gai to bind the A1 adenosine receptor, further supporting the unique 
importance of the C-terminal region for receptor-G protein signalling (Gilchrist et al., 
1998). More importantly, these minigenes are able to target individual members of the 
Ga family. G protein minigenes are therefore very useful tools for dissecting G protein 
signalling pathways.
The specific Gaq antagonist Q94 employed in the present study was also designed 
according to the 11 amino acids found at the carboxyl-terminus of Gaq. Q94 is a 
recently developed novel PARt selective Gaq protein signalling antagonist (for a more 
detailed description and the specificity of Q94 please see Introduction Section 1.7.5.2). 
In the present study, G protein minigenes, the specific Gaq antagonist Q94 and the 
classical Gai/0 inhibitor pertussis toxin were therefore employed to dissect PARr G 
proteins and downstream signal transduction in thrombin-induced CCL2 release in 
MLFs.
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5.1.4.1.2 Thrombin exerts its stimulatory effects on CCL2 release via PARi 
coupling to Gaq
The G protein minigenes have been demonstrated as powerful tools for identifying the 
G protein that mediates a given physiological function following thrombin activation 
(Ellis et al., 1999; Gilchrist et al., 2001; Vanhauwe et al., 2002). For example, thrombin- 
induced PARi gene expression in endothelial cells is mediated by Gaj as this effect of 
thrombin can be abolished by introducing the Gdj minigene into the cells. This result 
was verified by using pertussis toxin, a well-known general G^ inhibitor. In current 
study, the involvement of Gaj in PAR^mediated CCL2 release was also investigated by 
using both pertussis toxin and the Ga* minigene that encodes Gai C-terminal 
sequences. Pertussis toxin catalyses the irreversible ADP-ribosylation of a subunits of 
the Ga,/0 family, and this modification prevents the receptor-G protein interaction (Fields 
and Casey, 1997). The results obtained show that both pertussis toxin and the Gaj 
minigene did not interfere with PARr mediated CCL2 protein release. This provides 
convincing evidence that Gcti is not necessary for PARi-mediated CCL2 protein release.
Interestingly, interruption of PAR, coupling to Gaj by pertussis toxin upregulated both 
basal and thrombin-induced CCL2 production, whereas the Gaj minigene had no such 
effect. There is one possible explanation for these discrepant results. The 
enhancement of basal CCL2 production suggests that baseline production is under the 
control of a labile repressor protein, which is not overcome by the addition of thrombin. 
The Gaj minigene specifically blocks the activation of the GOj isoform only, whereas 
pertussis toxin blocks most of the members of the Gcij/o family which are pertussis 
toxin-sensitive except Gaz. It is therefore possible that pertussis toxin blocks some 
members of the Gaj/0 family that are responsible for regulating the labile repressor 
protein mentioned above.
In addition to Gaj, PARi can also interact with Ga12m and Gaq/n family members. The 
role of Ga-i2/i3 and Gaq was also examined using Gai2/13 and Gaq minigenes. The 
results demonstrated that Gaq but not Ga-12/13 is involved in PARi-mediated CCL2 
release. It is worth mentioning that there are five members within the G a ^  family, 
namely G a11( Ga14, and Gai5/i6. In terms of the distribution of the Ga<, family members, 
Gaq and Gan are ubiquitously distributed across tissues, and have been detected in 
almost every cell type screened, including fibroblasts; whereas Ga1S/16 is only 
expressed in hematopoietic cells and the distribution of Ga^ is much more limited 
(Shraga-Levine and Sokolovsky, 2000; Tian et al., 2004; Hubbard and Hepler, 2006). It 
is therefore unlikely that G a15/16 and G a14 are involved in thrombin-induced CCL2
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release in MLFs. As the Gaq minigene specifically targets Gaq isoform only, it is 
therefore likely that Gaq isoform participates in PARi-mediated CCL2 release.
By taking advantage of the newly developed PARi-Gaq antagonist Q94, the exclusive 
involvement of Gaq was then further investigated. Data from this work showed that Q94 
blocked PARi-mediated increases in both CCL2 mRNA and protein levels in a 
concentration-dependent manner, which is consistent with the results obtained with 
Goq minigene. As discussed previously, Q94 is highly specific for PARrGaq coupling. 
However, it is still important to ensure that the concentrations used here do not 
produce off-target effects that are independent of receptor-G protein interactions. TNF- 
a was chosen as the stimuli to test the specificity of Q94 as TNF-a has previously been 
shown to stimulate human lung fibroblast CCL2 release (Sabatini et al., 2002). More 
importantly, TNF-a-induced signalling events do not require the interaction of receptor- 
G proteins since TNF-a signals via TNF receptor 1 (TNFR1) and TNFR2 which are not 
GPCRs (Ihnatko and Kubes, 2007). As expected, Q94 at the highest concentration did 
not interfere with TNF-a-induced CCL2 release, further suggesting that the inhibitory 
effects of Q94 on thrombin-induced CCL2 release are specific. Taken together, the 
data obtained with both the Gaq minigene and the Gaq antagonist Q94 strongly suggest 
a major role for Gaq in thrombin-induced CCL2 release.
It is important to point out that functional selectivity over G proteins does exist as a 
feature of PARi-G protein interaction. Functional selectivity is the ligand-dependent 
selectivity that can be presented when a receptor has several possible signal 
transduction pathways. Distinct ligands may cause different conformational change of 
the same receptor, which ultimately leads to the activation of separate signalling 
cascades of this receptor (Urban et al., 2007). PARi can couple to Gaj/o, Gaq and 
Ga-12/13 family members, functional selectivity may therefore also occur in the present 
study. Indeed, current study has shown that the CCL2 response obtained was usually 
greater for TFLLR over thrombin. This can be explained by the functional selectivity of 
TFLLR-activated PARi towards Gaq binding in the present study. This notion is 
consistent with studies showing that the peptide TFLLR-induced activation of PARi 
alters PARi-G protein binding in favor of Gaq activation over (McLaughlin etat.,
2005). Compelling evidence has been provided that Gaq plays a critical role in PARi- 
mediated CCL2 response in MLFs, therefore enhanced CCL2 release obtained with 
TFLLR was due to the functional selectivity in Gaq compared to thrombin.
5.1.4.2 Role o f M AP kinases in PARi-mediated CCL2 production
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MAP kinase pathways are one of the major kinase cascades by which extracellular 
stimuli are transmitted as intracellular signals. There are three major members in this 
family, namely ERK1/2, p38s and JNKs. They have been shown to be involved in 
signal transduction downstream of receptor-Gaq coupling. In mouse lung fibroblasts, it 
has been clearly shown that thrombin can activate ERK1/2 and this is mediated by Gaq 
(Trejo et al., 1996). However, in terms of thrombin-induced CCL2 production, several 
studies have suggested that the p38 kinase pathway plays a major and critical role. For 
example, inhibition of p38 kinase diminished thrombin-induced CCL2 production in 
endothelial cells (Marin et al., 2001) and human smooth muscle cells (Brandes et al., 
2001). For other stimuli such as that obtained with the serine protease plasmin, the p38 
kinase pathway is also believed to be the major signalling pathway leading to CCL2 
production in human primary monocytes (Burysek et al., 2002). In the present study, by 
using both pharmacological inhibitors and genetic approaches, ERK1/2 pathway, but 
not the p38 or JNK pathways, was shown to be necessary for CCL2 protein release 
and mRNA levels mediated by PARi coupling to Gaq.
5.1.4.2.1 Role o f p38 kinase pathway
The p38 kinase pathway is strongly activated by cellular stresses, pro-inflammatory 
cytokines and bacterial lipopolysaccharide (Cuenda et al., 1995). The involvement of 
this kinase in thrombin-induced CCL2 production in MLFs was examined by using the 
specific p38 kinase inhibitor SB 203580. In this study, the role of p38 MAPK pathway 
was excluded although thrombin was found to activate this pathway in a time- 
dependent manner in MLFs. This conclusion is based on the findings that the p38 
MAPK inhibitor, SB 203580, had no effect on thrombin-induced CCL2 protein release 
at concentrations at which this compound effectively blocked thrombin-induced p38 
phosphorylation. It is worth pointing out that in these experiments, the inactive control 
compound SB 202474 at the highest concentration (2 pM) used, significantly inhibited 
thrombin-induced CCL2 release by about 50%, suggesting that at high concentrations 
these compounds may exert off-target effects. It was therefore concluded that although 
thrombin activates p38 MAPK in MLFs, p38 is not involved in mediating PARHnduced 
CCL2 release.
As explained above, this conclusion is not in agreement with previous reports 
demonstrating a role for p38 MAPK in thrombin-induced CCL2 production using 
comparable concentrations of SB 203580 in other cell types, including human 
endothelial cells (Marin et al., 2001) and human smooth muscle cells (Brandes et al., 
2001). The discrepancy between the current study in MLFs and others may have
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several explanations, including important differences in both the species and the cell 
type examined, as well as differences in the concentrations of thrombin employed in 
our (10 nM is equivalent to 0.5 U/ml) and other studies (8 U/ml) (Marin et al., 2001). It 
is generally accepted that mechanisms involved in thrombin signalling vary greatly in a 
concentration-dependent manner. For example, PARi was reported to mediate 
thrombin signalling in platelets as it can be inhibited by RWJ-58259. However, cells 
were refractory to RWJ-58259 when thrombin was used at elevated concentrations 
(e.g., 30 nM), suggesting that PAR-i is not involved in this response induced by 
thrombin at relatively higher concentration (Andrade-Gordon et al., 1999; Andrade- 
Gordon et al., 2001). In studies performed by Marin and colleagues, only around 40% 
inhibition of CCL2 release was achieved with SB203580 (2 pM), similar as the 
magnitude of inhibition obtained with the control peptide SB202474 in the current study. 
It is likely that the inhibition obtained may have been the consequence of off-target 
effects of SB203580, but this is not conclusive since this control peptide was not tested 
in parallel culture in their study. Moreover, as discussed in Section 4.1.2, thrombin is a 
proteinase and it is likely that at higher concentrations, CCL2 protein production may 
be mediated via the release of other stimulatory mediators bound to the pericellular 
matrix. It is therefore possible that non-PARi dependent pathways lead to activation of 
the p38 MAPK pathway to mediate thrombin-induced CCL2 release at high 
concentrations of the proteinase as shown in other studies. Although concentrations 
around 130 nM may be generated following intra-vascular coagulation and are 
therefore relevant in the context of thrombin signalling in vascular cell types, we believe 
that thrombin concentrations in extravascular compartments and hence in the context 
of fibroblast signalling responses, are likely to be much lower.
5.1.4.2.2 Role o f JN K  pathway
Like the p38 kinase pathway, the JNK pathway is also strongly activated by cellular 
stresses and pro-inflammatory cytokines. However, unlike p38, there are no previous 
reports linking JNK to thrombin-induced CCL2 release. In the present study, the role of 
JNK in mediating CCL2 production induced by thrombin was excluded as inhibition of 
the JNK pathway with the specific JNK inhibitor, TI-JIP, did not block this effect of 
thrombin. Conversely, inhibition of JNK increased basal CCL2 production in a 
concentration-dependent manner, suggesting that JNK interferes with basal CCL2 
production. Inhibition of JNK further increased thrombin-induced CCL2 production.
As already discussed for the data obtained with pertussis toxin, the enhancement in 
basal CCL2 production by the JNK inhibitor may also suggest that baseline production
201
Chapter 5 Discussion
is under the control by a labile repressor protein, which is not overcome by the addition 
of thrombin. Like other kinases, ERK1/2 is dephosphorylated by specific phosphatases: 
termed MAP kinase phosphatases (MKPs) (Sun et al., 1993). MKP-1 has been shown 
to be greatly upreguiated by thrombin in endothelial cells and plays a key role in 
regulating thrombin signalling (Chandrasekharan et ai., 2004). Therefore, in the present 
study, it is possible that inhibition of both the JNK pathway and Go, pathway may block 
thrombin-induced MKP-1 activation, which in turn enhances ERK1/2 phosphorylation 
and CCL2 production.
5.1.4.2.3 ERK1/2 pathway is necessary and sufficient in PARi-mediated CCL2 
production in MLFs
The ERK1/2 pathway has been reported to be essential for thrombin-mediated 
mitogenesis in MLFs (Trejo et al., 1996). There is a wealth of evidence that ERK1/2 is 
important in pulmonary fibrosis as it is involved in fibroblast proliferation, differentiation, 
collagen production and apoptosis (Yoshida et al., 2002). In the present study, by using 
two structurally unrelated and well documented inhibitors, U0126 and PD98259 
(inhibitors of the ERK1/2 activator MEK1/2), I have been able to show that the MEK1/2 
pathway is necessary for PAR,-mediated CCL2 release. In these experiments, basal 
CCL2 production was not affected by the inhibition of MEK1/2, suggesting that MEK1/2 
is not necessary for regulating basal CCL2 production. In contrast, inhibition of MEK1/2 
blocked the production of PAR,-mediated CCL2 production in a concentration- 
dependent manner from 0.3 pM onwards. As ERK1/2 is the direct downstream 
substrate of MEK1/2, the observations suggest that ERK1/2 is necessary for PAR, 
mediated-CCL2 production.
In order to further support the involvement of ERK1/2 in this response, the effect of 
PAR, on ERK1/2 phosphorylation induced by thrombin was then examined. Time- 
course data showed that ERK1/2 was rapidly phosphorylated by thrombin. This effect 
was transient and the signal reverted back to baseline levels within 30 minutes. 
Inhibition of MEK1/2 with U0126 completely abolished thrombin-induced ERK1/2 
phosphorylation at 1pM. Inhibition of thrombin-induced PAR, activation with 1pM of the 
selective PAR, antagonist RWJ-58259 also completely abolished ERK1/2 
phosphorylation. This suggests that PAR, is sufficient for ERK1/2 activation in mouse 
lung fibroblasts and is consistent with previous studies conducted by Trejo and 
colleagues in the context of mitogenic responses (Trejo et al., 1996). The results also 
suggest that PAR, signals via ERK1/2 to induce CCL2 release.
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Although U0126 and PD98259 are extensively used in both in vivo and in vitro studies, 
the specificity is always a concern. In the present study, MEK1 mutant constructs were 
employed to validate and consolidate findings from MEK1/2 pharmacological inhibitor 
studies. Wild type and mutant MEK1 gene constructs were introduced into MLFs in 
order to block or constitutively activate the ERK1/2 pathway. The wild type MEK1- 
pBabePuro encodes wild type rat MEK1 gene. The dominant-negative MEK1- 
pBabePuro construct was obtained by mutation with alanine substitution at Ser-221. 
The constitutively active MEK1-pBabePuro construct was derived from glutamic acid 
substitutions at Ser-217 and Ser-221 (Cowley et al., 1994). These constructs have 
been successfully used to demonstrate the pivotal role of ERK1/2 in mediating 
fibroblast proliferation and growth-factor-induced differentiation by interfering with 
ERK1/2 activation in PC12 cells (Pages etal., 1993; Cowley e t a l 1994).
In order to ensure high transfection efficiency, a retroviral transfection system was 
employed to deliver these constructs into MLFs. The retrovirus has a number of 
features that makes it unique as a gene delivery vehicle: genetic stability, high 
expression, and a flexible genome. Once transfected into cells, they exist as integrated 
proviruses in the chromatin of the host cells. The retroviral promoter can direct high- 
level, efficient expression of genes encoded within the confines of its genome (Zhang 
and Godbey, 2006). The retroviral genome can accommodate changes to its 
configuration, it is therefore possible for the inclusion of foreign genes. Unlike 
pharmacological inhibitors, this genetic approach only interferes with the kinase in 
question and non-specific effects can be controlled by direct comparison of results 
obtained with the wild type gene.
The dominant-negative MEK1 construct successfully attenuated PARr mediated CCL2 
production by 52±3.5% (p<0.01). Unlike the results obtained with U0126, dominant- 
negative MEK1 failed to achieve complete inhibition of this response. It is most likely 
that the tack of complete inhibition may be related to the transfection efficiency which 
was not sufficient to fully block MEK1. Indeed, only 70% knockdown of ERK1/2 
phosphorylation was obtained with this approach. It is worth mentioning that although 
both MEK1 and MEK2 are important upstream activators of ERK1/2, MEK1 has been 
shown to be the major activator and 10% activation of MEK1 is sufficient to fully 
activate ERK1/2 (Saito et a!., 1994). It is therefore possible that MEK2 may 
compensate the effect of MEK1 in the present study, which leads to the partial ERK1/2 
activation. Nevertheless, the inhibitory effect of dominant-negative MEK1 on PARi- 
mediated CCL2 production is consistent with the data obtained with the MEK1/2
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inhibitor U0126. Data from both dominant-negative MEK1 and U0126 therefore strongly 
suggest that MEK1 and by inference ERK1/2 is necessary for PARrmediated CCL2 
production by MLFs. In addition, the constitutively active MEK1 mutant increased basal 
ERK1/2 phosphorylation. Taken together, these data suggest that MEK1 (by inference 
ERK1/2) is sufficient for PARi-mediated CCL2 production by MLFs. Moreover, 
inhibition of ERK1/2 phosphorylation by the PARi antagonist RWJ-58259 and Q94 
further supports the notion that the ERK1/2 pathway is downstream of PARi coupling to 
Gaq in mediating CCL2 production in MLFs.
In summary, the data obtained using both pharmacological inhibitor and genetic 
approaches provide strong evidence that the ERK1/2 pathway is necessary and 
sufficient for PARi-mediated CCL2 production, whereas both JNK and the p38 
pathways play no role in this response of thrombin.
5.1.4.3 Ca2*-independent PKC-c-Raf -ERK1/2 pathway mediates PARi activation- 
induced CCL2 release via increased CCL2 gene expression
The downstream signalling molecules that mediate the actions of G proteins on 
ERK1/2 include ras, PKC, and c-Raf kinase (Blumer and Johnson, 1994), which can 
activate MEK (Cobb et al., 1994). It is well-established that activation of Gaq by PARi 
ultimately leads to the activation of PKC (Coughlin, 2000), and c-Raf has been shown 
to mediate thrombin-induced ERK1/2 activation in MLFs (Trejo et al., 1996). In the 
present work, compelling evidence has provided that both c-Raf and PKC regulated 
PARrmediated CCL2 release via the activation of ERK1/2 in MLFs. Further evidence 
was provided to demonstrate that the Ca2+-independent-PKC-c-Raf-ERK1/2 signalling 
module regulates PARi-mediated CCL2 release via a transcriptional mechanism.
5.1.4.3.1 The involvem ent o f c-Raf
There are three members in the Raf kinase family: A-Raf, B-Raf and c-Raf. c-Raf is the 
most extensively studied in the raf gene family and is ubiquitously expressed. 
Classically, the c-Raf-MEK-ERK1/2 cascade is considered as a signalling module 
(Kolch et al., 2002). Indeed, extensive in vitro evidence has demonstrated that c-Raf 
participates in thrombin-induced ERK1/2 activation in many cell types, including 
smooth muscle cells (Lin et al., 2002) and fibroblasts (Trejo et al., 1996). As already 
mentioned, the c-Raf-MEK-ERK1/2 cascade has also been shown to mediate several 
thrombin-induced cellular effects including mitogenesis in fibroblasts (Trejo etal., 1996).
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In the present study, the involvement of c-Raf in PARi-mediated CCL2 release was 
confirmed by using the specific c-Raf kinase inhibitor. This inhibitor inhibited PARr  
mediated CCL2 release in a concentration-dependent manner. This present study also 
showed that c-Raf-ERK1/2 cascade is indeed a linear pathway as inhibition of c-Raf by 
c-Raf kinase inhibitor attenuated thrombin-induced ERK1/2 phosphorylation in a 
concentration-dependent manner, and total inhibition was achieved with the 
concentration at which PAR ^ mediated CCL2 release was also completely abolished. It 
is therefore highly probable that c-Raf regulates PARr mediated CCL2 release via the 
activation of ERK1/2, in other words, the c-Raf-ERK1/2 signalling module is 
responsible for this response.
5.1.4.3.2 Ca2*-independent PKC-c-Raf-ERK1/2 signalling module mediates 
throm bin-induced CCL2 release
Members of the PKC family have been shown to be involved in the regulation of cell 
growth/cell cycle progression and differentiation (Maruyama et al., 2000; Parekh et al., 
2000). PKC-dependent signal transduction pathways have been found to regulate 
many intracellular events in fibroblasts involved in the development of fibrosis. For 
example, thrombin induces the differentiation of normal lung fibroblasts to a 
myofibroblast phenotype via the PAR^PKC pathway (Bogatkevich et al., 2003). PKC is 
responsible for increased synthesis of lL-8 by lung fibroblasts and regulates thrombin- 
induced tenascin-C expression in systemic sclerosis (SSc) lung fibroblasts (Ludwicka 
et al., 1992; Tourkina et al., 2001). PKC is also required for TGFPHnduced ERK1/2 
activation in fibroblasts (Axmann et al., 1998).
The important role of PKC in PARi-mediated CCL2 production in MLFs was examined 
using three structurally unrelated pharmacological inhibitors: Ro-318425, GF109203X, 
and G66976. PKC isozymes can be generally divided into two groups: Ca2+-dependent 
{conventional PKC), and Ca2+-independent (novel and atypical isozymes). Ro-318425 
and GF109203X are regarded as broad-spectrum inhibitors that theoretically inhibit all 
isozymes of PKC family members, whereas Go6976 inhibits Ca2+-dependent PKC 
isozymes only. It was shown here that all three PKC inhibitors attenuate PARr induced 
CCL2 production in a concentration-dependent manner. This provides strong evidence 
that PKC is involved in PARi-mediated CCL2 production in MLFs, in particular the 
Ca2*-dependent PKC as demonstrated by Go6976.
It has been demonstrated elsewhere that PKC is involved in thrombin-induced ERK1/2 
phosphorylation. For example, in rat astrocytes, thrombin-stimulated ERK1/2 activation
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has been shown to be mainly mediated by PARi and this is partially mediated via the 
Gaq-PKC pathway (Wang et al., 2002). More importantly, activation of c-Raf-ERK1/2 
cascade in MLFs by thrombin has also been reported to be mediated by PKC (Trejo et 
al., 1996). It is therefore tempting to speculate that PKC lies in upstream of c-Raf- 
ERK1/2 pathway for this response of thrombin. In the present study, PKC inhibition by 
Ro-318425 also attenuated c-Raf and ERK1/2 phosphorylation following PARi 
activation by thrombin. Interestingly, the Ca2+-dependent PKC inhibitor G66976 did not 
inhibit this response. These data raised the possibility that the Ca2+-dependent PKC 
and Ca2+-independent PKC may be involved in PARr mediated CCL2 protein 
production via a different mechanism. It is well-established that these PKC isozymes 
are not only activated via different mechanisms such as Ca2+-dependent and Ca2+- 
independent mechanisms, they also differ remarkably in mediating cellular signalling 
events. For example, both PKC-a and PKC-e have been shown to mediate fibroblast 
collagen deposition (Fang et al., 2004; Fang et al., 2008). PKC-a regulates this 
response by inducing caveolin-1 expression, whereas PKC-e regulates this response 
via the activation of ERK1/2 pathway. It is therefore not unexpected that the Ca2+- 
dependent PKC and Ca2+-independent PKC would regulate PARrmediated CCL2 
production via different mechanisms. This notion has been further confirmed by the 
effects of these PKC inhibitors on PARi-mediated CCL2 mRNA levels which will be 
discussed in the next section. To the best of my knowledge, this is the first report 
showing that PKC is involved in thrombin-induced CCL2 production.
5.1.4.3.3 Ca2+-independent PKC-c-Raf-ERK1/2 pathway mediates PARi activation 
induced CCL2 release via a transcriptional mechanism
The increase of CCL2 protein production induced after PAR! activation has been 
shown to be transcriptionally dependent, rather than mediated via the release of CCL2 
from intra-cellular stores. As discussed in section 4.2.3.2, the linear Ca2+-independent 
PKC-c-Raf -ERK1/2 pathway has been shown to be responsible for PARi-mediated 
CCL2 production. By using pharmacological inhibitors for these kinases, I have been 
able to show that inhibition of this pathway also inhibits PARi-induced increase of 
CCL2 mRNA levels. However, inhibition of Ca2+-dependent PKC by Go6976 had no 
effect on PARi-induced CCL2 mRNA accumulation. This further confirmed the notion 
that Ca2+-dependent PKC and Ca2+-independent PKC regulate PARi-mediated CCL2 
production via different mechanisms.
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5.1.4.4 The Ca2*-dependent PKC-Rho kinase pathway mediates the effects of 
P A ^  activation on CCL2 release via a post-transcriptional mechanism
Ca2+-dependent PKC is a well-recognized downstream effector of Gaq and is activated 
in response to a rise in intracellular Ca2+ concentration induced by PLC activation. It is 
therefore possible that both PLC and Ca2+ may be in a linear pathway with Ca2+- 
dependent PKC mediating PARi activation-induced CCL2 production. In the present 
study, the data obtained show that both PLC and Ca2+ were involved in this process as 
inhibition of PLC and Ca2+ inhibited thrombin-induced CCL2 release in a concentration- 
dependent manner. Further evidence provided also indicated that PLC and Ca2+ may 
lie in the same linear pathway with Ca2+-dpendent PKC to mediate this response. Like 
Ca2+-dependent PKC, inhibition of both PLC and Ca2+ also had no effect on ERK1/2 
phosphorylation induced by thrombin in MLFs. Furthermore, inhibition of both PLC and 
Ca2+ did not block the increase of CCL2 mRNA levels induced by PARi activation, 
consistent with the results obtained with Ca2+-dependent PKC inhibition. This led to the 
conclusion that PLC-Ca2+-Ca2+-dependent PKC lie in a linear pathway in mediating 
PARi activation-induced CCL2 production via a non-transcriptional mechanism.
It is well-established that the activation of the a subunit of Gaq triggers an increase in 
intracellular Ca2+ concentration by stimulating PLC-(3 activity (Babich et al., 1990) and 
that Gai2/13 activation preferentially induces Rho kinase activation (Wess, 1998). 
Recent emerging evidence suggests that Gaq could be another major G protein to 
signal via RhoA/Rho kinase, although how this occurs at the molecular level is not well 
understood (Booden et al., 2002; Chikumi et al., 2002; Vogt et aI., 2003). However, 
Gaq-dependent RhoA activation appears to be dependent on the receptors being 
stimulated and the cell types under investigation as there is also evidence against the 
primary role of Gaq in receptor-mediated RhoA activation (Reviewed in (Sah et al., 
2000)). Despite the controversy, PARi is one of the receptors that have been shown to 
activate RhoA via coupling to Gaq (Vogt et al., 2003; Singh etal., 2007). In particular, a 
recent study by Singh and colleagues demonstrated that Gaq can lead to Rho kinase 
activation via PLCP-Ca2+-dependent PKC to mediate thrombin-induced endothelial cell 
contraction (Singh et al., 2007). RhoA is one the best characterized members of the 
small Rho GTPase family and Rho kinase is a well-known major target of RhoA 
(Kaibuchi et al., 1999). RhoA/Rho kinase has been shown to be involved in many 
cellular responses triggered by thrombin, such as smooth muscle contraction, cell 
migration, fibroblast proliferation and transformation (reviewed in (Sah et al., 2000)). 
Specifically, thrombin-induced lung fibroblast proliferation has been shown to be 
mediated by the PKC-RhoA pathway (Bogatkevich et al., 2003). The present study has
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demonstrated that the PLC-Ca2+-dependent PKC pathway mediate PARi activation- 
induced CCL2 release independent of ERK1/2 activation. It was therefore possible that 
this pathway acts through RhoA/Rho kinase instead.
C3 exoenzyme is the RhoA inhibitor that irreversibly ADP-ribosylates RhoA. This 
inhibitor blocked thrombin-induced CCL2 production, suggesting that RhoA is involved. 
It is worth mentioning that C3 exoenzyme did not fully block this response because 
only relatively low concentrations of C3 exoenzyme were employed. At elevated 
concentrations, C3 exoenzyme caused cells to die. Inhibition of Rho kinase using two 
structurally unrelated inhibitors Y-27632 and H-1152 also blocked this response. Taken 
together, these data support the notion that RhoA/Rho kinase is involved in PARi 
activation-induced CCL2 release. However, RhoA/Rho kinase did not mediate 
thrombin-induced ERK1/2 phosphorylation or CCL2 mRNA accumulation since 
inhibition of RhoA/Rho kinase by C3 exoenzyme and Y-27632 had no effect on these 
responses. This is consistent with the finding that PLC-Ca2+-dependent PKC pathway 
also mediates the effects of thrombin via an ERK1/2-independent and post- 
transcriptional pathway. This raised the possibility that RhoA/Rho kinase is 
downstream of PLC-Ca2+-dependent PKC pathway and mediates thrombin-induced 
CCL2 release.
In the present study, further compelling evidence was provided that RhoA/Rho kinase 
activation is mediated by a Gaq-PLC-Ca2+dependent PKC pathway to mediate 
thrombin-induced CCL2 release. First, myosin light chain (MLC) was demonstrated to 
be involved in thrombin-induced CCL2 release via a post-transcriptional mechanism as 
inhibition of MLC by blebbistatin inhibited thrombin-induced CCL2 release, but had no 
effect on CCL2 mRNA accumulation. MLC is one of the major downstream substrates 
of RhoA/Rho kinase (Amano et al., 1996). Rho kinase can activate MLC directly via 
phosphorylation or indirectly by phosphorylating the myosin-binding subunit of MLC 
phosphatase, which in turn renders the phosphatase inactive and thus prevents MLC 
dephophorylation (Kimura et al., 1996). Second, in the present study, inhibitors of PLC, 
Ca2+ and Ca2+-dependent PKC, RhoA and Rho kinase all blocked thrombin-induced 
phosphorylation of MLC. Third, a direct link between this pathway and Gaq coupling to 
PARi was demonstrated by showing that the novel PARi selective Gaq antagonist 
(Q94) also abolished thrombin-induced MLC phosphorylation. Taken together, these 
data led us to conclude that the PLC-Rho kinase pathway mediates PARi-activation- 
induced CCL2 release in MLFs via a post-transcriptional mechanism.
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Although Rho kinase was first characterized as a major regulator of actin dynamics, it 
is now well recognised that Rho family proteins influence a range of other cellular 
processes, including gene transcription and protein secretion (reviewed in (Etienne- 
Manneville and Hall, 2002)). In the present study, we provide evidence that the Rho 
kinase pathway is involved in PARi mediated CCL2 protein release post- 
transcriptionally, likely by influencing protein secretion. This is based on two 
observations. First, inhibition of Rho kinase only blocked thrombin-induced CCL2 
protein release but not CCL2 mRNA accumulation. Second, immunocytofluoresence 
experiments to elucidate the mechanism by which the Rho kinase pathway influences 
CCL2 release, showed that intracellular protein production was blocked with the 
MEK1/2 inhibitor, U0126, but was unaffected by the Rho kinase inhibitor, Y27632. 
Taken together, these data indicate that blockade of Rho kinase signalling is not 
essential for PARi-mediated CCL2 gene expression and subsequent intracellular 
protein production. Given that Y-27632 does block PARi-mediated increases in CCL2 
protein levels measured in cell culture supernatants, this thesis proposes that this 
pathway most likely affects CCL2 protein secretion.
5.1.4.5 Speculation o f the involvement o f RhoGEFs in RhoA activation by Gaq
It is worth noting that although Gaq can activate RhoA/Rho kinase to mediate 
downstream cellular events, as suggested by the current study and others; whether the 
Rho GEFs are required for RhoA activation by Gaq is still a controversial issue. It is well 
established that the activation of RhoA requires its dissociation from the GDP/GDIs 
(Rho GDP dissociation inhibitors) complex followed by GTP exchange mediated by 
RhoGEFs. In terms of RhoA activation by GPCRs, the RhoGEF proteins, p115RhoGEF, 
PDZ-RhoGEF, p63RhoGEF and Leukemia-associated Rho guanine-nucleotide 
exchange factor (LARG) have been shown to stimulate Rho kinase activity (Hart et al., 
1998; Kozasa et al., 1998; Fukuhara et al., 2001; Suzuki etal., 2003; Lutz etal., 2007). 
In particular, p63RhoGEF has been shown to be a downstream effector of Gaq and 
interact selectively with Gaq/n, but not Gai2/13 (Lutz et al., 2005; Lutz et al., 2007). 
However, p63RhoGEF binding to Gaq has been shown to occur competitively with 
PLC-p, and inhibition of both PLC-p and PKC do not effect p63RhoGEF-Gaq activation 
of RhoA (Lutz et al., 2005). These findings provide compelling evidence that 
p63RhoGEF is a downstream effector of Gaq that is independent of PLC-p. In contrast, 
current study proposed that PLC-p mediated Gaq-induced RhoA activation as inhibition 
of PLC-p inhibited MLC phosphorylation. It is therefore unlikely that p63RhoGEF 
participates in Gaq-RhoA activation in terms of cellular responses examined in this 
study.
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Moreover, the findings presented here and those reported by Singh and colleagues 
contrast with another previous report demonstrating that Gaq-mediated Rho kinase 
activation occurs independently of PLC-0 in mouse embryonic fibroblasts (MEFs) (Vogt 
et al., 2003). Singh and colleagues provide evidence that Gaq-mediated Rho kinase 
activation is p115RhoGEF dependent following PLC-Ca2+-dependent PKC activation; 
whereas in studies by Vogt and colleagues, thrombin-induced Rho kinase activation in 
MEFs was shown to be mediated by the LARG. These differing observations may have 
several explanations. First, they may be related to cell type. From my experience, I am 
aware that thrombin is unable to induce CCL2 production in MEFs so that thrombin 
responses are cell-type specific. Second, they may also be explained by differences in 
the concentrations of thrombin employed. The current work and studies by Singh and 
colleagues used 10 nM thrombin (10 nM is equivalent to 0.5 U/ml), whereas studies by 
Vogt and colleagues in MEFs employed 1 U/ml thrombin. As discussed before, 
mechanisms leading to a given signalling event of thrombin are concentration- 
dependent so that the comparison of responses at different concentrations may not be 
easily comparable. Taken together, the findings mentioned here are consistent with a 
PLC-Ca2+-dependent PKC-dependent Rho kinase activation mechanism rather than a 
LARG-mediated mechanism. It is therefore tempting to speculate that PARr Gaq may 
also signal via p115RhoGEF to activate Rho kinase for thrombin-induced CCL2 release 
in MLFs, but this would require confirmation.
5.1.5 Specificity o f the inhibitors used
Each protein kinase phosphorylates more than one protein, and one protein 
phosphatase also dephosphorylates more than one protein. Therefore, inhibiting most 
protein kinases and phosphatases will alter the phosphorylation of many proteins, 
perhaps giving rise to unwanted side effects (Cohen, 1999). It is unlikely that small cell- 
permeable molecules could be developed to inhibit one kinase specifically without 
inhibiting at least a few others. Even if a drug inhibits just one out of several protein 
kinases tested, there is no guarantee that it does not inhibit other protein kinases or 
other types of enzymes that have not been examined (Davies et al., 2000). In cell 
signalling studies, it is important to minimize the risk of off-target effects. In order to 
address the concerns regarding the specificity of inhibitors, I designed my experiments 
according to the recommendations from previous studies (Davies et al., 2000; Bain et 
al., 2003; Bain et al., 2007) and our own experience. However, confirmation of the 
selectivity of PAR1 antagonists and G proteins inhibitors used in current study needs 
further clarification.
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First, I selected potent and cell-permeable protein kinase inhibitors whose specificities 
have been tested towards a wide range of protein kinases in vitro (Davies et ai., 2000; 
Bain et al., 2003; Bain et al., 2007). For example, it is well-recognised that SB 203580 
(p38 kinase inhibitor) and U0126 (MEK1/2 inhibitor) have the most impressive 
selectivity profiles (Davies et al., 2000). In particular, U0126 is not an ATP-competitive 
inhibitor but acts by suppressing the activation of MEK1, whereas the inhibitors that are 
ATP-competitive are usually less selective and require higher concentration to 
suppress the phosphorylation of a substrate in cells. TI-JIP has been recognized as a 
unique and most potent inhibitor of JNK activity when compared with other compounds 
such as sp600125 (Bain et al., 2003; Borsello et al., 2003; Bain et al., 2007). The PKC 
inhibitor Ro-318425 is also a potent inhibitor based on Ro-318220 that has been tested 
by others (Davies et al., 2000). Y-27632 is a typical Rho kinase inhibitor that has been 
extensively used by investigators.
Second, the role of the targeting kinases was verified by more than one structurally- 
unrelated inhibitor. For instance, the involvement of ERK1/2 was confirmed by both 
U0126 and PD98059. Similarly for PKC, I employed the broad-spectrum PKC inhibitors, 
Ro-318425 and GF 109203X, and the Ca2+-specific PKC inhibitor G66976. In addition, 
for Rho kinase, two compounds were used: Y-27632 and H-1152.
Third, wherever available, inactive control compounds for each inhibitor were tested in 
parallel cultures. For example, SB202474 was used as a negative control for p38 
kinase inhibitor SB203580, and U73343 was used as a negative control for PLC kinase 
inhibitor U73122. This was particularly important when high concentrations of the active 
compounds were used.
Fourth, for each inhibitor, a full range of concentrations was tested in order to 
determine the specific IC50. The IC50 of an inhibitor varies between cell-based and non 
cell-based assays; it is also determined by cell type and different stimuli. For instance, 
the concentration of U0126 that suppresses the activation of MEK1 by 50% in Swiss 
3T3 cells is 70 nM, whereas the concentration required to inhibit MEK1 activity by 50% 
in kinase assays was 13 pM which is 200-fold higher (Davies et al., 2000). In the 
current study, I employed concentrations of U0126 which provided no inhibition (0.03 
pM) to almost 100% (10 pM) inhibition of CCL2 production in MLFs, the final IC50 of 
U0126 in this study was determined to be 1.3 pM. Similarly, the IC50 of Ro-318425 is 
15 nM for rat brain PKC obtained in non cell-based protein assay (Wilkinson et al., 
1993), whereas the IC50 in the present study was determined to be 0.93 pM.
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Fifth, in order to further validate and consolidate the results obtained with 
pharmacological inhibitors, the role of the critical components in the signalling 
pathways was further assessed using a genetic approach. For example, although the 
role of ERK1/2 was examined using the well-recognized MEK1/2 inhibitors U0126 and 
PD98059, genetic MEK1 mutants were employed to strengthen the results obtained. In 
addition, the critical involvement of Gaq was also established based on the results 
obtained with both PAF^ specific Gaq antagonist and Gaq minigene approaches.
Finally, I demonstrated that most inhibitors blocked CCL2 release at the same 
concentrations that prevented the phosphorylation of an authentic physiological 
substrate of the protein kinase. For example, ERK1/2, p38 MAPK and MLC 
phosphorylation was assessed to identify the lowest concentration of respective 
inhibitors required for subsequent CCL2 release experiments. The concentration of 
each inhibitor used for subsequent CCL2 release experiments was also determined 
based on the IC50 value obtained in these experiments. In addition, the basal effect of 
each inhibitor was also monitored in parallel in order to minimize off-target or non­
specific toxic effects.
5.1.6 Integration o f the flow  o f information
The recent explosion of knowledge on the basic mechanisms regulating signal 
transmission now affords the unique opportunity to begin unravelling the intricacies of 
how these signals are integrated in space and time to elicit a final biological response. 
In this study, we provide evidence that thrombin-induced CCL2 release is mediated via 
coupling of PAR! to Gaq and the cooperation between ERK1/2 and Rho kinase 
signalling pathways. This raises the question as to how the flow of information to the 
two pathways, one directed at the nucleus the other at a specific secretory apparatus, 
is regulated? Signal transduction leading to cellular responses is a complex processes 
initiated by protein-protein interactions between ligands, receptors and kinases. Recent 
hypotheses including the formation of lipid rafts and 'transduceosomes’ have shed light 
on how these multiple components may work in harmony.
Lipid rafts are specialized structures on the plasma membrane that have an altered 
lipid composition as well as links to the cytoskeleton. Recent studies indicate that some 
GPCRs, G-proteins, and their effectors localize to lipid rafts or dynamically move in and 
out of microdomains (Simons and Toomre, 2000). A recent study has shown that PARi 
is present in endothelial cell plasma membrane rafts and caveolae, and that the 
localization of PARi specifically to rafts serves as an important mechanism for the
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regulation of thrombin-induced cytoskeletal changes in endothelial cells. Of particular 
interest to the current work, these authors further demonstrate a role for lipid rafts in 
mediating PARi activation of both RhoA/Rho kinase signalling and MLC 
phosphorylation (Carlile-Klusacek and Rizzo, 2007). Since PARi coupling to Gaq 
mediates thrombin-induced CCL2 secretion via the RhoA/Rho kinase pathway, we 
propose that it is likely that the components for secretion in this pathway might 
integrate on lipid rafts, but this clearly requires confirmation. In contrast, the role of lipid 
rafts in MAPK signalling remains controversial. For example, Gdq/n has been shown to 
activate p38 MAPK via lipid rafts, whereas, two studies have shown that Gaq does not 
mediate ERK1/2 phosphorylation via such rafts (Hiol et at., 2003; Sugawara et al., 
2007). In this study, we report that PAR, coupling to Gaq mediates thrombin-induced 
CCL2 production via ERK1/2 rather than p38 signalling so that current evidence would 
lead us to propose that the components involved in the transcriptional response may 
not float together on lipid rafts and would therefore be segregated from the components 
involved in CCL2 secretion.
It is also possible that these pathways involve the assembly of a ‘transduceosome’ 
which would act as a relay to assemble and integrate the signals derived from the two 
pathways in order to optimize the amplitude of downstream signalling. 
Transduceosomes are most well described in terms of the essential role of the scaffold 
and anchoring protein, A-kinase anchor proteins (AKAP) in cAMP signalling (Feliciello 
et al., 2001). cAMP-dependent protein kinase is targeted to discrete subcellular 
locations by the AKAPs. Localization recruits protein kinase A (PKA) holoenzyme close 
to its substrate/effector proteins, directing and amplifying the biological effects of cAMP 
signalling. Although AKAPs were identified on the basis of their interaction with PKA, 
AKAPs bind other signalling molecules, principally phosphatases and kinases, 
including notably PKC (Feliciello et al., 2001). It is therefore tempting to speculate and 
propose a role for both lipid rafts and tansduceosomes to integrate and assemble the 
signalling components leading from PARi activation of Gaq to CCL2 gene transcription 
via the ERK1/2 pathway and CCL2 release via the RhoA/Rho kinase pathway.
5.1.7 Summary
This work presented here provides compelling evidence that thrombin mediates its 
potent stimulatory effects on MLF CCL2 production and release by PARi coupling to 
Gaq and the cooperation between ERK1/2 and Rho kinase signalling pathways (Figure 
5.1). More specifically, the experiments conducted in chapter 3 have shown that:
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(i) Thrombin stimulates MLF CCL2 protein production and upregulates its 
mRNA levels, suggesting that thrombin induces CCL2 production via a 
transcriptional mechanism.
(ii) The stimulatory effects of thrombin on MLF CCL2 release and mRNA levels 
are mediated by PARi coupling to Gaq as inhibition of PAR^GOq interaction 
by the novel PAR^Gciq antagonist Q94 inhibited thrombin-induced CCL2 
release and mRNA levels.
(iii) Ca2+-independent PKC-c-Raf-ERK1/2 pathway mediates thrombin-induced 
CCL2 release by influencing CCL2 gene transcription as inhibition of this 
pathway not only blocked thrombin-induced CCL2 release measured with 
the cultured supernatant, but also inhibited intracellular CCL2 protein 
production and CCL2 mRNA levels.
(iv) In contrast, the PLC/Ca2+/Ca2+-dependent PKC/Rho kinase pathway is 
involved in thrombin-induced CCL2 release by post-transcriptional 
mechanism, possibly via protein secretion. This notion is based on the 
observations that inhibition of this pathway attenuated thrombin-induced 
CCL2 release but not CCL2 mRNA levels. The possible involvement of this 
pathway in CCL2 protein secretion has been further demonstrated by 
experiments showing that inhibition of Rho kinase by Y-27632 failed to block 
thrombin-induced intracellular CCL2 protein accumulation measured by 
immunofluoresecent.
(v) Blockade of PARt coupling to Gaq was found to inhibit both ERK1/2 and 
MLC phosphorylation induced by thrombin, indicating that these two 
pathways lie downstream of PARi coupling to Gaq in mediating the 
stimulatory effects of thrombin on MLFs.
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Figure 5.1 Proposed mechanisms for the signalling pathways involved in CCL2 release 
induced via the activation of PARi by thrombin in mouse lung fibroblasts. Thrombin 
ligation of PAF^ stimulates Gc^ ,. Activation of Ca2+-independent PKC leads to the sequential 
activation of c-Raf, MEK1 and ERK1/2 to stimulate CCL2 gene transcription. Gaq also leads to 
the activation of PLC, Ca2+, Ca2+-dependent PKC to activate Rho kinase (likely via 
p115RhoGEF, (Singh et al., 2007)) to mediate CCL2 protein release.
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5.2 Signal transduction in thrombin-induced CCL2 production in primary human 
adult lung fibroblasts
Previous sections discussed the detailed signalling pathways involved in thrombin- 
induced CCL2 release by mouse lung fibroblasts. However, whether thrombin can also 
induce CCL2 release by primary human lung fibroblasts remains unknown. To provide 
human disease relevance, this thesis also investigated whether the signalling pathways 
involved in mouse lung fibroblast CCL2 release are also involved in primary human 
adult lung fibroblasts (pHALFs).
5.2.1 Thrombin (10 nM) induces CCL2 release in both PARf-dependent and non- 
PAR mechanisms
It should be noted that the basal CCL2 level is much greater in pHALFs than in MLFs. 
This may be explained by differences between species. Nonetheless, as was the case 
for MLFs, thrombin was also found to induce CCL2 release in a concentration- and 
time-dependent manner in pHALFs.
Unlike MLFs, pHALFs were found to express PAR!, PAR2i and PAR3, but only low 
levels of PAR4. It has been reported that the response of any given cell to thrombin can 
potentially be mediated by more than one receptor. This has already been shown to be 
the case for platelets (Kahn et al., 1999) and endothelial cells (O'Brien et al., 2000). In 
the present studies with pHALFs, the possibility that more than one receptor is involved 
in this response to thrombin at 10 nM was examined.
5.2.1.1 Thrombin (10 nM)~induced pHALF CCL2 release is partially PARi-Gctq- 
dependent
Previous experiments with MLFs showed that PAR! is necessary and sufficient in 
mediating thrombin-induced MLF CCL2 release at 10 nM of this proteinase. Further 
experiments demonstrated that PARi is also important in pHALF CCL2 release. First, 
the PARi specific agonist peptide, TFLLR, was found to induce pHALF CCL2 release in 
a concentration-dependent manner and this response could be inhibited with PARi 
specific antagonist RWJ-58259, suggesting that PARi is sufficient for mediating pHALF 
CCL2 release. Second, although FXa is also an activator of PAR2, it is well-accepted 
that FXa signals mainly via PARt in human fibroblasts (Blanc-Brude et al., 2005). FXa- 
induced pHALF CCL2 release was indeed inhibited by RWJ-58259, further suggesting 
the involvement of PARi in mediating pHALF CCL2 release. Third, by taking advantage 
of two previously developed monoclonal antibodies with defined epitopes within the 
PAR! NH2 terminus that prevent the cleavage of PAR! by thrombin, work presented
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here shows that PARi is necessary for mediating thrombin-induced pHALF CCL2 
release as both antibodies (ATAP2 and WEDE15) significantly blocked this response of 
thrombin. Fourth, the Gaq selective PARi antagonist Q94 blocked this effect of 
thrombin, further suggesting that PARi is important, and moreover that PARi coupling 
to Gctq is involved in mediating thrombin-induced pHALF CCL2 release.
However in pHALFs, the PARt specific antagonist RWJ-58259 failed to inhibit this 
response of thrombin (10 nM). In contrast, RWJ-58259 completely abolished low 
concentration (0.3 nM) thrombin-induced CCL2 release. These data are consistent with 
previous reports showing that in human platelets, complete antagonism of thrombin 
with RWJ-58259 can be achieved at low thrombin concentrations, but the effect 
diminishes as thrombin levels rise above 10 nM (Andrade-Gordon et al., 2001). There 
are several potential explanations. First, this could have been due to insufficient 
inhibition of PAR! after thrombin stimulation by RWJ-58259. The highest concentration 
of RWJ-58259 (1 pM) used for pHALFs was lower than that (3 pM) used in MLFs as 
this antagonist affected baseline CCL2 at high concentrations. Second, RWJ-58259 is 
a competitive antagonist and the effectiveness of this antagonist is dependent on the 
degree of binding site occupancy by the tethered ligand after thrombin cleavage. 
Thrombin used in these studies was of human plasma origin and it is possible that the 
efficacy by which thrombin cleaves PAR! in pHALFs is greater than in MLFs. Third, 
RWJ-58259 is a reversible inhibitor and the off-rate may be faster for human PARi than 
murine PAR!. Fourth, transactivation of PAR2 by cleaved PARi may occur when RWJ- 
58259 is present in pHALFs. RWJ-58259 inhibits PARi activation by competing with 
the tethered ligand, but does not prevent unmasking of the tethered ligand. The 
unmasked tethered ligand of PARi may therefore in turn activate PAR2 that is located 
sufficiently close to PARi. In this regard, studies by O’Brien and colleagues have 
demonstrated that PARi can transactivate PAR2 to mediate thrombin-induced 
endothelial cell responses when PARi activation is blocked (O'Brien et al., 2000). In 
addition, PAR2 agonist peptide was found to induce pHALF CCL2 release, further 
suggesting that PAR2 is sufficient to mediate CCL2 release in these cells.
It is worth mentioning that full blockade of thrombin-induced pHALF CCL2 release at 10 
nM was not obtained when PARi cleavage was inhibited using PARi antibodies. This 
may be explained by the incomplete inhibition of PARi cleavage by thrombin in the 
presence of antibodies. However, pre-incubation time and concentration of both 
antibodies were chosen according to previous studies performed by O’Brien and 
colleagues, where the complete inhibition of PARi cleavage was obtained with the
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combination of ATAP2 and WEDE15, even at high thrombin concentration (50 nM) 
over prolonged periods of time (O’Brien et al., 2000). In addition, the Gaq selective 
PARt antagonist Q94 also only partially inhibited this response of thrombin in pHALFs. 
The maximal inhibition achieved was 53% and the effect of Q94 was saturated at 3 pM. 
Unlike RWJ-58259, Q94 is an allosteric antagonist that is uncompetitive. The effect of 
Q94 is not dependent on the degree of binding site occupancy by the tethered ligand 
after thrombin cleavage. Incomplete inhibition obtained with Q94 therefore suggests 
that PARt coupling to Gaq is only partially involved in thrombin-induced pHALF CCL2 
release at high concentrations (>10 nM) of the proteinase.
Taken together, these data indicate that thrombin at 10 nM induces pHALF CCL2 
release via both PAR-i-dependent and PARHndependent mechanisms. It is well- 
established that thrombin can signal via more than one receptor when multiple 
receptors are expressed, it is therefore possible that other PARs or non-PAR 
mechanisms are involved in mediating this response. These potential mechanisms will 
now be discussed in further detail.
5.2.1.2 Thrombin (10 nM)-induced pHALF CCL2 release is partially mediated via 
PAR-independent mechanism
As already mentioned, PAR2 is not a thrombin receptor, but emerging evidence 
suggests that PAR2 can be transactivated by PARi and therefore contribute to the 
cellular responses of thrombin, particularly in human endothelial cells (O'Brien et al., 
2000; Lidington et al., 2005). These studies propose that cleaved PAR, may donate its 
tethered ligand to PAR2 that is located sufficiently close to PAR1( especially when the 
PARt antagonist is present. In current study, although RWJ-58259 did not inhibit this 
response of thrombin at 10 nM and the PAR2 agonist peptide SLIGKV induced pHALF 
CCL2 release, it is unlikely that thrombin-induced PARr independent CCL2 release is 
mediated by PAR2. First, the PARt specific agonist TFLLR was found to induce pHALF 
CCL2 release in a concentration-dependent manner and this effect could be completely 
blocked with RWJ-58259. Second, PARi cleavage is required for PAR2 transactivation. 
At 10 nM, thrombin is still able to induce pHALF CCL2 release after inhibition of PAR! 
cleavage by both ATAP2 and WEDE15. Most importantly, the Gaq selective PARi 
antagonist Q94 which does not interfere with PARt cleavage inhibited this response of 
thrombin. As discussed before, it is likely that PAR2 plays a role in this response of 
thrombin at 10 nM only when PARt activation is blocked by RWJ-58259.
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in addition to PAR-,, PAR4 is another important functional receptor for thrombin. In 
human platelets, PAR! and PAR4 mediate aggregation and secretion in response to 
thrombin, whereas in murine platelets, thrombin triggers signalling through PAR3 and 
PAR4 (Nakanishi-Matsui et al., 2000). In the present study, PAR4 is expressed at very 
low levels compared with the other PARs, and the PAR4 agonist, AYPGKF at a 
comparable concentration (200 pM) used in studies by others (Bilodeau and Hamm, 
2007) failed to induce CCL2 release in pHALFs. These data suggest that PAR4 is not 
involved in thrombin-induced CCL2 release.
Although PAR3 is also a thrombin receptor, the ability of PAR3 to generate intracellular 
signals remains doubtful since it lacks the cytoplasmic tail domain which couples to G 
proteins in other PARs (Ishihara et al., 1997). However, emerging evidence suggests 
that PAR3 not only acts as a co-factor for PAR4 (Kahn et al., 1998), but also functions 
as an allosteric regulator of PARt signalling (McLaughlin et al., 2007). More recently, a 
study reported that PAR3 may signal to mediate thrombin-induced IL-8 release in A549 
cells (Ostrowska and Reiser, 2008). Despite this evidence, whether PAR3 can generate 
intracellular signals in fibroblasts remains unknown. In the current studies, the role of 
PAR3 in thrombin-induced CCL2 release was not examined. Ongoing studies in the 
host laboratory have shown that PARi is the principal receptor involved in thrombin- 
induced CCL2 release in A549 cells (Mercer et al, in revision). However, whether PAR3 
plays a role in mediating this response of thrombin (10 nM) in pHALFs remains at 
present an unsolved issue. Although the current evidence would suggest that this is 
unlikely, future studies with PAR3 siRNA may shed light on this issue but were beyond 
the scope of the present work.
Taken together, current evidence suggests that thrombin at concentrations of 10 nM 
induces CCL2 release in pHALFs via both PAR^dependent and PAR-independent 
mechanisms. Although the data presented do not allow us to draw any fine conclusion, 
there is a slight possibility that the PAR-independent mechanism may involve the 
release of CCL2 bound to the pericellular matrix by thrombin at 10 nM.
5.2.2 PARi coupling to Gaq plays a major role in mediating low concentration (0.3 
nM) thrombin-induced pHALF CCL2 release
Previous studies have demonstrated that thrombin at different concentrations mediates 
the cellular responses via different mechanisms (reviewed in (O'Brien et a!., 2001)). 
Indeed, findings from pHALFs in the present study are consistent with this notion. The 
data obtained led to the conclusion that PARi is the major receptor involved in
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mediating thrombin-induced pHALF CCL2 release at 0.3 nM as the PAR! specific 
antagonist, RWJ-58259, and anti-PARi antibodies completely abolished this response 
of thrombin. Moreover, the Gaq selective PARi antagonist Q94 also completely blocked 
this response, further suggesting that PARi coupling to Gaq plays a critical role in low 
concentration thrombin-induced CCL2 release in pHALFs. As discussed previously, 
thrombin used in this thesis may be more efficient in human cells as it is derived from 
human plasma. The data therefore also suggest that low concentration thrombin used 
in pHALFs may function via the same mechanism as shown in MLFs with 10 nM 
thrombin.
5.2.3 ERK1/2 and Rho kinase are involved in thrombin-induced pHALF CCL2 
release
In MLFs, thrombin was found to induce CCL2 production and release via PAR! 
coupling to Gaq and the cooperation between ERK1/2 and Rho kinase signalling 
pathways. In primary human lung fibroblasts, inhibition of ERK1/2 and Rho kinase also 
inhibited this response of thrombin at both high and low concentrations of thrombin. 
These data suggest that despite the differences observed for the involvement of PAR! 
in both murine and human cells, thrombin signals via similar downstream pathways to 
mediate CCL2 release in murine and human lung fibroblasts.
In summary, the work performed with pHALFs provides compelling evidence that 
thrombin at high concentration (10 nM) mediates pHALF CCL2 release via PAR! 
coupling to Gaq and PAR-independent mechanisms, whereas low concentration (0.3 
nM) thrombin mediates these effects mainly via PARi coupling to Gaq. In addition, 
downstream ERK1/2 and Rho kinase signalling play important roles in mediating 
thrombin-induced pHALF CCL2 release at both high and low concentrations of 
thrombin.
5.3 Sum m ary and conclusion
This thesis examined the hypothesis that PARi activation leads to the production and 
release of the pro-inflammatory and pro-fibrotic chemokine, CCL2, via its interaction 
with heterotrimeric G-proteins and activation of multiple downstream signalling 
cascades. The work performed with both MLFs and pHALFs provides compelling 
evidence that PARi coupling to Gaq, and downstream ERK1/2 and Rho kinase 
signalling are involved in thrombin-induced CCL2 release. However, data also suggest 
that 10 nM thrombin induces pHALF CCL2 release partially via PAR-independent 
mechanism, which contrasts with findings in MLFs where 10 nM thrombin induces
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CCL2 release mainly via PARi. The differences in receptor utilization between MLFs 
and pHALFs may be explained by differences of PAR receptor expression between 
species. In addition, current studies also show that low concentration (0.3 nM) thrombin 
mediates pHALF CCL2 release via the same mechanism as shown in MLFs with 10 nM 
thrombin.
In conclusion, this thesis represents the first demonstration of the complex cooperation 
between ERK1/2 and Rho kinase pathways in mediating the stimulatory effects of 
thrombin, or indeed any other extracellular stimulus, on the induction and release of the 
potent chemoattractant, CCL2.
5.4 Therapeutic implications
Current therapeutic intervention for fibroproliferative pulmonary diseases is inadequate 
and rather disappointing. The lung offers a rich opportunity for the development of 
therapeutic strategies as it interfaces with both air and blood, and drugs can be directly 
delivered to the lung by aerosol as well as oral and parenteral routes. However, the 
lung also poses a multifaceted dilemma since it contains both a pulmonary and 
systemic circulation and consists of numerous cell types. In addition, in the 
pathogenesis of pulmonary fibrosis, the number of inducers, cell types, secondary 
mediators, chemical changes, immune responses and tissue modifications are 
overwhelming. This further adds difficulties to the development of therapeutic strategies 
targeting this complexity. Detailed studies on signal transduction through which extend 
stimuli induce relative cellular responses may therefore allow the identification of novel 
therapeutic targets.
5.4.1 Therapeutic implications of PARi in pulmonary fibrosis
In the context of fibrotic lung disease, PARi is emerging as an important receptor. This 
thesis and previous work from the host laboratory has demonstrated a major role for 
PARi in mediating the cellular effects of thrombin on fibroblasts, including fibroblast 
proliferation, differentiation, collagen production and cytokine release (Chambers et al., 
1998; Blanc-Brude et al., 2005; Howell et al., 2005); Krupiczojc, unpublished; Mercer, 
in revision). In vivo studies in the bleomycin model of pulmonary fibrosis have shown 
that PARi deficiency is protective and associated with a reduction in lung oedema, 
inflammatory cell recruitment and fibrosis (Howell et al., 2005; Jenkins et al., 2006). 
This points to a central role for PARi in the crosstalk between coagulation, 
inflammation and fibrosis. In addition, clinical evidence also supports a role for PARt in 
human fibrotic lung disease as this receptor has been found to be upregulated on
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fibroblasts and macrophages within fibrotic foci in the lungs of patients with IPF (Howell 
et al., 2005), ALI/ARDS (Howell et at, unpublished) and pulmonary fibrosis associated 
with systemic sclerosis (Bogatkevich et at., 2005). Moreover, PARi belongs to family of 
GPCRs that mediate a great range of biological responses elicited by a remarkably 
diverse array of stimuli including growth factors, chemoattractants, proteinases, etc. 
GPCRs are the target for nearly 30% of all drugs currently available (Hopkins and 
Groom, 2002). Therefore, PARt has become a very attractive drug target in fibrotic lung 
disease. Indeed, there are currently a number of peptidomimetic and non-peptide PARi 
antagonists available for both experimental studies and for pharmaceutical use in 
humans (Please see Introduction 1.7.5).
The current studies and studies by others have shown that the effectiveness of PAR1 
tethered ligand antagonist is limited by the presence of other PARs (O'Brien et al., 
2000, Shi et a/., 2004; Lidington et at., 2005; Kaneider et al., 2007). This raises 
concerns in terms of the therapeutic potential of PARt antagonists. It is well-known that 
GPCRs can form hetero-oligomers, and the constitutive or ligand-induced 
oligomerization of GPCRs can lead to signal amplification and transactivation (Milligan, 
2001; George et al., 2002). Therefore other strategies will be required in order to avoid 
transactivation between PARs and the activation of PAR heterodimers. In this regard, 
this thesis demonstrated the effectiveness of blocking thrombin-induced CCL2 release 
using the recently developed novel PARi antagonist Q94 (Caden Biosciences). Q94 is 
an allosteric antagonist that requires PARi to be activated which unlike the 
conventional PARi antagonists. It blocks PARi at the intracellular interaction site with 
Gaq, therefore should not lead to the transactivation of other PARs and the tethered 
ligand will be free to interact with its receptor rather than being prevented by antagonist 
binding site occupancy. In addition, Q94 only blocks PARi coupling to Gaq and 
therefore allows more selective targeting of some, but not all, PARi-mediated cellular 
responses. This may therefore change the concept of therapeutic intervention from 
targeting all the cellular responses to selectively targeting deleterious responses, while 
preserving other cellular events that are essential for normal function.
5.4.2 Therapeutic implications of CCL2 in pulmonary fibrosis 
This thesis has shown a dramatic increase in CCL2 by fibroblasts following PARt 
activation. CCL2 is an important chemokine and exerts its potent pro-inflammatory and 
profibrotic effects. CCL2 is not only produced by numerous cell types, including 
fibroblasts, but can in turn activate and mediate cellular effects of these cells via 
autocrine and paracrine mechanisms (see Table 1.3 in introduction). For example,
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CCL2 stimulates fibroblast collagen production via the induction of TGF-p and a 
reduction in PGE2 production (See introduction section 1.8.3). More importantly, CCR2 
(major CCL2 receptor) deficiency has been shown to be protective not only in 
bleomycin-induced pulmonary fibrosis (Moore et al., 2001), but also in fluorescein 
isothiocyanate (FITC)-induced lung fibrosis (Gharaee-Kermani et al., 2003). These 
observations suggest that strategies aimed at interfering with CCL2 production may 
offer promise for therapeutic intervention in pulmonary fibrosis.
5.5 Future studies
5.5.1 Molecular mechanism of RhoA activation induced by PARi-Gaq in mouse 
lung fibroblasts
By using the recently developed novel PARi antagonist Q94, which blocks PARi at the 
intracellular interaction site with Gaq (Caden Biosciences), this thesis has 
demonstrated that PARi-induced CCL2 release is mediated via PARi coupling to Gaq 
and the activation of RhoA/Rho kinase. This indicates that Gaq can activate and signal 
via RhoA/Rho kinase directly. However, the molecular mechanisms involved in RhoA 
activation induced by Gaq have not been addressed in great detail in this thesis.
Fundamentally, GEFs play a critical role in RhoA activation as the activation of RhoA 
requires its dissociation from the RhoA.GDP.GDI complex followed by GTP exchange 
mediated by GEFs (Mehta and Malik, 2006). It is well-established that RhoGEFs 
including mainly LARG, p115RhoGEF and PDZ-RhoGEF are involved in mediating 
Ga12/i3-induced RhoA activation. However, the role of GEFs in Gaq-induced RhoA 
activation needs further investigation. A recent study has proposed that p63RhoGEF is 
a downstream effector of the Gaq and this study also demonstrated the crystal structure 
of the Gaq-p63RhoGEF-RhoA complex (Lutz et al., 2007). Nevertheless, this thesis 
proposes that p115RhoGEF might be involved in Gaq-mediated RhoA activation. This 
notion is based on the observations that p115RhoGEF contributes to PLC-p-Ca2+- 
dependent PKC-induced RhoA activation after thrombin stimulation (Holinstat et al., 
2003; Singh et al., 2007). Further experiments to address this notion are now 
warranted.
5.5.2 Further delineation of the signalling pathways involved in thrombin-induced 
CCL2 release in primary human adult lung fibroblasts
The work presented in this thesis showed that thrombin at 10 nM induced pHALF CCL2 
release via both PARi-dependent and PAR-independent mechanisms, whereas PARi 
is the major receptor involved in this response of thrombin in MLFs. To further compare
223
Chapter 5 Discussion
the signalling pathways downstream of PAR! that are involved in thrombin (10 nM)- 
induced CCL2 mRNA and protein levels in both human and murine cells, further 
studies are required. First, to investigate the involvement of other signalling molecules 
in thrombin-induced pHALF CCL2 release, including PLC, Ca2+, PKC and c-Raf that 
have been shown to mediate thrombin-induced CCL2 release in MLFs. Second, to 
investigate the effect of thrombin on pHALF CCL2 mRNA levels and downstream 
signalling pathways involved.
In addition, this thesis also showed that PAR, may transactivate PAR2 when PARi 
signalling is blocked by tethered ligand binding site occupancy with RWJ-58259. The 
mechanism by which PAR! transactivates PAR2 can be further investigated. To this 
end, PAR2 antagonist or PAR2 siRNA can be employed to block PAR2 signalling.
5.5.3 Mechanism  o f protection of PARrGaq signalling inhibition in pulmonary 
fibrosis
The data presented in this thesis have provided compelling evidence that PAR^Gc^ 
interaction acts as a fundamental component involved in thrombin-induced CCL2 
release in vitro. Further studies are needed to assess the contribution of the PARi-Gaq 
signalling pathway in pulmonary fibrosis in vivo. It has been reported that some 
patients given bleomycin as an anti-neoplastic drug, develop pulmonary fibrosis in an 
age- and concentration-dependent manner (Luna et al., 1972; Adamson, 1976, 1984; 
Papiris et al., 2005). Lung sections obtained from these patients revealed that 
bleomycin-induced lung injury pathologically resembles UIP, the histopathological 
pattern of IPF. The bleomycin-induced lung fibrosis model could therefore be employed 
to investigate the contribution of PARrGaq signalling pathway in pulmonary fibrosis.
The contribution of PARr Gaq signalling pathway following bleomycin-induced lung 
injury could be elucidated by performing the following experiments. First, the effect of 
PARi-Gaq inhibition by Q94 could be assessed. To this end, subsequent inflammation 
and fibrosis would be measured. Second, PKC, MAPKs, RhoA, and Rho kinase 
activation in the lungs of wild-type, bleomycin-injured and Q94 instilled mice could be 
measured by quantitative immunohitochemistry. Third, in order to address whether 
selectively interfering with some of the PARi signalling may hold promise for 
therapeutic intervention, the consequences of interruption on PAR^Gciq coupling could 
be compared with the outcome in PARi knockout mice after bleomycin injury or in mice 
treated with RWJ-58259.
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5.5.4 Molecular mechanisms o f high expression ofCCL2 in pulmonary fibrosis
Previous work conducted in our laboratory has shown that CCL2 expression is high in 
bleomycin-induced lung injury model. In addition, cultured primary human lung 
fibroblasts derived from fibrotic lesions from patients with IPF show greater ability to 
express CCL2 when stimulated (Standiford et al., 1993) and the reason for this is 
unknown. A detailed study of CCL2 production by primary human lung fibroblasts could 
determine the reason why it is switched on in IPF. Experiments involved in this study 
would include the investigation of transcriptional and post-transcriptional mechanisms 
involved in CCL2 release, as well as the determination of the site of the abnormal 
regulation of CCL2 release by fibroblasts in IPF. Identifying these key processes will 
likely identify new approaches to develop better treatments for IPF.
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APPENDIX
HABP C-terminal sequence IC50 [nM]
Gq L Q L N L K E Y N L V 320
T2-14 L Q L N L K K Y N R V 106
B2AR-X Q R L H L R G Y E F L 8277
RHO-8 L L E N L R D C G M F 8411
Table I. IC50 Values for high affinity C-terminal PARi receptor high affinity binding 
proteins (HABP). Using competitive ELISA the affinity of selected purified MBP-C-terminal 
fusion proteins for activated PARt was determined. |32AR-x contains a sequence obtained from 
screening the activated (32-adrenergic receptor with a Gas library, and there is either no binding 
or very low-affinity binding. There is also little or no binding with RH08, a peptide identified from 
a Gat library for its ability to bind activated Rhodopsin. This support the selective nature of the 
binding of peptide sequences to PARt.
A1 A2
1.0-,
*  0.4-
•8 -7 -6
1.B-, TRAP [5>iM]
TRAP+ 0 9 4  [0.1 nM) 
TRAP+ 094  [1 
TRAP+Q94 (10 j^M)
log(Q94J
75 100 125 150 175 200
Time (seconds)
Figure A. Q94 displaces the high affinity binding peptide MBP-T2-14 from activated PAR1
2+
and blocks thrombin induced Ca transients in HEK293 cells.
For the binding studies (left panel, A1), SF9 cells were treated with [100 nM] TRAP. Purified T2- 
14 fused with E. coli maltose binding protein (MBP-T2-14) [100 nM] was added to wells and 
allowed to bind to the receptor. Increasing amounts of Q94 were added to wells in triplicate, 
binding of MBP-T2-14 was measured using an ELISA for MBP. Data presented are the mean of
individual wells from 3 separate experiments. A non-linear regression analysis was generated
2+
using GraphPad Prism, version 5.0. For the Ca transient studies (right panel, A2), assays 
were performed using Molecular Devices Calcium Plus. TRAP: thrombin receptor activating 
peptide; MBP: maltose binding protein.
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M on ito ring  Editor: M ark Ginsberg
Uncontrolled activation of the coagulation cascade after tissue injury has been implicated in both inflammation and tissue 
fibrosis. Thrombin exerts pluripotent cellular effects via its high-affinity receptor, proteinase-activated receptor-1 (PAR!) 
and signaling via G ai/o/ G aq, or G a12/13. Activation of PAR, on fibroblasts, a key effector cell in fibrosis, results in the 
induction of several mediators, including the potent monocyte and fibrocyte chemoattractant CCL2. The aim of this study 
was to identify the G protein and signaling pathway involved in PAR,-mediated CCL2 production and release. Using a 
novel PAR, antagonist that blocks the interaction between PAR, and G aq/ we report for the first time that PAR, coupling 
to G a q is essential for thrombin-induced CCL2 gene expression and protein release in murine lung fibroblasts. We further 
demonstrate that these effects are mediated via the cooperation between ERK1/2 and Rho kinase signaling pathways: a 
calcium-independent protein kinase C (PKC), c-Raf, and ERKl/2 pathway was found to mediate PAR,-induced CCL2 gene 
transcription, whereas a phospholipase C, calcium-dependent PKC, and Rho kinase pathway influences CCL2 protein 
release. We propose that targeting the interaction between PAR, and G a may allow us to selectively interfere with PAR, 
proinflammatory and profibrotic signaling, while preserving the essential role of other PAR,-mediated cellular responses.
INTRODUCTION
Inflamm ation and the subsequent fibroproliferative re­
sp on se  are critical com ponents of tissue repair after injury. 
H ow ever, if uncontrolled, these processes can lead to the 
developm ent of tissue rem odeling and fibrosis of the skin, 
vasculature, and internal organs, including the lung. Previ­
ously , the fibroblast w as considered to be a passive partici­
pant in tissue repair through its end-stage contribution of 
extracellular matrix synthesis. However, emerging evidence 
now  points to a more active role for fibroblasts in the response 
to tissue injury by releasing a host of mediators, including the 
CC-chemokine: CCL2 (MCP-1 /CCL2/JE; Hogaboam et al., 
1998). A lthough primarily considered a potent chemoattrac­
tant for m onocytes, T-cells, and natural killer cells, CCL2 is 
also involved in the direct activation of fibroblasts leading to 
extracellular matrix generation via the induction of the po­
tent profibrotic mediator, transforming grow th factor /31 
(TGF-/31; Gharaee-Kermani et al., 1996). Recent evidence fur­
ther suggests that CCL2 m ay also contribute to excessive
This article was published online ahead o f p rin t in  MBC in Press 
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collagen deposition via the recruitment of fibrocytes (Moore 
et al., 2005), w hich are believed to represent a source of 
fibroblasts and myofibroblasts during the fibroproliferative 
response to tissue dam age (Phillips et al., 2004).
One of the earliest responses to tissue injury involves the 
highly coordinated activation of the coagulation cascade 
w ith the resultant generation of thrombin. In addition to its 
central role in hemostasis, thrombin exerts a number of cel­
lular effects that initiate and influence subsequent inflamma­
tory and tissue repair responses (Chambers, 2003). Thrombin 
exerts potent profibrotic effects by influencing fibroblast 
function and has also been show n to up-regulate CCL2 
expression by several cell types, including monocytes (Co- 
lotta et al., 1994), endothelial cells (Colotta et al., 1994; Marin 
et al., 2001), sm ooth m uscle cells (Brandes et al., 2001), and 
dermal fibroblasts (Bachli et al., 2003). The cellular effects of 
thrombin are largely, but not exclusively, mediated via the 
activation of a unique family of cell surface receptors 
termed, proteinase-activated receptors (PARs). To date, four 
PARs have been described, of w hich three (PAR,, PAR3, and 
PAR4) are activated by thrombin. These receptors belong to 
the seven transmembrane domain G protein-coupled recep­
tor (GPCR) superfamily, but are activated by a unique mech­
anism involving limited proteolytic cleavage of the N-termi- 
nal extracellular domain leading to the unmasking of a 
tethered ligand that in turn activates the receptor by in­
tramolecular binding (Vu et al., 1991) .
PAR, is the high-affinity thrombin receptor and the major 
receptor responsible for mediating many of the proinflam­
matory and profibrotic effects of thrombin via the induction 
and activation of a host of secondary mediators(Chambers, 
2003). PAR, exhibits the ability to couple to multiple G
2520 © 2008 by The American Society for Cell Biology
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protein family subunits, including G ai/o/ G aq, or G a12/13 
within the sam e cell type. In general, the G ai/(, pathway 
inhibits adenylate cyclase and the generation of cyclic aden­
osine m onophosphate (cAMP); the G aq pathway involves 
phospholipase C-/3 (PLC-/3) activation and concomitant cal­
cium  mobilization and protein kinase C (PKC) activation, 
whereas the G a12/13 pathw ay activates Rho kinase and reg­
ulates actin rem odeling (Coughlin, 2000).
Studies em ploying PAR, antagonists and PAR,-deficient 
mice have provided strong evidence that PAR, signaling 
plays an important role in inflamm ation and tissue remod­
eling in a number of tissues, including the vasculature 
(Cheung et al., 1999), the kidney (Cunningham et al., 2000), 
the liver (Fiorucci et al., 2004), and the lung (Howell et al., 
2005). In the context of lung injury, w e have recently re­
ported that protection from bleom ycin-induced lung inflam­
mation and fibrosis in PAR,-deficient mice is accompanied 
by a marked attenuation of the characteristic increase in 
CCL2 lung levels (H ow ell et al., 2005). In human fibropro­
liferative lung diseases, CCL2 levels in bronchoalveolar la­
vage fluid (BALF) correlate w ith the severity of lung injury 
in acute respiratory distress syndrom e (ARDS; Goodman et 
al., 1996). CCL2 lung levels are also increased in patients 
w ith  interstitial lung disease (ILD) and in patients w ith the 
fatal chronic fibrotic lung condition, idiopathic pulmonary 
fibrosis (IPF), where CCL2 m ay serve as a useful biomarker 
for the clinical course of the disease (Suga et al., 1999). In 
patients with fibrotic lung disease and in animal m odels, 
fibroblast numbers are dramatically increased, and num er­
ous cells are strongly im m unoreactive for both CCL2 and 
PAR, (Mercer, Johns, Scotton, Krupiczojc, Koenigshoff, How­
ell, McAnulty, Das, Eickelberg, and Chambers, unpublished  
data). H ow ever, the signaling pathw ays involved in PAR,- 
mediated CCL2 production remain poorly understood. The 
aim of this study w as therefore to begin to delineate the 
signaling pathways by w hich thrombin induces CCL2 pro­
duction by lung fibroblasts. We report for the first time that 
thrombin induces fibroblast CCL2 production and release 
via coupling of PAR, to G aq and the cooperation betw een  
ERK 1/2 and Rho kinase signaling pathways. We further 
provide evidence that the Ca2+-independent PKC, c-Raf, 
and ERK1/2 pathw ay is responsible for thrombin-induced 
CCL2 gene expression, w hereas the second PLC, Ca2+, 
Ca2+-dependent PKC, Rho kinase pathway influences CCL2 
protein release via a posttranscriptional mechanism. These 
data dem onstrate a central role for G aq in thrombin-induced 
CCL2 signaling. In this report, w e further demonstrate the 
effectiveness of blocking this response using a recently de­
veloped novel sm all-m olecule PAR, antagonist, w hich  
blocks PAR, at the intracellular interaction site w ith G aq 
(Caden Biosciences, M adison, WI). This antagonist may al­
low  more selective targeting of som e, but not all, PAR,- 
mediated cellular responses and m ay hold promise for in­
terfering w ith deleterious PAR, signaling in a number of 
inflammatory and fibrotic conditions associated with uncon­
trolled activation of the coagulation cascade.
MATERIALS A N D  M ETH O DS  
Materials
Human thrombin, Ro-318425, GF109203X, G66976, U0126, SB 203580, Y- 
27632, H-1152, U73122, BAPTA-AM, and c-Raf inhibitor were purchased from 
Calbiochem (Merck Biosciences, Nottingham, United Kingdom). Tumor ne­
crosis factor a (TNF-a) was purchased from Peprotech (London, United 
Kingdom). Anti-phospho-p38, anti-p38, anti-phospho-ERKl/2, anti-ERKl/2, 
anti-phospho-e-Raf, anti-c-Raf, and anti-MLC antibodies were purchased 
from New England Biolabs (Hitchin, United Kingdom). Anti-phospho-MLC 
antibody was a kind and generous gift from Dr. James M . Staddon (Eisai
London Research Laboratories, United Kingdom). Anti-CCL2 antibody was 
obtained from R&D Systems (Abingdon, United Kingdom). Wild-type M EK l 
(w t-M EKl), dominant negative M EK l (dn-MEKl), and constitutively active 
M EK l (ca-MEKl) cloned to pBABEpuro eukaryotic expression vectors were 
generous gifts from Professor Chris Marshall (Cancer Research UK, London, 
United Kingdom). Selective PAR, agonists, corresponding to the sequence 
TFLLR-NH2 (TF) and the reverse control peptide RLLFT-NH2 (RL), were 
obtained from Dr. Robert P. Mecham (University of Washington Medical 
School, St. Louis, M O). pRev Tet-on vector was purchased from BD Bio­
sciences (San Jose, CA). The pRevTRE2-dEGFP (a control vector encoding 
enhanced green fluorescent protein [F.GFP]), pRevTRF2-G«q, pRevTRE2- 
G «12, pRevTRE-Galv  and pRevTRE-G«,/0 minigenes and the PAR, antago­
nist Q94 were developed by Dr. Annette Gilchrist (Caden Biosciences). These 
C-terminal G alpha minigenes encode 11 amino acid C-terminal sequences of 
Gaq, G « 12, G «, v and Gu, which act as highly specific competitive inhibitors 
for each isoform (Gilchrist et a t, 2001, 2002). The novel PAR, antagonist, Q94, 
is a small molecule (M W  <500) that meets the Lipinski rule of five and was 
identified during an ELISA screen for competition of a high-affinity peptide 
that mimics the C-terminus of G«q using a commercially available library 
(ChemDiv). Further details of the Q94 selection criteria and binding affinity 
for PAR, are provided as supplementary data (see Supplementary Data Table 
SI and Figure 1). A  patent application for this compound has been filed 
(patent application EFS ID  2841714; application number 61027665) This com­
pound will be made freely available to qualified investigators upon applica­
tion to Dr. A. Gilchrist (Caden Biosciences).
Fibroblast Culture
Mouse lung fibroblasts (MI.Fs) from PAR, knockout (PAR, KO) and corre­
sponding wild-type MLFs were a kind gift from Professor Shaun Coughlin 
(University of California, San Francisco, CA) and have been described previ­
ously (Trejo et al., 1996). Cells were maintained in DM EM  supplemented with 
penicillin (100 U /m l), glutamine (100 U /m l), streptomycin (100 U /m l), and 
10% (vol/vo l) FCS (D M EM , 10‘Xi FCS), in a humidified atmosphere containing 
10% C 0 2. Cells were routinely passaged every 5-6  d. There were no notice­
able effects on the parameters measured for cells used between passages 8 and 
20. Cells were routinely tested and found negative for mycoplasma infection. 
For all experiments, cells were grown to confluence and 0.01% serum-starved 
for 24 h before stimulation.
Detection o f  CCL2 by ELISA
Cells were seeded in 96-well plates (Nunc, Naperville, IL). For each condition 
there were three biological replicates, and after the specified period, super­
natants from each replicate were evaluated for CCL2 levels in duplicate by 
sandwich ELISA according to the manufacturer's instructions (BD Bio­
sciences, Bath, United Kingdom). The lowest detection limit of the assay was 
15.6 pg ml -  *, and the standard curve was linear up to 1000 pg m l-1 .
Western B lotting  o f  Phosphorylated Kinases and Proteins
MLFs monolayers from six-well plates were washed twice with ice-cold 
phosphate-buffered saline (PBS), and cells were lysed by adding 100 p.1 
Laemmli sample buffer directly to the monolayer, followed by scraping with 
a cell scraper. The cell lysate was passed through a 2-gauge needle several 
times to shear D N A  and heated for 10 min at 85°C. Proteins from each lysate 
were separated by electrophoresis on a 10% or 12.5% SDS-polyacrylamide gel 
with a 7% stacking gel. Separated proteins were transferred onto Hybond- 
ECL nylon membranes (GE Healthcare, Waukesha, Wl). The membranes were 
incubated with various primary antibodies; anti-phospho-p38 (1/1000), anti- 
p38 (1/2500), anti-phospho-ERK (1/2000), anti-ERK (1/2500), anti-phospho- 
Raf (1/2500), anti-Raf (1/2500), anti-phospho-MLC (1/500), and anti-MLC 
(1/1000) overnight at 4°C. A horseradish peroxidase-conjugated anti-rabbit 
IgG (D AK O , Cambridge, United Kingdom) was added at a 1:5000 dilution 
for 1 h at room temperature. Immunoreactive bands were visualized by 
standard enhanced chemiluminescence detection (Amersham Pharmacia 
Biotech, Piscataway, NJ).
Q uantitative Real-Time RT-PCR Analysis o f  CCL2 
m RNA Levels
Total RNA from cell cultures was isolated with TRIzol reagent per the 
manufacturer's protocol. RNA was DNase-treated using a DNAfree kit (Am- 
bion, Europe, Ltd, Huntingdon, United Kingdom). Random hexamers were 
used as the primer for reverse transcription (RT) of 1 Mg °1 total RNA in a 
reaction volume of 20 /d  using the Applied Biosystems Geneamp RNA PCR 
core kit (Applied Biosystems, United Kingdom) following the manufacturer's 
instructions. Real-time RT-PCR was conducted using the Platinum SYBR 
Green qPCR SuperMix UDG (Invitrogen, Paisley, United Kingdom) on a 
LightCycler 1.5 Real-Time Detection System (Roche, Lewes, United Kingdom) 
and analyzed using LightCycler Real-time PCR Detection System (software 
version 3.5). Cycling conditions were as follows: one cycle of 50°C (2 min) and 
95°C (2 min) and 45 cycles of 95°C (5 s), 55°C (5 s), and 72°C (15 s). The 
specificity of the PCR product was confirmed by melting curve analysis and 
gel electrophoresis. Relative quantitation was performed using the 2 AACp
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method, with 18S as the reference gene. The CCL2 primers were as follows: 
5 -AGCTCTCTCTTCCTCCACCAC-3' and 3 -CGTTAACTGCATCTG- 
GCTGA-5'.
Retroviral Transduction w ith  M utant M EKl Constructs
Ecotropic Phoenix packaging cells were transiently transfected with either 
wild-type M E K l, dominant negative M E K l, or constitutively active M EK l 
using a calcium phosphate precipitation transfection protocol. Virus contain­
ing supernatants were harvested and used to infect target MLFs as previ­
ously described (Janes and W att, 2004). Stably transduced MLFs were 
grown in the presence of puromycin (2.5 jxg/ml; Calbiochem, Nottingham, 
United Kingdom).
Retroviral Transduction w ith  G Protein Minigenes
Ecotropic Phoenix packaging cells were transiently transfected with either 
pRevTet-On vector or pRevTRE2 minigenes (pRevTRE2-EGFP and pRe- 
vTRE2-Gaq) according to the instructions from the manufacturer (CLON- 
TECH, Palo Alto, CA), and virus-containing supernatants were used to infect 
and transducer target MLFs. Transduced Tet-On-MLFs were selected in me­
dium containing 400 pig/m l G418. Tet-On-MLFs were subsequently infected 
with pRevTRE2-EGFP, pRevTRE2-G«q, pRevTRE2-G<«,2, pRevTRE2-Ga,v or 
pRevTRE2-Gar, minigenes containing viral supernatants. The Tet-On-MLFs 
transduced with EGFP or G protein minigenes were selected by culture in 
medium containing 400 pig/m l G418 and 500 pig/ml hygromycin. Expression 
of EGFP or minigenes was induced by incubation with 2 pig/ml doxycycline. 
Subsequent experiments were performed 48 h after doxycycline addition. 
Transduction efficiency was —90% as determined by assessing the expression 
obtained with the EGFP encoding RevTRE2-EGFP vector.
lmmunocytofluoresence
MLFs were plated on eight-well chamber glass slides. After stimulation, cells 
were rinsed with PBS and then fixed for 10 min with 4% formaldehyde in PBS 
and permeabilized with 0.2% Triton X-100 at room temperature. To avoid 
nonspecific binding, the cells were incubated with 4% rabbit normal serum for 
1 h at room temperature and then washed three times with PBS. Primary 
antibody (goat polyclonal anti-CCL2; R&D Systems, Europe, Ltd, Abingdon,
United Kingdom) was incubated for 1 h at room temperature after three 
washes with PBS. Secondary antibody (FTTC-conjugated rabbit anti-goat IgG) 
was incubated in the dark for 1 h at room temperature, and subsequently 
slides were washed three times with PBS. Immunofluoresence images were 
acquired by confocal microscopy using the Bio-Rad MRC 1024 confocal 
system (Hercules, CA), and the images were analyzed for the pixel intensity 
of the fluorescence using the Bio-Rad LaserPix image analysis software.
Statistical Analysis
Data were analyzed by two-tailed Student's t test for single and by one-way 
analysis of variance with the Newman-Keuls post hoc analysis for multiple 
group comparisons. Differences were considered significant at p <  0.05.
RESULTS
Thrombin Induces CCL2 Production and CCL2 mRNA  
Accumulation in Murine Lung Fibroblasts (MLFs)
To determine the effect of thrombin on MLF CCL2 produc­
tion and release, MLFs were exposed to various concentra­
tions of thrombin, and CCL2 protein levels in culture super­
natants were assessed by ELISA. Figure 1, A and B, show s 
that thrombin stimulates CCL2 protein release in a time- and 
dose-dependent manner from 0.03 nM onward. CCL2 pro­
duction continued to increase at all concentrations exam­
ined, and the effect did not plateau at the highest concentra­
tion of thrombin (300 nM) examined. Time-course experiments 
(Figure IB) w ith thrombin at a physiologically relevant con­
centration (10 nM) show ed that the sharpest increase in 
CCL2 release occurs over the first 12 h.
To determine whether thrombin influences CCL2 gene 
expression, the effect of thrombin on CCL2 mRNA levels
A B  1000-1 
800-
p<0.05p<0.05
~  600-
—  200 -
2  400- Control 
- 0 -  (Thrombin] (10nM)“  100 -
200-
0.001 0.01 0.1 1 10 100 1000 50 10 15 20 25
£ 200
[Thrombin] (nM ) Tim* (hours)
p<0 05
Control
(Thrombin) (10 nM)
Tim * (hours)
Figure 1. Thrombin stimulates fibroblast 
CCL2 gene expression and protein produc­
tion. (A and B) Dose-response (A) and time- 
course (B) data for the effect o f throm bin on 
MLF CCL2 protein release. MLFs were ex­
posed to thrombin (0.001-300 nM ) for 6 h or to 
10 nM  thrombin for varying durations (2-24 
h). Supernatants from cell cultures after incu­
bation were analyzed for CCL2 protein secre­
tion by ELISA. (C) Time-course data for the 
effect o f thrombin on CCL2 m RNA levels. 
MLFs were exposed to serum-free control me­
d ium  (DMEM) or thrombin (10 nM ) for incu­
bation times from 0.5 to 24 h. CCL2 mRNA 
levels at each time point were assessed by 
quantitative real time RT-PCR. Data are ex­
pressed as fo ld change relative to time zero for 
each time point (mean ± SEM from  tr ip l i­
cates) after normalization to 18S RNA. (D) The 
effect ActD on thrombin-induced CCL2 
m RNA levels. MLFs were exposed to throm­
bin for 2 h w ith  or w ithout preincubation w ith  
ActD  (1 j ig /m l)  for 30 min. CCL2 mRNA 
levels were determined as in C. (E) The effect 
o f ActD  on thrombin-induced CCL2 protein 
release. MLFs were preincubated w ith  ActD (1 
j ig /m l)  for 30 m in before exposure to throm ­
bin fo r 6 h. CCL2 release into cell culture were 
analyzed by ELISA as in A. Data are ex­
pressed as the mean ± SEM from  triplicates, 
p <  0.05, comparison w ith  unstimulated cells 
or time point-matched media control cells; 
+ * p <  0.01, comparison w ith  medium con­
trol; "  p <  0.01, comparison w ith  thrombin 
alone.
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w as assessed by quantitative real-time RT-PCR. Figure 1C 
show s that thrombin increases CCL2 mRNA levels w ithin 30 
min, w ith a maximal increase (21 ± 3-fold relative to control) 
observed at 6 h (p <  0.01). Thrombin-induced CCL2 protein  
release is com pletely blocked by actinomycin D (ActD; Fig­
ure IE) at concentrations at w hich this transcriptional inhib­
itor also blocked the increase in thrombin-induced mRNA  
levels (Figure ID). Thrombin-induced CCL2 protein release 
is therefore not due to the release of prestored CCL2.
The Stim ulatory Effects o f Thrombin on Fibroblast CCL2 
Gene Expression and Protein Production Are M ediated via  
PARj Coupling to G aq
To begin to unravel the mechanisms by w hich thrombin  
exerts its stimulatory effects on CCL2 mRNA and protein  
levels, w e first examined the potential involvem ent of the 
high-affinity thrombin receptor PAR,. W ild-type and PAR, 
knockout (KO) MLFs were exposed to thrombin (10 nM) and  
the specific PAR, agonist peptide TFLLR (200 pM ) for 6 h 
(Figure 2A). W ild-type MLFs responded to thrombin and 
TFLLR, w hereas PAR, KO MLFs were com pletely unrespon­
sive (Figure 2A). The inactive reverse peptide RLLFT had no  
effect on either w ild-type or PAR, KO MLFs. Experiments 
w ere also performed with TNF-a (10 n g /m l) as a positive  
control know n to induce CCL2 independent of PAR signal­
ing. The results show  that both w ild-type and PAR, KO 
MLFs respond normally to TNF-a (Figure 2A). Taken to­
gether, these data show  that thrombin exerts its effects on
CCL2 protein production and release via PAR, at this con­
centration of the proteinase.
PAR, exerts its pluripotent cellular effects via the ability to 
interact with multiple downstream G proteins, including 
G ai/<y G aq/,„  and G a ,2 /,3. To identify the G protein in­
volved in mediating PAR, activation-induced CCL2 release, 
w e used minigene vectors that encode 11 unique carboxyl- 
terminal amino acid residues of the G aq, Ga,, G a ,2, and G a,3 
subunits. These minigenes have previously been shown to 
effectively inhibit G protein signaling, including thrombin- 
mediated cellular effects (Ellis et al., 1999; Gilchrist et al., 
2001; Vanhauwe et al., 2002). Retroviral plasm ids encoding 
EGFP or the C-terminal G a minigenes were transduced into 
MLFs in parallel culture. Transduction efficiency was mon­
itored by visualization of EGFP expression. Approximately 
90% of EGFP-transduced cells were EGFP positive (data not 
shown). Figure 2B shows that the Ga C-terminal antagonist 
encoding minigene completely abolished thrombin-induced 
CCL2 release. In contrast, transduction with a control mini­
gene encoding EGFP, or C-terminal Ga,, G a12, or G a,3 had 
no effect on this response.
To further confirm the role of G aq in this response, we 
examined the effect of a novel small molecule antagonist, 
Q94, which specifically targets PAR, coupling to Gaq. Q94 
has been show n to compete for binding at the carboxy 
terminus of activated PAR, with a high-affinity peptide 
mimic of carboxy terminal G aq, w ith an IC50 of 916 nM (see 
Supplementary Data Figure SI, left panel). Additionally, this
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Figure 2. PAR, coupling to Ga is necessary 
and sufficient for thrombin-induced CCL2 
m R N A  levels and protein release. (A) The 
effects o f throm bin, PAR, agonist TFLLR- 
N H 2, the reverse peptide RLLFT-NH2, and 
TNF-a on CCL2 protein release in MLFs and 
PAR, KO fibroblasts. Cells were exposed to 
throm bin  (Thr, 10 nM), TFLLR-NH2 (TF, 200 
pM ), RLLFT- N H 2 (RL, 200 pM ), or TNF-a (10 
n g /m l)  fo r 6 h. CCL2 levels in culture super­
natants were measured by ELISA. Data are 
presented as fold-increase relative to media con­
trol. (B) The effects o f pRevTRE2-EGFP, pRe- 
vTRE2-Gaq, pRevTRE2-Ga„ pRevTRE2-Ga12, 
or pRevTRE2-Ga,3 on thrombin-induced CCL2 
protein release. MLFs transduced w ith  the 
pRevTRE2-EGFP or the C-term inal Ga m in i­
genes were exposed to throm bin (10 nM ) for 
6 h, and CCL2 levels in  culture supernatant 
were measured by ELISA. Data are presented 
as fo ld  change over control. (C and D) The 
effect o f antagonist Q94 (targeting PAR, cou­
p ling  to G aq) on throm bin- and TN F-a-in- 
duced CCL2 prote in release. Data are pre­
sented as a percentage o f the maximal 
response obtained w ith  throm bin and drug 
vehicle alone (0.1% DMSO in DMEM). Cells 
were treated w ith  increasing concentrations o f 
Q94 for 3 h before exposure to throm bin for 
6 h. Final concentrations o f DMSO were kept 
constant fo r all treatment conditions. The first 
bar represents the highest dose o f Q94 used 
and shows that this compound has no effect 
on basal CCL2 production. Negative log o f the 
concentrations o f Q94 are presented. (E) The 
effect o f Q94 on throm bin-induced CCL2 
m RNA levels. MLFs were exposed to throm ­
bin for 2 h w ith  or w ithou t preincubation w ith  
Q94 (10 p M ) fo r 3 h. Data represent the 
mean ±  SEM o f triplicates. ++ p <  0.01, comparison w ith  m edium  control; and ** p <  0.01, comparison w ith  throm bin alone.
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com pound has been show n to inhibit thrombin receptor 
activating peptide (TRAP) induced calcium transients in a 
concentration-dependent manner (see Supplementary Data 
Figure SI, right panel). Figure 2C show s that Q94 blocked 
PAR,-mediated CCL2 production in a dose-dependent man­
ner with com plete inhibition obtained at 10 p.M. Experi­
ments performed with TNF-a as the stim ulus show ed that 
Q94 had no effect on TNF-a-stim ulated CCL2 production 
(Figure 2D), indicating that the antagonist w as specific for 
PAR, in blocking this response. We also examined the role 
of this antagonist on thrombin-induced CCL2 mRNA levels. 
Figure 2E show s that Q94 (10 /xM) blocked thrombin-in­
duced CCL2 mRNA levels by —70% (p <  0.01). Taken to­
gether, these data show  that G aq plays a central role in 
PAR,-induced CCL2 protein release and gene expression.
ERK1/2 Is Required fo r  Thrombin-induced CCL2 Gene 
Expression and Protein Production
It has previously been reported that activation of G aq by 
PAR, leads to the activation of ERK1/2 in MLFs (Trejo et al.,
1996). H ow ever, in terms of thrombin-induced CCL2 release 
by other cell types, the p38 MAPK pathway has been shown  
to play an important role (Brandes et al., 2001; Marin et al., 
2001). Thus, w e next performed experim ents to determine 
the relative roles of the p38 MAPK and ERK1/2 pathw ays in 
PAR ,-induced CCL2 expression. Figure 3A show s that inhi­
bition of p38 MAPK with SB203580 had no effect on throm­
bin-induced CCL2 protein release at concentrations at which  
this com pound w as effective at blocking thrombin-induced  
p38 phosphorylation (Figure 3B). It is worth pointing out 
that in these experiments, the inactive control com pound  
SB202474 at the highest dose used significantly inhibited 
throm bin-induced CCL2 release by —50% (data not shown), 
suggesting that at high concentrations these com pounds 
m ay exert off-target effects. We therefore conclude that al­
though thrombin activates p38 MAPK in MLFs, p38 is not 
involved in mediating PAR,-induced CCL2 release. In con­
trast, preincubation of MLFs w ith the M EK1/2 inhibitor 
U0126 blocked this response in a dose-dependent manner 
from 0.3 /xM onward (Figure 3C). The IC ^ of U0126 was 
determ ined to be 1.3 /xM for this response. U0126 also in­
hibited thrombin-induced phosphorylation of the MEK1/2 
substrate, ERK1/2, in a dose-dependent manner (Figure 
3D). We next determ ined the role of ERK1/2 in thrombin- 
induced CCL2 mRNA levels. Figure 3E show s that U0126 (1 
jxM) blocked the effect of thrombin on CCL2 mRNA levels 
by -70%  (p <  0.01).
To further exam ine the role of the ERK1/2 pathway in 
throm bin-induced CCL2 production, a genetic approach 
w as used. W ildtype-(wt-M EKl), dom inant-negative (dn- 
MEK1), or constitutively active (ca-MEKl) constructs were 
transduced into MLFs (C ow ley et al., 1994). Figure 3F show s 
that thrombin-induced ERK1/2 phosphorylation was blocked 
by up to 70% in cells transduced w ith dn-M EKl. Figure 3G 
show s that ca-MEKl significantly increased basal ERK1/2 
phosphorylation, but had no additive effect on thrombin- 
induced ERK1/2 phosphorylation. Transduction w ith dn- 
MEKl also significantly reduced throm bin-induced CCL2 
production, w hereas transduction with ca-MEKl signifi­
cantly increased basal CCL2 production by about fourfold 
(p <  0.01), but had no additive effect on thrombin-stimu­
lated CCL2 production (Figure 3H). These results provide 
strong evidence that the MEK1-ERK1/2 pathway rather 
them the p38 MAPK pathw ay is both necessary and sufficient 
for PAR,-m ediated CCL2 production in MLFs.
We next exam ined the role of PKC and c-Raf in thrombin- 
induced ERK1/2 activation and CCL2 expression. Both
broad spectrum PKC inhibitors Ro-318425 (Figure 4A) and 
the c-Raf inhibitor (Figure 4B) blocked thrombin-induced 
ERK1/2 phosphorylation in a dose-dependent manner from 
1 piM onward for Ro-318425 and 0.3 /xM onward for c-Raf 
inhibitor. To determine whether PKC is upstream of c-Raf, 
cells were preincubated with Ro-318425, and c-Raf phos­
phorylation was assessed by Western blotting. As shown in 
Figure 4C, Ro-318425 (1 p.M) completely blocked c-Raf phos­
phorylation induced by thrombin.
We next determined whether PKC and c-Raf are involved  
in thrombin-induced CCL2 production and gene expression. 
Figure 4, E>-F, show s that both PKC broad spectrum inhib­
itors Ro-318425 and GF109203X, and the c-Raf inhibitor in­
hibited thrombin-induced CCL2 release in a dose-dependent 
manner. At concentrations of Ro-318425 and c-Raf inhibitor 
that blocked thrombin-induced ERK1/2 phosphorylation, 
thrombin-induced CCL2 production was blocked by 56 ± 
4% (p <  0.01) w ith Ro-318425 (1 /xM) and by 61 ± 5% (p <  
0.01) with the c-Raf inhibitor (3 /xM). At these concentra­
tions, these inhibitors inhibited thrombin-induced CCL2 
mRNA accumulation by 75 and 81%, respectively (Figure 4, 
F and G). Taken together, these data show that PKC, c-Raf, 
and ERK1/2 are in a linear pathway for thrombin-induced 
CCL2 gene expression and protein production.
The Rho Kinase P athw ay M ediates Thrombin-induced 
CCL2 Protein Release via a Nontranscriptional 
Mechanism
The data obtained so far point to a central role for Ga and 
ERK1 /2  in m ediating the effects of PAR, activation on (_CL2 
production. A lthough, G a ,2/13 is generally considered as a 
major activator of Rho kinase, there is emerging evidence 
that G aq is also able to signal via Rho kinase by activating 
the PLC-Ca2+ pathw ay (Singh et al., 2007). Moreover, throm­
bin is known to m ediate Ca2+ signaling via PAR, in fibro­
blasts, and this can be inhibited by BAPTA (Trejo et al., 1996; 
Tanaka et al., 2004). We therefore next examined the role of 
the PLC-Ca2+ pathw ay and Rho kinase in PAR,-mediated 
CCL2 release. Cells w ere treated with increasing concentra­
tions of U73122 (PLC inhibitor, Figure 5A), BAPTA-AM 
(Ca2+ chelator, Figure 5B), G66976 (Ca2+-dependent PKC 
inhibitor, Figure 5C), or Y-27632 and H-1152 (Rho kinase 
inhibitors, Figure 5, D and E). The data obtained show that 
all these inhibitors blocked PAR,-mediated CCL2 produc­
tion in a dose-dependent manner. The ICgo of each inhibitor 
was determined to be 1.5 p.M for U 73122,1 /xM for BAPTA- 
AM, 0.5 pM  for G66976, 3 pM  for Y-27632, and 2.7 pM  for 
H-1152, for this response. In contrast, the inactive control 
com pound for U73122, U73343, was found to have no effect 
on PAR,-mediated CCL2 production at the highest concen­
trations used (data not shown).
To determine w hether these kinases are upstream of the 
ERK1/2 pathway, w e examined the effects of these inhibi­
tors at their respective IC50 concentrations on thrombin- 
induced ERK1/2 phosphorylation. Figure 5F show s that 
none of the four inhibitors interfered with thrombin-induced 
ERK1/2 phosphorylation, indicating that PLC, Ca2 *, Ca2 f - 
dependent PKC, and Rho kinase mediate their effects on 
thrombin-induced CCL2 protein release in an ERK1 /2-inde­
pendent manner.
To determine whether PLC, Ca2+, and Ca2+-dependent 
PKC signal via Rho kinase, w e examined the effects of the 
above inhibitors on the phosphorylation of myosin light 
chain (MLC), a downstream  substrate of Rho kinase (Amano 
et al., 1996). Figure 5G show s that PAR, activation induces 
MLC phosphorylation within 10 min of stimulation and that 
this response is blocked by U73122, BAPTA-AM, G6679, and
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Figure 3. ERK1/2 is necessary and sufficient for thrombin-induced CCL2 mRNA levels and protein release. (A) The effect of SB203580 on 
CCL2 protein release in  response to thrombin. Data are presented as a percentage of the maximal response obtained w ith thrombin and drug 
vehicle alone (0.2% DMSO in DMEM). Cells were treated w ith  increasing concentrations of SB203580 for 30 min before exposure to thrombin 
(10 nM) for 6 h. Final concentrations o f DMSO were kept constant for all treatment conditions. The first bar represents the highest dose of 
SB203580 examined and shows that this compound has no effect on basal CCL2 production. Negative log of the concentration of SB203580 
is presented. (B) The effect o f SB203580 (2 pM) on thrombin-induced p38 phosphorylation. Cells were treated with or w ithout SB203580 for 
30 min before exposure to thrombin for 2 min. p38 phosphorylation was assessed by Western blotting of cell lysates using an anti-phospho- 
p38 antibody (B, p-p38). Protein loading was verified by blotting w ith  an anti-p38 antibody (B, t-p38). The blot is representative of three 
separate experiments performed. (C) The effect of U0126 on CCL2 protein release in response to thrombin. Data were analyzed as in A. (D) 
Dose-response data for the effect o f U0126 on thrombin-induced ERK1/2 phosphorylation. Cells were treated w ith increasing concentrations 
of U0126 for 30 m in before exposure to thrombin for 2 min. ERK1/2 phosphorylation was assessed by Western blotting of cell lysates as in 
B. (E) The effect o f U0126 on thrombin-induced CCL2 mRNA levels. MLFs were exposed to thrombin (10 nM) for 2 h w ith  or w ithout 
preincubation w ith  U0126 (1 jiM ) for 30 min. CCL2 mRNA levels were determined by quantitative RT-PCR. (F and G) The effects of wt-MEKl, 
dn-MEKl, or ca-MEKl on thrombin-induced ERK1/2 phosphorylation. MLFs transduced w ith  MEKl-pBabePuro constructs expressing the 
wt-M EKl, dn-M EK l (F) or ca-MEKl (G) were exposed to thrombin (10 nM) for 2 min. ERK1/2 phosphorylation was assessed by Western 
blotting of cell lysates using an anti-phospho-ERKl/2 antibody (F and G, p-ERKl/2). Protein loading was verified by blotting w ith  an 
anti-ERKl/2 antibody (F and G, t-ERKl/2). The blot is representative of three separate experiments performed. The column graphs represent 
the densitometry analysis o f the blots as a result of phospho-ERKl/2 relative to total ERK1/2 and are representative of three separate
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Y-27632. These data indicate that PLC, Ca2+, and Ca2+- 
dependent PKC signals to Rho kinase rather than ERK1/2 to 
mediate the effects of thrombin on CCL2 release.
We also exam ined the effect of PLC-Rho kinase pathway  
on throm bin-induced CCL2 mRNA levels. As show n in 
Figure 6, A -D , none of the four inhibitors blocked PAR,- 
stimulated CCL2 mRNA levels. Taken together the data 
obtained suggest that the PLC-Rho kinase pathway influ­
ences CCL2 release via a posttranscriptional mechanism.
Inhibition o f  Rho Kinase by Y-27632 Has No Effect on 
Intracellular Protein Production
The results obtained thus far demonstrate an essential role 
for ERK1/2 in PAR, activation-induced CCL2 production by 
influencing CCL2 mRNA levels, whereas the Rho kinase 
pathway acts via a posttranscriptional mechanism. To begin  
to elucidate the mechanism  by which the Rho kinase path­
w ay influences this response, we used im munocytofluores- 
cence to exam ine thrombin-induced intracellular CCL2 pro­
tein production. The isotype-matched control antibody 
panels are com pletely negative, indicating that the signal 
obtained w ith the CCL2 antibody was specific (Figure 7A). 
U nstim ulated cells also yielded no im munostaining or a 
very w eak signal for CCL2 (Figure 7B). In contrast, up to 
60% cells w ere positive for intracellular CCL2 staining for 
both thrombin alone and for Y-27632 pretreated cultures, 
whereas only 5-10% of cells were positive for thrombin- 
treated cells in the presence of U0126. The pixel intensity of 
each treatment group w as also analyzed (Figure 7F). The 
m ean pixel intensity of three randomly chosen fields of view  
w as calculated for each group, and the data are presented as 
fold change over control. Thrombin induced a 2.8 ± 0.1-fold 
increase in fluorescent signal over control, and this w as 
significantly inhibited by U0126. In contrast, pretreatment of 
cells w ith  Y-27632 did not block thrombin-induced intracel­
lular CCL2 accumulation (3.2 ± 0.5-fold increase over con­
trol). We therefore conclude that blockade of ERK1/2 sig­
naling results in near total blockade of thrombin-induced 
CCL2 production. In contrast, blockade of Rho kinase sig­
naling is not essential for CCL2 protein production but likely 
affects the subsequent release of CCL2 from the cell, because 
throm bin-induced CCL2 levels in cell culture supernatants 
are inhibited by Y-27632 (Figure 5D).
The ERK1/2 and Rho Kinase Pathw ays Are Both 
Doionstream o f  P A R , Coupling to G aq 
To determ ine w hether ERK1/2 and Rho kinase pathways 
are both dow nstream  of PAR,-coupling to G aq/ w e evalu­
ated the effect o f the G aq selective PAR, antagonist Q94 on 
throm bin-induced ERK 1/2 and MLC phosphorylation. Fig­
ure 8 show s that Q94 com pletely blocked thrombin-induced 
ERK1/2 (Figure 8A) and MLC phosphorylation (Figure 8B). 
These data confirm that ERK 1/2 and Rho kinase pathw ays 
are dow nstream  of PAR ,-coupling to G aq and act in coop­
eration to m ediate the effects of PAR, activation on CCL2 
gene expression, protein production and release.
Figure 3 (cont). experiments performed w ith  three replicates per 
sample. (H ) The effects o f w t-M E K l, dn -M E K l, or ca-M EKl on 
throm bin-induced CCL2 protein release. MLFs transduced w ith  
MEKl-pBabePuro constructs expressing the w t-M E K l, dn -M E K l, or 
ca-MEKl were exposed to throm bin (10 nM ) for 6 h, and subsequent 
CCL2 protein levels in  culture supernatants were measured by 
ELISA. p <  0.01, comparison w ith  m edium  control; ’ p  <  0.05 
and " p  <  0.01, comparison w ith  throm bin alone.
D IS C U S S IO N
The activation of the coagulation cascade leading to the 
generation of thrombin is one of the earliest events after 
tissue injury. PAR,, the main high-affinity thrombin signal­
ing receptor, contributes to excessive inflammation and tis­
sue remodeling in a number of disease settings, including 
atherosclerosis (Major et al., 2003), vascular neointima for­
mation (Cheung et al., 1999), glomerulonephritis (Cunning­
ham et al., 2000), liver fibrosis (Fiorucci et al., 2004), inflam­
matory bowel disease (Vergnolle et al., 2004), acute lung 
injury (Jenkins et al, 2006), and fibrotic lung disease (Howell 
et al., 2005). In this setting, w e have recently show n that the 
dramatic attenuation of the acute inflammatory and late 
fibrotic response in PAR,-deficient mice after bleomycin- 
induced lung injury is associated with a marked reduction in 
pulmonary levels of CCL2 (Howell et al., 2005). However, 
the signal transduction pathways involved in the induction 
of CCL2 after PAR, activation are currently poorly under­
stood. This study sheds important light on both the G pro­
tein pathway and subsequent signaling cascades involved 
and identifies a central role for Gaq, ERK1/2, and Rho 
signaling pathways in this response.
Thrombin Stim ulates CCL2 Protein Production via CCL2 
Gene Transcription
In this report, w’e show  that thrombin induces CCL2 protein 
production in a dose-dependent manner from 0.03 nM on­
ward. Strikingly, this response did not reach a plateau at 300 
nM, the highest concentration examined. In normal human 
plasma, the zym ogen prothrombin is present at concentra­
tions around 1.4 p.M, but concentrations of around 130 nM 
have been calculated to represent the maximum concentra­
tion of active thrombin generated during blood clotting in 
vivo (Walz et al., 1985). We further show  that the stimulatory 
effects of thrombin at the protein level were accompanied by 
a rapid and ActD-sensitive increase in CCL2 mRNA levels, 
indicating that the observed increase in CCL2 release is not 
due to the release of prestored CCL2. These data are consis­
tent w ith previous reports of thrombin-induced CCL2 pro­
duction in endothelial cells and monocytes (Colotta et al., 
1994).
Thrombin Exerts Its Stim ulatory Effects on CCL2 
Expression via PAR, Coupling to G aq 
Thrombin exerts m ost of its cellular effects via activation of 
at least three PARs (PAR,, PAR3, and PAR4) by limited 
proteolytic cleavage of the N-terminus. We and others have 
show n that PAR, is the major receptor involved in mediat­
ing the mitogenic and profibrotic effects of thrombin in 
fibroblasts (reviewed in Chambers, 2003). In the present 
study, the involvem ent of PAR, in mediating CCL2 produc­
tion w as demonstrated in experiments em ploying the highly 
selective PAR, peptide agonist, TFLLR-NH2. This agonist 
activates PAR, independently of receptor cleavage, and un­
like the comm only used peptide agonists, based on the 
tethered ligand sequence of PAR, (SFLLRN), does not acti­
vate PAR2 in human mesenchymal cells (Hollenberg et al.,
1997). The necessity for PAR, in mediating the effects of 
thrombin at 10 nM was confirmed in experim ents demon­
strating that CCL2 production w as not up-regulated in fi­
broblasts derived from PAR, KO mice.
Although many of the resultant biological consequences 
of PAR, activation in fibroblasts are known, less is known 
about w hich G proteins mediate these events. The C-termi­
nal region of Ga subunits has been show n to be critical in 
determ ining the specificity of GPCR-G protein interactions
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Figure 4. Inhibition o f c-Raf kinase and PKC attenuates thrombin-induced ERK1/2 phosphorylation, CCL2 protein production, and CCL2 
mRNA levels. (A  and B) Dose-response data for the effects o f Ro-318425 (A) and c-Raf inhibitor (B) on thrombin-induced ERK1/2 
phosphorylation. Cells were treated w ith increasing concentrations of inhibitors for 30 min before exposure to thrombin (10 nM) for 2 min. 
ERK1/2 phosphorylation was assessed by Western blotting o f cell lysates using an anti-phospho-ERKl/2 antibody (A and B, p-ERKl/2). 
Protein loading control was verified by blotting w ith an anti-ERKl /2  antibody (A and B, t-ERK). The blots are representative of three separate 
experiments performed. (Q  The effect of Ro-318425 on thrombin-induced c-Raf phosphorylation. Cells were treated with Ro-318425 (1 pM) for 30 
min before stimulation w ith thrombin (10 nM) for 10 min. c-Raf phosphorylation was assessed by Western blotting of cell lysates using an 
anti-phospho-c-Raf antibody (C, p-c-Raf). Protein loading was verified by blotting w ith an anti-c-Raf antibody (C, p-c-Raf). The blot is representative 
o f three separate experiments performed. (D-F) The effects of Ro-318425 (D), GF109203X (E), and c-Raf inhibitor (F) on CCL2 protein production 
in response to thrombin. Data are presented as a percentage of the maximal response obtained w ith thrombin (10 nM) and drug vehicle alone (0.1% 
DMSO in DMEM). Cells were treated with increasing concentrations of Ro-318425, GF109203X, or c-Raf kinase inhibitor for 30 min before exposure 
to thrombin for 6 h. Final concentrations of DMSO were kept constant for all treatment conditions. The first bar in each graph represents the highest 
doses of inhibitors examined and shows that these compounds have no effect on basal CCL2 production. Negative log of the concentrations of 
inhibitors are presented. (G and H) The effects of Ro-318425 (G) and c-Raf inhibitor (H) on thrombin-induced CCL2 mRNA levels. MLFs were 
exposed to thrombin (10 nM) for 2 h with or without preincubation w ith c-Raf inhibitor (3 pM) or Ro-318425 (1 /aM) for 30 min. CCL2 mRNA levels 
were determined by quantitative RT-PCR. Final concentrations of DMSO were kept constant for all treatment conditions (0.01% DMSO in DMEM). 
Data represent the mean ± SEM from triplicates. * p <  0.01, comparison w ith  medium control; "  p <  0.01, comparison with thrombin alone.
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Figure 5. Inhibition of PLC (U73122), Ca2+ 
(BAPTA-AM), Ca2+-dependent PKC (Go6976), 
and Rho kinase (Y-27632 and H-1152) attenuate 
thrombin-induced CCL2 production in an 
ERK1 /  2-independent mechanism. (A-E) The ef­
fects of U73122 (A), BAPTA-AM (B), G66976 
(C), Y-27632 (D), and H-1152 (E) on thrombin- 
induced CCL2 protein release. Cells were pre­
incubated with increasing concentrations of 
each inhibitor for 30 min before exposure to 
thrombin (10 nM) for 6 h. Data are presented as 
a percentage of the maximal response obtained 
w ith thrombin and drug vehicle alone (0.1% 
DMSO in DMEM). Final concentrations of DMSO 
were kept constant for all treatment conditions. 
The first bar in each graph represents the high­
est dose of each inhibitor examined and shows 
that these compounds have no significant effect 
on basal CCL2 production. Negative log of the 
concentrations of each inhibitor are presented. 
(F) The effect of U73122, BAPTA-AM, Go6976, 
and Y-27632 on thrombin-induced ERK1/2 
phosphorylation. MLFs were treated with U73122 
(2 /xM), BAPTA-AM (2 fiM), Go6976 (1 /xM), or 
Y-27632 (3 pM) for 30 min before exposure to 
thrombin (10 nM) for 2 min. ERK1 /2  phosphor­
ylation was assessed by Western blotting of cell 
lysates using an anti-phospho-ERKl/2 anti­
body (F, p-ERKl/2). Protein loading was veri­
fied by blotting w ith an anti-ERKl /2  antibody 
(F, t-ERKl/2). The blot is representative of three 
separate experiments performed. (G) The effect 
of U73122, BAPTA-AM, Go6976, and Y-27632 
on thrombin-induced MLC phosphorylation. 
MLFs were treated with U73122 (2 jiM), BAPTA- 
AM  (2 /iM), Go6976 (1 ,iM), or Y-27632 (3 *iM) for 
30 min before stimulation with thrombin (10 nM) 
for 10 min. MLC phosphorylation was assessed by 
Western blotting of cell lysates using an anti-phos­
pho-MLC antibody (G, p-MLC). Protein loading 
was verified by blotting with an anti-MLC anti­
body (G, t-MLC). The blot is representative of 
three separate experiments performed. Data rep­
resent the mean ± SEM from triplicates. " p <  
0.01, comparison with medium control;"  p <  0.01, 
comparison with thrombin alone.
(Hamm and Gilchrist, 1996; Hamm, 1998). This interaction is 
highly specific. For example, substituting a single amino 
acid has been shown to annul the ability of Ga, to bind the 
A, adenosine receptor (Gilchrist et al., 1998). Dominant- 
negative constructs of the a subunit of G proteins (termed G 
protein minigenes), encoding the C-terminal sequence for 
each family of Ga subunits, have been developed as pow­
erful tools for identifying the G protein that mediates a given 
physiological function after thrombin activation (Gilchrist 
et al., 2001). In experiments em ploying such a Ga subunit 
minigene approach, w e were able to show  that only Ga is 
necessary for PAR,-mediated CCL2 protein release, and that 
G a,2> G a13, and G„, play no role. The critical involvement of 
Ga was further confirmed with a recently developed novel 
PAR, selective Ga protein signaling antagonist (Q94, Ca­
den Biosciences), wnich blocked PAR,-mediated increases in 
both CCL2 mRNA and protein levels in a dose-dependent 
manner. It is worth mentioning that in these experiments, 
the CCL2 response obtained was usually greater for TFLLR- 
NH 2 over thrombin. This observation might be explained by 
recent evidence that there are differences between thrombin 
and peptide agonists in terms of the subsequent ability of 
PAR, to activate different G proteins (McLaughlin et al.,
2005). PAR, activation studies in endothelial cells showed 
that peptide activation altered receptor/G protein binding 
to favor Gaq activation over G a12/13. It is tempting to spec­
ulate that such functional selectivity may also occur in fi­
broblasts and may similarly explain the finding that TFLLR- 
NH 2 induces a greater CCL2 response compared with the 
physiological activator thrombin in our experiments.
PAR, Activation Induces CCL2 Release via a 
Ca2+-dependent PKC/ERK1/2 Pathway and 
Increased CCL2 Gene Expression
Gaq has been shown to be necessary for mediating throm­
bin-induced ERK1/2 phosphorylation in MLFs (Trejo et al., 
1996). We therefore examined the possibility that the 
ERK1/2 pathway may be downstream of PAR, coupling to 
Ga and therefore may be involved in thrombin-induced 
CCL2 gene expression and protein production. Using either 
the pharmacological inhibitor, U0126, or dn-MEKl gene 
constructs, we show that the ERK1/2 pathway is necessary 
for CCL2 protein production and release mediated by PAR, 
coupling to Gaq. Gaq was further found to be necessary for 
mediating thrombin-induced ERK1/2 phosphorylation be-
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Figure 6. Inh ib ition  o f PLC, Ca2*, Ca2+-de- 
pendent PKC or Rho kinase does not interfere 
w ith  thrombin-induced CCL2 m R N A levels. 
(A -D ) The effects o f U73122 (A), BAPTA-AM 
(B), G66976 (C), and Y-27632 (D) on thrombin- 
induced CCL2 m R N A levels. MLFs were ex­
posed to throm bin (10 nM ) for 2 h w ith  or 
w ithout preincubation w ith  U73122 (2 p.M), 
BAPTA-AM (2 /rM ), G66976 (1 #iM), or 
Y-27632 (3 fiM )  fo r 30 m in. CCL2 m RNA lev­
els were determ ined by quantitative RT-PCR. 
Final concentrations o f DMSO were kept con­
stant for all treatment conditions (0.01% 
DMSO in  DM EM ). Data represent mean ± 
SEM from  triplicates at each condition. + + p <  
0.01, comparison w ith  untreated cells.
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cause the PAR, selective G aq antagonist Q94 blocked this 
response.
In this study, w e exclude a role for the p38 MAPK path­
w ay since although thrombin w as found to activate the p38 
MAPK pathway in our cells, the p38 MAPK inhibitor, SB 
203580, had no effect on thrombin-induced CCL2 protein 
production This latter finding is not in agreement with  
previous reports dem onstrating a role for p38 MAPK in 
thrombin-induced CCL2 production using comparable 
doses of SB203580 in other cell types, including human  
endothelial cells (Marin et a l, 2001) and human sm ooth  
muscle cells (Brandes et al, 2001). The discrepancy between  
our findings in MLFs and others may have several explana­
tions, including important differences in both the species 
and the cell type exam ined, as w ell as differences in the 
concentrations of thrombin used in our (10 nM is equivalent 
to 0.5 U /m l) and other studies (8 U /m l; Marin et al, 2001). 
Moreover, from our experience with PAR, KO fibroblasts, 
w e are aware that thrombin can induce CCL2 release at 
higher concentrations via a non-PAR mediated mechanism  
because on ly  PAR, and PAR4 are expressed, and PAR4 
agonist peptides fail to induce CCL2 release in PAR, KO 
fibroblasts (data not show n). As thrombin is a proteinase, w e  
propose it is likely that at higher concentrations, CCL2 pro­
tein production m ay be m ediated via the release of other 
stimulatory m ediators bound to the pericellular matrix. In 
this regard, thrombin has previously been shown to release 
TGF-/3 bound to the pericellular matrix of fibroblasts (Tai- 
pale et al., 1992). It is therefore possible that non-PAR,-  
dependent pathw ays lead to activation of the p38 MAPK 
pathway to m ediate throm bin-induced CCL2 release at high  
concentrations of the proteinase. Although concentrations 
around 130 nM m ay be generated after intravascular coag­
ulation and are therefore relevant in the context of thrombin 
signaling in vascular cell types, thrombin concentrations in 
extravascular com partm ents and hence in the context of 
fibroblast signaling responses are likely to be much lower.
The downstream  signaling m olecules that mediate the 
actions of G proteins on ERK1 /2  include ras, PKC, and c-Raf 
kinase (Blumer and Johnson, 1994), w hich can activate MEK 
(Cobb et a l, 1994). Indeed, our data show  that both c-Raf and 
PKC are involved in PAR,-m ediated ERK1/2 phosphoryla­
tion as previously reported (Trejo et al, 1996). We also 
exam ined w hich class of PKC isozym es are involved in this 
response. PKC isozym es can be generally divided into two 
groups: Ca2+-dependent (conventional PKC) and Ca2+-in­
dependent (novel and atypical isozymes). Experiments us­
ing the specific Ca2+-dependent PKC inhibitor, G66976, 
show ed that Ca2 4-dependent PKC is not involved in the 
activation of ERK1/2 after PAR, activation. Our data further 
show  that the Ca2+-independent PKC-ERK1/2 pathway me­
diates CCL2 protein production by influencing CCL2 gene 
transcription because inhibition of ERK1/2, c-Raf, and PKC 
using the broad-spectrum inhibitor, Ro-318425, abolished 
PAR,-induced CCL2 mRNA accumulation and protein pro­
duction, whereas inhibition of Ca2* -dependent PKC by  
G66976 had no effect on PAR,-induced CCL2 mRNA accu­
m ulation but did inhibit CCL2 release into cell culture su­
pernatants.
The Ca2*-dependent PKC Rho Pathw ay M ediates the 
Effects o f  PARj Activation  on CCL2 Release via a 
Posttranscriptional Mechanism
Ca2+-dependent PKC is a well-recognized downstream ef­
fector of G aq and is activated in response to a rise in intra­
cellular Ca2+ concentration. Although the a-subunit of Gaq 
is w ell-know n to trigger an increase in intracellular Ca2+ 
concentration by stimulating PLC-/3 activity and G a ,2/13 
activation preferentially induces Rho kinase activation, a 
recent study by Singh et al (2007) demonstrated that Gaq can 
lead to Rho kinase activation via PLC-/3-Ca2+-dependent 
PKC to m ediate thrombin-induced endothelial cell contrac­
tion. In the present study, our data similarly suggest that 
Rho kinase activation is mediated by a G aq-PLC-Ca2+- d e ­
pendent PKC pathway to mediate thrombin-induced CCL2 
release. First, w e show  that inhibitors of PLC, Ca2+, and 
Ca2+-dependent PKC all block thrombin-induced phosphor­
ylation o f MLC, one of the major downstream substrates of 
Rho kinase (Amano et al, 1996). Second, a direct link be­
tw een  this pathw ay and Ga coupling to PAR, w as dem ­
onstrated by show ing that tne novel PAR, selective G a  
antagonist (Q94) also abolishes throm bin-induced MLC 
phosphorylation.
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Figure 7. Immunocytofluorescence demonstrates 
that CCL2 intracellular protein production is 
blocked by MEK1/2 inhibition (U0126) but not by 
Rho kinase inhibition (Y-27632). (A) Iso type control; 
(B) untreated cells; (C) the effect of thrombin on 
CCL2 intracellular protein production; (D) the effect 
of U0126 on CCL2 intracellular protein production 
induced by thrombin; (E) the effect of Y-27632 on 
CCL2 intracellular protein production induced by 
thrombin. Cells were preincubated with or without 
U0126 (10 /xM) or Y-27632 (10 *xM) for 30 min before 
stimulation with thrombin (10 nM) for 3 h. At the 
end of incubation, cells were immunostained with 
normal goat IgG (A) or anti-CCL2 antibody (B—E) 
followed by DAPI staining. Areas of CCL2 localiza­
tion are shown in green, and nuclei appear blue. (F) 
The mean pixel intensity of three randomly chosen 
fields of view, expressed as fold increase over 
DMSO control, for each group. + + p <  0.01, com­
parison with untreated cells. ** p <  0.01, compar­
ison with thrombin alone.
Our findings and those reported by Singh et al. (2007) 
contrast with a previous report demonstrating that G aq- 
mediated Rho kinase activation occurs independently of 
PLC/3 in mouse embryonic fibroblasts (MEFs; Vogt et al., 
2003). The activation of Rho A requires its dissociation from 
the Rho kinase/GDP/GDI-1 complex followed by GTP ex­
change mediated by guanine nucleotide exchange factors 
(GEFs). In terms of Rho kinase activation by GPCRs, the 
RhoGEF (Rho guanine nucleotide exchange factor) proteins, 
pll5RhoGEF, PDZ-RhoGEF, and leukemia-associated Rho 
guanine-nucleotide exchange factor (LARG), have been 
shown to stimulate Rho kinase activity (Hart et al., 1998; 
Kozasa et al., 1998; Fukuhara et al., 2001; Suzuki et al., 2003). 
Singh and colleagues provided evidence that Gaq-mediated 
Rho kinase activation is pll5RhoGEF dependent after PLC- 
Ca2+-dependent PKC activation, whereas in studies by 
Vogt and colleagues in MEFs, thrombin-induced Rho kinase 
activation was shown to be mediated by the RhoGEF, 
LARG. Taken together, our findings are consistent with a 
PLC-Ca2+-dependent PKC-dependent Rho kinase activa­
tion mechanism rather than a LARG-mediated mechanism.
Although Rho kinase was first characterized as a major 
regulator of actin dynamics, it is now well recognized that
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Figure 8. ERK1/2 and MLC pathways are downstream o f PAR, 
coupling to Gar_. (A and B) The effect of Q94 on thrombin-induced 
ERK1/2 (A) and M LC (B) phosphorylation. Cells were treated w ith 
Q94 (10 jaM ) for 3 h before exposure to thrombin (2 min for ERK1 /2 , 
10 min for MLC). Phosphorylation o f ERK1/2 or MLC was assessed 
by Western blotting o f cell lysates using an anti-phospho-ERKl /2  
antibody (A, p -E R K l/2 ) or an anti-phospho-MLC antibody (B, p- 
MLC). Protein loading was verified by blotting w ith  an anti-ERKl /2  
antibody (A, t-E R K l/2 ) or an anti-MLC antibody (B, t-MLC). The
blots are representative o f three separate experiments.
Rho family proteins influence a range of other cellular pro­
cesses, including gene transcription and protein secretion 
(reviewed in Etienne-Manneville and Hall, 2002). In the 
present study, w e provide evidence that the Rho kinase 
pathway is involved in PAR,-mediated CCL2 protein re­
lease posttranscriptionally, likely by influencing protein se­
cretion. This is based on two observations. First, inhibition of 
Rho kinase only blocks thrombin-induced CCL2 protein re­
lease but not CCL2 mRNA levels. Second, immunocytofluo- 
rescence experiments to elucidate the mechanism by which 
the Rho kinase pathway influences CCL2 release, demon­
strate that intracellular protein production is blocked with 
the MEK1/2 inhibitor, U0126, but is unaffected by the Rho 
kinase inhibitor, Y-27632. Taken together, these data indicate 
that blockade of Rho kinase signaling is not essential for 
PAR,-mediated CCL2 gene expression and protein produc­
tion. Given that Y-27632 blocks PAR,-mediated increases in 
CCL2 levels measured in cell culture supernatants, we pro­
pose that this pathway most likely affects CCL2 protein 
secretion.
Specificity o f Pharmacological Inhibitors Used 
In this study we used a range of small cell-permeable inhib­
itors of protein kinases to dissect the signaling pathways 
involved in PAR,-mediated CCL2 release. These inhibitors 
exhibit a relatively high degree of specificity for the target 
kinase, but these compounds are not always totally specific 
and need to be used with caution. In this study, all experi­
ments involving such inhibitors were designed according to 
expert recommendations (Davies et al., 2000; Bain et al., 
2003). First, the role of most of the targeting kinases was 
verified by more than one structurally unrelated inhibitor. 
For instance, the involvement of ERK1/2 was confirmed by 
both U0126 and PD98059 (data no shown). Similarly for 
PKC, we used the broad-spectrum PKC inhibitors, Ro- 
318425 and GF109203X. For Rho kinase, we used two com­
pounds: Y-27632 and H-1152. Second, wherever available, 
inactive control compounds (e.g., SB202474 as a negative 
control for SB203580 and U73343 as a negative control for 
U73122) for each inhibitor were tested in parallel cultures. 
This was particularly important when high concentrations
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of the active compounds were used. Third, genetic ap­
proaches were used to strengthen the results obtained with 
M EK1/2 inhibition and to identify the G protein involved in 
coupling to PAR,. Finally, w e demonstrated that most in­
hibitors blocked CCL2 release at the same concentrations 
that prevented the phosphorylation of an authentic physio­
logical substrate of the protein kinase. For example, ERK1/2, 
p38 MAPK, and MLC phosphorylation w as assessed to 
identify the lowest concentration of respective inhibitors 
required for subsequent CCL2 release experiments.
Integration o f the Flow o f Information 
In this study, we provide evidence that thrombin-induced 
CCL2 release is mediated via coupling of PAR, to G aq and 
the cooperation between ERK1/2 and Rho kinase signaling 
pathways. This raises the question as to how  the flow of 
information to the two pathways, one directed at the nucleus 
and the other at a specific secretory apparatus, is regulated? 
Signal transduction leading to cellular responses is a com­
plex processes initiated by protein-protein interactions be­
tween ligands, receptors, and kinases. Recent hypotheses 
including the formation of lipid rafts and "transduceo- 
somes" have shed light on how these multiple components 
work in harmony. Lipid rafts are specialized structures on 
the plasma membrane that have an altered lipid composi­
tion as well as links to the cytoskeleton. Recent studies 
indicate that some GPCRs, G proteins, and their effectors 
localize to lipid rafts or dynamically m ove in and out of 
microdomains (Simons and Toomre, 2000). A recent study 
has shown that PAR, is present in endothelial cell plasma 
membrane rafts and caveolae and that the localization of 
PAR, specifically to rafts serves as an important mechanism  
for the regulation of thrombin-induced cytoskeletal changes 
in endothelial cells. Of particular interest to the current 
work, these authors further demonstrate a role for lipid rafts 
in mediating PAR, activation of both R hoA/Rho kinase 
signaling and MLC phosphorylation (Carlile-Klusacek and 
Rizzo, 2007). Because PAR, coupling to Ga mediates 
thrombin-induced CCL2 secretion via the RhoA/Kho kinase 
pathway, we propose that it is likely that the components for 
secretion in this pathway might integrate on lipid rafts. In 
contrast, the role of lipid rafts in MAPK signaling remains 
controversial. For example, G aq/1, has been shown to acti­
vate p38 MAPK via lipid rafts, whereas tw o studies have 
show n that Ga does not mediate ERK1/2 phosphorylation  
via such rafts (Hiol et al., 2003; Sugawara et al., 2007). In this 
study, w e report that PAR, coupling to G aq mediates throm­
bin-induced CCL2 production via ERK1/2 rather than p38 
signaling so that current evidence w ould lead us to propose 
that the components involved in the transcriptional re­
sponse may not float together on lipid rafts and would  
therefore be segregated from the components involved in 
CCL2 secretion. It is also possible that these pathways in­
volve the assembly of a transduceosome that w ould act as a 
relay to assemble and integrate the signals derived from the 
tw o pathways in order to optim ize the amplitude of dow n­
stream signaling. Transduceosomes are most well described 
in terms of the essential role of the scaffold and anchoring 
protein, A-kinase anchor proteins (AKAP) in cAMP signal­
ing (Feliciello ef al., 2001). cAM P-dependent protein kinase is 
targeted to discrete subcellular locations by the AKAPs. 
Localization recruits protein kinase A (PKA) holoenzym e 
close to its substrate/effector proteins, directing and ampli­
fying the biological effects of cAMP signaling. Although  
AKAPs were identified on the basis of their interaction with  
PKA, AKAPs bind other signaling molecules, principally 
phosphatases and kinases, including notably PKC (Feliciello
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Figure 9. Model for thrombin-induced CCL2 production and re­
lease. Thrombin ligation of PAR, stimulates Gaq. Activation of 
Ca2 * -independent PKC leads to the sequential activation of c-Raf, 
M EK l and ERK1 /2  to stimulate CCL2 gene transcription. Ga also 
leads to the activation of PLC, Ca2 *, and Ca2' -dependent PKC to 
activate Rho kinase (likely via pll5RhoGEF, Singh et al., 2007) to 
mediate CCL2 protein release.
et al., 2001). It is therefore tempting to speculate and propose 
a role for both lipid rafts and transduceosomes to integrate 
and assemble the signaling components leading from PAR, 
activation of Ga to CCL2 gene transcription via the ERK1/2 
pathway and CCL2 release via the RhoA/RhoA pathway.
Summary and Therapeutic Implications 
We provide compelling evidence that thrombin mediates its 
potent stimulatory effects on fibroblast CCL2 production 
and release by coupling to G aq and the cooperation between 
ERK1/2 and Rho kinase signaling pathways (Figure 9). In­
hibition of the Ca2+-independent PKC-ERK1 /2  pathway not 
only inhibits CCL2 protein levels, but also inhibits intracel­
lular CCL2 protein production and CCL2 mRNA levels, 
suggesting that this pathway mediates thrombin-induced 
CCL2 release by influencing CCL2 gene transcription. Inhi­
bition of the PLC-Rho kinase pathway inhibits CCL2 protein 
release, but has no effect on thrombin-induced intracellular 
CCL2 protein production and CCL2 mRNA levels. The 
RhoA/Rho kinases are well known for their regulatory role 
in stress fiber formation and secretory vesicle trafficking, 
suggesting that this pathway mediates thrombin-induced 
CCL2 secretion. Blockade of PAR, coupling to Ga was 
found to inhibit both ERK1/2 and MLC phosphorylation 
induced by thrombin, indicating that these two pathways 
both lie downstream of PAR, coupling to Gaq.
To the best of our knowledge, this report represents the 
first demonstration of the cooperation between these two 
pathways in mediating the stimulatory effects of thrombin, 
or indeed any other extracellular stimulus, on the induction 
and release of the potent chemoattractant, CCL2. In this 
report, we further demonstrate the effectiveness of blocking 
this response using the recently developed novel PAR, antag­
onist, Q94, which blocks PAR, at the intracellular interaction
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site with Gaq (Caden Biosciences) and therefore allows more 
selective targeting of some, but not all, PAR,-mediated cel­
lular responses. We propose that such an antagonist ap­
proach may hold promise for selectively interfering w ith  
deleterious thrombin signaling in the context of tissue in­
flammation and fibroproliferative disease, while preserving 
other essential PARj-mediatedcellular responses.
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